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ABSTRACT 
The fresh roots of Clerodendrum phlomidis (family Lamiaceae) and whole plant of Stellaria 
media (family Caryophyllaceae) have been tested for their anti-obesity and obesity associated 
T2DM (Type 2 diabetes mellitus).  We have examined effect of C. phlomidis and S. media on 
digestive enzyme activity, lipid metabolism & theromogenesis, adiposities cell number & 
diameter, histology of fat pad and fatty liver changes by using three different animal models 
i.e. Progesterone induced obesity in Swiss albino mice, Cafeteria diet induced obesity in 
Wistar rats and DIO (diet induced obesity) induced obesity in C57BL/6J mice. We have 
selected methanolic and alcoholic extracts of both the plants i.e. methanolic extract of 
Clerodendrum phlomidis (MESM),  alcoholic extract of Clerodendrum phlomidis (AECP), 
methanolic extract of Stellaria media (MESM) and alcoholic extract of Stellaria media) 
(AESM). MECP and MESM have prevented the increase in body weight; adipose tissue 
weight and size are upturned in all three models. Fatty liver changes only observed in 
C57BL/6J mice where obesity induced by a high-fat diet which was reversed by only MECP. 
Among these two plants MECP have shown more promising effects compare to MESM may 
be because of its multiple mechanisms. Anti-obesity activity produced by MECP is because 
of inhibition of pancreatic lipase activity and β-sitosterol content and moreover MECP have 
inhibited pancreatic lipase activity (in-vitro) study and up-regulated lipid metabolism. These 
findings suggest that the anti-obesity actions of MECP may be partly mediated through 
delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity and 
partly by β-sitosterol content which is having structural similarity with dietary fat do the 
physical competition in the GIT. Before carrying out pharmacological activity detail 
pharmacognostic and phytochemical analysis was carried out. The plants have shown 
presence of some common constituents like saponin, flavonides, steroids and triterpenoids, 
glycosides, and anthocynidine. MECP and MESM are beneficial for the suppression of 
obesity and some associated complications.  
Key words: Clerodendrum phlomidis, Stellaria media, β-sitosterol, fat cell isolation and 
counting, pancreatic lipase.   
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1.0: INTRODUCTION 
Obesity has turned up as one of the major health concerns in the 21st century 
and is one of the leading causes of preventable death (Barness, Opitz & Gilbert-
Barness, 2007). Obesity is a term applied to excess body weight with an abnormally 
high proportion of body fat. Thermodynamically speaking, imbalance between energy 
intake (feeding) and energy expenditure (physical activity) leads to obesity (Pilch & 
Bergenhem, 2006). Development of obesity is, however, more complicated than that; 
sedentary life style, genetic factors, medical illness, microbiological aspects, social 
factors and neurobiological mechanisms are also involved (Sugerman, 2005; Bleich & 
Cutler, 2008). 
Obesity has reached epidemic proportions globally, with more than 1 billion 
adults overweight - at least 300 million of them clinically obese - and is a major 
contributor to the global burden of chronic disease and disability. Often coexisting in 
developing countries with under-nutrition, obesity is a complex condition, with 
serious social and psychological dimensions, affecting virtually all ages and 
socioeconomic groups (WHO, 2009). 
Increased consumption of more energy-dense, nutrient-poor foods with high 
levels of sugar and saturated fats, combined with reduced physical activity, have led 
to obesity rates that have risen three-fold or more since 1980 in some areas of North 
America, the United Kingdom, Eastern Europe, the Middle East, the Pacific Islands, 
Australasia and China. The obesity epidemic is not restricted to industrialized 
societies; this increase is often faster in developing countries than in the developed 
world (WHO, 2009). 
A growing public health concern is that the prevalence of obesity among 
children aged 6–19 is up to 16.5% in the USA (Hedley et. al, 2004) and has also 
increased in Europe, Asia, Africa and South American countries (Antipatis  & Gill, 
2001). Despite increased attention given to overweight and obesity by virtually every 
major body concerned with public health, including the National Institutes of Health 
(NIH) (National Task Force, 1994) the Centers for Disease Control (Mokdad et. al., 
2001), the United States Department of Agriculture (Freedman King & Kennedy, 
2001) and the World Health Organization (World Health Organization, 2000) primary 
and secondary prevention efforts have generally been disappointing. Obesity impacts 
many facets of society. For example, it is economically costly to society (World 
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Health Organization, 1998) increases mortality rate (Allison, Fontaine, Manson, 
Stevens & VanItallie, 1999) reduces quality of life (Fontaine, Bartlett & Barofsky, 
2000) and increases the risk of various morbidities (Billington, 2000). Extreme 
obesity has been estimated to truncate the lifespan of young adults by 5–20 years 
(Fontaine, Bartlett & Barofsky, 2000). 
The medical problems caused by obesity begin at the head and end at the toes 
and involve almost every organ in between (page no- 19). Several of these problems 
contribute to the earlier mortality associated with obesity and include coronary artery 
disease, severe hypertension that may be refractory to medical management, impaired 
cardiac function, adult-onset (type 2) diabetes mellitus, obesity hypoventilation and 
sleep apnea syndromes, cirrhosis, venous stasis and hypercoagulability with an 
increased risk of pulmonary embolism, and necrotizing panniculitis (Sugerman, 
2005).  
The association of obesity with T2DM (Type 2 DM) has been observed in 
comparisons of different populations and within populations (West & Kalbfleisch, 
1971; Joslin, 1921). Approximately 10% of the obese population develop T2DM 
(Harris, Flegal & Cowie, 1998). This may be because of “glucotoxicity” (expression 
of glucose allostasis and increase in „allostatic load), “lipotoxicity” fatty acid supply 
to peripheral tissues impairs glucose uptake and storage in the muscle (Boden, 1997; 
Balasse & Neef, 1973; Gomez, Jequier, Chabot, Buber, & Felber, 1972; Kumar, 
Boulton, Beck-Nielsen, 1996) and adipokines (adipose tissue) hormones that are 
secreted by the adipose tissue (TNF-α, IL-6, complement C3, MIF, adiponectin) are 
associated with insulin resistance, often independently of the degree of adiposity 
(Straczkowski, et. al., 2002; Weyer, 2000; Weyer, Funahashi  & Tanaka, 2001; 
Vozarova, Metz & Stefan, 2002). 
Unfortunately, with the exception of surgery (a procedure appropriate for only 
a minority of obese individuals), available treatments for obesity are, at best, of 
modest efficacy. With regard to nonsurgical treatments for obesity, Ayyad and 
Andersen (Ayyad & Andersen, 1999), in a quantitative synthesis of the literature, 
found that even in the best of conditions, the median percentage of patients who 
achieved and maintained clinically meaningful weight loss for at least 3– 5 years was 
only about 20%, whereas others have reported that of those who lose weight, 90–95% 
eventually regain it (World Health Organization, 2000). 
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Ayurvedic system of medicines is one of the oldest system of medicine having 
a history of more than 3000 years. Several prototype derived from these herbal 
medicines are in use for various kind of disease and disorders. It not only gives new 
molecule but also with newer mechanism of action, hence is called Gold mine. 
Several infusions or decoctions of plants used in traditional medicine to reduce 
obesity could be utilized to delete the clinical side effects of the current chemically 
formulated antiobesity agents; examples include Camellia sinensis (L.) Kuntze 
(Theaceae), Chlorella pyrenoidosa Chick. (Oocystaceae), Citrus aurantium L. 
(Rutaceae), Garcinia cambogia L. (Clusiaceae), Lagerstroemia speciosa (L.) Pers. 
(Lythraceaea), Panax ginseng C.A. Meyer (Araliaceae), Salix matsudana Koidzumi 
(Salicaceae), Nelumbo nucifera Gaertn. (Nymphaeaceae) and Stellaria media and 
Clerodendrum phlomites (Calapai, et, al., 1999; Han et. al., 2003; Hidaka, Okamoto 
& Arita, 2004; Dilip, Manashi & Nazim, 2005; Katewa & Galav, 2006). A large study 
of literature indicates that substantial progress has been made concerning our 
knowledge of bioactive components in plant foods and their links to obesity. For the 
present research protocol we have chosen Stellaria media and Clerodendrum 
phlomides to evaluate its anti-obesity and related complications like T2DM etc.   As 
per the literature survey it was found that flavonides, sitosterols, tannins and 
saponines have shown the anti-obesity activity by various mechanisms, both of these 
selected plants have shown the presence of some common phytoconstituents in their 
extracts like sitosterols, triterpenoids, flavonoids etc. Moreover traditional system of 
Indian medicine also claims for its anti-obesity activity. With this back ground we 
have selected these plants for its phytochemical analysis, screening its anti-obesity 
and obesity associated hyperglycema as well as to substantiate the folklore claim.  
Pre-clinical evaluatory study of these plant extracts was done by using three 
animal models i.e. drug induced obesity, food induced obesity and genetically 
modified C57BL/6J female mice.  
The neuroactive steroid, progesterone is a female reproductive hormone. Its 
level increases during the later phase of the menstrual cycle and controls the secretory 
phase of the endometrium. Substantial evidence links progesterone excess in 
pathophysiology of eating and affective disorders. Some reports suggest the use of 
progesterone containing preparations as contraceptive or for the hormone replacement 
therapy to cause sufficient weight gain by causing hyperphagia and increased fat 
deposition in the body (Amatayakul, Sivasomboon & Thanangkul, 1980; Wallace, 
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Shively & Clarkson, 1999). Reports also suggest that progesterone can produce these 
effects by inducing myriad of neurotransmitter changes of which alterations of 
serotonin level can be important. With this setting we have chosen this neuroactive to 
induce obesity in female mice.  
It is well known that high fat intake and sedentary life style, white collar jobs, 
lack of exercise etc.  causes fat acclamation an increase in body weight. Cafeteria 
diets animal models of obesity have been reported to bear close resemblance to 
human obesity (Sclafani & Springer, 1976). Cafeteria diet is the combination of 
different composition like supermarket highly palatable food. Cafeteria diets have 
been previously reported to increase energy intake and cause obesity in humans as 
well as animals (Bull 1988; Rothwell, Stock & Warwick, 1983).  
In general, C57BL/6J (ob/ob) models have been used for investigation of 
human obesity and metabolic syndrome (Feldstein, et. al., 2003). When raised on a 
low-fat diet, the C57BL/6J (ob/ob) mice are lean and euglycemic with normal insulin 
levels and blood pressure. However, when raised on a high-fat (HF) diet, animals 
develop central adiposity, hyperinsulinemia, hyperglycemia and hypertension (Surwit, 
Kuhn, Cochrane, McCubbin & Feinglos, 1988). These syndromes appear to be related 
to abnormalities in adrenergic control of adipocyte function, which, in turn, appear to 
be related to hyperinsulinemia (Surwit, Kuhn, Cochrane, McCubbin, & Feinglos, 
1988). Also, the development of insulin resistance, hyperglycemia and obesity in the 
C57BL/6J (ob/ob) mice closely parallel the progression of common forms of the 
human diseases (Crevel, Friend, Goodwin & Parish, 1992). 
This study also involves state of the art animal model to elucidate its probable 
mechanism of industrial guidelines of FDA, USA for pre-clinical evaluation of anti-
obesity and anti diabetic activity (Rockville, 1994). 
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2.0: REVIEW OF LITERATURE 
2.1- Disease profile: 
2.1-a:  Introduction:  
Definition:  
Obesity is a chronic disease that causes risks ill health, impaired quality of life, and 
premature mortality. Obesity results from a complex interaction of genetic 
predisposition, environmental, societal and individual psychological factors that all 
summate to produce a chronic positive energy balance (Finer, 2002). 
Obesity results from a positive energy balance i.e., when caloric intake chronically 
exceeds energy expenditure. This in turn causes excess of adipose tissue mass with 
body mass index (BMI) > 30 kg/m2 ) (Caterson, 1999).  
The classification of body weight according to WHO is as follows: 
 
BMI < 18.5 Underweight 
BMI 18.5 - 24.9 BMI 18.5 - 24.9 
BMI 25 - 29.9 Overweight 
BMI 30 - 39.9 Obese 
BMI 40 or higher Severely obese 
 
Although there is a correlation between obesity and cardiac disease, BMI is not a 
precise predictor of cardiovascular disease; absolute waist circumference or waist to 
hip ratio are more precise measures of central obesity and correlate better to health 
risks than BMI (Janssen, Katzmarzyk & Ross, 2004).  
According to the American Cancer Society, obesity cost an estimated $75 
billion in 2003 because of the long and expensive treatment for several of its 
complications. According to the National Institute of Health, $75-$125 billion is spent 
on indirect and direct costs due to obesity-related diseases. 
Eric Schlosser in his book "Fast Food Nation" states that the annual health care costs 
in the United States stemming from obesity approaches $240 billion.  
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2.1-b:  OBESITY AND INSULIN RESISTANCE DIABETES  
The medical problems caused by obesity begin at the head and end at the toes and 
involve almost every organ in between. Several of these problems contribute to the 
earlier mortality associated with obesity include adult-onset (type 2) diabetes mellitus, 
coronary artery disease, severe hypertension that may be refractory to medical 
management, impaired cardiac function, obesity hypoventilation and sleep apnea 
syndromes, cirrhosis, venous stasis and hypercoagulability with an increased risk of 
pulmonary embolism, and necrotizing panniculitis (Dibaise, et. al., 2008).  
One of the most common physical consequences of obesity is the development 
of insulin resistance. Insulin resistance is an irreversible and progressive condition; 
once the body's cells do not respond to insulin, the glucose levels must be controlled 
through human intervention and monitoring. In obese persons, insulin resistance is 
another stressor on the body that heightens the considerable risk of early mortality. 
Insulin resistance has other serious consequences, as it will often lead to the 
progressive illness known as the metabolic syndrome, which is the combination of a 
series of distinct physical conditions. Each component of the metabolic syndrome is 
potentially dangerous to human health when present alone: type 2 diabetes mellitus, 
hypertension, hyperlipidimedia (the production of excessive levels of low density 
lipoproteins, a harmful cholesterol that causes plaque to form inside the blood vessels, 
which causes a narrowing and the potential for restricted blood flow), cardiovascular 
disease, renal failure, risk of various infections, particularly when the skin is cut or a 
sore develops. 
2.1-c:  EPIDEMIOLOGY:   
Globally, more than 1.1 billion adults worldwide are overweight,  and 312 million of 
them are obese. In addition, at least 155 million children worldwide are overweight or 
obese, according to the International Obesity Task Force. This task force and  the 
World Health Organization (WHO) have revised the definition of obesity to adjust for 
ethnic differences, and this broader definition may reflect an even higher prevalence 
— with 1.7 billion people classified as overweight worldwide (Haslam & James, 
2005). 
Chapter 2                                                                  REVIEW OF LITERATURE  
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 7 
 
About 18 million people die every year from cardiovascular disease, for which 
diabetes and hypertension are major predisposing factors. Propelling the upsurge in 
cases of diabetes and hypertension is the growing prevalence of overweight and 
obesity (Haslam & James, 2005).  
Data from the National Health and Nutrition Examination Surveys (NHANES) show 
that the percent of the American adult population with obesity (BMI > 30) has 
increased from 14.5% (between 1976 and 1980) to 30.5% (between 1999 and 2000). 
As many as 64% of U.S. adults ≥ 20 years of age were overweight (defined as BMI > 
25) between the years of 1999 and 2000. Extreme obesity (BMI ≥ 40) has also 
increased and affects 4.7% of the population. The increasing prevalence of medically 
significant obesity raises great concern. Obesity is more common among women and 
in the poor; the prevalence in children is also rising at a worrisome rate (Kasper, et. 
al., 2005). 
In the past 20 years, the rates of obesity have tripled in developing countries that have 
been adopting a Western lifestyle involving decreased physical activity and 
overconsumption of cheap, energy-dense food. Such lifestyle changes are also 
affecting children in these countries; the prevalence of overweight among them ranges 
from 10 to 25% and the prevalence of obesity ranges from 2 to 10%. The Middle East, 
Pacific Islands, Southeast Asia and China face the greatest threat.  In India currently, 
almost 1 in 5 men and over 1 in 6 women are overweight. In some urban areas, the 
rates are as high as 40%. Published in the Lancet the Organization for Economic Co-
operation and Development (OECD), the study warns that low-income countries 
cannot cope with the health consequences of wide scale obesity (Kounteya, 2010). 
The growing prevalence of type 2 diabetes, cardiovascular disease, and some cancers 
is tied to excess weight. The burden of these diseases is particularly high in the 
middle-income countries of Eastern Europe, Latin America, and Asia, where obesity 
is the fifth-most-common cause of the disease burden — ranking just below 
underweight. The high risk of both diabetes and cardiovascular disease associated 
with obesity in Asians may be due to a predisposition to abdominal obesity, which can 
lead to the metabolic syndrome and impaired glucose tolerance.  
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The serious cardiovascular complications of obesity and diabetes could overwhelm 
developing countries that are already straining under the burden of communicable 
diseases. The increase in the prevalence of type 2 diabetes is closely linked to the 
upsurge in obesity. About 90% of type 2 diabetes is attributable to excess weight. 
Furthermore, approximately 197 million people worldwide have impaired glucose 
tolerance, most commonly because of obesity and the associated metabolic syndrome. 
This number is expected to increase to 420 million by 2025. Cardiovascular  disease is 
considerably greater among obese people, and this group has an incidence of 
hypertension that is five times the incidence among people of normal weight. Hence, 
overweight and obesity are contributing to a global increase in hypertension: 1 billion 
people had hypertension in 2000 and 1.56 billion people are expected to have this 
condition by 2025 (Kearney, Whelton, Reynolds, Muntner & Whelton, 2005). 
Obesity, diabetes, and hypertension also affect the kidneys. Diabetic nephropathy 
develops in about one third of patients with diabetes and its incidence is sharply 
increasing in the developing world, with the Asia–Pacific region being the most 
severely affected. According to a survey published in 2003 , diabetic nephropathy was 
the most common cause of end-stage renal disease in 9 of 10 Asian countries, with an 
incidence that had increased from 1.2% of the overall population with end-stage renal 
disease in 1998 to 14.1% in 2000 (Lee, 2003; Parvez, Bisher, Meguid, & Nahas, 
2007).  
2.1-d:  ETIOLOGY OF OBESITY  
The exact etiology of obesity is unclear. The multiple causative factors like genetic, 
environmental, nutritional, physiological, psychological, social and cultural factors 
have been linked to its development and progression (Rippe, Crossley & Ringer, 
1998).  
Though the molecular pathways regulating energy balance are beginning to be 
illuminated, the causes of obesity remain elusive. In part, this reflects the fact that 
obesity is a heterogeneous group of disorders. At one level, the pathophysiology of 
obesity seems simple: a chronic excess of nutrient intake relative to the level of 
energy expenditure. However, due to the complexity of the neuroendocrine and 
metabolic systems that regulate energy intake, storage, and expenditure, it has been 
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difficult to quantitate all the relevant parameters (e.g., food intake and energy 
expenditure). 
Environmental factors 
The current environmental risk factors include over consumption of energy (increase 
in fat to carbohydrate ratio) and decrease in physical activity. These factors offer more 
reasonable explanation for the recent dramatic surge in the prevalence of obesity 
(Poppitt, 1995).  
Nutritional factors 
Numerous metabolic studies have shown that high fat diets may lead to a high energy 
intake and hyperphagia. The reason may be that fat has a weaker effect on the satiety 
centre and on heat production (diet-induced thermogenesis) and it possesses a higher 
energy density compared to carbohydrates. Also fats are highly palatable and heighten 
the flavour of food stuffs which leads to their passive overconsumption. This 
ultimately increases fat deposits and causes obesity and related problems (Zhang, et. 
al., 1994). 
Physiological factors  
These involve the impairment of the central mechanism regulating appetite and food 
intake which is thought to be regulated by a complex interplay of neurotransmitters in 
the hypothalamic region of the brain. Approximately 1 - 2% of obesity can be 
ascribed to lesions in hypothalamic regulatory centres. Such lesions may be due to 
trauma, tumours, inflammatory processes, or carotid artery aneurysms (Bray & York, 
1979).  
Psychological factors 
The psychogenic theory of obesity long held that obesity resulted from an emotional 
disorder in which food intake, relieved the anxiety and depression to which obese 
persons are usually susceptible. Stress associated with traumatic emotional events has 
been held responsible for certain cases of obesity and has been implicated in the 
pathogenesis of eating disorders such as night-eating syndrome and bulimia (Kissebah 
et. al., 1982). 
Role of Genes versus Environment   
Obesity is commonly seen in families, and the heredibility of body weight is 
similar to that for height. Inheritance is usually not Mendelian, however, and it is 
difficult to distinguish the role of genes and environmental factors. Adoptees usually 
resemble their biologic rather than adoptive parents with respect to obesity, providing 
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strong support for genetic influences. Likewise, identical twins have very similar 
BMIs (Body Mass Index) whether reared together or apart, and their BMIs are much 
more strongly correlated than those of dizygotic twins. These genetic effects appear to 
relate to both energy intake and expenditure. 
Whatever the role of genes, it is clear that the environment plays a key role in 
obesity, as evidenced by the fact that famine prevents obesity in even the most 
obesity-prone individual. In addition, the recent increase in the prevalence of obesity 
in the United States is too rapid to be due to changes in the gene pool. Undoubtedly, 
genes influence the susceptibility to obesity when confronted with specific diets and 
availability of nutrition. Cultural factors are also important— these relate to both  
vailability and composition of the diet and to changes in the level of physical activity. 
In industrial societies, obesity is more common among poor women, whereas in 
underdeveloped countries, wealthier women are more often obese. In children, obesity 
correlates to some degree with time spent watching television. High fat diets may 
promote obesity, as may diets rich in simple (as opposed to complex) carbohydrates 
(Kasper et. al., 2005). 
Specific Genetic Syndromes  
For many years obesity in rodents has been known to be caused by a number of 
distinct mutations distributed through the genome. Most of these single-gene 
mutations cause both hyperphagia and diminished energy expenditure, suggesting a 
link between these two parameters of energy homeostasis. Identification of the ob 
gene mutation in genetically obese (ob/ob) mice represented a major breakthrough in 
the field. The ob/ob mouse develops severe obesity, insulin resistance, and 
hyperphagia, as well as efficient metabolism (e.g., it gets fat even when given the 
same number of calories as lean littermates). The product of the ob gene is the peptide 
leptin, a name derived from the Greek root leptos, meaning thin. Leptin is secreted by 
adipose cells and acts primarily through the hypothalamus. Its level of production 
provides an index of adipose energy stores (Fig 1). High leptin levels decrease food 
intake and increase energy expenditure. Another mouse mutant, db/db, which is 
resistant to leptin, has a mutation in the leptin receptor and develops a similar 
syndrome. The OB gene is present in humans and expressed in fat. Several families 
with morbid, early-onset obesity caused by inactivating mutations in either leptin or 
the leptin receptor have been described, thus demonstrating the biologic relevance of 
leptin in humans. The obesity in these individuals begins shortly after birth, is severe, 
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and is accompanied by neuroendocrine abnormalities. The most prominent of these is 
hypogonadotropic hypogonadism, which is reversed by leptin replacement. Central 
hypothyroidism and growth retardation are seen in the mouse model, but their 
occurrence in leptin-deficient humans is less clear. To date, there is no evidence to 
suggest that mutations or polymorphisms in the leptin or leptin receptor genes play a 
prominent role in common forms of obesity. Mutations in several other genes cause 
severe obesity in humans; each of these syndromes is rare. Mutations in the gene 
encoding proopiomelanocortin (POMC) cause severe obesity through failure to 
synthesize α-MSH, a key neuropeptide that inhibits appetite in the hypothalamus. The 
absence of POMC also causes secondary adrenal insufficiency due to absence of 
adrenocorticotropic hormone (ACTH), as well as pale skin and red hair due to 
absence of MSH. Proenzyme convertase 1 (PC-1) mutations are thought to cause 
obesity by preventing synthesis of α-MSH from its precursor peptide, POMC. α- 
MSH binds to the type 4 melanocortin receptor (MC4R), a key hypothalamic receptor 
that inhibits eating. Heterozygous mutations of this receptor appear to account for as 
much as 5% of severe obesity. These five genetic defects define a pathway through 
which leptin (by stimulating POMC and increasing MSH) restricts food intake and 
limits weight. 
In addition to these human obesity genes, studies in rodents reveal several 
other molecular candidates for hypothalamic mediators of human obesity or leanness. 
The tub gene encodes a hypothalamic peptide of unknown function; mutation of this 
gene causes late-onset obesity. The fat gene encodes carboxypeptidase E, a peptide-
processing enzyme; mutation of this gene is thought to cause obesity by disrupting  
production of one or more neuropeptides. AgRP is coexpressed with NPY in arcuate 
nucleus neurons. AgRP antagonizes α- MSH action at MC4 receptors, and its 
overexpression induces obesity. In contrast, a mouse deficient in the peptide MCH, 
whose administration causes feeding, is lean. A number of complex human 
syndromes with defined inheritance are associated with obesity. Although specific 
genes are undefined at present, their identification will likely enhance our 
understanding of more common forms of human obesity. In the Prader- Willi 
syndrome, obesity coexists with short stature, mental retardation, hypogonadotropic 
hypogonadism, hypotonia, small hands and feet, fish-shaped mouth, and hyperphagia. 
Most patients have a chromosome 15 deletion. Laurence-Moon-Biedl syndrome is 
Chapter 2                                                                  REVIEW OF LITERATURE  
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 12 
 
characterized by obesity, mental retardation, retinitis pigmentosa, polydactyly, and 
hypogonadotropic hypogonadism (Kasper, et. al., 2005). 
Other Specific Syndromes Associated with Obesity:  
Insulinoma Patients with insulinoma often gain weight as a result of overeating to 
avoid hypoglycemia symptoms. The increased substrate plus high insulin levels 
promote energy storage in fat. This can be marked in some individuals but is modest 
in most (Kasper, et. al., 2005). 
Cushing’s syndrome  
Although obese patients commonly have central obesity, hypertension, and glucose 
intolerance, they lack other specific stigmata of Cushing‘s syndrome. Nonetheless, a 
potential diagnosis of Cushing‘s syndrome is often entertained. Cortisol production 
and urinary metabolites (17OH steroids) may be increased in simple obesity. Unlike 
in Cushing‘s syndrome, however, cortisol levels in blood and urine in the basal state 
and in response to corticotropin-releasing hormone (CRH) or ACTH are normal; the 
overnight 1-mg dexamethasone suppressiontest is normal in 90%, with the remainder 
being normal on a standard 2-day low-dose dexamethasone suppression test. Obesity 
may be associated with local reactivation of cortisol in fat by 11 β hydroxysteroid 
dehydrogenase 1, an enzyme that converts cortisone to cortisol (Kasper et. al., 2005). 
Hypothyroidism  
The possibility of hypothyroidism should be considered, but it is an uncommon cause 
of obesity; hypothyroidism is easily ruled out by measuring thyroid-stimulating 
hormone (TSH). Much of the weight gain that occurs in hypothyroidism is due to 
myxedema (Kasper et. al., 2005). 
Craniopharyngioma and other disorders involving the hypothalamus  
Whether through tumors, trauma, or inflammation, hypothalamic dysfunction of 
systems controlling satiety, hunger, and energy expenditure can cause varying degrees 
of obesity. It is uncommon to identify a discrete anatomic basis for these disorders. 
Subtle hypothalamic dysfunction is probably a more common cause of obesity than 
can be documented using currently available imaging techniques. Growth hormone 
(GH), which exerts lipolytic activity, is diminished in obesity and is increased with 
weight loss. Despite low GH levels, insulin-like growth factor (IGF) I (somatomedin) 
production is normal, suggesting that GH suppression is a compensatory response to 
increased nutritional supply (Kasper et. al., 2005). 
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2.1-e:  TYPES OF OBESITY 
Central (android) (apple) versus Peripheral (gynoid) (pear) 
It has been noted that central (android, more prevalent in men) obesity is associated 
with a higher mortality than peripheral (gynoid, more prevalent in women) obesity. 
This discrepancy has been attributed to the fact that visceral adipose tissue is 
metabolically more active than subcutaneous fat, causing a greater rate of glucose 
production, type II diabetes mellitus, and hyperinsulinism. Increased insulin secretion 
is thought to increase sodium reabsorption and result in hypertension. Central obesity 
is also associated with increased production of cholesterol, primarily in the form of 
low-density lipoprotein, leading to increased incidence of atherosclerotic 
cardiovascular disease and gallstones. The increased visceral fat has been related to an 
increased waist: hip ratio or, in more common terms, as the ―apple‖ versus ―pear‖ 
distribution of fat (Figure 1). Computed tomography (CT) scans, however, have 
noted a much better correlation between anterior-posterior abdominal diameter and 
visceral fat distribution than the waist: hip ratio, especially in women with both 
central and peripheral obesity. In this situation the peripheral obesity ―dilutes‖ the 
central obesity as measured by the waist: hip ratio, so either waist circumference 
alone or sagittal abdominal diameter should be used as a measurement of central 
obesity. 
A recent study documented increased bladder pressure in morbidly obese 
women that was associated with a high incidence of urinary incontinence. It is quite 
probable that much of the comorbidity of severe obesity is related to increased intra-
abdominal pressure secondary to a central fat distribution and that urinary bladder 
pressure, a surrogate for intra-abdominal pressure, is highly correlated with sagittal 
abdominal diameter or waist circumference (Sugerman, 2005). 
With analysis of surface area and volume, analysis of subcutaneous fat and 
intra-abdominal visceral fat could be done and a novel classification of obesity was 
proposed - visceral fat obesity (VFO) and subcutaneous fat obesity (SFO) based on 
the ratio of visceral fat area and subcutaneous fat area (V/S ratio) at the level of 
umbilicus (Yamashita, et. al. 1996; Arner, 1998). 
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Apple Vs Pear Obesity 
 
Figure 1: Left figure indicating the apple shape obesity where the fat 
mainly deposited above the waist where as right figure indicating pear 
shaped obesity where fat is mainly deposited below the waist.  
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2.1-f:  PHYSIOLOGIC REGULATION OF ENERGY BALANCE 
Energy intake and energy expenditure play a pivotal role in controlling body 
fat stores (Arner, 1998). The energy intake depends on appetite which is mainly 
controlled by glucostatic and lipostatic feedback systems. The energy expenditure 
depends on heat production (diet induced thermogenesis, DIT, 10 - 12%), metabolism 
(basal metabolic rate, BMR 65%) and physical exercise (variable). Any imbalance 
between these two is translated into a change in fat stores and obesity (Bray, 1992). 
A large number of hypothalamic neurotransmitters have also been implicated in the 
control of energy balance as mentioned in the following table. Those that increase 
food intake generally suppress sympathetic nervous system activity and thus 
thermogenesis, whereas the reverse is true for neurotransmitters that decreases the 
appetite (Amatruda, Livingstone, & Lockwood, 1985).  
Neurotransmitters affecting energy balance (Amatruda, Livingstone, & Lockwood, 
1985). 
Factors increasing food intake Factors inhibiting food intake 
Noradrenaline  
GABA  
Growth hormone releasing hormone 
Galanin  
Melanin-concentrating hormone 
Neuropeptide - Y  
Opioids  
Orexin 
 
Serotonin 
Dopamine 
Cholecystokinin 
Corticotrophin-releasing factor 
Neurotensin 
Bombesin 
Calcitonin gene-related peptide 
Amylin 
Adrenomedullin 
Glucagon 
Glucagon - like peptide - 1 
α -Melanocyte stimulating hormone 
Anorectin 
CART (Cocaine and amphetamine-regulated 
transcript) 
Thyrotropin-releasing factor 
Cyclo - histidyl praline diketopiperazine 
Pituitary adenylate cyclase activating polypeptide 
Acidic fibroblast growth factor 
Oxytocin 
Interleukin- 1 
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 Substantial evidence suggests that body weight is regulated by both endocrine 
and neural components that ultimately influence the effector arms of energy 
intake and expenditure. This complex regulatory system is necessary because 
even small imbalances between energy intake and expenditure will ultimately 
have large effects on body weight.  
 Apparently, this fine balance is maintained by an internal set point, or 
"lipostat," that can sense the quantity of the energy stores (adipose tissue) and 
appropriately regulate the food intake as well as the energy expenditure. 
 In recent years, several "obesity genes" have been identified. As might be 
expected, they encode the molecular components of the physiologic system 
that regulates energy balance. A key player in energy homeostasis is the Ob 
gene and its product, leptin.  
 Leptin is a unique member of the cytokine family, secreted by adipocytes, 
regulates both sides of the energy equation-intake of food and expenditure of 
energy (Figure 2).  
 Leptin exerts its actions through a complex cascade of signaling pathways 
referred to as the leptin-regulated central melanocortin circuit (Figure 3).  
 Leptin actions are initiated by binding to specific receptors on two classes of 
neurons in the hypothalamus:  
1) One class of leptin-sensitive neurons produces the feeding-inducing 
(orexigenic) neuropeptides, neuropeptide Y (NPY) and agouti-related 
protein (AgRP).  
2) The other class of leptin receptor-bearing neurons produces 
anorexigenic      peptides, α-melanocyte-stimulating hormone (α-MSH) 
and cocaine- and       amphetamine-related transcript (CART). These 
two molecules reduce food     
      intake.  
 The actions of the orexigenic and anorexigenic neuropeptides are exerted by 
binding to another set of receptors, the two most important being the NPY 
(Neuro peptide Y) receptor and the melanocortin 4 receptor (MC4R), to which 
latter receptor α-MSH and AgRP bind. The pathways down-stream of these 
receptors have not been fully characterized.  
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 By mechanisms not clearly understood, the output of leptin is regulated by the 
adequacy of fat stores. With abundant adipose tissue, leptin secretion is 
stimulated and the hormone travels to the hypothalamus, where it binds to 
leptin receptors.  
 This interaction reduces food intake by stimulating the production of α-MSH 
and CART (anorexigenic) and inhibiting the synthesis of NPY and AgRP 
(orexigenic). The opposite sequence of events occurs when there are 
inadequate stores of body fat-leptin secretion is diminished and food intake is 
increased. In individuals with stable weight, the activities of these pathways 
are balanced.  
 As indicated earlier, leptin regulates not only energy intake (appetite) but also 
energy expenditure, through a distinct set of pathways. Thus, abundance of 
leptin increases physical activity, production of heat, and energy expenditure. 
The neurohumoral mediators of leptin-induced energy expenditure are less 
well defined. Thermogenesis seems to be controlled in part by leptin receptor-
mediated hypothalamic signals that increase the release of norepinephrine 
from sympathetic nerve endings in adipose tissue.  
 The fat cells express β3-adrenergic receptors that when stimulated by 
norepinephrine cause fatty acid hydrolysis and also uncouple energy 
production from storage. Thus, the fats are literally burned and the energy so 
produced is dissipated as heat.  
 In many obese individuals, blood leptin levels are high, suggesting that leptin 
resistance rather than leptin deficiency may be more prevalent in humans 
(Kumar, Cotran,  & Robbins, 2004).  
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Figure 2:  A simplified schema of the circuitry leptin that regulates energy balance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The neurohumoral circuits in the hypothalamus that regulate energy balance.  
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2.1-g:  COMPLICATIONS OF OBESITY: The medical problems caused by 
obesity begin at the head and end at the toes and involve almost every organ in 
between. 
Obesity Comorbidity: “from the top of the head to the tip of the toes and almost every 
organ in-between”. (Sugerman, 2005) 
Head 
Brain 
Depression 
Stroke 
Headaches 
Hypertension 
Pseudotumor cerebri: 
Headaches 
I. Optic nerve: 
Visual field cuts 
Blindness 
III. Oculomotor nerve palsy 
V. Trigeminal nerve: tic 
doloreaux 
VII. Facial nerve: Bell‘s palsy 
VIII. Auditory nerve: pulsatile 
tinnitus 
Eyes: diabetic retinopathy _ 
pseudotumor complications 
Mouth/throat 
Sleep apnea 
Chest 
Breast cancer 
Obesity hypoventilation 
Heavy chest wall 
Elevated diaphragm 
Increased Intrathoracic pressure 
Decreased expiratory reserve 
volume 
Heart 
Left ventricular hypertrophy 
Eccentric: increased cardiac 
output 
Concentric: increased peripheral 
vascular resistance 
Increased cardiac filling 
pressures (CVP, PAP, WP) 
Right heart failure 
Tricuspid insufficiency 
Esophagus 
Acid reflux 
Asthma 
Adenocarcinoma 
Esophageal varices 
 
 
Abdomen 
Gallbladder 
Cholecystitis 
Adenocarcinoma 
Liver 
Nonalcholic liver disease 
(NALD) 
Nonalcoholic steatohepatitis 
(NASH) 
Cirrhosis 
Type 2 diabetes mellitus 
Spleen 
Splenomegaly (portal 
hypertension) 
Hypersplenism (portal 
hypertension) 
Pancreas 
Type 2 diabetes mellitus 
Necrotizing pancreatitis 
Colon 
Adenocarcinoma 
Diverticulitis 
General 
Difficulty diagnosing peritonitis 
Hernia 
Incsional 
Inguinal 
Spighelian 
Wound infection 
―Apron‖ 
Peau d‘orange lymphatic stasis 
Kidney 
Hypertension 
Proteinuria 
Renal cell carcinoma 
Urinary bladder 
Stress incontinence 
Ovaries/uterus 
Increased estradiol, 
androstenedione 
Polycystic ovary syndrome, 
Stein–Leventhal syndrome 
Infertility 
Dysmenorrhea 
Hirsutism 
Endometrial carcinoma 
Breast cancer 
Pregnancy complications 
 
Maternal, fetal mortality 
Pre-eclampsia, eclampsia 
Gestational diabetes 
Thromboembolism 
Complicated childbirth: 
cephalopelvic disproportion, 
increased cesarean section 
Fetal complications: 
macrosomia, shoulder dystocia, 
small for 
gestational age 
 
Prostate: adenocarcinoma 
Anus 
Periananal abscess 
Necrotzing panniculitis 
Integument 
Necrotizing panniculitis 
Hirsutism 
Increased risk of operative 
complications 
Cardiac 
Colectomy 
Hysterectomy 
Kidney, liver transplantation 
Spine 
Herniated disc 
Upper Extremties 
Shoulder girdle pain 
Edema 
Lower extremities 
Osteoarthritis 
Hip arthralgia 
Knee arthralgia 
Venous stasis 
Edema 
Thrombophlebitis 
Stasis ulcers 
Pulmonary embolism 
Lymphedema 
Toes 
Diabetic neuropathy 
Diabetic ulcers 
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2.1-h:  OBESITY, METABOLIC SYNDROME AND INSULIN RESISTANCE:  
One of the obesity-associated health risks is development of metabolic syndrome. 
According to the WHO metabolic syndrome is characterized by the presence of 
central obesity, dyslipidemia (elevated triglycerides and decreased HDL cholesterol), 
impaired glucose tolerance or insulin resistance, type 2 diabetes and high blood 
pressure. In order to be diagnosed with metabolic syndrome an individual must be 
obese (BMI > 30 kg/m2) plus at least 2 additional risk factors, e.g. dyslipidemia and 
hypertension or dyslipidemia and impaired fasting glucose (Sierra-Johnson et. al., 
2006). 
More than 40 years ago Randle proposed that fatty acid (FA) compete with glucose as 
an energy substrate in rat heart and diaphragm muscle, and speculated that increased 
fatty acid oxidation was responsible for the obesity-induced insulin resistance 
(Randle, Garland, Hales & Newsholme, 1963; Randle, Garland, Newsholme & Hales, 
1965). The proposed mechanism was that an increased FA uptake ultimately resulted 
in an increase in the intramitochondrial acetyl CoA/CoA and NADH/NAD+ ratios 
with subsequent inactivation of the pyruvate dehydrogenase. The high uptake of FA 
will lead to an increase in the intracellular concentration of citrate, leading to 
inhibition of phosphofruktokinase (Figure 4) (a rate limiting enzyme of glycolysis) 
and as a consequence, glucose 6 phosphate will accumulate and inhibit glucose 
uptake. Roden also indicated an inhibitory effect of fatty acids on glucose transport 
and phosphorylation (Roden, et. al., 1996). More recently, it has been shown that an 
increase in the intracellular concentration of FA metabolites (diacylglycerol, fatty acyl 
CoA) leads to activation of protein kinase C (PKC), c-Jun N-terminal kinase (JNK) 
and inhibitory kappa B kinase (IKK), which ultimately block the insulin signaling 
pathway through functional inhibition of insulin receptor substrate -1 (IRS-1) 
(Blaschke, Takata, Caglayan, Law & Hsueh, 2006 ; Itani, Ruderman, Schmieder, & 
Boden, 2002). Last, but not least, release of endocrine factors from adipose tissue, 
alone or in combination with other factors like tumor necrosis factor alpha (TNFα), 
can lead to insulin resistance (Pittas, Joseph, & Greenberg, 2004).  
Inhibition of glucose oxidation by increased FA supply. The uptake and 
oxidation of FA lead to citrate accumulation and inhibition of glucose utilization via 
inhibition of PFK. In addition FA inhibits glucose utilization via PDK-mediated 
inhibition of PDH via the PPARα pathway, as well as via inhibition of insulin 
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signaling. PDH, pyruvate dehydrogenase; PFK, phosphofructokinase; IRS, Insulin 
receptor substrate; PKB, Protein kinase B; FA, Fatty acid; PPARα, Peroxisome 
proliferator-activated receptor alpha.    
 
 
Figure 4: Inhibition of glucose oxidation by increased FA supply. The uptake and oxidation of FA lead 
to citrate accumulation and inhibition of glucose utilization via inhibition of PFK. In addition FA 
inhibits glucose utilization via PDK-mediated inhibition of PDH via the PPARα pathway, as well as via 
inhibition of insulin signaling. PDH, pyruvate dehydrogenase; PFK, phosphofructokinase; IRS, Insulin 
receptor substrate; PKB, Protein kinase B; FA, Fatty acid; PPARα, Peroxisome proliferators-activated 
receptor alpha. 
 
Diabetes and cardiac disease 
Diabetes mellitus is classified into type 1 and type 2 diabetes. Hereditary factors, diet 
and lifestyle, obesity and fat distribution, gestational predisposition and age are the 
main etiological factors of type 2 diabetes (Romao & Roth, 2008). Type1 diabetes is 
most often of genetic origin, although a combination of genetic predisposition with 
viral infection and autoimmune disorders cannot be ruled out. The increased 
prevalance of type 2 diabetes worldwide is associated with significant increase in 
cardiovascular morbidity and mortality. Diabetes is presently estimated to affect more 
than 150 million patients worldwide, and this number is expected to double by 2025 
(King, Aubert & Herman, 1998; Wild, Roglic, Green, Sicree & King, 2004). Type 2 
diabetic patients are more prone to develop angina and acute myocardial infarction, 
and the mortality rate is much higher among diabetics compared to non-diabetics 
suffering from acute myocardial infarction (Haffner, Lehto, Ronnemaa, Pyorala & 
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Laakso, 1998). The estimated four year survival rate is approximately 50% (Donnan, 
et. al., 2002). There are two pathophysiological processes leading to type 2 diabetes-
related cardiac complications: ischemic heart disease as a result of accelerated 
atherosclerosis and a specific diabetic cardiomyopathy, characterized initially as 
diastolic dysfunction which progresses to symptomatic heart failure (Fein, 1990). 
Although the pathogenesis of diabetic cardiomyopathy is multi-factorial and complex 
(figure 5), metabolic disturbances related to hyper-lipidemia, hyper-glycemia and 
insulin resistance, as well as myocardial fibrosis, oxidative stress, and pro-
inflammatory cytokines are proposed to be contributing factors (Fang, Prins, & 
Marwick, 2004).   
 
 
Figure 5: Potential mechanisms for the development of diabetic cardiomyopathy; ROS, reactive 
oxygen species; TNFα, tumor necrosis factor alpha; IN-6, interlukin-6; AGE, advanced glycation end 
products.  
 
 
Myocardial substrate utilization 
The cardiac muscle needs a continuous supply of fuel in order to keep pumping. The 
daily ATP requirement of the heart is between 3.5 and 5 kg ATP (Opie, 2004). The 
heart demonstrates a great deal of flexibility with respect to its substrate selection, 
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relying mainly on carbohydrates in the fed state, while lipids are the main source of 
energy during fasting, as suggested by Bing in the early 1950s (Bing, 1995). Long 
chain FA and glucose are the predominant sources of energy for the myocardium 
during normal resting conditions, but lactate 6 can also contribute to energy 
production, especially during periods of increased workload (Neely, Rovetto & Oram, 
1972; Drake, Haines & Noble, 1980).  
Fatty acids. Oxidation of FA (unesterified, albumin-bound FA from adipose tissue or 
FA produced by lipoprotein lipase-mediated hydrolysis of triglyceride-rich 
lipoproteins) accounts for 60-70% of cardiac energy production. Fatty acid uptake in 
cardiac myocytes is mediated by FA transport proteins (FATP), FA translocase 
(FAT/CD36) and FA binding protein (FABP) (Luiken, 2004). In the cytosol FA is 
activated by acyl-CoA synthase (ACS) to form acyl-CoA, which can either be 
transported into the mitochondria for β-oxidation or undergo esterification to form 
intracellular TG (Lewin & Coleman, 2003). Before entering into the mitochondria 
acyl CoA is converted by carnitine palmitoyl transferase1 (CPT-I) to acyl carnitine 
(Mynatt, Lappi, & Cook, 1992) which in turn is reconverted to fatty acyl-CoA by 
CPT-II. Malonyl-CoA (produced by acetyl-CoA carboxylase) inhibits the activity of 
CPT1 and is considered a major inhibitor of FA oxidation (McGarry, & Mills, 1983). 
On the other hand, degradation of malonyl-CoA by malonyl CoA decarboxylase 
results in increased mitochondrial FA uptake. Once taken up by the mitochondria long 
chain fatty acyl CoA undergoes β-oxidation to yield acetyl CoA    (figure 6) which is 
further oxidized in the krebs cycle to CO2, resulting in generation of NADH and 
FADH2 which ultimately provide reducing equivalents to the electron transport chain 
in oxidative phosphorylation (Mitchell  & Moyle, 1967).  
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Figure 6: Fatty acid and glucose uptake and metabolism. Intracellular FA uptake is mediated by passive diffusion 
or via transporters (CD36, FABP). Mitochondrial  FA uptake is mediated by CPT-I and CPT-II, followed by entry 
into the β-oxidation, yielding acetyl-Co-A and reducing equivalents which are channeled through the electron 
transport chain. Glucose is taken up by the transporters GLUT1/4, undergoes glycolysis to yield pyruvate, which 
thereafter is converted to acetyl Co-A, by PDH and further processed in the TCA cycle. FABP, fatty acid binding 
protein; CPT-I- carnitine palmitoyl transferase 1; CPT-II, carnitine palmitoyl transferase-II; GLUT1, glucose 
transporter 1; GLUT4, (insulin-regulated) glucose transporter 4; PDH, pyruvate dehydrogenase; TCA, 
tricarboxylic acid cycle.  
 
Glucose. Glucose transport into cardiomyocytes is facilitated by GLUT1 and GLUT4 
members of glucose transporter (GLUT) family (Mueckler, 1994). Myocardial glucose 
transport in basal conditions is mainly regulated by GLUT1 because of its more 
pronounced localization in the sarcolemma. GLUT4 is predominantly stored 
intracellularly, and its sarcolemmal translocation is mainly regulated by insulin-
mediated phospho-inositol-3-kinase (PI3-K) pathway (Luiken, et. al., 2004). However 
contraction induced myocardial glucose uptake is regulated by AMP-dependent kinase 
(AMPK)-mediated translocation of GLUT4. Inside the cell, glucose combines with a 
phosphate radical (glucose trapping) in the presence of hexokinase to form glucose 6-
phosphate. Thereafter activated glucose 6-phosphate can enter into three different 
pathways: a catabolic pathway (glycolysis), glycogenesis or the pentose phosphate 
pathway. Pyruvate being the end product of glycolysis can be converted into acetyl 
CoA which enters into TCA cycle in the mitochondria. This key metabolic step is 
controlled by the pyruvate dehydrogenase (PDH) complex, which in turn is inhibited 
by pyruvate dehydrogenase kinase 4 (PDK4).  
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2.1-i:  ADIPOSE TISSUE: 
More than 90% of body energy is stored as triglyceride in adipose tissue. Protein and 
glycogen provide important but smaller quantities of energy. Adipose tissue has two 
principal functions: the synthesis and storage of fatty acids in triacylglycerols and the 
release of fatty acids as a source of metabolic fuel. Triglyceride is stored in fat cells 
that differ in size between one region of the body and another. There may be 
important regional differences in the total number of fat cells and this number appears 
to vary in different types of obesity (Bjorntorp & Ostman, 1971). The storage of fat in 
the first months of life occurs primarily by an increase in the size of already existing 
fat cells. By the end of the first year, fat cell size has nearly doubled, with little 
change in the total number, both in children who become obese and in those who do 
not. In children who are lean, the size of the fat cells decreases after the first year of 
life (Knittle et. al., 1979). Obese children, on the other hand, retain throughout 
childhood the large fat cells that developed during the first year of life. Fat cells 
multiply in number throughout the growing years in a process that usually stops in 
adolescence. The number of fat cells in obese children increases more rapidly than 
that in lean children, reaching adult levels by 10 to 12 years of age. Current evidence 
suggests that, after puberty, acute changes in body fat stores occur primarily by an 
increase in the size of adipocytes that already exist, with little or no change in the total 
number. Severe weight loss is likewise accomplished primarily by a reduction in the 
size of extant fat cells. Recent evidence suggests, however, that the number of fat 
cells may change in adult life. A steady increase in body fat, on the one hand, may 
lead to an increase in the number of fat cells; conversely, a prolonged reduction in 
body fat may possibly lead to a decrease in the number of fat cells (Sjostrom, & 
William-Olsson, 1981).   
Knowing the size, number and distribution of fat cells may be useful in classifying 
obesity and in estimating the prognosis with different forms of therapy (Krotkiewski, 
Sjostrom & Bjorntorp, 1977). Substantially overweight persons almost always have 
hypercellular fat organs, whereas those with modest degrees of overweight may be 
hypercellular but are much more likely to have only an increase in fat cell size or 
hypertrophic obesity. The duration of weight loss that follows successful dietary 
treatment is shorter and the rate at which weight is regained is more rapid in persons 
with hypercellular obesity compared with those with hypertrophic obesity 
(Krotkiewski, Sjostrom & Bjorntorp, 1977).  
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2.1-j:  PREVALENCE OF OBESITY 
A number of factors influence body fat, including age, sex, race, and physical activity. 
At birth the human body contains about 12% fat, a content that is higher than in any 
other mammal except the whale. During the newborn period, the body fat content 
rises rapidly to reach a peak of about 25% at 6 months of age and then declines to    
15 % to 18% in the prepubertal years. At puberty there is a notable increase in the 
percentage of fat in girls and a notable decrease in boys. By age 18 boys have about 
15% to 18% body fat and girls, 20% to 25 %. The amount of body fat increases in 
both sexes after puberty and during adult life rises to between 30% and 40% of body 
weight. Between ages 20 and 50, the fat content in men approximately doubles and 
that in women increases by about 50%. Total body weight, however, rises by only 
10% to 15 %. The increased fat is accounted for in part by an increase in body weight 
and in part by a reduction in lean body mass (Bray, 1976). The composition of the 
body is also influenced by the level of physical activity (Wilmore, 1983).  During 
physical training, body fat usually decreases and lean tissue increases. After training 
ends, however, this process is reversed. These shifts between body fat and lean tissue 
can occur without any changes in body weight, but if regular activity is maintained 
throughout adult life, the increase in body fat that usually occurs even when body 
weight is stable may be prevented. Racial differences in body weight (Figure 7) may 
exist, but it is often difficult to separate racial from environmental factors.  
Socioeconomic conditions, however, clearly play an important role in the 
development of obesity. Excess body weight is 7 to 12 times more frequent in women 
from lower social classes than in women from the upper social classes (Goldblatt, 
Moore & Stunkard, 1965). Among men, social class has a much smaller relationship 
to being overweight. The patterns of body weight in men and women are changing. 
Data obtained at the time of evaluation for military service show that men inducted 
into the army in the 1950s were heavier than men of the same height drafted in 1943. 
The 1943 inductees were in turn heavier than those inducted in 1918. The 
Framingham study shows similar changes for men but suggests that women may not 
be getting fatter (Bray, 1976). The composition of the body is also influenced by the 
level of physical activity (Wilmore, 1983). During physical training, body fat usually 
decreases and lean tissue increases. After training ends, however, this process is 
reversed. These shifts between body fat and lean tissue can occur without any changes 
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in body weight, but if regular activity is maintained throughout adult life, the increase 
in body fat that usually occurs even when body weight is stable may be prevented. 
Racial differences in body weight (figure 7) may exist, but it is often difficult to 
separate racial from environmental factors. Socioeconomic conditions, however, 
clearly play an important role in the development of obesity. Excess body weight is 7 
to 12 times more frequent in women from lower social classes than in women from 
the upper social classes (Goldblatt, Moore & Stunkard, 1965). Among men, social 
class has a much smaller relationship to being overweight. 
 
 
 
 
 
 
 
 
 
 
Figure 7: Data from National Center for Health Statistics shows the percentage of overweight man (A) 
and women (B) by age and race using the 85 percentage of weights for height of 20- to 24-years-olds as 
the upper limits for weight. The crosshatched bars show percentage for whites, the solid bars those fir 
blacks.  
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2.1-k:  BODY FAT DISTRIBUTION AND HEALTH RISKS 
One of the most important developments in understanding the health risks associated 
with obesity has been realizing the important role of body fat distribution. There are 
two types of fat distribution: the abdominal, android, upper body, or male type; and 
the gynoid, lower body, or female type. The former has a higher ratio of abdominal to 
gluteal circumference (android to gynoid ratio or waistto- hip ratio). As early as the 
1950s, Vague suggested (Vague J, 1956) that a preponderance of abdominal fat 
increases the risk for diabetes and cardiovascular disease. Five prospective studies 
have examined the relation of fat distribution to morbidity and mortality (Lapidus, 
et.al., 1984; Larsson, Svardsudd, & Welin, 1984; Stokes, Garrison, & Kannel, 1985; 
Ducimetiere, Richards, & Cambien, 1986; Donahue et. al., 1987). Whether the ratio 
of abdominal to gluteal circumference, the subscapular skin fold, or a combination of 
skin folds was used as the indicator of abdominal fat, all five studies found a clear-cut 
and significant increase in the risk of death or an increased risk of diabetes mellitus, 
hypertension, or stroke. Fat distribution was a more important risk factor for 
morbidity and mortality than overweight or obesity per se and had a relative risk ratio 
of two or more. The data for waist-to-hips ratio divided into fifths of the population 
(quintiles) showed a much greater chance of remaining free of myocardial infarction 
and of long-term survival in the quintile with the lowest waist-to-hips ratio compared 
with the quintile with the highest waist-to-hips ratio (Lapidus, et. al., 1984). 
This effect was independent of total fatness. In addition to the prospective data 
described here, cross sectional studies have also clearly shown an increased 
prevalence of glucose intolerance, insulin resistance, elevated blood pressure, and 
elevated blood lipid levels in both men and women with increased abdominal fat 
(Krotkiewski, Bjorntorp & Sjostrom, 1983; Kissebah et. al., 1982). It has been 
suggested that the abdominal or android fat pattern may represent an increase in the 
size or number of more metabolically active intra-abdominal fat cells. These fat cells 
release free fatty acids directly into the portal circulation, which might interfere with 
insulin clearance in the liver and thus affect various metabolic processes. It is 
interesting to note in this context that a recent study from Japan used abdominal 
computed tomographic scanning of fat distribution to separateintra-abdominal or 
visceral fat from subcutaneous fat and thus defined a visceral- subcutaneous fat ratio. 
The visceral- subcutaneous ratio is correlated inversely with glucose tolerance 
(Fujioka et. al., 1987). 
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2.1-l:  THE ADIPOCYTE AND ADIPOSE TISSUE  
Adipose tissue is composed of the lipid-storing adipose cell and a stromal/vascular 
compartment in which preadipocytes reside. Adipose mass increases by enlargement 
of adipose cells through lipid deposition, as well as by an increase in the number of 
adipocytes. The process by which adipose cells are derived from a mesenchymal 
preadipocyte involves an orchestrated series of differentiation steps mediated by a 
cascade of specific transcription factors. One of the key transcription factors is 
peroxisome  proliferatoractivated receptor γ (PPARγ), a nuclear receptor that binds 
the thiazoladinedione class of insulin-sensitizing drugs used in the treatment of type 2 
diabetes. 
Although the adipocyte has generally been regarded as a storage depot for fat, it is 
also an endocrine cell that releases numerous molecules in a regulated fashion. These 
include the energy balance-regulating hormone leptin, cytokines such as tumor 
necrosis factor (TNF) γ, complement factors such as factor D (also known as adipsin), 
prothrombotic agents such as plasminogen activator inhibitor I, and a component of 
the blood pressure regulating system, angiotensinogen. Adiponectin (or ACRP30) 
enhances insulin sensitivity andlipid oxidation, whereas resistin may induce insulin 
resistance. These factors, and others not yet identified, play a role in the physiology of 
lipid homeostasis, insulin sensitivity, blood pressure control, and coagulation and are 
likely to contribute to obesity-related pathologies. 
 
2.1-m:  MANAGMENT OF OBESITY 
Currently three options are available for the treatment of obesity and associated 
complications are non pharmacological treatment, pharmacotheropy and surgical 
procedures, each of these are having their own advantageous and drawbacks.   
2.1-m-i:  Non Pharmacological approach: 
Non-pharmacological measures are preferred for many reasons for many reasons 
including adverse effects of anti-obesity drugs, contraindications or allergic reactions 
to drugs, perceptions of adverse effects of drugs, or personal preference for natural or 
alternative therapies. A more aggressive integrative approach to the management of 
obesity is recommended to improve outcomes, minimize adverse effects, and reduce 
health care costs. Non-pharmacological treatment consists of lifestyle modification, 
reduction of total caloric intake and regular aerobic exercise.  
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Lifestyle Modifications  
The primary approach for achieving weight loss, in the vast majority of cases, is 
lifestyle modification, including a reduction in energy intake and an increase in 
physical activity (Scheen, 2008; Scheen, 2004).  
Diet  
There is no evidence to suggest that specific components of the diet (ie, carbohydrate, 
fat, protein, vitamins, micronutrients) influence the ways in which food energy is 
absorbed or used. Therefore, the main dietary approach for reducing weight is to 
reduce the total amount of calories consumed, and this is best achieved by a reduction 
in the amount of fat in the diet and calories from soft drinks. A moderate decrease in 
caloric balance (500-1000 kcal/d) will result in a slow but progressive weight loss 
(Franz, et. al., 2002). In addition, evidence suggests that the components of diet 
currently recommended as healthy--including low consumption of saturated and trans 
fats, intake of carbohydrates that are rich in dietary fiber, high fruit and vegetable 
intake, and the inclusion of low-fat dairy foods—are likely to protect against 
metabolic syndrome (Feldeisen & Tucker, 2007). However, even if dietary efforts are 
the primary treatment approach for people who are overweight or obese, dietary 
counseling interventions generally produce only modest weight loss that diminishes 
over time, as emphasized in a recent meta-analysis (Dansinger et. al., 2007).  
Exercise 
Most obesity studies have not adequately measured physical activity and functional 
capacity, and the independent contributions of "fitness" versus "fatness" to health 
risks associated with obesity are still being debated (Blairi & Church, 2004). 
Nonetheless, the role of physical activity as a treatment and/or preventive strategy for 
combating obesity has been the subject of substantial research. A systematic review of 
the literature concluded that limited evidence from a number of studies that used 
imaging techniques to quantify changes in abdominal obesity suggests a beneficial 
influence of physical activity on reduction of abdominal fat and VAT in overweight 
and obese subjects (Kay & Fiatarone, 2006). Reductions in VAT and total abdominal 
fat may occur in the absence of changes in body mass and waist circumference. 
Because the deposition of fat in the abdomen and in nonadipose tissues such as liver 
(Yki-Jiirvinen, 2005) and muscle (Moro, Bajpeyi & Smith, 2008) plays a major role 
in the development of obesity-related health risks, these depots have emerged as 
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alternative targets for obesity treatment and may partly explain the utility of physical 
activity with only minimal or no weight loss in the treatment of obesity (Janiszewsk & 
Ross, 2007). However, more rigorous studies are needed to confirm these 
observations. 
2.1-m-ii:  Pharmacological measures of obesity: 
Obesity therapies include reducing nutrient absorption and applying anorectic drugs, 
thermogenic drugs or drugs that affect lipid mobilization and utilization. With the 
exception of Orlistat, a recently approved gastrointestinal lipase inhibitor, all drugs 
approved for the treatment of obesity are either catecholaminergic or serotonergic 
CNS-active (activating the sympathetic nervous system) anorectic agents. Since some 
of these drugs may lead to dependency, they are recommended for short-term use like 
amphetamine-like drugs. Upon termination of therapy with these drugs, weight is 
rapidly regained in many cases (Kang, et. al., 2004).  
Dinitrophenol was the first synthetic thermogenic drug used to treat obesity, 
unfortunately during clinical use there were number of deaths from multisystem side-
effects and the drug was rapidly withdrawn. The discovery of ephedrine led to 
synthesis of amphetamines which suppressed appetite and food intake, but stimulation 
actions of these drugs produced strong liability to abuse (Finer, 2002).   
Currently used anti-obesity drugs include inhibitors of 5-hydroxytryptamine uptake 
like fenfluramine and sympathomimetics like phentermine. Fenfluremine is reported 
to cause pulmonary hypertension and heart valve defects whereas phentermine may 
produce rebound weight gain. ALT-962 is a new molecule as the sole competitor of 
orlistat, which is found to be safe and well tolerated in phase I of clinical trials, is now 
being forwarded for phase II and III studies (Goyal & Shah, 2002). 
Concern of risk factors associated with anti-obesity drugs the British National 
Formulary recommends that ―drugs (for obesity) should only be considered for those 
with a BMI of 30 or greater if supervised diet, exercise and behaviour modification 
fail to achieve a realistic reduction in weight‖ (Greenway, 1996). 
Surgery can provide palliation for severe obesity when all medical approaches have 
failed. It can result in decreased food intake (gastric procedures - jaw wiring, vertical 
banded gastroplasty, gastric stapling), affect calorie absorption (intestinal shunting, 
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biliopancreatic bypass), or remove excess fat (lipectomy, liposuction) (Pasquali & 
Casimirri, 1993). 
2.1-m-iii:  Surgical Approach:  
The contrasting effects of various surgical procedures on the metabolic profile have 
underscored the crucial role of intra-abdominal adipose tissue (ie, VAT) rather than 
subcutaneous abdominal adipose tissue (Figure 8). Indeed, whereas large volume 
liposuction that reduces abdominal subcutaneous fat depots by 8 to 10 kg has almost 
no favorable effects on the metabolic profile, Omental fat reduction (corresponding to 
only 0.8% of total body fat) in connection with adjustable gastric banding results in a 
dramatic improvement in insulin resistance and associated glucose disturbances 
(Klein, et. al., 2004; Thörne, Lönnqvist, Apelman, Hellers, & Arner, 2002). Bariatric 
surgical procedures (i.e. gastroplasty, gastric bypass) are the only procedures that 
provide marked and sustained weight reduction in morbidly obese patients, leading to 
improvements in associated metabolic disorders, especially type 2 DM, and a more 
favorable long-term prognosis, including a reduction in total mortality (Sjöström, et. 
al., 2007). However, considering the risk/benefit ratio of bariatric surgery, it may not 
yet be considered an early option in the management of the abdominally obese 
patient.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Surgical Approach 
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Medicinal plants and plant extracts represent the oldest and most widespread 
form of medication. At least 25% of the active compounds in currently prescribed 
synthetic drugs were first identified in plant sources (Balandrin, Klocke, Wurtele & 
Bollinger, 1985). Dissatisfaction with the high costs and potentially hazardous side 
effects of pharmaceuticals have resulted in a larger percentage of people in the United 
States purchasing and exploring the applications of medicinal plants than before 
(Kessler et. al., 2001). Several plants like willow, poppy, foxglove, cinchona, aloe and 
garlic have been verified as medicinally beneficial through repeated clinical testing 
and laboratory analyses (Youngkin, & Israel, 1996; O'Hara, Kiefer, Farrell, & 
Kemper, 1998) and a number of plant extracts like green tea (Hasegawa, Yamda, & 
Mori, 2003), garlic compounds (Elkayam, et. al., 2003) and conjugated linoleic acid 
(CLA) (Hargrave, et. al., 2002) were shown to possess either antidiabetic effects or 
have direct effects on adipose tissue. A large body of literature indicates that 
substantial progress has been made concerning our knowledge of bioactive 
components in plant foods and their links to obesity. Polyphenols constitute one of the 
ubiquitous groups of plant metabolites (Bravo, 1998) widely found in fruits, 
vegetables, cereals, legumes and wine (Aherne, O'Brien, 2002; Harborne, 1989). A 
number of studies have been carried out to investigate the antiobesity effects of 
polyphenols like apigenin and luteolin (Han, et. al., 2003), kaempferol (Yu, et. al., 
2006), myricetin and quercetin (Kwon, et. al., 2007), genistein and diadzein (Kim et. 
al., 2006; Naaz et. al., 2003; Dang & Lowik 2004), cyaniding (Tsuda, Ueno, Kojo, 
Yoshikawa & Osawa, 2005) grape seed proanthocyanidin extract (GSPE) (Preuss, et. 
al., 2000), xanthohumol (Nakagawa et. al., 2005) and epigallocatechin gallate 
(EGCG) (Wolfram et. al., 2006). Likewise, studies involving the effects on lipid 
metabolism have been carried out with carotenoids like fucoxanthin (Maeda et. al., 
2005), coumarin derivatives like esculetin (Yang et. al., 2006) and phytoalexins like 
resveratrol (Picard et. al., 2004). Other bioactive components of food with antiobesity 
effects include phytosterols, polyunsaturated fatty acids and organosulfur compounds. 
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2.2 DRUG PROFILE- TITLE PLANTS 
Clerodendrum phlomidis Linn. 
2.2-a: Taxonomical hierarchy: The taxonomical hierarchy of C. phlomidis is listed 
as follows (Nadkarni, Nadkarni, & Chopra, 1954; Singh, 1955; Kirtikar & Basu, 
1975; Anonymous, 2001, Pandey et. al., 2008).   
Taxonomical hierarchy of C. phlomidis: 
Taxonomical Hierarchy Name 
Domain Eukaryaota 
Kingdom Plantae 
Subkingdom Viridaeplantae 
Phylum Tracheophyta 
Subphylum Euphyllophytiya 
Infraphylum Radiatopses 
Class Magnoliopsida 
Subclass Lamiidae 
Superorder Lamianae 
Order Lamiales 
Family Lamiaceae 
Subfamily Ajugoideae 
Genus Clerodendrum 
Species Phlomidis 
Vernacular names: 
Sanskrit:  Agnimantha, Agnimanthini, Arani, Gandhapushpa, Ganikarika, 
jaya, Jatja, jayarini, Krishanuga, kshudra-Agnimantha, 
Laghumantha, Nadeyi, Parnaka, Prasarini, Tapana, Tanutvacha, 
Tarkari, Tejovriksha, Vaijayanti, Vataghni, Vijaya 
Tamil:  Takkari, Thalanji, Thalludhalai, Sayandi, Vadamadakki 
Marathi:  Airanamula, Arani, Arni, Iran, Takalimula, Tekar 
Hindi:  Arni, Pirani, Pirun, Urni 
Telugu:  Nelli, Taluki, Takkolamu, Tekkali, 
Malayalam:   Munja, Peruvelum, Tirutalai,  
Bengali:  Arani, Ganiyari, Goniari, 
Gujarati:  Aranimula, Arni, Irun,  
Kannada:  Taggi, Taggi-Beru 
Parts used: Roots. 
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2.2-b: Botanical and geographical sources:  C. phlomidis is a common shrub of arid 
plains, low hills and tropical deserts. They are distributed throughout the drier parts of 
India (Andhra Pradesh, Uttar Pradesh, Diu Island, Delhi, Gujarat, Haryana, 
Karnataka, Madhya Pradesh, Maharashtra, Bihar, Orissa, Punjab, Rajasthan, Tamil 
Nadu, Uttar Pradesh and West Bengal), Pakistan (Sindh, Baluchistan and north-
western provinces), Sri Lanka, Myanmar and south-east Asia (Kirtikar & Basu, 1975; 
Anonymous, 2001, Pandey et. al., 2008; Watt, 1889; Moldenke, 1948; Chopra, Nayar, 
& Chopra, 1956).   
2.2-c: Anatomy, histology, microscopy and proximate analysis  Anatomical, 
histological and powder characteristics of different parts of C. phlomidis are shown in 
following table (Anonymous, 2001; Krishnamurthy, Masilamoney, & Govindraj, 
1972; Haines, 1961; Matthew, 1995; Chunekar, & Raghunathan, 1967). The leaf 
constant values vary from those reported by Chunekar et. al. (Chunekar, & 
Raghunathan, 1967) and Krishnamurthy et al. (Krishnamurthy, Masilamoney, & 
Govindraj, 1972). The Ayurvedic Pharmacopoeia of India has specified the thin-layer 
chromatography (TLC) pattern and some parameters, viz., foreign matter (not more 
than 2%), total ash (not more than 6%), acid insoluble ash (not more than 1%), 
alcohol soluble extractive (not less than 2%) and water soluble extractive (not less 
than 5%) values for recognizing the identity, purity and strength of roots of C. 
phlomidis (Anonymous, 2001). 
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2.2-d: Ethnomedical uses 
Indian system of medicines particularly Ayurveda and Siddha uses C. phlomidis as a 
single drug or in combination with other drugs. The Ayurvedic properties of C. 
phlomidis are: Rasa (taste) — Tikta (bitter), Katu (pungent/acrid), Kashaaya 
(astringent), and Madhura (sweet); Guna (quality) — Rooksha (non-unctuous), and 
Laghu (light); Veerya (potency) — Ushna (heat); Vipaka (transformation with 
digestion) — Katu (pungent) (Anonymous, 2001). Due to its bitter and pungent nature 
C. phlomidis is considered to normalize the vitiated Kapha and Vata dosa (Chaturved, 
Subramaniyam, Tiwari & Singh, 1983). It is constituted as a number of Ayurvedic 
formulations indicated for digestive disorders, acidity, gas, diarrhoea, laxative, liver 
tonic and general health tonic (Tyagi, 2005).  The roots are used in different 
Ayurvedic formulations such as Ayushyavardhaak tel, Bhratpanchamula, 
Chandraprabha vati, Lavanbhasker churna, Abhayarisht, Chavanprasha, 
Dasamularista, Ashwagandharishta, Mritasanjivani, Dasamula Kvatha Churna, 
Haritakiavleh, Indukanta Ghrta, Dhanvantara Ghrta, Gorocanadi Vati, Narayana 
Taila, Ras pitari, Vrahat Panchamuli and Muthu Marunthu (a Siddha polyherbal 
formulation). C. phlomidis is also an ingredient of many stress/pain relief massage oil 
blends and many polyherbal formulations that are used as rejuvenation tonic. Though 
root is considered to be the authentic drug it is the leaf that finds application in 
folklore medicines. The ethnomedical uses of different parts of C. phlomidis are given 
below (Nadkarni, Nadkarni, Chopra, 1954; Anonymous, 2001; Chaturved, 
Subramaniyam, Tiwari & Singh, 1983; Tyagi, 2005; Puri, 2002; Chunekar & 
Bhavaprakash, 1960). 
Part Ethnomedical Uses 
Root 
 12 to 24 G as decoction is used in Sotha (Inflammation, swelling), 
Pandu (jaundice), Arsa (hemorrhoids, piles), Vibandha (constipation), 
Agnimandya (slowness of digesation, dyspepsia), Adhmana (Swelling of 
the body), Gulma (a chronic enlargement of the spleen or any glandular 
enlargement in the abdomen), Mutrakrcchra (painful discharge of the 
urine), class of urinary affections) and Mutraghata (Urinary disease) 
(Anonymous, 2001). 
Used as bitter tonic, antidote, analgesic, anti-asthmatic; for inflammatory 
disease and in rheumatism (Kirtikar & Basu, 1975; Katewa, Chaudhary & 
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Jain, 2004). 
 Used as bitter tonic, for nervous disorder and in debility (Khare, 2007).  
Root bark 
Used in cough, asthma, cold, oedema and nervous disorders (Singh, 
Sharma, & Khare, 1980). 
Root and root 
bark 
Used as alternative, bitter tonic, and is given in the convalescence of 
measles by native of Western India (Nadkarni, Nadkarni, Chopra, 1954; 
Watt, 1889; Chopra, Chopra, Handa, & Kapu, 1958). 
Root 
Decoction 
Used as aromatic, astringent and as demulcent in gonorrhea (Nadkarni, 
Nadkarni, Chopra, 1954; Katewa, Chaudhary, & Jain, 2004). 
Root  juice Used to reduce over corpulence (Manohar, 2005). 
Whole plant 
Used as hypoglycemic (Manohar, 2005; Marles, & Farnsworth, 1995). 
Used for aliments involving swelling, joints pains and inflammation. The 
properties are quoted same as those of P. intergrifolia but C. phlomidis is 
considered better in inflammation (Nair, 2004; Krishnamurthy, 
Masilamoney, & Govindraj, 1972; Puri, 2002).  
Whole plant 
The tribes ―Santals‖ rub the plant over their body for dropsy.  
The tribals ‗Sahariya‖ used the plant in fever, postnatal complaints, 
dyspepsia, colic and anthrax (Anis, & Sharma, 2000). 
Used in colic body ache, diarrhea, cholera, dysentery, dyspepsia, fever, 
headache, post natal fever, stomach pain, during convulsions from measles 
and specially used for mental diseases (Tyagi, 2005; Khare, 2007; Mitra, & 
Rangesh, 2003; Patil,  & Patil, 2006). 
Whole plant 
decoction 
Used to treat diabetes (Mishra, 2003).  
Whole plant 
and root 
Used as a bitter tonic and for neglected syphilitic complaints (Shafi, Ashraf 
& Sarwar, 2001).  
Leaf 
Used as a remedy to treat diabetes in southern parts of India especially 
tribals of Nilgiris (Dhanabal, Mohan Maruga Raja & Suresh, 2008). 
Used in fever due to sun stroke and malaria and as febrifuge; ground leaves 
are given in stomach pain, dyspepsia, digestive disorders, eye complaints, 
lung diseases, rheumatism, asthma, inflammatory diseases, swellings 
(Pandey, Raval, Mali & Salvi, 2005; Anonymous, 2001).  
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Locally tied for the treatment of guinea worm (Katewa, Chaudhary, & Jain, 
2004).  
Leaf juice 
Used to treat mental tension and mental disturbances in Tamilnadu 
(Murugesan, Saravanan, Lakshmi, Ramya & Thenmozhi, 2001). 
Leaf and leaf 
juice 
Used as bitter tonic, alternative and prescribed in neglected syphilitic 
complaints in doses of half an ounce or more twice daily in southern India.  
(Nadkarni, Nadkarni, Chopra, 1954; Kirtikar KR, & Basu, 1975; Shafi, 
Ashraf, & Sarwar, 2001; Watt, 1889; Anjaria, Parabia, Bhat, & Khamar 
2002). 
Leaf 
decoction 
Used for inflammation, and is effective in treating bronchitis, headache, 
weakness, drowsiness and digestive problems (Picard, 2004). 
Leaf and root Used for body-ache, head ache and unconsciousness (Patil, & Patil, 2006).  
Aerial parts 
The tribals ―Sahariya‖ apply the paste on body joints for about a month to 
reduce pain or stiffness of joints (Anis, Sharma & Iqbal, 2000). 
 
Other uses: C. phlomidis finds a lot of applications in Indian traditional veterinary 
practices (Srivastava, Hasan, Bagchi, & Kumar, 2000). The tribals Santals feed C. 
phlomidis to their cattle for diarrhea and worms or when the stomach swells (Kirtikar 
& Basu, 1975; Pandey, Kaur, Malasoni, & Gupta, 2008; Anjaria, Parabia, Bhatt, & 
Khamar, 2002). Extracts of leaves are applied on body of domestic animals to kill 
lice. Leaves are good fodders especially for goats (Pawar &  Patil, 2008). Leaf paste is 
applied to infested hooves to give a relief for the animals and reportedly cures foot 
and mouth diseases and secondary infections (Bhagore, 1991). Fresh leaf extracts are 
pasted on animals with skin problems and used for hypothermia or shivering in cattle 
(Vaidyar, 1997). In Chittoor, Ananthapur districts of Andhra Pradesh and Southern 
India C. phlomidis is used for alleviating diseases of livestock by the local traditional 
herbal practitioners. Leaves are given orally twice daily to cure convulsive seizures 
and trypanosomosis infection until cured (Sanyasi & Varma, 2008). 
2.2-e: Phytochemistry: 
 
Leaf: A crystalline non-glucoside bitter principle (C17H16O6, melting point (m.p.) 
213 ℃), ceryl alcohol, β-sitosterol, γ-sitosterol, palmitic acid, cerotic acid and an 
unidentified sterol (C28H48O, m.p. 155 ℃) (R-199.). Scutellarein (5,6,7,4′-
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tetrahydroxy flavones), pectolinaringenin (6,4′-dimethoxy scutellarein) and a 
flavanone have been isolated from the leaf (Subramanian, & Nair, 1972). A 
chemotaxonomic marker of the genus, (24S)-ethylcholesta-5, 22, 25-triene-3β-ol 
(C29H46O, m.p. 151— 153 ℃) was isolated from the leaf (Subramanian, & Nair, 
1973). The water extracts were found to contain glucose, arabinose and potassium 
nitrate (Bhakuni, Srivastava, Seghal, & Kaul, 1962).  
Stem: D-mannitol, β-D-glucoside of β-sitosterol, β-sitosterol and ceryl alcohol were 
also isolated from the stem (Gupta, Chandra & Mahadevan, 1967). The stem, leaf and 
flower parts were reported for presence of alkaloids.  
Flower: Seth et al, 2001 reported 6, 4′-dimethyl-7-acetoxyscutellarein, 
pectolinarigenin, hispidulin, apigenin and luteolin isolated from the flower.  
Flower and the leaf:  Chalcone glycoside (4, 2′,4′-trihydroxy-6′-methoxychalcone-
4,4′α-D-diglucoside, m.p. 186— 188 ℃, C28H34O15), pectolinarigenin, 7-hydroxy 
flavone and 7-hydroxy flavanone 7-O-glucoside were reported isolated from the 
flower and the leaf (Roy, & Pandey, 1994; Anam, 1999).  
Root:  β-sitosterol, γ-sitosterol, ceryl alcohol, clerodin (C24H34O7), clerosterol 
(C29H48O) and clerodendrin-A (C27H26O17) were also isolated from the root 
(Joshi, Singh, & Mehra, 1979).  
α-L-rhamnopyranosyl-(1→2)-α-D-glucopyranosyl-7-O-naringin-4′-O-α-D-
glucopyranoside-5-methyl ether (C34 H44 O19) was reported isolated from the root 
by Anam (Anam, 1999). 
Lup-20(29)-en-3-triacontanoate (C60H108O2), tetratriacontanol and 24β-
ethylcholesta-5,22E,25-triene-3β-ol were reported isolated from aerial parts (Pandey, 
Kaur, Malasoni, & Gupta, 2008). Shanker et al (Shanker, et. al., 2008) reported a new 
validated TLC method for the quantification of a marker sterol, 24β-ethylcholesta-5, 
22E, 25-triene-3β-ol with chloroform-methanol (98.5∶1.5) (Rf 0.54 ± 0.05) and 
densitometric evaluation at 650 nm after anisaldehyde-sulphuric acid derivatization. 
The amounts quantified in different solvent extracts were hexane 0.0552, chloroform 
0.054 7, ethanol (95%) 0.033 8, methanol 0.092 7 and ethyl acetate 0.104 7% w/w. 
Following figures show the chemical structures of some isolated compounds from C. 
phlomidis. 
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2.2-f: Reported pharmacological activity: 
2.2-f-i: Pre-clinical investigations 
Many studies have reported the diversified biological activities of C. phlomidis which 
are described in details as followed. 
 
Analgesic activity An ethanolic extract of leaves (150 and 300 mg/kg, i.p.) was 
evaluated for analgesic activity in albino mice (either sex, 20 to 25 g) by Eddy‘s hot 
plate method. The extract at 300 mg/kg showed significant activity, supporting the 
folklore claim as analgesic (Srinivasa, Rao, Krupanidhi, & Babu, 2007). 
 
Anti-amnesic activity  An aqueous extract of bark (yield 2% w/w) at 100 and 200 
mg/kg, p.o. was evaluated for anti-amnesic activity in young Swiss mice (8 weeks, 
either sex) and old Swiss mice (28 weeks, either sex). Acute toxicity studies showed 
hypersensitivity, grooming, convulsions, sedation, hypothermia, ptosis and mortality 
at dose of above 1000 mg/kg. The dose at 200 mg/kg more significantly enhanced the 
learning and memory of aged animals rather than the young ones. The extract 
profoundly increased step-down latency (SDL) indicating improvement in the 
memory of younger mice and significantly inhibited the acetylcholinesterase (AchE) 
activity indicating its potential in the attenuation of learning and memory deficits 
especially in aged mice (Joshi & Megeri, 2008). The study concluded C. phlomidis as 
a potential nootropic and anti-cholinesterase agent (Joshi & Megeri, 2008).  
 
Anti-asthmatic activity An aqueous extract (yield 7.9% w/w) of leaves was studied 
for anti-asthmatic activity in male albino mice (Swiss strain, 22 to 25 g). The effect of 
extract (2, 4, 10 mg/mL) on goat tracheal chain was also studied, indicating a 
significant activity at 4 and 10 mg/mL with the relaxant effect (depression of 
histamine receptor 1). The extract at dose levels of 25, 50 and 100 mg/kg, i.p. in milk-
induced eosinophilia showed significantly at 100 mg/kg the antagonizing effect. In 
three-day treatment by the aqueous extract (25, 50 and 100 mg/kg, i.p.), the 100 
mg/kg dose showed 73.25% protection of mast cell degranulation. The aqueous 
extract, when studied for capillary permeability (25, 50 and 100 mg/kg, i.p.), at 100 
mg/kg dose level significantly decreased transmittance, indicating its effect on optical 
density of the eye. The overall study lends credence to the beneficial use of aqueous 
extract in the treatment of asthma and related conditions (Vadnere, Somani, & 
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Singhai, 2007). The authors have quoted a back reference regarding the anti-
ulcerogenic activity of C. phlomidis, which is misleading. In fact, C. splendens was 
screened for anti-ulcerogenic activity in the mentioned reference (Tan, Nijimi & 
Ayafor, 1997).  
Antidiarrhoeal activity A successive methanolic extract (yield 7.5% w/w) of leaves 
showed no mortality till an oral dose of 1 g/kg. The methanolic extract at doses of 
200, 400, 600 and 800 mg/kg was evaluated for castor oil-induced diarrhea, 
gastrointestinal motility and prostaglandin E2-induced enteropooling in albino rats 
(Wistar strain, 180 to 200 g, either sex). The methanolic extract at 600 and 800 mg/kg 
showed significant inhibition of defecation frequency and decrease in propulsion of 
the charcoal meal through gastrointestinal tract. The extract also significantly 
inhibited prostaglandin E2-induced enteropooling in almost all the dose levels. The 
mechanism appears to be spasmolytic and anti-enteropooling (Rani, et. al., 1999). 
Although the extract has shown only the presence of steroids, alkaloids and 
flavonoids, the authors concluded that the activities of the extract might be due to 
tannins, which is controversial. 
 
Anti-inflammatory activity The aqueous and alcoholic leaf extract-treated group 
showed general decrease in the size of the swelling following certain initial 
fluctuations and reduction in suppuration especially in speed of general drying up of 
the pus (Krishnamurthy, Masilamoney, & Govindraj, 1972). No details were found 
regarding the dose of the extract administered. 
Antimicrobial studies  Twenty microliters of defatted methanolic (yield 4.4% w/w) 
and acetone (yield 1.7% w/w) extracts of stems and leaves (combined) were screened 
for five Gram-positive bacteria, seven Gram-negative bacteria and three fungi species 
by an agar diffusion method, respectively. Acetone extract was not active while the 
methanolic extract showed inhibition against Citrobacter freundii and Staphylococcus 
epidermidis (Vaghasiya, & Chanda, 2007). The preliminary phytochemical analysis of 
C. phlomidis extracts was not clear whether it is for methanolic or acetone extract. 
Furthermore, it was astonishing to note that although the data indicated the absence of 
alkaloids, tannins, cardiac glycosides, steroids, flavonoids and saponins, the authors 
concluded that the antimicrobial activity might be attributed to various active 
constituents present in either mono or combined way of them Ethyl acetate and 
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hexane extracts of leaves (yield 8.4% and 1.1% w/w) and stems (yield 3.21% and 
0.52% w/w) at concentration of 1 mg/ml were screened for human pathogens and 
plant pathogens by poison plate technique, respectively. The leaf extract (particularly 
hexane extract) was more active than stem extract on both pathogens. However, the 
stem extract was only inhibitory to plant pathogens. The study revealed that both 
extracts were more effective in controlling plant pathogens than human pathogens and 
could be utilized in pesticide formulations (Rajasekaran, & Kannan, 2006).  
Antifungal activity of two flavones, flavonone glucoside and one chalcone glucoside 
isolated from C. phlomidis were studied. Chalcone glucoside was highly promising 
followed by pectolinaringenin, flavonone glucoside and flavones (Roy, Singh, 
Pandey, 1995). 
 
Antiplasmodial activity  An ethanolic leaf extract showed 96% inhibition at 100 
μg/mL and a 50% inhibitory concentration (IC50) value of 25 μg/mL against 
Plasmodium falciparum. The study concluded that the activity might be due to the 
presence of iridoids but no iridoids have been reported yet from C. phlomidis 
(Simonsen, et. al., 2001).  
 
Antiviral studies  An ethanolic extract of leaves was evaluated for antiviral activity 
against sunnhemp rosette virus (SRV) on Cyamopsis tetragonoloba. The virus 
inhibitory activity was 29% with no significant antiviral response (Khan, et. al., 
1991). 
 
Brine shrimp lethality study Both biological activity and toxicity of a root aqueous 
extract using Artemia salina (Brine shrimp test) were studied. The extract with a 
median lethal concentration (LC50) value of 3,750 μg/mL showed no brine shrimp 
lethality (Krishnaraju, et. al., 2006).  
 
Hypoglycemic activity  Chaturvedi et. al.,  (Chaturvedi, et. al., 1983) studied the 
effect of decoction and alcoholic extract of C. phlomidis on adrenaline-induced 
hyperglycemia and alloxan-induced diabetics in rats, in which the alcoholic extract 
had a more significant inhibitory effect. Both decoction and alcoholic extract brought 
down the blood sugar levels effectively and exhibited the same degree of action in 
alloxan-induced diabetic rats. In a comparative study between the immediate effect 
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(hourly basis) and long term effect (30 days) of decoction in normal rats, C. phlomidis 
produced comparable fall in blood sugar both on immediate as well as on long term 
use.  
A defatted ethanol extract of leaves was screened for hypoglycemic activity in 
alloxan- induced diabetic rats at two dose levels, 100 and 200 mg/kg. The extract at 
200 mg/kg exhibited significant hypoglycemic activity and also correction of altered 
cholesterol and triglycerides levels. In the histopathological studies more prominent 
islet cells were seen in both metformin and ethanol extract (200 mg/kg) treated groups 
(Dhanabal, Mohan Maruga Raja & Suresh, 2008).  
 
Immunomodulatory activity  A methanolic extract of roots was evaluated for 
specific immune response (antihyaluronidase titer, plaque forming cell assay and 
delayed-type hypersensitivity test) and non-specific immune response (carbon 
clearance and E. coli-induced abdominal sepsis). The specific immune response was 
studied in BLAB/c albino mice (either sex, 22 to 25 g) for 7 days. The extract at 300 
mg/kg showed significance in antihyaluronidase titre, plaque forming cell assay and 
delayed-type hypersensitivity test. In carbon clearance test (5-day treatment) and E. 
coli-induced abdominal sepsis (15-day treatment) the extract showed increased 
phagocytic index, significant clearance of carbon particles and only 20% mortality in 
24 h particularly without any symptoms of peritonitis in surviving animals. The study 
concluded that the methanolic extract exhibited a high response in most of the studied 
models and the chemical constituents diterpenoids and flavonoids might contribute to 
the immunomodulatory activity (Gokani, Lahiri, Santani, & Shah, 2007).  
 
Nematicidal activity An aqueous leaf extract showed a moderate nematicidal activity 
against larvae of root-knot nematode Meloidogyne incognita and antifungal effect 
(43.58% inhibition) against Fusarium oxysporum f. sp. Cumini (Sharma, & Trivedi, 
2002).  
 
Psychopharmacological activity  A successive methanolic leaf extract (yield, 7.5% 
w/w) was studied in Swiss albino mice (either sex, 20 to 25 g) for phenobarbitone 
sodium-induced sleep, general behavior test, muscle relaxant activity and exploratory 
behavior (rat model) at doses of 200, 400 and 600 mg/kg, respectively. The dose at 
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400 and 600 mg/kg, i.p. significantly lengthened the phenobarbitone sodium-induced 
sleep time in mice. The same dose levels produced slight/moderate spontaneous, 
sound, pain and touch responses. The studies at all dose levels showed significant 
losses of motor coordination and tone of muscles. A significant decrease was shown 
by all three dose levels in the extraploratory behavior of rats in Y-maze test and in 
head dips responses in mice. The study concluded that the extract possessed most of 
the pharmacological activities of minor tranquilizers (Murugesan, et. al., 2001). The 
authors have quoted that the extract is non-toxic and causes no death even up to an 
oral dose of 3.2 mg/kg while the doses selected for the study was 200, 400 and 600 
mg/kg, i.p. which is contradictory. 
 
Pharmacological effects of pure compounds The isolated compound 7-hydroxy 
flavone acts on targets like aromatase, alcohol dehydrogenase, 17β hydroxyl steroid 
oxydoreductase, multidrug resistance transporter (MDR-TR)- P-glycoprotein 
transporter (PGP-TR) and 3,5- cyclic nucleotide phosphodiesterase. This flavone also 
exerts in-vivo antinociceptive activity (Polya, 2003) and is active towards fatty acid 
amide hydrolase (FAAH) with an IC50 value of 0.5 to 1 μmol/L. Furthermore, it was 
reported that it also reduced the FAAH-dependent uptake of anandamide and its 
metabolism in intact RBL2H3 basophilic leukaemia cells (Thors, & Belghiti, 2008). 
  
Studies on formulation containing C. phlomidis  A 50% ethanolic extract of 
Chyavanprasha showed a nitric oxide scavenging activity (Jagetia, Rao, Baliga & 
Babu, 2004). A defatted 50% ethanolic extract of Chyavanprasha showed a 
radioprotective effect in mice exposed to lethal dose of γ-radiation (Jagetia, Rao, 
Baliga & Babu, 2004). Muthu Marunthu showed a very good controlling capacity on 
the biochemical events during tumor progression without producing any toxic effects 
(Palani, Senthilkumaran & Govindasamy, 1999). The aqueous and alcoholic extracts 
of Amrit nectar tablets and the herbal Ayurvedic food supplement M-4 (Maharishi-4) 
reduced toxicities induced by Adriamycin and Cisplatin, showing antineoplastic 
activities (Sharma, et. al., 1990; Engineer, Sharma, & Dwivedi, 1992; Prasad, et. al., 
Prasad, 1992; Prasad, & Parry, 1993; Mazzoleni, et. al., 2002). The studies with 
formulations containing C. phlomidis were not emphasized much as it would be 
unscientific to attribute the overall activities of the formulation to a single plant.  
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2.2-f-ii: Clinical investigations 
In a clinical study, a 22% reduction of blood sugar was observed when 8 pills with an 
alcoholic extract were administered to 10 normal and 33 maturity-onset diabetic 
patients (Bhattacharya, & Bajpai, 1975).  Effects of age, sex and complications on the 
results were not considered in this study.  
A case report stated that a 70 year male patient with complaints of polyuria, 
polydypsia, constipation, loss of vision, tingling, and numbness in extremities for the 
duration of 10 years and complicated with pulmonary tuberculosis responded well 
without any adverse effect, when administered with C. phlomidis decoction daily in 4 
divided doses for three weeks along with anti-tubercular treatment simultaneously. 
Significant lowering of fasting blood sugar and improvement of polydypsia and 
polyuria were reported (Chaturvedi, et. al., 1983). In another clinical claim reported 
of 23 patients, 46% treated with C. phlomidis (a 1:4 decoction prepared from 15 to 30 
g in daily divided doses for 5 weeks) showed 7.1% mean fall of blood sugar and 
18.2% fall in urine sugar with no side effects (Bhattacharya & Bajpai, 1975). But the 
report did not contain sufficient data for re-analysis as well as statistical analysis, e.g., 
no means, no standard deviations. The small number of patients in the multiple arms 
of the study made generalization difficult. However the authors still assumes that C. 
phlomidis might be a good oral hypoglycemic agent. 
Namboodari et al (Namboodari, et. al., 1948) reported that the combination of 
Dasmularista, Pippalyasava and Vettumaran Gutika was effective in the 90-day 
treatment of acute rheumatoid arthritis. Park et al have evaluated the methodological 
quality of all randomized controlled trials (RCTs) on the effectiveness of Ayurvedic 
medicine for rheumatoid arthritis (RA). The Jadad score assigned for the study by 
Namboodari et al (Namboodari, et. al., 1948) was 2 due to poor study design and the 
inability to draw any meaningful conclusions.  
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Pictures: 
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                                   Photograph C. phlomidis 
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Stellaria media Linn. 
 
2.2-g: Taxonomical hierarchy: The taxonomical hierarchy of Stellaria media 
Linn is listed as follows 
Taxonomical hierarchy of C. phlomidis:  
Taxonomical Hierarchy Name 
Domain: Eukaryaota 
Kingdom: Plantae 
Subkingdom: Tracheobionta 
Class: Magnoliopsida 
Subclass: Caryophyllidae 
Order: Caryophyllales 
Family: Caryophyllaceae 
Genus: Stellaria L. 
Species: Stellaria media (L.) Vill. 
 
Synonyms: (Vernacular names): Chickweed, Chickenwort, craches, Naruns, 
Winterweed Alsine media L., Stellaria Apetala Ucria,  
Parts used: Entire whole plant is used in medicine (The wealth of India, 1976). 
 
Flowering: Typically March-November, can flower all year 
Habit: Moist shaded locations. 
2.2-h: Botanical and geographical sources: Stellaria media, is found throughout the 
Himalayas up to an altitude of 4300 m & also at 600-1650 m. (The Wealth of India--
Raw Materials, 1976; Khare, 2007). The plant is also found in the Dibrugarh district 
situated in the eastern part of Assam with the total area of 3381 sq km surrounded by 
Brahmaputra river in the north. Tinsukia district in the east and Sivanagar district and 
Arunachal Pradesh in the south and Sivanagar district in the west. (Dilip K, Manashi 
D, and Nazim FI, 2005). 
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2.2-i: Morphological characters: 
Part Morphological characteristics 
Stem 
To 50 cm long (20-30cm tall), decumbent, rooting at lower nodes, 
herbaceous, somewhat succulent, mostly glabrous but with a single 
longitudinal line of pubescence. Pubescence hirsute to tomentose. 
Leaf 
Opposite, ovate (sometimes truncate at base), short-mucronate, 
petiolate. Blades about 2 cm wide, about 2cm long, glabrous, green 
above, lighter green below, entire. Petiole about 2cm long, sometimes 
winged, pubescent.  
Flowers 
Corolla white, rotate, 5-6 mm broad. Petals 5, deeply notched and 
appearing as 10, glabrous, to 2mm long, free. Petal lobes oblong. 
Stamens typically 3-5, attached at base of ovary, alternating with 
petals. Styles 3, spreading. Sepals 5, free, 5mm long, pubescent with 
glandular-tipped hairs, ovate-lanceolate, green. Capsules about 6mm 
long, 4mm wide, glabrous, with +/- 15 seeds. Seeds 1mm in diameter, 
tuberculate, rotund. 
 
2.2-j: Ethano medical uses: As per ethnobotanical claims Stellaria media can be 
used as astringent, carminative, antiasthmatic, demulcent, depurative, diuretic, 
emmenagogue, expectorant, galactogogue, kidney complications, inflammation in 
rheumatic joints, wounds and ulcers (Howard, 1987).   
Stellaria media is used in various kinds of skin diseases, and also for bronchitis, 
rheumatic pains, arthritis and period pain. A poultice of chickweed can be applied to 
cuts, burns and bruises. As traditional folk it is also used in obesity, and remedy after 
snake bite (Dilip, Manashi & Nazim, 2005; Katewa, & Galav, 2006). 
The plant is employed in plasters used for broken bones and swelling. It also possess 
diuretic, expectorant, and anti-asthmatic property (Pande, Shukla & Tripathi, 1995).  
In the poultry farms the aerial part of Stellaria media increases the laying of eggs, 
probably due to the remarkable quantity of alkaline salts, tannins, gums, a glycosidic 
saponins, fatty acids, of antioxidant flavonoids and carotenoids (Paolo & Leporatti, 
2007).   
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2.2-k: Phytochemistry:  
Chemical constituents:  Whole plant contains contains hentriacontane, hexacosanyl 
palmitate, methyl stearate, pentacosanol, triacontanol, triacontanoic acid, sitosterol 
and its β-D -glucoside, 6, 7-dimethylheptacosane, 3-methyl-6-hydroxyheneicos-3-enyl 
acetate and 5-acetoxydotetracont-3-en-1-ol (Pande, Shukla, & Tripathi, 1995). 
On the dry matter bases it contains protein, fat, carbohydrates, fibers, Vit A, Thiamine 
(B1), riboflavin (B2), niacin, B6 and Vit C (Pande, Shukla, & Tripathi, 1995).   
   
2.2-l: Reported pharmacological activities:  
Pre-clinical and clinical study: Yet no data have been reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Photograph of Stellaria media 
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3.0: NEED FOR THE STUDY 
Obesity is a serious health problem. This is rising in all age groups worldwide. 
Around the globe, about 1.7 billion people are overweight, according to the 
International Obesity Task Force, of those about 312 million are obese- at least 30 
pounds over their top recommended weight (Ross, & Verrengia, 2004). The multiple 
causative factors, like genetic, environmental, nutritional, physiological, 
psychological, social & cultural have been linked to its development & progression. 
Besides, gender differences have also been reported in the control of eating patterns & 
development of eating disorders in human & animal with predominant occurrence in 
female subjects especially during adolescent years (Kaur, & Kulkarni, 2001). The 
medical problems caused by obesity begin at the head and end at the toes and involve 
almost every organ in between. Several of these problems contribute to the earlier 
mortality associated with obesity and include coronary artery disease, severe 
hypertension that may be refractory to medical management, impaired cardiac 
function, adult-onset (type 2) diabetes mellitus, obesity hypoventilation and sleep 
apnea syndromes, cirrhosis, venous stasis and hypercoagulability with an increased 
risk of pulmonary embolism, and necrotizing panniculitis (Sugerman, 2005). 
Insulin resistance (IR) is the basic pathophysiological characteristic of the 
‘Metabolic Syndrome’. Reversing insulin resistance would be an important factor in 
the prevention of this cluster of pathologies including obesity, type 2 diabetes 
(T2DM), hypertension, and other cardiovascular diseases. Notably, as a result of a 
high calorie/fat diet (HFD) and a sedentary lifestyle, the prevalence of obesity related 
T2DM is expanding in most parts of the world. As the prediabetic onset of insulin 
resistance is usually preceded by weight gain, more than 80% of type 2 diabetics are 
overweight (Paula, 2005). Therefore, it is necessary to reinforce an effective 
prevention and relief of this metabolic disorder, especially to control the formation 
and development of HFD related insulin resistance. 
The drugs which are available in the market for the treatment of obesity and related 
complications are either catecholaminergic or serotonergic CNS- active (activating 
sympathetic nervous system) anorectic agents, since some of these drugs may lead to 
dependency, they are recommended for short-term use only like amphetamine like 
drugs, upon termination of therapy with these drugs weight rapidly regains in many 
cases, that’s why it become one of the thirst area to develop remedy that should 
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overcome obesity and associated complications (Kang, et. al., 2004). However, there 
is hardly drug in the market that overcomes from obesity and related complications 
without any side effects like T2DM etc. without any side effect. Ayurvedic system of 
medicines is one of the oldest system of medicine having a history of more than 200 
years. Several prototype derived from these herbal medicines are in use for various 
kind of disease and disorders. It not only gives new molecule but also with newer 
mechanism of action, hence is called Gold mine. As per the literature survey it was 
found that flavonides, sitosterols, tannins and saponines  have shown the anti-obesity 
activity by various mechanisms, both of these selected plants have shown the 
presence of some common phytoconstituents in their extracts like sitosterols, 
triterpenoids, flavonoids, other saponins etc. Moreover traditional system of Indian 
medicine also claims for its anti-obesity activity with this back ground we have 
selected these plants for its phytochemical analysis, screening its anti-obesity and 
obesity associated hyperglycema as well as to substantiate the folklore claim. The 
information emerging from this research may not only useful in preventing 
continuous deterioration but may even be half value in developing new modalities for 
treatment of obesity and related complications. 
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OBJECTIVES 
The present study was carried out with an objective to extract and fractionate 
Clerodendrum phlomidis (roots) and stellaria media (whole plant) with benzene, 
followed by methanol and water. These extracts were used for testing 
pharmacological screening in the genesis and control of food, drug and high fat diet 
induced obesity and obesity induced DM. In this view the following objectives were 
taken up to evaluate and elucidate the role of Clerodendrum phlomidis (roots) and 
Stellaria media (whole plant) in fat deposition and obesity induced DM. 
 
1. Preparation of Clerodendrum phlomidis roots and Stellaria media aerial parts 
extracts using benzene and methanol by successive soxhlet extraction and water 
by mechanical shaking and 24 h maceration. 
2. Detail pharmacognostic study  of  Clerodendrum phlomidis and Stellaria media 
3. To study effect of Clerodendrum phlomidis and Stellaria media on CD induced 
obesity in female Wistar rats. 
4. To study effect of Clerodendrum phlomidis and Stellaria media on progesterone 
induced obesity in female Swiss albino mice. 
5. To study effect of Clerodendrum phlomidis and Stellaria media on high fat diet 
induced obesity in C57BL/6J female mice. 
6. To study effect of Clerodendrum phlomidis and Stellaria media in food 
consumption modulation induced by progesterone in mice. 
7. To study effect of Clerodendrum phlomidis and Stellaria media on CD and 
progesterone induced body weight changes. 
8. To study effect of Clerodendrum phlomidis and Stellaria media on high fat diet 
induced body weight changes in C57BL/6J female mice. 
9. To study effect of Clerodendrum phlomidis and Stellaria media on CD, 
progesterone, and high fat diet induced serum biochemical changes in Wistar 
rats, Swiss albino mice and C57BL/6J mice receptively.  
10. To study effect of Clerodendrum phlomidis and Stellaria media on CD induced 
changes in body temperature in Wistar rats and C57BL/6J female mice 
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11. To study effect of Clerodendrum phlomidis and Stellaria media on CD, 
progesterone and high fat diet induced changes in organ to body weight ratio in 
Wistar rats and C57BL/6J female mice receptively.  
12. To study effect of Clerodendrum phlomidis and Stellaria media on CD, 
progesterone and high fat diet induced changes in exploratory behavior in 
Wistar rats and C57BL/6J female mice receptively. 
13. To study effect of Clerodendrum phlomidis and Stellaria media on CD and high 
fat diet induced changes in fat cell size and count in female rat and C57BL/6J 
mice. 
 
 
 CHAPTER                                                  
 
 
 
 
 
 
 
 
 
 
PHARMACOGNOSTIC 
STUDY 
 
  
4 
Chapter 4                                                PHARMACOGNOSTIC STUDY 
 
                                      Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 56 
 
4.0: Collection, Authentication & Preparation and storage of plant 
materials:  
4.1: Collection of plant: 
 
Clerodendrum phlomidis Linn. and Stellaria media Linn were collected from village 
Bichari (Rajkot district, Gujarat) and Dibrugarh district situated in the eastern part of 
Assam surrounded  by Brahamputra river in the North respectively. Clerodendrum 
phlomidis Linn was collected in the month of December-January 2007 while Stellaria 
media was collected in the month of July-August 2007. At the time of collection, 
whole plant of Stellaria media including stem, seeds, roots and flowers were 
collected, while collection roots of Clerodendrum phlomidis other aerial parts 
including stem, flowers and leaves were also collected for authentication and 
preparation of herbarium. 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Herbarium C. phlomidis 
 
 
 
 
 
 
 
 
 
 
 
 
Herbarium S. media 
Figure 9: Herbarium of C. phlomidis & S. media 
 
Authentication of plant material: 
The herbarium of C. phlomidis and S. media were supplied for authentication (figure 
9). The plant was authenticated by Prof. (Dr.) H. B. Singh, NISCAIR, New Delhi 
(India). The voucher No. of specimen is HNSIPER/herb/04 and HNSIPER/herb/09 for 
C. phlomidis and S. media respectively was deposited at Institute level. 
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Preparation and storage:  
All aerial parts were cleaned and washed with distilled water and then dried at room 
temperature, until they were free from moisture. After drying root of C. phlomidis and 
S. media milled and pass from sieve # 40. The milled powder material kept in air tight 
container up to further use. 
 
Pharmacognostic study  
4.2: Morphology 
1.   Clerodendrum phlomidis Linn. Root  
Diameter and Length of roots:  0.2-2 mm and from some cm to several meters, and 
angle between main stem and branch at internode:  750-850.  
Color: Pale yellow to brownish 
Odor: None 
Taste: Roots are slightly bitter and astringent. 
Size: Roots are long, rather stout, closely twinning and glabrous and grows up to 
several centimeters to meters.  
Shape: Roots are slender 
  Photograph of Clerodendrum phlomidis Linn 
 
 
 
 
 
 
 
 
Flowers  
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Leaves 
 
 
 
 
 
 
 
 
 
 
 
Roots 
Photographs of Clerodendrum phlomidis Linn 
2. Stellaria media Linn. (Whole plant) 
Morphology 50 cm long (20-30cm tall), decumbent, rooting at lower nodes, 
herbaceous, somewhat succulent, mostly glabrous but with a single longitudinal line of 
pubescence. 
Color:  Glabrous, green above, lighter green below 
Odor: No 
Taste: Slightly astringent and unpleasant bitter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular tissue of stem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem 
Photographs of Stellaria media Linn. 
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Photographs of Stellaria media Linn 
 
4.3: Microscopy 
The roots of Clerodendrum phlomidis & Stellaria media were studied transversely 
and longitudinally, using surface preparations and sections. The different parts of leaf 
like lamina and midrib were studied according to the methods of Brain and Turner. 
For the microscopical studies, cross sections were prepared and stained as per the 
procedure of K. R. Khandelwal. The different lens of photomicroscope as, 
OLYMPUS iNEA 5X, 10X/0.2; India, and 100X/1.25 oil India were used for 
capturing the photographs.   
 
4.4: Powder characteristics  
Clerodendrum phlomidis & Stellaria media powder characteristic was performed 
according to methods Khandelwal, 2005 (Khandelwal, 2005).  
 
4.5: Extraction Methodology 
Extraction of crude drug: 
The crude drug contains the different types of chemical constituents, which can be 
isolated by using various methods of extraction.  
Materials and methods 
The dried roots of C. phlomidis and whole weed of S. media was taken and  powered 
by using the pulverizer. The powdered drug was then pass through sieves # 40 and 
used for extraction process. 
       
 
 
 
 
 
Flowers 
 
Flowers 
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Extraction procedure – The extraction was done by two methods 
1. Extraction by cold maceration, 
2. Successive extraction by using soxhlet apparatus. 
1) Successive extraction by using Soxhlet apparatus: 
In successive solvent extraction, a dried material is extracted with different solvents, 
starting from solvent of low polarity. After extraction by one solvent, material is 
removed from thimble, dried and recharged, extracted with solvent of successively 
high polarity. Successive solvent extraction was done by using methanol (Kokate, 
1994). 
The extract was filtered and concentrated by using rotary flash vaccum evaporator 
(Roteva, Equitron, Mumbai). The extract was dried in vaccum drier and stored below 
10  C. 
2) Extraction by cold maceration – 
The powdered of both plants subjected for alcoholic extraction by cold maceration 
with daily shaking for three days or stirring at room temperature. Flask was plugged 
with cotton and aluminium foil and kept aside with intermittent shaking. The fluid 
extract was separated by filtration. The filtrate was concentrated using rotary vacuum 
evaporator. The dried extract is collected and preserved in desicator (Kokate, 1994). 
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4.6: Results of microscopy & powder characteristics 
1. C.  phlomidis root 
Microscopy / Histology (Fig 10) 
Transverse section of C.  phlomidis root 
Cork: - Seven to eight layers of rectangular cells in radial rows compactly arranged. 
Outer layer contain brownish matter and the inner layers show thin colorless cell.                                                                                                                         
Phellogen & Phelloderm: - not separateble  
Cortex: - two to three layers tangentially elongated cells containing reddish brown 
matter. 
Pericycle: About four layers of lignified oval to squarish stone cells are seen. 
Stone cell:  Continuous band of four layers lignified, pitted and oval to rectangular 
stone cells are observed. The continuous U- shaped one layer of lignified stone cell is 
also observed. The rectangular band & U-shaped layer separated by two to three layers 
of reddish brown cells. 
Secondary Phloem:- 
Unlignified secondary phloem shows sieve tube, companion cells and phloem 
parenchyma with starch grain, above the cambium. The stone cells found in phloem 
region are rectangular in shape, having thickening on three sides; the stone cells of 
middle row region are lignified, while that of upper and lower rows are non-lignified.  
Secondary Xylem:- 
Lignified secondary xylem (Fig 10 a) shows simple lignified xylem vessels, xylem 
fibres are highly thickened with pointed ends in tangential bands,  xylem parenchyma 
are lignified, thick walled containing simple starch grains.  
Medullary rays- are parenchymatous and lignified, run radially from the centre to the 
cortex, multiserieate. Cells contain starch grains (Fig 10 b).      
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Fig. 10 T.S. of C. phlomidis root (45X) 
Mr: Medullary rays 
Xl: Xylem 
Ph: Phloem 
NISC: Non Lignified Stone Cells 
Pf: Pericyclic fibers 
Ct: Cortex 
Cr: Cork 
Sg: Starch grains 
Sc: Sclerenchyma 
45 X 
Fig 10 a Cr 
Ct 
Pf 
NISC 
Sc 
Xl 
Ph 
Mr 
Mr 
Sg 
Xl 
Fig 10 b 
45 X 
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Powder characteristic of C. phlomidis root (Fig. 11) 
The following cells/ tissue/ tissue inductions were observed.  
Starch grain: Spherical starch grain. 
Xylem vessel: Sclariform xylem vessels were observed. 
Lignified tissues and Fibers 
 
 
 
 
 
 
 
 
 
 
Starch grains in xylem (100X) 
 
 
 
 
 
 
 
 
 
 
Lignified tissues (100 X) 
 
 
 
 
 
 
 
 
 
 
 
 
Xylem Fibers 
 
 
 
 
 
 
 
 
 
 
 
 
Scleriform xylem vessel 
 
Fig. 11: Powder characteristic of C. phlomidis Root 
Sg: Starch grains 
2. S. media  
Microscopy / Histology (Fig. 12) 
Cork 
It consists of more than six layers of tabular cells, with pale brownish amorphous 
content.  
Phellogen & Phelloderm 
Not separable, one to two layers of phellogen lies underneath cork followed by cortex.  
Cortex 
Five to six rows of parenchymatous cortex transverse with simple starch grains cells.  
Pericycle: scattered lignified cells are seen. 
Sg 
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Secondary Phloem 
Lignified secondary phloem shows sieve tube, companion cells and phloem 
parenchyma with starch grain, above the cambium. 
Powder characteristics of root  
Powder characteristics of root  
Following cells/ tissue/ cell inductions were observed. 
Cork Cell (Fig 12 c), Starch grain (Fig 12 d), Xylem vessel (Fig 12 e) and Lignified 
cell (Fig 12 f). 
 
 
Cr: Cork 
Ct: Cortex 
LPF: Lignified pericyclic fibers 
Sp: Secondary phloem  
Mr: Medullary rays 
Xl: Xylem 
Sg: Starch grains 
 
 
Fig 12 a Fig 12 b 
Cr 
Ct 
LPF 
Sp 
Mr 
Xl 
Cr 
Ct 
Sg 
Sp 
Mr 
Sg Xl 
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Cork Cell (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Starch grain (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Xylem vessel (100X) 
 
 
 
 
 
 
 
 
 
 
 
 
Lignified cell (10X) 
Fig 12: Microscopy & Powder characteristic of S. media roots 
Fig 12 c 
Fig 12 e 
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4.7: Preliminary phytochemical investigation of C. phlomidis 
and S. media 
The powdered of C. phlomidis and S. media used for preparation of extract. Methanol, 
Ethanol and aqueous extracts were prepared by successive extraction method. The 
marc remains after the successive extraction used for aqueous extract preparation. All 
the extracts were subjected to qualitative chemical investigation (Kokate, 1994).  
Details of various tests performed for the presence of phytoconstituents in the extracts 
are as under.  
Table 1: Qualitative chemical tests of plant extracts: 
Sr. 
no 
 
Test performed Observation Inference 
1. Tests for Acidic compounds: 
a) To the test solution add sodium 
bi-carbonate 
b) Test solution treated with warm 
water and filter. Test the filtrate 
with litmus paper.  
Effervescence 
produces 
 
Red litmus paper 
turns blue 
Acidic compounds 
present 
Acidic compounds 
present 
2. Tests for Alkaloids: 
a) Dragendorff’s Test:  Test 
solution treated with      
Dragendorff’s reagent (potassium 
bismuth iodide) 
 
Gives reddish brown 
colored precipitate  
 
 
Alkaloids present 
 
b) Mayer’s Test: Test solution 
treated with Mayer’s reagent 
(Potassium mercuric iodide). 
Gives cream colored 
precipitate  
Alkaloids present 
 
c) Wagner’s Test: Test solution 
treated with Wagner’s reagent 
(Iodine in potassium iodide). 
Gives reddish brown 
colored precipitate  Alkaloids present 
d) Hager’s Test: To the test 
solution add with Hager’s reagent 
(Saturated picric acid solution). 
Gives yellow colored 
precipitate 
 
Alkaloids present 
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 e) Tannic acid test: Test solution 
treated with tannic acid solution. 
Gives buff colored 
precipitate  
Alkaloids present 
f) Picrolonic acid test: Test 
solution treated with picrolonic 
acid. 
Gives yellow colored 
precipitate  Alkaloids present 
3. 
 
Test for amino acids: 
a) Million’s Test: Test solution 
treated with Million’s reagent and 
heated on a water bath.  
 
Milky white colored 
precipitate. 
 
Amino acids 
present. 
b) Ninhydrin Test: Test solution 
boiled with Ninhydrin reagent.  
Gives violet color Amino acids 
present. 
4. Test for Carbohydrates: 
a) Molisch’s Test: To the test 
solution add with few drops of 
Molisch’s reagent (Alcoholic -
naphthol) and 2 ml of conc. 
sulphuric acid is added slowly from 
the sides of the test tube.  
 
Purple to violet ring 
appears at the 
junction of two 
liquids 
 
Carbohydrates 
present 
b) Barford’s Test: Test solution 
heated with Barford’s reagent on 
water bath.  
If red cupric oxide is 
formed  
Monosaccharides 
are present. 
c) Selivanoffs test (Test for 
ketones): To the test solution add 
crystals of resorcinol and equal 
volumes of concentrated 
hydrochloric acid and heat on a 
water bath. 
 
Rose color is 
produced 
 
 
Carbohydrates 
present 
 
 d) Test for pentoses: To the test 
solution add equal volumes of 
hydrochloric acid containing small 
amount of phloroglucinol and heat.  
 
Red color produced. 
 
 
Carbohydrates 
present 
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 e) Osazone formation test: Heat 
the test solution with the solution of 
phenyl hydrazine hydrochloride, 
sodium acetate, and acetic acid. 
Yellow crystals 
formed. 
Observe under 
microscope. 
Carbohydrates 
present 
 
5. Test for Flavonoids: 
a) Shinoda Test: Test solution 
treated with fragments of 
magnesium ribbon and conc. 
hydrochloric acid.  
Shows pink scarlet, 
crimson red or 
occasionally green to 
blue color after few 
minutes. 
Flavonoids present 
 
c) Zinc-Hydrochloride test: Treat 
test solution with zinc dust  and few 
drops of HCL 
Shows red color after 
few minutes. 
Flavonoids present 
6. Test for glycosides:   
I) 
 
General test: Extract 200 mg of 
drug with 5 ml of dilute sulphuric 
acid by warming on a water bath, 
filter it, and neutralize the acid 
extract with 5 % solution of sodium 
hydroxide. Add 0.1 ml of Fehling’s 
solution A and B until it becomes 
alkaline (test with pH paper) and 
heat on water bath for 2 minutes. 
Red Precipitate 
formed  
compared with 
precipitate of test A 
 
If the precipitate in 
Test A is greater 
than in Test B then 
glycoside may be 
present. 
 
 Test B: Repeat Test A procedure 
by using 5 ml of water instead of 
dilute sulphuric acid. Note the 
quantity of red precipitate formed.  
  
II) 
 
Chemical tests for specific 
glycosides: 
  
A) 
 
Tests for Anthraquinone 
glycosides: 
  
 a) Borntrager’s test: Boil the test 
material with 1ml of sulphuric acid 
A rose pink to red 
color is produced in 
Anthraquinone 
glycosides present 
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for 5minutes. Filter while hot. Cool 
the filtrate; shake with equal 
volume of dichloromethane or 
chloroform. Separate the lower 
layer of dichloromethane or 
chloroform; shake it with half of its 
volume of dilute ammonia. 
ammonical layer. 
 
 
 b) Modified Borntrager’s test: 
Boil 200 mg of test material with 
2ml of sulphuric acid. Treat with 2 
ml of 5 % aqueous ferric chloride 
solution (freshly prepared) for 5 
minutes, shake it with equal volume 
of chloroform and continue the test 
as above.  
A rose pink to red 
color is produced in 
ammonical layer. 
 
Anthraquinone 
glycosides present 
 
 c) Test for hydroxy 
anthraquinones: treat the sample 
with potassium hydroxide solution 
Red color produced Hydroxy 
anthraquinones 
present 
B) Tests for cardiac glycosides:   
 a) Kedde’s test: Extract the drug 
with chloroform, evaporate to 
dryness. Add one drop of 90 % 
alcohol and 2 drops of 2 % sodium 
hydroxide solution.  
Purple color is 
produced. 
 
Cardiac glycosides 
present 
 
 b) Keller-Killiani Test: (Test for 
deoxy sugars) Extract the drug 
with chloroform and evaporate it to 
dryness. Add 0.4 ml of glacial 
acetic acid containing ferric 
chloride, add carefully 0.5 ml of 
conc. sulphuric acid by the side of 
test tube.  
Acetic acid layer 
shows blue colour. 
 
Cardiac glycosides 
present 
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 c) Raymond’s number: Treat the 
test solution with hot methanolic 
alkali.  
Violet colour 
produced 
Cardiac glycosides 
present 
 d) Baljet’s Test: The test solution 
treated with sodium picrate or 
picric acid.  
Gives yellow to 
orange color 
Cardiac glycosides 
present 
 e) Legal’s Test: Test solution 
treated with pyridine [made 
alkaline by adding sodium 
nitroprusside solution.  
Gives blood red 
color 
 
Cardiac glycosides 
present 
 
C) 
 
Tests for coumarins glycosides: 
Place small amount of sample in 
test tube and covered it with a filter 
paper, moistened with dilute 
sodium hydroxide solution. Placed 
the covered test tube on water bath 
for several minutes. Remove the 
paper and expose it to ultraviolet 
(UV) light.  
Reddish purple color  
 
Coumarins 
glycosides present 
 
D) 
 
Cynogentic glycosides:  
Place 200 mg of drug in conical 
flask and moisten with few drops of 
water.( Flask should be completely 
dry because hydrogen cyanide 
produced will dissolve in the water 
rather than come off as gas to react 
with paper) moisten a piece of 
picric acid paper with 5% aqueous 
sodium carbonate solution and 
suspended in neck of flask. Warm 
gently at about 37oC. Observe the 
change in color.  
Reddish purple color  
 
Cynogentic 
glycosides present 
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E) 
 
Saponin glycosides: 
 Froth test: Place 2 ml solution of 
drug in water in a test tube, shake 
well.  
Stable froth (foam) 
formed 
Saponin glycosides 
Present 
F) 
 
 
 
 
 
 
 
 
Test for Anthocynidine 
1. Place 2ml solution of 
extract in test tube, add 
conc. H2SO4 
2. Place 2ml solution of 
extract in test tube, add 
NaOH 
Yellow or Orange 
color  
 
Blue color 
Anthocynidine 
Present 
 
Anthocynidine 
Present 
7. 
 
Tests for steroids and 
triterpenoids: 
a) Libermann Burchard Test: 
Treat the extract with few drops 
of acetic anhydride, boil and 
cool, add conc. sulphuric acid 
from the sides of test tube.  
 
 
 
Brown ring is 
formed at the 
junction of two 
layers,  
If upper layer turns 
green 
If upper layer turns 
deep red  
 
 
 
 
 
Steroids present  
Triterpenoids 
present 
 b) Salkowski test: Treat the 
extract with few drops of conc. 
sulphuric acid.  
Red color at lower 
layer  
Yellow color at 
lower layer 
Steroids present 
  
Triterpenoids 
present 
 c) Sulfur powder test: Add small 
amount of sulfur powder to the test 
solution. 
It sinks at the bottom 
 
Steroids present 
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8. 
 
Tests for insulin: To the test 
solution add the solution of -
naphthol and sulphuric acid. 
Brownish red color 
formed 
Insulin Present 
9. 
 
Tests for Lignin: Treat the sample 
with hydrochloric acid and 
Phloroglucinol.  
Pink color formed 
 
Lignin Present 
10. 
 
Tests for Mucilage: 
Treat the sample with thionine 
solution. After 15 min wash with 
alcohol  
Mucilage turns violet 
red. 
Mucilage present 
11. Tests for tannins:  
a) Ferric-Chloride Test: Treat test 
solution with few drops of ferric 
chloride solution. 
Gives dark blue 
color  
Green color appears  
Hydrolysable 
tannins  
Condensed tannins  
 b) Gelatin test: To the test solution 
add 1 % gelatin solution containing 
10 % sodium chloride.  
Precipitate formed 
 
Tannins présent 
 
12. Tests for proteins:   
 a) Heat test: Heat the test solution 
in boiling water bath. 
Proteins gets 
coagulated 
Proteins present 
 b) Biuret Test: Test solution 
treated with Biuret reagent (40% 
sodium hydroxide and dilute copper 
sulfate solution). 
 
Gives violet color 
 
Proteins present 
13. Test for starch: To the test 
solution, add weak aqueous iodine 
solution.  Blue color indicates 
presence of starch, which 
disappears on heating and reappears 
on cooling. 
Blue color, which 
disappears on 
heating and 
reappears on cooling. 
 
Starch present  
 
The results of preliminary phytochemical analysis given in table 3.  
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Qualitative elemental analysis of Ash of C. phlomidis and S. media: 
 
Details of various tests performed for the presence of elemental analysis are as under 
Table 2: Elemental analysis of ash: (Khandelwal, 2005) 
SR.NO. TEST OBSERVATION 
1. For Aluminium: 
a) Test solution + dilute ammonia 
solution.  
 Gelatinous precipitate, soluble in 
hydrochloric acid, acetic acid and 
sodium hydroxide solution but nearly 
insoluble in dilute ammonia solution. 
b) Test solution + solution of 
ammonium sulphide. 
Gelatinous precipitate, soluble in 
hydrochloric acid, acetic acid and 
sodium hydroxide solution but nearly 
insoluble in dilute ammonia solution. 
2. 
 
For Chlorides: 
a) Test solution + manganese dioxide 
+ sulphuric acid. 
 
Odour of chlorine. 
b) Test solution + solution of 
potassium iodide 
Blue colour. 
c) Test solution + solution of silver 
nitrate 
A white, curdy precipitate soluble in 
dilute ammonia solution but insoluble 
in nitric acid. 
 c) Test solution + Solution of starch. Blue colour. 
3. For Copper: 
a) Test solution + hydrogen sulphide. 
 
Brownish-black precipitate. 
 
b) Test solution + solution of sodium 
hydroxide. 
Light blue precipitate. 
 c) Test solution + solution of 
ammonium thiocyanate. 
Black precipitate 
 
 d) Test solution + dilute ammonia 
solution. 
Greenish blue precipitate 
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4. 
 
For Calcium: 
a)  Test solution + solution of 
ammonium carbonate. 
A white precipitate which after boiling 
and cooling is insoluble in solution of 
ammonium sulphide. 
b) Test solution + solution of 
ammonium oxalate. 
A white precipitate, soluble in 
hydrochloric acid but insoluble in 
acetic acid. 
d) Test solution + solution of 
potassium chromate. 
A yellow, crystalline precipitate. 
d) Test solution + solution of 
potassium ferrocyanide. 
 
No immediate precipitate, but on 
addition of excess of reagent in 
presence of excess of ammonium 
chloride, yield a white precipitate 
5. For Carbonates and Bicarbonates: 
a) Test solution + dilute hydrochloric 
acid 
Effervescence due to liberation of 
carbon dioxide gas. 
b) Test solution + solution of 
mercuric chloride. 
 
Brownish-red precipitate. 
c) Test solution + solution of silver 
nitrate. 
A white precipitate, which does not, 
becomes yellow on addition of excess 
of reagent.  
6. For Iron: 
a) Test solution + dilute hydrochloric 
acid and solution of potassium 
permanganate. 
No faint pink colour. 
b) Test solution + dilute hydrochloric 
acid and solution of ammonium 
thiocyanate. 
No blood red colour. 
c) Test solution + solution of 
potassium ferrocyanide. 
 
No white precipitate. 
e) Test solution + solution of sodium 
hydroxide. 
No dull green precipitate 
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7. For Magnesium:   
 a) Test solution + solution of 
ammonium carbonate, boil. 
No white precipitate. 
 
 b) Test solution + dilute ammonia 
solution and solution of sodium 
phosphate. 
No white crystalline precipitate. 
 
 
 c) Test solution + solution of sodium 
hydroxide. 
No white precipitate. 
 
8. For Nitrates:  
 a) Test solution + sulphuric acid and 
copper, warm. 
Liberation of red fumes. 
 
  
b) Test solution solution of ferrous 
sulphate. 
Brown precipitate, but when sulphuric 
acid is added to form a lower layer, 
brown colour is produced, at the 
junction of the two liquids. 
 c) Test solution + solution of sodium 
hydroxide and zinc powder, boil. 
 
Liberation of ammonia detected by its 
odour and its action on moistened 
litmus paper. 
9. For Phosphates:  
a) Test solution + solution of silver 
ammonio-nitrate. 
A light yellow precipitate, readily 
soluble in dilute ammonia solution and 
in cold nitric acid. 
b) Test solution + magnesium 
ammonio-sulphate. 
A white crystalline precipitate. 
 
 c) Test solution solution of 
ammonium molybdate and nitric 
acid. 
A yellow precipitate. 
10. For Potassium:  
 a) Test solution + perchloric acid. A white crystalline precipitate. 
 b) Test solution + solution of sodium 
cobalt nitrite and acetic acid. 
A yellow precipitate. 
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 c) Sample moistened with 
hydrochloric acid and introduced on 
platinum wire into the flame of 
Bunsen burner. 
Violet colour to the flame. 
11. For Sodium:  
 a) Test solution + solution of uranyl 
zinc acetate. 
A yellow crystalline precipitate. 
 
 b) Sample moistened with 
hydrochloric acid and introduced on 
platinum wire into the flame of 
Bunsen burner. 
Yellow colour to the flame. 
12. For Sulphates:  
 a) Test solution + solution of barium 
chloride. 
A white precipitate insoluble in 
hydrochloric acid. 
 b) Test solution + solution of lead 
acetate. 
A white precipitate soluble in solution 
of sodium hydroxide. 
13. For Zinc:  
a) Test solution + solution of 
ammonium sulphide and solution of 
sodium hydroxide 
A white precipitate soluble in 
hydrochloric acid. 
 
b) Test solution + solution of 
potassium ferrocyanide. 
 
A white precipitate insoluble in dilute 
hydrochloric acid. 
 
The results of qualitative elemental analysis given in table 4.  
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Quantitative elemental analysis for Ash of C. phlomidis and S. media 
The quantitative analysis of both plant carried out by using instrument AAS 
The results are given in table 5. 
Table 3: Results of phytochemical investigation of C. phlomidis and S. media 
Extract 
C. phlomidis  S. media  
MECP AECP MESM AESM 
Steroids and 
Triterpenoids 
+ + + + 
Carbohydrates + + + + 
Proteins + + + + 
Glycosides _ + _ _ 
Flavonoids + _ + _ 
Anthocynidine + _ + _ 
Alkaloids _ _ + _ 
Saponin _ + _ + 
MECP: Methanolic extract of C. phlomidis 
AECP: Alcoholic extract of C. phlomidis  
MESM: Methanolic extract of S. media  
AESM: Alcoholic extract of S. media  
+ indicates presence of constituents  
 - indicates absence of constituents.  
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Table 4: Results of Elemental Analysis of Ash of C. phlomidis & S. media 
 
Element Inference 
C. phlomidis S. media 
Aluminum Absent Absent 
Chlorides Absent Present 
Copper Absent Absent 
Calcium Present Present 
Iron Absent Present 
Magnesium Absent Present 
Nitrates Absent Absent 
Phosphates Absent Present 
Potassium Present Present 
Sodium Present Present 
Sulphates Absent Present 
Zinc Absent Absent 
Carbonates and bicarbonates Absent Absent 
 
Table 5:  Results of Quantitative Elemental Analysis for Ash of C. phlomidis and 
S. media: 
 
Element 
Quantity 
C. phlomidis S. media 
Chlorides _ 512 mg/kg 
Calcium 6.61 % w/w 5.12 % w/w 
Potassium 709 mg/kg 913 mg/kg 
Sodium 3000 mg/kg 3200 mg/kg 
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4.8: Physicochemical parameters: 
 
C. phlomidis and S. media evaluated by following physicochemical parameters 
Physical constants: 
A) Ash values: 
Ash values are indicative to some extent of care taken in collection and 
preparation of drug for market and of foreign matter content of natural drug. 
The object of ashing is to remove all traces of organic material interfering in 
an analysis of inorganic elements. 
Total ash, acid insoluble ash and water soluble ash of whole plant of C. 
phlomidis and S. media was obtained by reported methods (Anonymous, 
1996; 2007). 
1) Total ash value:  
This method is designed to measure total amount of material remaining after 
ignition. It includes both physiological ash and non-physiological ash. The 
physiological ash is derived from plant tissue itself and non-physiological ash 
is residue of extraneous matter (e.g. sand and soil) adhering to plant surface. 
2 gm of air-dried powder was taken in tarred platinum crucible. Drug material 
was spread in fine even layer at bottom of the platinum crucible. This platinum 
crucible with drug material was kept in muffle furnace for ignition at high 
temperature. Temperature of furnace increased gradually up to 4500C. The 
material was kept  at this temperature for 6 hours till complete ignition of drug 
occurred, that is till complete white coloured ash was obtained, intermittent 
weighing was also done and heating continued till constant weight of crucible. 
Crucible was then taken out from furnace, cooled and weighed. 
The total ash was calculated by subtracting the weight of crucible with ash of 
drug after ignition from weight of crucible with drug powder before ignition. 
Percentage of total ash was calculated with reference to air-dried drug. 
2) Acid insoluble ash value: 
The acid insoluble ash value has been undertaken to remove variations caused 
by calcium oxalate. The ash obtained in the total ash method was taken and 
boiled with 25 ml of 2 N hydrochloric acid for 5 min. Insoluble matter was 
collected on ash less filter paper and washed with hot water. The material was 
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further ignited and weighed. Percentage of acid insoluble ash was calculated 
with reference to air dried material (Anonymous, 1996; 2007). 
 3) Water soluble ash value:  
The aqueous extract of crude drug C. phlomidis Linn. and S. media Linn 
shown to have various biological activities. Therefore exhausted powder may 
be used as adulterant for this drug. Total ash value also varies from wide 
range; therefore, water-soluble ash value is quite reliable parameter to judge 
such type of adulteration.  
The ash obtained from total ash was taken, boiled with 25 ml water for 5 min. 
All insoluble matter was collected on ash less filter paper, washed with hot 
water and ignited for 15 min at the temperature not exceeding 4500C. The 
percentage of water-soluble ash was calculated by subtracting weight of 
insoluble matter from weight of total ash. The difference between weights 
represents water-soluble ash. Percentage of water-soluble ash was calculated 
with reference to air-dried drug (Anonymous, 1996; 2007). 
The results are given in table 6. 
B) Extractive values: 
 It is employed for material to which as yet no suitable chemical or  biological 
assays exist. Extractive values determine amount of active constituents present 
in given plant material in given solvent. Extracts were prepared with various 
solvents by standard methods (Anonymous, 2007).  
 Percentage of dry extract was calculated in terms of air-dried stem powder.  
1) Water soluble extractive value:   
Accurately weighed 5 gm of powdered drug was taken in the glass stoppered 
conical flask. Macerate with 25 ml of distilled water for 6 hours with frequent 
shaking, then allowed to stand for 18 hours. 
After completion of 18 hours filtered the contents of flask and transferred the 
filtrate in tarred flat bottom porcelain dish. Then filtrate was evaporated to 
dryness on water bath and dried at 1050C for 6 hours cooled in dessicator for 
30 min and weighed. Calculated content of extractable matter in milligrams 
per gram of air dried material (Anonymous, 2007).  
The results of extractive value are given in table 7.  
 
Chapter 4                                                PHARMACOGNOSTIC STUDY 
 
                                      Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 81 
 
2) Alcohol soluble extractive value:  
Accurately weighed 5 gm of powdered drug placed in the glass stoppered conical 
flask and macerated with 25 ml of ethanol (95%) for 6 hours with frequent 
shaking, mixture allowed to stand for 18 hours. 
After completion of 18 hours, filtered rapidly taking care not to lose any solvent. 
Transferred the filtrate in tared flat bottom porcelain dish. Filtrate was evaporated 
to dryness on water bath, dried at 1050C for 6 hours cooled in dessicator for 30 
min and weighed. Calculated content of extractable matter in milligrams per gram 
of air dried material (Anonymous, 2007). 
3) Ether soluble extractive value: 
 Same procedure was followed as per water soluble extractive but instead  of 
water, petroleum ether was used as solvent. The results of extractive value are 
given in table 7.  
C) Loss on Drying (LOD):  
Loss on drying is the loss in weight in percent w/w resulting from loss of water 
and volatile matter of any kind that can be driven off under specific conditions. 
2 gm of air-dried drug reduced to powder was placed in a crucible of silica. 
Originally the crucible was cleaned and dried and weight of empty dried crucible 
was taken. The powder was spread in a thin uniform layer. The crucible was then 
placed in the oven at 105oC. The powder was dried for 4 hours and cooled in a 
dessicator to room temperature and weight of the cooled crucible plus powder was 
noted (Anonymous, 2007). 
 
Table 6: Results of Ash values of C. phlomidis & S. media 
Ash values -particulars 
% w/w 
C. phlomidis S. media 
Total ash value 8.54 12.88 
Acid insoluble ash value 2.14 1.78 
Water soluble ash value 3.98 2.91 
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Table 7: Results of Extractive values of C. phlomidis & S. media 
Extracts 
 
C. phlomidis S. media 
Color 
Extractive 
value (%w/w) 
Color 
Extractive 
value (%w/w)  
Petroleum ether Yellow 1.48 ±  0.21 Yellow 1.28 ±  0.11 
Methanol Brown 2.73 ± 0.09 Brown 2.41 ± 0.11 
Ethanol  Brown 2.58 ± 0.14 Dark brown 2.61 ± 0.17 
Aqueous Brownish 
black 
3.75 ± 0.08 Black 3.39 ± 0.22 
 
Table 8: Results of Loss on Drying of C. phlomidis & S. media  
Parameter 
C. phlomidis 
(%w/w) 
S. media  
(%w/w) 
        LOD 3.07 ± 0.12 4.76 ± 0.17 
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4.9: Estimation of Total Flavonoid Content (Chang, Yang, Wen & Chern, 
2002).  
Flavonoid concentration was determined as follows; 
Known volume of methanolic extract was diluted with 80% aqueous ethanol (0.9ml). 
Aliquot of 0.5 ml was added to test tube containing 0.1 ml of 10% aluminum nitrate, 
0.1 ml 1 M aqueous potassium acetate and 4.3 ml of 80% ethanol. After 40min at 
room temperature the absorbance was determine at 415 nm with UV 
spectrophotometer. Total Flavonoid content was calculated according to a standard 
curve established with Quercetin. 
Flavonoid Content
y = 0.0946x + 0.0322
R2 = 0.9702
0
0.2
0.4
0.6
10 20 30 40 50
Concentration (mcg/ml)
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Graph 1: Calibration curve for total flavonoid content  
Total flavonoid content was found to be 0.388% w/w and 0.321 % w/w for C. 
phlomidis and S. media methanolic extract of C. phlomidis respectively. 
 
4.10: Estimation of Total Saponin Glycosides: (Rajpal, 2002) 
1. Take 5 gm sample; extract with 90 % v/v methanol 25 ml refluxing for half an 
hour. 
2. Extract the residue two or more times by taking 25 ml methanol, combine the 
methanolic extract and distil off the solvent. 
3. Treat the soft extract left after distillation of methanol with Pet. Ether 60-80, 
25 ml by refluxing for half an hour. Cool and remove the solvent by 
decantation and discard. 
4. Treat the residue left with 25 ml ethyl acetate and reflux the contents for half 
an hr., cool and decant off the solvent and discard. 
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5. Dissolve the residue left in 25 ml of 90 % v/v methanol. Filter and concentrate 
to 5 ml 
6. Add the above drop by drop with constant stirring to 25 ml solvent ether to 
precipitate the saponin. Filter the precipitate or if the filtrate is settled in the 
beaker, decant off the solvent ether and dry the residue to constant weight. 
 Total Saponin content was found to be 0.121%w/w and 0.108 %w/w for C. phlomidis 
& S. media methanolic extracts respectively  
4.11: TLC Pattern for Methanolic Extract (Fig.13) 
The stationary phase & mobile phase set for β-sitosterol as per the Harborne, J.B., 
(Harborne, 1984) 
TLC for β-sitosterol – 
Plate dimension : 5×15 cm. 
Stationary phase : Silica gel G for TLC. 
Sample preparation : 5mg methanolic extract was dissolved in 5ml of   acetone 
Mobile phase : Various solvent systems have been tried for optimization of 
better resolution mainly using chloroform and ethyl acetate as 
the methanol extracts contain sterols which are non-polar to 
semi polar in nature 
.  
Best resolution and separation was observe with chloroform and ethyl acetate 
(8:0.6) 
Visualisation   : Spraying by 20 % Sulphuric acid in methanol. 
Treatment after spraying : Heated in oven at 1050c for 2-5 min. 
The TLC profile has revealed the presence of seven spots after spraying with 20% 
methanolic sulphuric acid.  
TLC profile of Methanolic ether extract is given in table no.9 
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MESM: Methanolic Extract of Stellaria media 
MECP: Methanolic extract of Clerodendrum phlomidis 
Std.: Standard (β sitosterol) 
Figure 13: TLC pattern of C. phlomidis & S. media 
 
 
Table 9: Description of TLC Pattern for Methanolic Extract of C. phlomidis & S. 
media 
Color of spot  
(after spray) 
Rf Value 
C. phlomidis S. media Std. 
Yellow 0.34 0.35 -- 
Brown 0.48 0.48 -- 
Pink 0.59 0.64 0.61 (β sitosterol) 
Yellow -- 0.78 -- 
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4.12:  In-vitro evaluation of pancreatic lipase activity 
Material and Methods: Triolein and pancreatic lipase were purchased from Sigma 
Chemical, India. Taurocholic acid, 0.1M N-tris (hydroxymethyl) methyl-2-
aminoethanesulfonic acid (TES), chitin-chitosan etc. All the chemicals used in the 
study are of AR grade.  
 
Measurement of pancreatic lipase activity  
Lipase activity was determined by measuring the rate of release of oleic acid from 
triolein. A suspension of triolein (80 mg), lecithin (10 mg) and taurocholic acid (5 
mg) in 9ml of 0.1M N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid 
(TES), pH 7.0,containing 0.1M NaCl was sonicated for 5 min. This sonicated 
substrate suspension (100 ml) was incubated with 50 ml (10 units) of pancreatic lipase 
and 100 ml of various concentrations of chitin-chitosan suspension for 30 min at 37oC 
in a total volume of 250 ml. The amount of oleic acid produced was determined by 
the method of Zapf et. al. (Zapf et. al., 1981) with a slight medication (Tsujita & 
Okuda, 1983). The incubation mixtures were added to 3ml aliquots of a 1:1 (v/v) 
mixture of chloroform and heptane containing 2% (v/v) methanol and extracted by 
shaking the tubes horizontally for 10 min in a shaker. The mixture was centrifuged at 
2000 rpm for 10 min, and the upper aqueous phase was removed by suction. Copper 
reagent (1 ml) was then added to the lower organic phase. The tube was shaken for 10 
min, the mixture was centrifuged at 2000 rpm for 10 min, and 0.5 ml of the upper 
organic phase, which contained copper salts of the extracted free fatty acids (FFA), 
was treated with 0.5 ml of 0.1% (v/v) bathocuproine in chloroform containing 0.05% 
(w/v) 3-(2)-tert-butyl-4- hydroxy-anisol. The absorbance was then measured at 480 
nm. In addition, pancreatic lipase activity was determined using gum arabic (acidic 
polymer) or Triton X-100 (neutral polymer) as emulsier; 45mg gumarabic or 2.25mg 
Triton X-100, instead of lecithin, were used and the enzyme activity assayed as 
described above. Lipase activity was expressed as mmol oleic acid released per ml 
reaction mixture per 1 h. 
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RESULTS:  
 
 
Sr. No. Addition %  Lipase Activity 
1 Control 100 
2 MESM (0.25 mg/mL) 104.15 ± 0.400 
3 MESM (0.5 mg/mL) 106.34 ± 0.908 
4 MESM (0.75 mg/mL) 116.64 ± 0.219 
5 MESM (1 mg/mL) 131.27 ± 0.941 
6 MECP (0.25 mg/mL) 59.21 ± 0.403** 
7 MECP (0.5 mg/mL) 32.06 ± 0.554** 
8 MECP (0.75 mg/mL) 19.03 ± 0.687** 
9 MECP (1 mg/mL) 11.98 ± 0.110** 
10 Orlistate 2.37 0.673** 
 
 
 
 
Figure: 14 Effects of MECP and MESM on pancreatic lipase activity. Lipase activity 
was measured using porcine pancreatic lipase and triolein with lecithin as substrate. 
Inhibiting effect was shown as the lowering of pancreatic lipase activity (%) against 
the lipase activity of control (0 mg/mL of additions). Values are expressed as means 
±SEM of five experiments. The mean difference is significant from control (0 mg/mL 
of additions). 
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4.13: Quantitation of Β-Sitosterol in MECP & MESM by HPTLC:  
The HPTLC pattern for MECP and MESM were recorded using HPTLC (CAMAG, 
Switzerland) using pre-coated silica gel plates (E. MERCK KGaA) at following 
specific criteria.  
1) Sample Preparation: 
The 10 mg of MECP & MESM was dissolved in 10 ml of chloroform, separately to 
give concentration 1 µg/µL.  
 
2) Standard Preparation: β-sitosterol  
2 mg was dissolved in 2 ml of chloroform to give concentration 1 g L-1.  From this 
stock solution  100 g mL-1 solution was prepared. 
 
3) Chromatographic Condition: 
a) Adsorbent: TLC Aluminum precoated plates i.e. HPTLC plates, Silica gel 60 
F254 size 10x10 cm (E. MERCK KGaA).  
b) Solvent system: Chloroform: Methanol (8:0.6) 
 
4) Sample Application: 
Sample application in bands provides high resolution as compared to spot application; 
Linomat-5 allows sample application in narrow by a spray technique.  Sample volume 
of more than 2 l to 100 l can be applied on HPTLC plate.  The precoated aluminum 
plate of 10 x 20 cm was taken and sample applied as follows: 
I. MECP was applied on Ist track in 20 l volume  
II. MESM was applied on  IInd track in 20 l volume 
III. Standard β-sitosterol was applied on IIIrd track in 10 l volume 
IV. Standard β-sitosterol was applied on IVth track in 8 l volume 
V. Standard β-sitosterol was applied on  Vth track in 6 l volume  
VI. Standard β-sitosterol was applied on  VIth track in 4 l volume  
VII. Standard β-sitosterol was applied on  VIth track in 2 l volume  
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5) Chromatographic Development: 
The plate was developed with Chloroform: Methanol (8:0.6) as mobile phase in Twin 
Trough Chamber with lid.  Solvent front position kept 8cm, and then developed plates 
were dried in oven at 100oC for 5 minutes and subjected to scanning.  
 
6) Chromatogram Evaluation and Estimation: 
Derivatization of plate carried out by spraying 10% ethanolic H2SO4 followed by 
heating at 110oC for 10 minutes. The CAMAG TLC Scanner was used for 
chromatogram evaluation.  Plate was scanned at 254 nm and 366 nm (Figure 16)  
See Figure  & observation of HPTLC plate given in Table 9 a. 
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Results of Quantitation of β-sitosterol in MECP & MESM  
 
Chromatogram : Peak display of MECP 
 
Chromatogram : Peak display of AECP 
 
Chromatogram : Peak display of standard β-sitosterol 
Figure 15: Chromatogram of MECP, MESM & β-sitosterol 
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Figure 16: HPTLC Fingerprinting of MECP, MESM & β-sitosterol (After 
Derivatization)   
A:  Track Ist in 20 l MECP  
B:  Track IInd in 20 l MESM 
S1: Track IIIrd Standard β-sitosterol 10 l  
S2: Track IVth Standard β-sitosterol 8 l  
S3: Track Vth Standard β-sitosterol 6 l 
S4: Track VIth Standard β-sitosterol 4 l 
S5: Track VIth Standard β-sitosterol 2 l  
 
Table 9 a: Observation of HPTLC Plate of MECP, MESM & β-sitosterol 
Track No. Volume (μl) Max. Rf for β-
sitosterol 
AUC 
I 20 0.64 6542.6 
II 20 0.67 6050.4 
III 10 0.66 10226.9 
IV 8 0.65 7858.7 
V 6 0.64 7749.6 
VI 4 0.64 4155.5 
VII 2 0.67 4029.2 
Chapter 4                                                PHARMACOGNOSTIC STUDY 
 
                                      Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 92 
 
 
Figure 17: Graph of Conc. Vs AUC for Calculations for β-sitosterol 
MECP: 
y = 804.9x + 1974 
x = 6542.6 – 1974/804.9, therefore; x = 5.676 
20 µg/20 µl of MECP contains 5.676µg of β-sitosterol 
So, 1000 µg/1000 µl of MECP contain 283.8 µg of β -sitosterol 
i.e., 1 mg/1 mL of MECP contain 0.2838 mg of β -sitosterol 
 1000 mg = 1 g   0.2838 g of β -sitosterol 
MECP have extractive value 2.73 % w/w with respective to CP powder.  
As,  1 g MECP contains  0.2838 g of β -sitosterol, 
2.73 g MECP contains  0.78 g β -sitosterol.  
 Result: β -sitosterol in the MECP was found to be, 0.78 %w/w  
MESM: 
y = 804.9x + 1974 
x = 6050.4– 1974/804.9, therefore; x = 5.064 
20 µg/20 µl of MESM contains 5.064 µg of β -sitosterol 
So, 1000 µg/1000 µl of MESM contain 253.22 µg of β -sitosterol 
i.e., 1 mg/1 mL of MESM contain 253.22 mg of  β -sitosterol 
 1000 mg = 1 g   0.25322 g of β -sitosterol 
MESM have extractive value 2.41% w/w with respective to SM powder.  
As,  1 g MESM contains  0.25322 g of β -sitosterol, 
2.41 g MESM contains  0.61 g β -sitosterol.  
Result: β -sitosterol in the MESM was found to be, 0.61 %w/w. 
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5.0: TOXICITY STUDIES 
Clerodendrum phlomidis:  
Procedure: Acute toxicity studies were performed according to OECD-423 
guidelines category IV substance (acute toxic class method). Albino mice (n=3) of 
either sex selected by random sampling technique were employed in this study. The 
animals were fasted for 4 hrs with free access to water only. The plant extracts of 
Clerodendrum phlomidis were administered orally with an initial dose of 1000 mg/kg 
body weight. The mortality was observed for three days. If mortality was observed in 
2/3 or 3/3 of animals, then the dose administered was considered as a toxic dose. 
However, if the mortality was observed only one mouse out of three animals then the 
same dose was repeated again to confirm the toxic effect. If mortality was not 
observed, the procedure was then repeated with higher dose (Organization for 
economic Co-operation and development, 2001). 
Results 
The plant extracts of Clerodendrum phlomidis didn’t shown any mortality and 
toxicity even at highest dose of 2000 mg/kg body weight employed. The present 
research study was carried out using three different doses (low, medium and high) 
methanolic and alcoholic extract’s of Clerodendrum phlomidis such as 100, 200 and 
400 mg/kg body weight for anti-obesity & and anti-diabetic activity.  
Stellaria media: 
 Above procedure was repeated for S. media have not shown any signs of toxicity.  
Toxicity record sheet: Toxicity record sheet is shown as follows for the C. phlomidis 
and S. media.   
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Acute Toxicity Record Sheet of Clerodendrum phlomidis 
             
Title: Evaluation of LD50 Clerodendrum phlomidis.   
Drug: Clerodendrum phlomidis    Dose: 2000 mg/kg BW  Species: Albino mice Sex: Male & Female 
  Date: 21/03/2009                      Duration: 24 hours   
Sl. 
No 
Code 
Toxicity Time 
Of 
Death 
Observations 
Skin 
& Fur 
Eyes Resp CNS Tre Con Sali Diah Sleep Let Coma On 
Set Stop 
1 MECP X x x x x x x x x x x x x x 
2 AECP x x x x x x x x x x x x x x 
 
 (*TRE-Tremor, CON-Convulsions, SALI- Salivation, Diah - Diarrhea, LET-Lethargy)   x = Negative, = Positive  
MECP. = Methanolic extract of Clerodendrum phlomidis,                     AECP: Alcoholic  extract of Clerodendrum phlomidis 
   
Study Director: - Prof.  (Dr.) K. N Patel 
Study Pharmacologist: Vijay R. Chidrawar 
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Acute Toxicity Record Sheet of Stellaria media   
             
Title: Evaluation of LD50 Stellaria media   
Drug: Stellaria media    Dose: 2000 mg/kg BW              Species: Albino mice Sex: Male & Female           
Date: 24/03/2009                    Duration: 24 hours   
Sl. 
No 
Code 
Toxicity 
Time Of 
Death 
Observations 
Skin & 
Fur 
Eyes Resp CNS Tre Con Sali Diah Sleep Let Coma 
On Set Stop 
1 MECP X x x x x x x x x x x x x x 
2 AECP x x x x x x x x x x x x x x 
 
 (*TRE-Tremor, CON-Convulsions, SALI- Salivation, Diah - Diarrhea, LET-Lethargy)    x = Negative, = Positive  
MESM = Methanolic extract of Clerodendrum phlomidis,                        AESM: Alcoholic extract of Stellaria media 
Study Director: - Prof.  (Dr.) K. N Patel 
Study Pharmacologist: Vijay R. Chidrawar 
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Selection of Dose: In the present study we have selected three doses i.e. 100 mg/kg, 200 
mg/kg and 400 mg/kg of body weight, selection of doses is based upon toxicity study.  In 
the toxicity studies up to 2000 mg/kg body weight animals have not shown any signs of 
toxicity, morbidity and mortality so 10% of the maximum dose have been chosen i.e  200 
mg/kg body weight, other two doses were selected one is submax and other is supramax 
of 200 mg/kg body weight.  
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6.0: ANIMAL MODEL NO. 1: DRUG INDUCED OBESITY 
6.1 Bases of experimental Design: The neuroactive steroid progesterone is a female 
reproductive hormone. Its level increases during the second part of the menstrual 
cycle and control the secretory phase of endometrium. It also exerts various metabolic 
effects such as rising basal insulin levels, stimulating lipoprotein lipase activity and 
enhancing fat storage in the body. As the name suggesting, (Pro= for, gest = 
gestation), the higher endogenous levels of progesterone and its metabolites in 
pregnant women are reported to enhance food ingestion throughout pregnancy and 
conserve energy for the growing fetus. Further, some reports suggest that use of 
progesterone containing preparation as contraceptive or for hormonal replacement 
therapy to cause significant weight gain by increasing fat deposition. Progesterone 
also exerts antiesterogenic effects, which also been shown to increase in food intake. 
Furthermore, progesterone has been reported as the most fattening of steroids 
hormone that promotes synthesis and storage of fats. Therefore, progesterone–induced 
hyperphagia causes weight gain and fat deposition is useful as animal model of drug-
induced obesity. This may also useful to study pharmacological agents useful for 
treatment of obesity caused in the female by consumption of progesterone containing 
contraceptive pills (which is a major cause of obesity in females), disturbances in 
menstrual cycle resulting alterations in level of progesterone, estrogen and 
testosterone as their secretion is interdependent.    
6.2 Justification of the design:  
6.2-a: Strain: Swiss albino mice has been used, in this present study we have 
studied animal behavior, for the behavioral study female mice is generally the 
choice of experimental animal, easily available, handling is easy and on past 
literature study on these we have chosen the female mice in this study. 
6.2-b: Gender: Normally level of progesterone is low in male compared to 
female, so female mice have been used in the present study to avoid high 
effect of progesterone in male mice like gynocomestia and other endocrine 
and metabolic effects.   
6.2-c: Age: Adult mice have been chosen in the study, as menstrual cycle will 
start in the adult age level and progesterone is maintained.   
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6.3: Materials and Methods 
Materials 
Remi research centrifuge (R-24), Soxhlet extractor, Olampus Research 
microscope with computer connectivity and image capturing capacity, HPTLC, 
Shimadzu UV-visible spectrophotometer (UV1800), micrtone, Open field test was 
fabricated, based on earlier standard literature. Inco rectal telethermometer, Stat Fax 
autoanalyser (2000), Afcoset digital balance (ER-180A). Sibutramine was gifted by 
the Ranbaxy Laboratory Ltd, Devas, MP. Progesterone Sun Pharmaceutical Ind. Ltd., 
Mumbai; manuf date: 09/2008; batch no: HK40553; conc: 50 mg/ml; brand name: 
Susten 200; was purchased from local market.  
6.4: Animal selection:  
84 (14 x 6) female albino mice (20-25 g) were used in this first model. They 
were housed six per cage under standard laboratory conditions at a room temperature 
at 22 ± 2oC with 12h light/dark cycle. The animals were maintained under standard 
nutritional and environmental conditions throughout the experiment. The experiment 
ware carried out between 9:00–16:00 hours at ambient temperature. All the 
pharmacological experimental protocols were approved by the Institutional Animals 
Ethics Committee (Ref: IAEC/HNSIPER/RJK/05/2009) Shree H. N. Shukla Institute 
of Pharmaceutical Education and Research. Rajkot- Gujarat. India. 
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6.5: Animal grouping: 
The animals were randomly divided into following 14 groups; each group consists 
of six animals. Animal grouping and their treatment is as follows:  
Group- I:  Control (Effect of arachis oil on mice) 
Group- II:  Effect of Progesterone on mice 
Remaining groups have received different types of extracts at various doses 
as follows. 
Group- III:  AESM (100 mg/kg) + Progesterone 
Group- IV:  AESM (200 mg/kg) + Progesterone 
Group- V:  AESM (400 mg/kg) + Progesterone 
Group- VI:  MESM (100 mg/kg) + Progesterone 
Group- VII:  MESM (200 mg/kg) + Progesterone 
Group- VIII:  MESM (400 mg/kg) + Progesterone 
Group- IX:  AECP (100 mg/kg) + Progesterone 
Group- X:  AECP (200 mg/kg) + Progesterone 
Group- XI:  AECP (400 mg/kg) + Progesterone 
Group- XII:  MECP (100 mg/kg) + Progesterone 
Group- XIII:  MECP (200 mg/kg) + Progesterone 
Group- XIV:  MECP (400 mg/kg) + Progesterone 
Group- XIV:  Sibutramine 10 mg/kg + Progesterone 
Drug preparations:  
Test drug preparation: 
All plant extracts (methanolic and alcoholic) were soluble in water so distilled water 
(DW) was used as media to dissolve extracts and preparation of test drugs. Standard 
Sibutramine is also soluble in water. While preparation of test drug concentration 
precaution has been taken that all animal groups should receive approximate same 
volume of dose i.e. volume of the dose should be around 400 µl. All the test drugs and 
standard were given by oral gavages by p.o, route.  
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6.6: Induction of Progesterone induced obesity:  
Progesterone vial contents were dissolved in arachis oil and dose of 10 mg/ kg 
was administered subcutaneously in the dorsal neck region to mice for 28 days, 
control group received the vehicle. All drugs were given at a dose of 0.4 ml/100 gm 
body weight. The test drugs were injected 30 minutes before to progesterone 
administration. 
6.7:  Evaluation  
6.7-a: Assessment of food consumption behavior in Mice: The food intake studies 
were carried out on days 1, 7, 14, 21 and 28. The mice were deprived of food 1 h prior 
to experimentation and the test feed for the feeding experiments was standard mice 
chow modified for palatability by adding 10 % of sucrose. On experimental days, 30 
min after last drug administration, 10 g of sweetened chow was presented to groups of 
mice in glass Petri dishes and food intake was recorded at 0.5, 1 and 2 h time 
intervals. Nearest to 0.1 g with correction for spillage and the amount of food 
consumed/20 g body weight was calculated (Kaur G and Kulkarni SK, 2002).  
6.7-b: Change in Body weight: The body weight of mice (g) was recorded every 
week for 28 days in each group just before dosing. 
6.7-c: Exploratory behavior:  It was recorded on day 28 using open field behaviour 
test apparatus and 30 min after test drug administration to treatment groups. The 
apparatus consists of Fabricated chess board (black and white squares) was used it 
consists of 64 squares (5 x 5 cm) with wall of 15 cm. Open field test was performed 
by placing the mice in the center and recording the ambulatory activity (squares 
crossed by horizontal movement), the frequency of rearing (standing up vertically) 
and grooming (face washing and repetitive licks directed to body). The mouse was 
placed in the center of the field and observed was recorded by Sony handy cam for 5 
min.  Animals were kept under laboratory condition 1hour prior to test. Behavior was 
recorded by Sony handy cam for noting exact reading and storage of data. Between 
the trials the field was cleaned after every reading with wet sponge and tissue papers. 
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6.7-d: Biochemical parameters 
Preparation of serum/plasma: On 29th day of study after the last test drug 
administration animals were anaesthetized under light ether anesthesia and blood for 
plasma preparation was collected by retro orbital puncture, using 10 µl x 20mm (L) x 
0.8 mm (2R) glass capillary into sterile EDTA-coated tube (3 mg/ml) for the 
estimation. Blood was kept in wet ice for 30 min, centrifuged for 5 min at 4000g at 4 o 
C (REMIMAK, India) and plasma was aspirated out for the analysis of lipid profile 
and glucose. The plasma was stored in the refrigerator for the analysis of biochemical 
parameters. All analyses on plasma were completed within 24 h of sample collection. 
Plasma samples were analyzed for glucose, Triglyceride and total cholesterol, using 
biochemical kits of Span diagnostics Glucose: GOD/POD method (Trinder, 1969); 
Cholesterol: one step method of Wybenga and Pilleggi (Henry, 1974); Triglycerides: 
GPO-PAP, end point method (Mc Gown, 1983) and HDL-C by Henry, 1974 method.  
6.7-e: Procedure for Biochemical Estimations: 
Estimation of serum total cholesterol (TC) CHOD-PAP method was used for the 
estimation of serum cholesterol. For this method the following were pipetted into the 
reaction vessels using a micropipette. Test sample (T): 0.02 ml serum, 2.00 ml 
reaction solution; the standard sample (S): 0.02 ml standard and 2.00 ml reaction 
solution, while for the blank sample (B): 0.02 ml DW and 2.00 ml reaction solution. 
The mixture were mixed well and incubated for 10 min at +20 to 25 ◦C or 5 min at 37 
o C. The absorbance was read at 546 nm against the reagent blank (Henry, 1974). 
Estimation of serum triglycerides (TG): 
GPO-PAP method was used to estimate the serum triglycerides. For this 0.01 ml of 
serum were taken in a test tube (T) in which 1ml reaction solution were added. In an 
another test tube (S) 0.01 ml standard and 1ml reaction solution were added. The 
solutions were mixed well and incubated at +20 to 25 ◦C for 10 min. The absorbance 
of the sample and standard were measured against reaction solution of same amount 
within 1 h at 546 nm (Mc Gown et. al., 1983). 
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Estimation of HDL-cholesterol:  
CHOD-PAP method (Henry, 1974) was used to estimate the serum HDL cholesterol 
level. For this 2ml of serum was taken in a test tube and 0.5 ml of precipitation 
reagent was added. The mixture was shaked thoroughly and left to stand for 10 min at 
+15 to 250 C and then centrifuged for 15 min at 4000 rpm. Within 2 h after 
centrifugation, the clear supernatant was used for the determination of HDL-C. One 
millilitre of the supernatant was taken in a test tube (T) and 1ml reaction solution was 
added to it. In an another test tube 0.1 ml DW was taken and 1ml reaction solution (B) 
was added. The mixtures were mixed thoroughly, incubated for 10 min at 15–25 ◦C or 
for 5 min at 37 O C and measured the absorbance of the sample against reagent blank 
at 546 nm.  
Estimation of LDL cholesterol 
LDL cholesterol was estimated by using Friedwald’s (1972) formula as follows: 
                Triglycerides 
LDL in mg % = Total cholesterol − HDL-C – ------------------ 
                           5 
Estimation of VLDL cholesterol 
VLDL cholesterol was estimated by using following formula: 
              Triglycerides 
VLDL in mg % = ------------------ 
                         5 
6.7-f: Organ weights: The mice were sacrificed by cervical dislocation on day 30 and 
mice were euthanised by ether over dose on day 31 then different organs (kidneys, 
liver, heart) were removed and weighed, the organ to body weight (mg/gm) ratio was 
recorded. 
6.8: Statistical analysis:  The results are expressed as mean ± SEM. Comparisons 
between the treatment groups and positive control; positive control and control were 
performed by one way analysis of variance (ANOVA) followed by Dunnett test. In all 
tests the criterion for statistical significance was P < 0.05 (95% level). The analysis 
was performed by using GraphPad Prism 4.  
P value P<0.05 is considered as significant *P<0.05, **P<0.01. 
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6.9 Results     Table- 10 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on progesterone 
modulated female mice food consumption (gm / group). 
Sr. No. 
(Groups) Treatment 
Time 
0.5 hr 1 hr 2 hr 
Group I Control (Vegetable oil) 2.86  ± 0.6 3.8 ± 0.28 5.26 ± 0.51 
Group II Progesterone 4.16 ± 1.13 5.14 ± 0.81 6.58 ± 0.81 
Group III AESM (100 mg/kg) + Pro. 1.72 ± 0.65# 3.88 ± 0.69 6.62 ± 1.02 
Group IV AESM (200 mg/kg) + Pro. 2.24 ± 0.17 4 ± 0.31 6.8 ± 0.22 
Group V AESM (400 mg/kg) + Pro. 1.76 ± 0.2 3.02 ± 0.2# 6.02 ± 0.28 
Group VI MESM (100 mg/kg) + Pro. 2.68 ± 0.2# 4.44 ± 0.48 6.42 ± 0.22 
Group VII MESM (200 mg/kg) + Pro. 4.12 ± 1.06 4.88 ± 0.51 5.98 ± 0.21 
Group VIII MESM (400 mg/kg) + Pro. 1.40 ± 0.32 3.08 ± 0.38# 6.24 ± 0.33 
Group IX AECP (100 mg/kg) + Pro. 2.16 ± 0.33## 3.86 ± 0.6 7 ± 0.44 
Group X AECP (200 mg/kg) + Pro. 2.7 ± 0.32 4.50 ± 0.33 6.84 ± 0.54 
Group XI AECP (400 mg/kg) + Pro. 2.16 ± 0.1 3.74 ± 0.29 6.56 ± 0.28 
Group XII MECP (100 mg/kg) + Pro. 2.44 ± 0.29# 3.94 ± 0.31# 6.34 ± 0.24 
Group XIII MECP (200 mg/kg) + Pro. 1.32 ± 0.36 2.98 ± 0.24* 4.70 ± 0.3# 
Group XIV MECP (400 mg/kg) + Pro. 0.96  ± 0.17## 1.44 ± 0.2**## 2.72 ± 0.18**## 
Group XIV Sibutramine 10 mg/kg + Pro. 0.46 ± 0.1*## 1.68 ± 0.25**## 2.26±  0.1**## 
 
Pro.: Progesterone,  
Food consumption pattern was recorded on every week 30 min after drug administration in 
all groups. Results collected are analyzed by one way analysis of variance (ANOVA) 
followed by Dunnett test.  P value less than 0.05 is considered as significant. *P<0.05, 
**P<0.01 
*Comparison with normal control 
# Comparison with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on progesterone modulated female mice food consumption (gm / group). 
Administration of Progesterone to the control animals caused significant increase in the food consumption at 30 min, 1hr and 2hr in the drug 
induced obesity model which was significantly reduced by the administration of AESM (100 mg/kg), MESM (100 mg/kg), AECP (100 mg/kg) at 30 
min, AESM (400 mg/kg), MESM (400 mg/kg) and MECP (100 mg/kg) at 1hr as compared to the disease control animals. Whereas MECP (400 mg/kg) 
and the standard Sibutramine significantly decreased the food consumption at 30 min, 1hr and 2hr as compared to both normal control as well as disease 
controls. 
 
Figure 18 
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Table - 10.1 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on progesterone 
modulated female mice food consumption (gm / group). 
Sr. No. 
(Groups) 
Treatment 
Day / Time 
1st 7th 14th 21st 28th 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
Group I Control (Vegetable oil) 3.5 3.5 4 4.6 4.6 6.8 1.9 3.5 5.1 1.2 4.3 4.4 3.1 3.1 6 
Group II Progesterone 8.1 8.3 8.3 3.4 3.8 4.2 1.1 4.3 5.7 4.2 5 6.2 4 4.3 8.5 
Group III 
AESM (100 mg/kg) + 
Progesterone 
2.6 4.7 8.9 3.5 5.6 8 2 3.6 7.2 0.5 4 6 0 1.5 3 
Group IV 
AESM (200 mg/kg) + 
Progesterone 
2.2 4.2 6.8 2.1 4.2 7.6 2.9 4.2 6.6 2.1 4.6 6.2 1.9 2.8 6.8 
Group V 
AESM (400 mg/kg) + 
Progesterone 
1.5 2.9 6.7 2.2 3.7 6.1 2.1 3.2 5 1.1 2.7 6.4 1.9 2.6 5.9 
Group VI 
MESM (100 mg/kg) + 
Progesterone 
2.4 3.9 6.2 3.1 4.9 6.6 2.2 2.9 5.9 2.5 4.8 6.2 3.2 5.7 7.2 
Group VII 
MESM (200 mg/kg) + 
Progesterone 
3.5 5.8 6.1 3.1 4.8 6.4 2.2 3.7 5.2 2.1 4.2 5.9 2.7 4.4 6.3 
Group VIII 
MESM (400 mg/kg) + 
Progesterone 
2.4 3.9 7.4 1.9 4.1 5.6 0.8 2.3 5.6 0.9 2.6 6.4 1.0 2.5 6.2 
Group IX 
AECP (100 mg/kg)  + 
Progesterone 
1.9 2.6 6.6 3.1 5.5 8.4 2.5 5.0 7.1 2.2 2.6 5.7 1.1 3.6 7.2 
Group X 
AECP (200 mg/kg) + 
Progesterone 
2.1 4.4 7.2 2.7 5.5 8.1 3.5 4.6 6.0 3.3 4.6 .7.7 1.9 3.4 5.2 
Group XI 
AECP (400 mg/kg) + 
Progesterone 
1.8 2.9 5.6 2.4 4.0 7.2 2.2 4.3 6.8 2.1 3.2 6.3 2.3 4.3 6.9 
Group XII 
MECP (100 mg/kg)  + 
Progesterone 
2.6 3.4 5.7 1.9 4.1 6.3 2.7 3.6 7.2 1.7 3.5 6.3 3.3 5.1 6.2 
Group XIII 
MECP (200 mg/kg) + 
Progesterone 
1.3 3.2 4.5 00 2.1 4.2 1.7 3 4.2 1.5 3.1 4.8 2.1 3.5 5.8 
Group XIV 
MECP (400 mg/kg) + 
Progesterone 
1.6 1.2 2.1 0.7 1.2 2.6 1 1.5 3.2 0.6 1.1 2.9 0.9 2.2 2.8 
Group XIV 
Sibutramine 10 mg/kg + 
progesterone 
0.8 1.6 2.4 0.3 1.1 2.3 0.5 2.4 2.5 0.5 1.2 1.9 0.2 2.1 2.2 
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Tables: 11 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone 
modulated female mice % change in body weight. 
Sr. No. 
(Groups) 
Treatment % Change in body weight 
Group I Control (vegetable oil) 5.84 ± 0.473 
Group II Progesterone 20.95 ±  0.746** 
Group III AESM (100 mg/kg) + Progesterone 18.55 ±  0.23** 
Group IV AESM (200 mg/kg) + Progesterone 19.72 ± 0.86** 
Group V AESM (400 mg/kg) + Progesterone 19.81 ± 0.61**## 
Group VI MESM (100 mg/kg) + Progesterone 16.87 ± 0.57**## 
Group VII MESM (200 mg/kg) + Progesterone 10.5 ± 0.44**## 
Group VIII MESM (400 mg/kg) + Progesterone 7.06  ±0.66## 
Group IX AECP (100 mg/kg)  + Progesterone 16.24 ± 0.76** 
Group X AECP (200 mg/kg) + Progesterone 18.47 ± 0.85**## 
Group XI AECP (400 mg/kg) + Progesterone 15.12 ± 0.78**## 
Group XII MECP (100 mg/kg)  + Progesterone 8.48 ±  0.603*## 
Group XIII MECP (200 mg/kg) + Progesterone 9.31 ± 0.726**## 
Group XIV MECP (400 mg/kg) + Progesterone 3.557 ± 0.249## 
Group XIV Sibutramine 10 mg/kg + Progesterone - 3.48 ± 0.533## 
 
The percent change in body weight was calculated based on initial weight of mice 
and weight of mice on 28th day. Results collected are analysed by one way analysis 
of variance (ANOVA) followed by Dunnett test in between normal control and 
treatment; disease control and treatment   P value less than 0.05 is considered as 
significant. *P<0.05, **P<0.01  
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone modulated female mice % change in body weight. 
The administration of Progesterone caused significant increase in the body weight as compared to the disease control group animals which was 
significantly decreased by co-administration of MESM 200 and 400 mg/kg as well as MECP 100, 200 and 400 mg/kg. Standard Sibutramine was 
found to be more significant in this case.  
 
Figure 19 
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Table – 11.1 
Effect of Arachis Oil on body weight (gm) in female mice. 
 
Animal 
No. 
Dose of 
Treatment 
(0.4ml/100gm) 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.085 0.085 21.4 22.3 23.0 23.0 23.08 
2 0.08 0.08 20.0 22.8 23.1 23.6 23.5 
3 0.09 0.09 22.6 22.8 23 23.0 23.0 
4 0.09 0.09 23.2 23.4 23.9 24.0 24.0 
5 0.1 0.1 25.0 25.0 25.3 25.4 25.8 
6 0.09 0.09 24.4 24.7 25.1 25.1 25.2 
Mean 22.76 23.5 23.9 24.01 24.09 
% Change in Body weight 00 3.25 5 5.49 5.84 
SD 1.865 1.106 1.06 1.032 1.159 
SEM 0.761 0.451 0.434 0.421 0.473 
 
 
 
Table – 11.2 
Effect of Progesterone on body weight (gm) in female mice. 
 
Animal 
No. 
Dose of 
Treatment 
10 mg/kg 
Volume of 
Treatment 
ml 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.203 0.101 20.3 20.6 22.6 23.2 23.9 
2 0.214 0.101 21.4 23.3 23.9 25.44 27.08 
3 0.211 0.105 21.1 23.6 24.2 26.3 27.0 
4 0.234 0.117 23.4 23.81 25.6 27.1 29.49 
5 0.246 0.123 24.6 25.3 26.2 27.8 27.9 
6 0.232 0.116 23.2 23.6 25.2 26.6 26.7 
Mean 22.33 23.36 24.61 26.07 27.01 
% Change in Body weight 00 4.61 10.2 16.76 20.95 
SD 1.64 1.52 1.309 1.61 1.82 
SEM 0.67 0.62 0.534 0.658 0.746 
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Table – 11.3 
Effect of ‘AESM’ (100 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.244 0.122 2.44 0.488 23 25.6 25.9 26.7 28.2 
2 0.232 0.116 2.32 0.446 26.4 24.3 25 26.3 28.9 
3 0.244 0.122 2.44 0.488 23.9 25.8 27.8 28.3 29.6 
4 0.25 0.125 2.5 0.5 24.2 26.2 27.1 27.9 29.1 
5 0.226 0.133 2.26 0.45 25.2 26 27.3 27.6 29.3 
6 0.248 0.124 2.48 0.49 26.3 25.6 26.2 27.2 30.2 
Mean 24.83 25.58 26.55 27.33 29.02 
% Change in Body weight 00 3.02 6.92 10.06 18.55 
SD 1.37 0.671 1.036 0.75 0.52 
SEM 0.561 0.274 0.423 0.306 0.23 
 
 
 
 
Table -11.4 
Effect of ‘AESM’ (200 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.211 0.105 4.2 0.422 21.1 21.4 21.9 22.6 24.7 
2 0.209 0.104 0.18 0.418 20.9 21.3 22.2 23.1 26.5 
3 0.234 0.117 4.68 0.468 23.4 23.4 23.8 24.3 27.8 
4 0.149 0.124 4.98 0.498 24.9 25.3 26.2 26.9 29.1 
5 0.25 0.125 5.0 0.50 25 26.3 27.1 27.8 29.4 
6 0.225 0.112 4.5 0.45 22.5 22.8 23.2 24.1 27.2 
Mean 22.97 23.42 24.07 24.8 27.5 
% Change in Body weight 00 1.95 4.78 7.96 19.72 
SD 1.791 2.039 2.133 2.092 1.94 
SEM 0.731 0.832 0.871 0.854 0.86 
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Table – 11.5 
Effect of ‘AESM’ (400 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.206 0.103 8.24 0.412 20.6 20.9 22.1 23.3 25.6 
2 0.244 0.122 9.76 0.488 24.4 24.4 25.7 26.4 28.7 
3 0.236 0.188 9.44 0.472 23.6 23.9 25.4 26.8 28.9 
4 0.226 0.113 8.92 0.446 22.3 22.8 23.3 25.5 27.4 
5 0.234 0.117 9.36 0.468 23.4 24.5 25.6 26.7 28.5 
6 0.25 0.125 10.0 0.5 25 25.6 26.1 27.8 29.3 
Mean 23.22 23.68 24.42 25.74 27.82 
% Change in Body weight 00 1.98 5.61 10.85 19.81 
SD 1.578 1.639 1.63 1.45 1.37 
SEM 0.644 0.669 0.72 0.65 0.61 
 
 
 
Table – 11.6 
Effect of Drug ‘MESM 100 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 
mg/kg) 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.261  0.108 2.16 0.432 21.6 22.2 24.7 25.6 27.2 
2 0.224 0.112 2.24 0.448 22.4 22.4 23.8 24.5 25.4 
3 0.201 0.1 2.01 0.402 20.1 21.1 23.2 25.0 25.5 
4 0.246 0.123 2.46 0.492 24.6 25.0 26.3 27.3 28.5 
5 0.237 0.118 2.37 0.474 23.7 23.7 24.7 25.6 26.4 
6 0.242 0.121 2.42 0.484 24.2 26.0 27.4 28.5 29.8 
Mean 22.76 23.40 24.54 25.6 26.6 
% Change in Body weight 00 2.81 7.82 12.47 16.87 
SD 1.72 1.85 1.17 1.05 1.29 
SEM 0.70 0.75 0.52 0.47 0.57 
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Table – 11.7 
Effect of Drug ‘MESM 200 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.221 0.110 4.42 0.442 22.1 22.3 22.6 23.3 23.8 
2 0.244 0.122 4.88 0.488 24.4 24.4 24.8 25.7 25.5 
3 0.231 0.115 4.62 0.462 23.1 23.4 24.3 25.5 26.1 
4 0.209 0.104 4.18 0.418 20.9 21.3 21.7 23.4 24.8 
5 0.216 0.108 4.32 0.432 21.6 22.4 23.1 23.6 23.9 
6 0.227 0.113 4.54 0.454 22.7 23.1 22.8 23.2 23.5 
Mean 22.46 22.76 23.3 24.3 24.82 
% Change in Body weight 00 1.33 3.76 8.19 10.5 
SD 1.22 1.18 1.25 1.19 0.99 
SEM 0.50 0.52 0.56 0.53 0.44 
 
 
 
 
 
 
 
Table – 11.8 
Effect of Drug ‘MESM 400 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.213 0.108 8.64 0.432 21.6 21.8 22.5 23.1 23.3 
2 0.227 0.113 9.08 0.454 22.7 23.2 24.1 24.8 25.9 
3 0.236 0.118 9.44 0.472 23.6 24.2 25.1 25.6 25.1 
4 0.218 0.109 8.72 0.436 21.8 22.3 22.8 23.4 23.4 
5 0.246 0.123 9.84 0.492 24.6 25.2 26.0 26.4 26.6 
6 0.25 0.125 10.00 0.5 25.0 25.4 26.1 26.6 27.0 
Mean 23.22 23.34 24.1 24.66 24.86 
% Change in Body weight 00 0.51 3.78 6.2 7.06 
SD 1.42 1.38 1.48 1.4 1.47 
SEM 0.58 0.619 0.66 0.63 0.66 
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Table - 11.9 
Effect of ‘AECP’ (100 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.25 0.125 2.5 0.5 25.0 25.7 26.6 27.8 28.7 
2 0.201 0.1 2.01 0.402 20.1 21.3 22.8 23.4 24.6 
3 0.216 0.108 2.16 0.432 21.6 22.2 23.2 24.8 25.8 
4 0.225 0.112 1.25 0.45 22.5 23.4 23.9 24.6 25.9 
5 0.242 0.121 2.42 0.484 24.2 25.1 25.7 26.7 28.1 
6 0.240 0.12 2.4 0.48 24.0 24.8 25.6 26.3 27.8 
Mean 22.90 23.54 24.44 25.4 26.62 
% Change in Body weight 00 2.79 6.72 10.9 16.24 
SD 1.84 1.86 1.64 1.76 1.71 
SEM 0.75 0.83 0.733 0.78 0.76 
 
 
 
 
 
 
 
Table - 11.10 
Effect of ‘AECP’ (200 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.242 0.121 4.84 0.484 24.2 25.7 26.5 27.3 28.6 
2 0.237 0.135 4.74 0.474 23.7 24.1 25.2 25.8 26.7 
3 0.242 0.121 4.84 0.484 24.2 26.2 27.4 28.5 29.2 
4 0.217 0.108 4.34 0.434 21.7 22.3 23.9 24.6 25.9 
5 0.206 0.103 4.12 0.412 20.6 21.2 22.1 22.8 24.6 
6 0.23 0.115 4.6 0.46 23.0 23.7 23.1 23.1 24.7 
Mean 22.79 23.9 25.02 25.8 27 
% Change in Body weight 00 4.87 9.79 13.2 18.47 
SD 1.47 2.14 2.1 2.23 1.9 
SEM 0.60 0.95 0.93 0.99 0.85 
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Table - 11.11 
Effect of ‘AECP’ (400 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.216 0.108 8.64 0.432 21.6 22.8 23.7 24.8 25.4 
2 0.246 0.123 9.84 0.492 24.6 25.2 26.1 27.4 28.7 
3 0.214 0.107 8.56 0.428 21.4 21.6 22.7 23.8 24.7 
4 0.226 0.113 9.04 0.452 22.6 23.1 23.7 24.4 25.2 
5 0.231 0.115 9.24 0.462 23.1 24 25.3 26.2 27.7 
6 0.24 0.12 9.6 0.48 24 25.5 26.6 27.8 28.5 
Mean 22.88 23.34 24.3 25.32 26.34 
% Change in Body weight 00 2.01 6.2 10.6 15.12 
SD 1.278 1.34 1.37 1.46 1.75 
SEM 0.521 0.6 0.61 0.65 0.78 
 
 
 
 
 
Table – 11.12 
Effect of ‘MECP 100 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.244 0.122 2.44 0.488 24.4 25.2 25.9 26.3 26.1 
2 0.248 0.124 2.48 0.196 24.8 25.6 25.6 26.2 26.7 
3 0.218 0.109 2.18 0.436 21.8 22.3 22.6 23.1 23.9 
4 0.224 0.112 2.24 0.448 22.4 23.0 23.4 23.3 23.6 
5 0.237 0.118 2.37 0.474 23.7 24.1 24.5 25.2 25.9 
6 0.207 0.103 2.07 0.414 20.7 21.4 21.8 23.1 23.3 
Mean 22.97 23.60 23.97 24.53 24.92 
% Change in Body weight 00 2.74 4.35 6.79 8.48 
SD 1.60 1.66 1.65 1.55 1.48 
SEM 0.65 0.68 0.67 0.63 0.603 
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Table – 11.13 
Effect of ‘MECP 200 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.217 0.108 4.34 0.434 21.7 22.1 22.6 22.6 23.2 
2 0.211 0.105 4.22 0.422 21.2 21.6 22.2 22.2 22.9 
3 0.104 0.102 4.04 0.404 20.4 21.1 22.7 22.9 23.7 
4 0.246 0.123 4.92 0.492 24.6 25.2 25.8 26.3 26.8 
5 0.25 0.125 5.0 0.5 25.0 26.1 26.2 26.1 26.3 
6 0.236 0.118 4.72 0.472 23.6 24.2 25.1 25.6 26.3 
Mean 22.75 23.38 24.10 24.28 24.87 
% Change in Body weight 00 2.32 5.93 6.72 9.31 
SD 1.91 2.07 1.80 1.91 1.78 
SEM 0.78 0.84 0.73 0.78 0.726 
 
 
 
 
 
 
Table – 11.14 
Effect of  ‘MECP 400 mg/kg’ on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.224 0.112 8.96 0.448 22.4 22.9 23.2 23.0 23.5 
2 0.242 0.121 9.68 0.484 24.2 24.7 24.3 24.6 24.3 
3 0.234 0.117 9.36 0.468 23.4 23.1 23.7 23.6 23.5 
4 0.241 0.120 9.64 0.482 24.1 24.0 24.4 25.1 24.9 
5 0.219 0.109 8.76 0.438 21.9 22.7 22.4 22.6 23.3 
6 0.229 0.114 8.92 0.446 22.3 22.0 22.7 23.2 23.7 
Mean 23.05 23.23 23.45 23.68 23.87 
% Change in Body weight 00 0.78 1.73 2.73 3.557 
SD 0.99 0.97 0.83 0.97 0.61 
SEM 0.40 0.39 0.34 0.40 0.249 
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Table – 11.15 
Effect of ‘Sibutramine’ (10 mg/kg) on Progesterone modulated female mice body 
weight (gm). 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
10 mg/kg 
Volume of 
Treatment 
(ml) 
Day and body weight (gm) 
1st 7th 14th 21st 28th 
1 0.233 0.116 0.233 0.233 23.6 23.6 23.6 23.1 22.8 
2 0.217 0.108 0.217 0.217 21.9 21.3 21.2 21.0 20.7 
3 0.224 0.112 0.224 0.224 21.4 21.9 22.0 21.6 21.2 
4 0.204 0.104 0.204 0.204 20.4 20.4 20.3 20.1 19.8 
5 0.246 0.123 0.246 0.246 24.6 24.1 24.2 23.7 23.3 
6 0.222 0.111 0.222 0.222 22.2 22.0 22.1 21.6 21.6 
Mean 22.35 22.22 22.23 21.85 21.57 
% Change in Body weight 00 - 0.58 - 0.53 - 1.70 - 3.48 
SD 1.52 1.40 1.46 1.33 1.31 
SEM 0.62 0.57 0.59 0.54 0.533 
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Table: 12 
Effect of ‘Stellaria media’ and  ‘Clerodendrum phlomidis’ on exploratory behavior in Progesterone induced obesity in female mice. 
Sr. No. 
(Groups) 
Treatment Ambulation Rearing Grooming 
Group I Control (Vegetable oil) 61.8 ± 85 9.33 ± 2.43 3.33 ± 0.76 
Group II Progesterone 67.33± 9.37 6.33± 1.96 3.50 ± 0.99 
Group III AESM (100 mg/kg) + Progesterone 70.33 ± 4.04 6.67 ± 1.67 4 ± 0.77 
Group IV AESM (200 mg/kg) + Progesterone 64.17±7.21 6.50 ±1.26 3.33± 0.88 
Group V AESM (400 mg/kg) + Progesterone 69.33 ± 7.36 8.33 ± 1.69 3.67 ± 0.76 
Group VI MESM (100 mg/kg) + Progesterone 64.67 ± 8.55 7  ± 1.46 3.33 ± 0.71 
Group VII MESM (200 mg/kg) + Progesterone 70.33 ± 7.19 11.33 ± 1.56 3.83 ± 0.70 
Group VIII MESM (400 mg/kg) + Progesterone 68.83 ± 9.15 9.83 ± 1.17 3.17 ± 0.60 
Group IX AECP (100 mg/kg)  + Progesterone 64.5 ± 10.57 7.17 ± 1.66 2.83 ± 0.6 
Group X AECP (200 mg/kg) + Progesterone 70.5 ±  16.12 6.67 ±  1.52 3.5 ±  0.72 
Group XI AECP (400 mg/kg) + Progesterone 60.67 ± 4.57 7.5 ± 0.76 2.5 ± 0.62 
Group XII MECP (100 mg/kg)  + Progesterone 76  ± 8.41 13.33 ± 1.2# 2.83 ± 0.79 
Group XIII MECP (200 mg/kg) + Progesterone 106.33 ±  6.9# 21.67 ± 1.02**## 2.83 ±  0.7 
Group XIV MECP (400 mg/kg) + Progesterone 119 ± 8.4## 25.17 ± 1.68**## 3.17 ± 0.7 
Group XV Sibutramine 10 mg/kg + Progesterone 124.5 ± 2.91## 26.5 ± 2.69**## 4.5 ±1.18 
Exploratory behaviour of progesterone induced obesity in female mice was studied by open field test on 28th day of study. Open 
field test carried out for 5 minutes, total number of ambulation, rearing and grooming were counted for each animal, and expressed 
as mean ± SE. Results collected are analysed by one way analysis of variance (ANOVA) followed by Dunnett test in between 
normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. *P<0.05, 
**P<0.01 
*Comparison of test and disease control with normal control, # Comparison test with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on exploratory behavior in Progesterone induced obesity in female mice. 
There was no significant change in the exploratory behavior of Progesterone control animals as compared to the control group animals but co-
administration of  MECP 200 and 400 mg/kg significantly increased the number of ambutations and rearings but not the number of groomings. 
  
Figure 20 
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Table - 12.1 
Effect of Vegetable oil on exploratory behavior in female mice. 
Animal No. 
Dose of 
Treatment 
Volume of 
Treatment (ml) 
Ambulation Rearing Grooming 
1 0.085 0.085 60 01 01 
2 0.08 0.08 65 11 02 
3 0.09 0.09 41 12 03 
4 0.09 0.09 32 13 03 
5 0.1 0.1 80 03 06 
6 0.09 0.09 88 16 05 
Mean 61 9.33 3.33 
SD 21.67 5.96 1.86 
SEM 8.85 2.43 0.76 
 
 
 
 
 
 
 
Table - 12.2 
 
Effect of Progesterone on exploratory behavior in female mice. 
 
Animal No. 
Dose of 
Treatment 
 
Volume of 
Treatment 
ml 
Ambulation Rearing Grooming 
1 0.203 0.101 44 07 02 
2 0.214 0.101 64 05 05 
3 0.211 0.105 64 02 06 
4 0.234 0.117 94 01 01 
5 0.246 0.123 95 09 06 
6 0.232 0.116 43 14 01 
Mean 67.33 6.33 3.50 
SD 22.96 4.80 2.43 
SEM 9.37 1.96 0.99 
Chapter 6                                                     DRUG INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 119 
 
Table - 12.3 
Effect of ‘AESM’ (100 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.244 0.122 2.44 0.488 76 11 06 
2 0.232 0.116 2.32 0.446 70 04 04 
3 0.244 0.122 2.44 0.488 64 12 03 
4 0.25 0.125 2.5 0.5 79 04 01 
5 0.226 0.133 2.26 0.45 54 02 04 
6 0.248 0.124 2.48 0.49 79 07 06 
Mean 70.33 6.67 4.00 
SD 9.89 4.08 1.90 
SEM 4.04 1.67 0.77 
 
 
 
 
 
 
Table - 12.4 
Effect of ‘AESM’ (200 mg/kg) on Progesterone exploratory behavior parameters 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.211 0.105 4.2 0.422 65 7 2 
2 0.209 0.104 0.18 0.418 82 9 00 
3 0.234 0.117 4.68 0.468 54 11 5 
4 0.149 0.124 4.98 0.498 39 4 3 
5 0.25 0.125 5.0 0.50 86 5 4 
6 0.225 0.112 4.5 0.45 59 3 6 
Mean 64.17 6.50 3.33 
SD 17.66 3.08 2.16 
SEM 7.21 1.26 0.88 
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Table - 12.5 
Effect of ‘AESM’ (400 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.206 0.103 8.24 0.412 65 12 1 
2 0.244 0.122 9.76 0.488 51 4 2 
3 0.236 0.188 9.44 0.472 56 7 4 
4 0.226 0.113 8.92 0.446 84 4 5 
5 0.234 0.117 9.36 0.468 98 9 6 
6 0.25 0.125 10.0 0.5 62 14 4 
Mean 69.33 8.33 3.67 
SD 18.02 4.13 1.86 
SEM 7.36 1.69 0.76 
  
 
 
 
 
 
 
 
Table – 12.6 
Effect of ‘MESM’ (100 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.261  0.108 2.16 0.432 62 10 4 
2 0.224 0.112 2.24 0.448 98 4 6 
3 0.201 0.1 2.01 0.402 81 6 2 
4 0.246 0.123 2.46 0.492 43 2 1 
5 0.237 0.118 2.37 0.474 55 11 3 
6 0.242 0.121 2.42 0.484 49 9 4 
Mean 64.67 7 3.33 
SD 20.94 3.58 1.75 
SEM 8.55 1.46 0.71 
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Table – 12.7 
Effect of ‘MESM’ (200 mg/kg) on Progesterone exploratory behavior parameters 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.221 0.110 4.42 0.442 67 12 3 
2 0.244 0.122 4.88 0.488 82 16 4 
3 0.231 0.115 4.62 0.462 94 13 1 
4 0.209 0.104 4.18 0.418 56 5 4 
5 0.216 0.108 4.32 0.432 77 9 5 
6 0.227 0.113 4.54 0.454 46 13 6 
Mean 70.33 11.33 3.83 
SD 17.60 3.83 1.72 
SEM 7.19 1.56 0.70 
 
 
 
 
Table – 12.8 
Effect of ‘MESM’ (400 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.213 0.108 8.64 0.432 98 9 4 
2 0.227 0.113 9.08 0.454 77 14 4 
3 0.236 0.118 9.44 0.472 50 6 2 
4 0.218 0.109 8.72 0.436 43 8 3 
5 0.246 0.123 9.84 0.492 56 10 1 
6 0.25 0.125 10.00 0.5 89 12 5 
Mean 68.83 9.83 3.17 
SD 22.41 2.86 1.47 
SEM 9.15 1.17 0.60 
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Table - 12.9 
Effect of ‘AECP’ (100 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.25 0.125 2.5 0.5 109 12 3 
2 0.201 0.1 2.01 0.402 56 9 5 
3 0.216 0.108 2.16 0.432 42 5 2 
4 0.225 0.112 1.25 0.45 47 2 4 
5 0.242 0.121 2.42 0.484 82 11 2 
6 0.240 0.12 2.4 0.48 51 4 1 
Mean 64.5 7.17 2.83 
SD 25.9 4.07 1.47 
SEM 10.57 1.66 0.6 
 
 
 
 
 
Table - 12.10 
Effect of ‘AECP’ (200 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.242 0.121 4.84 0.484 10 9 2 
2 0.237 0.135 4.74 0.474 47 00 6 
3 0.242 0.121 4.84 0.484 74 5 5 
4 0.217 0.108 4.34 0.434 95 7 2 
5 0.206 0.103 4.12 0.412 125 9 4 
6 0.23 0.115 4.6 0.46 72 10 2 
Mean 70.5 6.67 3.5 
SD 39.49 3.72 1.76 
SEM 16.12 1.52 0.72 
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Table - 12.11 
Effect of ‘AECP’ (400 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.216 0.108 8.64 0.432 45 6 4 
2 0.246 0.123 9.84 0.492 53 8 2 
3 0.214 0.107 8.56 0.428 76 5 2 
4 0.226 0.113 9.04 0.452 65 9 00 
5 0.231 0.115 9.24 0.462 57 7 4 
6 0.24 0.12 9.6 0.48 68 10 3 
Mean 60.67 7.5 2.5 
SD 11.18 1.87 1.52 
SEM 4.57 0.76 0.62 
 
 
 
 
 
 
 
Table – 12.12 
Effect of ‘MECP’ (100 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.244 0.122 2.44 0.488 76 17 00 
2 0.248 0.124 2.48 0.196 108 12 4 
3 0.218 0.109 2.18 0.436 54 16 1 
4 0.224 0.112 2.24 0.448 90 9 5 
5 0.237 0.118 2.37 0.474 72 12 3 
6 0.207 0.103 2.07 0.414 56 14 4 
Mean 76 13.33 2.83 
SD 20.59 2.94 1.94 
SEM 8.41 1.2 0.79 
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Table – 12.13 
Effect of ‘MECP’ (200 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.217 0.108 4.34 0.434 113 20 4 
2 0.211 0.105 4.22 0.422 91 21 3 
3 0.104 0.102 4.04 0.404 86 26 2 
4 0.246 0.123 4.92 0.492 132 19 3 
5 0.25 0.125 5.0 0.5 114 23 00 
6 0.236 0.118 4.72 0.472 102 21 5 
Mean 106.33 21.67 2.83 
SD 16.91 2.5 1.72 
SEM 6.9 1.02 0.7 
 
 
 
 
 
 
 
Table – 12.14 
Effect of ‘MECP’ (400 mg/kg) on Progesterone modulated exploratory behavior 
in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.224 0.112 8.96 0.448 80 24 3 
2 0.242 0.121 9.68 0.484 129 23 6 
3 0.234 0.117 9.36 0.468 136 25 2 
4 0.241 0.120 9.64 0.482 113 21 4 
5 0.219 0.109 8.76 0.438 126 33 1 
6 0.229 0.114 8.92 0.446 130 25 3 
Mean 119 25.17 3.17 
SD 20.57 4.12 1.72 
SEM 8.4 1.68 0.7 
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Table - 12.15 
Effect of ‘Sibutramine’ (10 mg/kg) on Progesterone modulated exploratory 
behavior in female mice. 
 
Animal 
No. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 0.233 0.116 0.233 0.233 112 29 4 
2 0.217 0.108 0.217 0.217 127 36 9 
3 0.224 0.112 0.224 0.224 124 18 7 
4 0.204 0.104 0.204 0.204 125 27 2 
5 0.246 0.123 0.246 0.246 134 29 2 
6 0.222 0.111 0.222 0.222 125 20 3 
Mean 124.5 26.5 4.5 
SD 7.12 6.6 2.88 
SEM 2.91 2.69 1.18 
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Table - 13 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone modulated bio-chemical parameters in female mice. 
Treatment Glu. (mg/dl) TC (mg/dl) TG (mg/dl) HDL-C (mg/dl) LDL-C (mg/dl) VLDL-C mg/dl SGOT (IU/L) SGPT (IU/L) 
Control (Vegetable oil) 128.67 ±14.01 100.17 ± 16.75 79.905 ±7.29 27.06±0.555 57.29±16.61 15.81±1.457 137.23 ±6.51 68.88 ±6.99 
Progesterone 168.33 ± 10.19 133.17 ±11.37 147.15±13.23# # 19.28±0.713** 84.45±13.01 29.43±2.646** 153.68 ±11.77 97.25 ±9.31 
AESM(100mg/kg) + Pro. 165 ±10.88 135.42 ±11.39 126.73 ±4.81 19.75±0.889** 90.31±10.52 25.346±0.962* 148.47 ±8.03 108.2 ±3.21 
AESM(200mg/kg) + Pro. 155 ±16.96 123.12 ±11.60 127.93 ±8.30 20.12±0.989** 77.406±25.815 25.586±1.659* 134.33 ±16.27 101.97 ±5.04 
AESM (400 g/kg) + Pro. 152.8 ±11.52 124.85 ±13.6 130.4 ±8.03 20.21±0.856** 78.543±12.84 26.093±1.606* 143 ±14.64 100.9 ±6.37 
MESM (100 mg/kg) + Pro. 159.6 ±16.24 156.23 ±10.9 150.45 ±16.84 19.59±1.013** 106.55±9.224 30.09±3.368** 175.11 ±9.17 142.67 ±24.82 
MESM (200 mg/kg) + Pro. 137.35 ±9.63 147.18 ±14.65 113.43 ±9.28 21.31±1.024** 103.18±14.63 22.686±1.856 144.2 ±14.04 141.58 ±14.54 
MESM (400 mg/kg) + Pro. 118.3 ±5.69 126.01 ±7.67 94.8 ±6.11* 26.89±1.045## 80.165±8.00 18.96±1.22 109.1 ±21.06 107.03 ±18.35 
AECP (100mg/kg) + Pro. 159.5 ±13.04 117.5 ±11.46 131.5 ±5.69 16.48±0.909** 74.733±11.84 26.316±1.137* 139.1 ±9.65 106.6 ±11.28 
AECP (200 mg/kg) + Pro. 151.3 ±16.83 110.6 ±12.6 105.8 ±20.72 19.29±1.00 70.13±11.14 21.173±4.144 148.3 ±10.61 100.2 ±10.22 
AECP (400 mg/kg) + Pro. 132 ±12.67 110.9 ±9.95 141.3 ±8.97 19.98±1.143** 62.68±10.37 28.27±1.794** 144.9 ±17.12 107.1 ±11.89 
MECP (100 mg/kg) + Pro. 123 ±11.2 139.9 ±11.8 128 ±13.15 22.35±0.852** 91.97±11.29 25.603±2.63* 140.1 ±20.97 106.5 ±5.93 
MECP (200 mg/kg) + Pro. 111.9 ±7.95* 122.2 ±13.54 87.07 ±12.62** 25.71±0.915**## 79.163±13.46 17.41±2.524## 113 ±15.58 105.05 ±10.63 
MECP (400 mg/kg) + Pro. 109.47 ±11.95** 92.4 ±7.45 63.1 ±9.94** 28.99±0.834## 50.77±8.217 12.62±1.987## 114.4 ±10.28 74.32 ±15.43 
Sibutramine 10 mg/kg + Pro. 135.33 ±6.63* 54.4 ±4.75** 57.37 ±5.95** 30.97±0.841**## 30.97±0.841# 11.47±1.18## 114.7 ±12.16 80.97 ±7.56 
 
Vegetable oil, Sibutramine 10 mg/kg and extracts of Stellaria media and Clerodendrum phlomides in doses of 100, 200 & 400 mg/kg; was administered daily by 
oral route for 4 weeks. On 29th day of study serum was obtained from blood collected by retro orbital method and Glucose, Total cholesterol, triglyceride, SGOT 
and SGPT were estimated by using commercial enzyme kits. Results collected are analysed by one way analysis of variance (ANOVA) followed by Dunnett test in 
between normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01 
*Comparison of test and disease control with normal control, # Comparison test with Disease Control. 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone modulated bio-chemical parameters in female mice. 
Progesterone caused significant increase in the TG, and VLDL-C levels decrease in HDL-C levels as compared to the normal control animals 
which were significantly reversed by coadministration of  MECP 100, 200 and 400 mg/kg as well as Standard Sibutramine. 
 
Figure 21 
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Figure 27 
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Figure 29 
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Table - 13.1 
Effect of vegetable oil on biochemical parameters in female mice. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.085 0.085 117 142 92.0 28.00 95.60 18.4 142.2 84.4 
2 0.08 0.08 145 92 104.0 28.9 42.30 20.8 129.2 56.2 
3 0.09 0.09 191 104 64.2 27.32 63.84 12.84 149.0 92.9 
4 0.09 0.09 110 151 69.1 26.14 111.04 13.82 121.2 49.2 
5 0.1 0.1 98 49 86.6 25.04 6.64 17.32 160.4 59.2 
6 0.09 0.09 111 63 58.4 27.00 24.32 11.68 121.4 71.4 
Mean 128.67 100.17 79.05 27.06 57.29 15.81 137.23 68.88 
SD 34.32 41.02 17.85 1.361 40.68 3.57 15.95 17.12 
SEM 14.01 16.75 7.29 0.555 16.61 1.457 6.51 6.99 
 
Table - 13.2  
Effect of Progesterone on biochemical parameters in female mice. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment (ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.203 0.101 145 164 109.1 16.47 125.71 21.82 126.3 103.9 
2 0.214 0.101 171 159 113.6 19.63 116.65 22.72 138.2 100.2 
3 0.211 0.105 182 99 139.4 21.64 49.48 27.88 156.2 94.6 
4 0.234 0.117 190 102 159.2 18. 37 51.79 31.84 171.0 54.2 
5 0.246 0.123 131 144 191.0 20.21 85.59 38.2 129.2 119.6 
6 0.232 0.116 191 131 170.6 19.36 77.52 34.12 201.2 111 
Mean 168.33 133.17 147.15 19.28 84.45 29.43 153.68 97.25 
SD 24.96 27.85 32.41 1.748 31.868 6.481 28.82 22.81 
SEM 10.19 11.37 13.23 0.713 13.01 2.646 11.77 9.31 
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Table - 13.3 
Effect of ‘AESM’ (100 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Vol of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.244 0.122 2.44 0.488 148 142.4 129.4 21.63 94.89 25.88 123.1 112.4 
2 0.232 0.116 2.32 0.446 180 151.6 120.0 20.63 106.97 24 142.2 107.4 
3 0.244 0.122 2.44 0.488 194 96.4 109.3 17.3 57.24 21.86 171.6 102.6 
4 0.25 0.125 2.5 0.5 136 104.5 144.6 16.73 58.85 28.92 169.2 99.2 
5 0.226 0.133 2.26 0.45 140 156.4 126.1 20.63 110.55 25.22 132.1 106.2 
6 0.248 0.124 2.48 0.49 192 161.2 131.0 21.63 113.37 26.2 152.6 121.4 
Mean 165 135.42 126.73 19.75 90.31 25.346 148.47 108.2 
SD 26.65 27.91 11.78 2.178 25.78 2.356 19.66 7.86 
SEM 10.88 11.39 4.81 0.889 10.52 0.962 8.03 3.21 
 
Table - 13.4 
Effect of ‘AESM’ (200 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(200 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.211 0.105 4.2 0.422 188 162.4 147.4 17.63 115.29 29.48 138.6 103.2 
2 0.209 0.104 0.18 0.418 142 109.1 109.2 18.36 68.9 21.84 177.1 86.4 
3 0.234 0.117 4.68 0.468 112 142.6 152.1 23.74 88.44 30.42 103.6 89.2 
4 0.149 0.124 4.98 0.498 192 91.3 101.7 22.03 48.93 20.34 186.2 119.2 
5 0.25 0.125 5.0 0.50 103 96.4 123 20.62 51.18 24.6 91.9 104.6 
6 0.225 0.112 4.5 0.45 193 136.9 134.2 18.36 91.7 26.84 108.6 109.2 
Mean 155 123.12 127.93 20.12 77.406 25.586 134.33 101.9 
SD 41.53 28.41 20.33 2.424 10.539 4.065 39.86 12.35 
SEM 16.96 11.60 8.30 0.989 25.815 1.659 16.27 5.04 
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Table - 13.5 
Effect of ‘AESM’ (400 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.206 0.103 8.24 0.412 141 169.1 136.2 20.63 121.23 27.24 102.6 114.6 
2 0.244 0.122 9.76 0.488 172 143.4 144.4 23.73 90.79 28.88 144.6 120.4 
3 0.236 0.188 9.44 0.472 191 138.1 129.0 17.36 94.94 25.8 123.6 101.2 
4 0.226 0.113 8.92 0.446 110 72.8 104.3 19.63 32.31 20.86 192.0 96.0 
5 0.234 0.117 9.36 0.468 142 106.7 156.7 20.62 54.74 31.34 179.2 76.2 
6 0.25 0.125 10.0 0.5 161 119.0 112.2 19.31 77.25 22.44 116.4 97.2 
Mean 152.8 124.85 130.4 20.21 78.543 26.093 143 100.9 
SD 28.22 33.32 19.68 2.097 31.454 3.935 35.86 15.59 
SEM 11.52 13.6 8.03 0.856 12.84 1.606 14.64 6.37 
 
Table – 13.6 
Effect of ‘MESM’ (100 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.261 0.108 2.16 0.432 142.1 129.4 89.9 20.51 90.91 17.98 174.2 107.6 
2 0.224 0.112 2.24 0.448 193.4 156.6 201.3 19.21 97.13 40.26 189.4 209.4 
3 0.201 0.1 2.01 0.402 104.6 199.4 179.5 17.63 145.87 35.9 153.2 231.4 
4 0.246 0.123 2.46 0.492 212.0 151.0 121.6 16.63 110.05 24.32 188.2 100.2 
5 0.237 0.118 2.37 0.474 170.1 129.4 138.8 19.83 81.81 27.76 144.1 97.2 
6 0.242 0.121 2.42 0.484 135.4 171.6 171.6 23.73 113.55 34.32 201.6 110.2 
Mean 159.60 156.23 150.45 19.59 106.55 30.09 175.11 142.67 
SD 39.79 26.71 41.26 2.481 22.595 8.251 22.45 60.8 
SEM 16.24 10.9 16.84 1.013 9.224 3.368 9.17 24.82 
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Table – 13.7 
Effect of ‘MESM’ (200 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(200 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.221 0.110 4.42 0.442 142.2 145.2 116.3 19.53 102.41 23.26 189.4 121.6 
2 0.244 0.122 4.88 0.488 165.4 123.8 81.2 23.74 83.82 16.24 114.3 134.2 
3 0.231 0.115 4.62 0.462 103.0 159.4 110 24.74 112.66 22 123.0 109.4 
4 0.209 0.104 4.18 0.418 160.2 91.3 123.6 19.5 47.08 24.72 159.3 181.8 
5 0.216 0.108 4.32 0.432 131.3 171 148.9 21.73 119.49 29.78 173.2 112.2 
6 0.227 0.113 4.54 0.454 122.0 192.4 100.6 18.63 153.65 20.12 106.0 190.3 
Mean 137.35 147.18 113.43 21.31 103.18 22.686 144.2 141.58 
SD 23.6 35.87 22.74 2.508 14.63 4.547 34.39 35.62 
SEM 9.63 14.65 9.28 1.024 14.63 1.856 14.04 14.54 
 
Table – 13.8 
Effect of ‘MESM’ (400 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT  
(IU/L) 
SGPT 
(IU/L) 
1 0.213 0.108 8.64 0.432 102.4 121.4 113.1 27.73 71.05 22.62 100.2 111.4 
2 0.227 0.113 9.08 0.454 113.7 156.4 77.3 31.63 109.31 15.46 79.2 170.0 
3 0.236 0.118 9.44 0.472 143.2 104.2 101.3 26.53 57.41 20.26 56.3 142.3 
4 0.218 0.109 8.72 0.436 119.2 113.9 89.4 25.41 70.61 17.88 112.6 100.9 
5 0.246 0.123 9.84 0.492 121.4 139.2 79.6 24.63 98.65 15.92 206.3 68.4 
6 0.25 0.125 10 0.5 110.2 121.0 108.1 25.42 73.96 21.62 100 49.2 
Mean 118.3 126.01 94.8 26.89 80.165 18.96 109.1 107.03 
SD 13.93 18.8 14.97 2.559 19.605 2.99 51.58 44.95 
SEM 5.69 7.67 6.11 1.045 8.00 1.22 21.06 18.35 
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 Table - 13.9 
Effect of ‘AECP’ (100 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.25 0.125 2.5 0.5 152 104 129.5 19.77 58.33 25.9 149.6 118.4 
2 0.201 0.1 2.01 0.402 178 142.3 142.1 17.53 96.35 28.42 177.2 134.2 
3 0.216 0.108 2.16 0.432 193 159.6 126.7 14.65 119.61 25.34 144.5 92.3 
4 0.225 0.112 1.25 0.45 101 101.5 132 13.83 61.27 26.4 132.6 58 
5 0.242 0.121 2.42 0.484 161 84.4 149.9 15.44 38.98 29.98 111.2 124 
6 0.240 0.12 2.4 0.48 172 113.4 109.3 17.68 73.86 21.86 119.6 113.2 
Mean 159.5 117.5 131.5 16.48 74.733 26.316 139.1 106.6 
SD 31.94 28.07 13.94 2.227 29.019 2.787 23.63 27.62 
SEM 13.04 11.46 5.69 0.909 11.84 1.137 9.65 11.28 
 
Table - 13.10 
Effect of ‘AECP’ (200 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Anima
l No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(200 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.242 0.121 4.84 0.484 109 119.9 120.2 16.63 79.23 24.04 170.6 110.4 
2 0.237 0.135 4.74 0.474 204 134.2 102 18.59 95.21 20.4 130.4 124.2 
3 0.242 0.121 4.84 0.484 103 142.4 156.6 17.94 93.14 31.32 152.4 71.2 
4 0.217 0.108 4.34 0.434 142 64.5 12.5 18.35 43.65 2.5 186.0 86.4 
5 0.206 0.103 4.12 0.412 189 121.4 101.3 20.72 80.42 20.26 131.4 131.0 
6 0.23 0.115 4.6 0.46 161 81.2 142.6 23.52 29.16 28.52 119.4 78.4 
Mean 151.3 110.6 105.8 19.29 70.13 21.173 148.3 100.2 
SD 41.23 30.86 50.76 2.458 27.3 10.15 25.99 25.04 
SEM 16.83 12.6 20.72 1.00 11.14 4.144 10.61 10.22 
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Table - 13.11 
Effect of ‘AECP’ (400 mg/kg) on Progesterone modulated biochemical parameters in female mice 
Anima
l No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.216 0.108 8.64 0.432 129 109.2 162.1 17.63 59.15 32.42 192.1 134.5 
2 0.246 0.123 9.84 0.492 136 76.8 113.4 19.63 34.49 22.68 91.6 79.5 
3 0.214 0.107 8.56 0.428 184 143.6 142.3 16.53 98.61 28.46 113.8 144.5 
4 0.226 0.113 9.04 0.452 142 134 129.2 19.63 88.53 25.84 118.6 118.4 
5 0.231 0.115 9.24 0.462 102 102.6 171.6 23.71 44.57 34.32 172.3 86.2 
6 0.24 0.12 9.6 0.48 99 99.4 129.5 22.75 50.75 25.9 181.2 79.5 
Mean 132 110.9 141.3 19.98 62.68 28.27 144.9 107.1 
SD 31.04 24.37 21.98 2.801 25.44 4.396 41.94 29.11 
SEM 12.67 9.95 8.97 1.143 10.37 1.794 17.12 11.89 
 
Table – 13.12 
Effect of ‘MECP’ (100 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-
C mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.244 0.122 2.44 0.488 117.0 109.3 128.4 20.63 62.99 25.68 116.6 112.3 
2 0.248 0.124 2.48 0.196 100.2 186.2 141.9 23.73 134.09 28.38 108.2 109.6 
3 0.218 0.109 2.18 0.436 123.3 117.2 121.6 19.53 73.35 24.32 209.1 81.3 
4 0.224 0.112 2.24 0.448 168.4 161.2 100.4 24.66 116.46 20.08 120.6 99.03 
5 0.237 0.118 2.37 0.474 92.3 129.3 93.2 21.53 89.13 18.64 200.1 114.4 
6 0.207 0.103 2.07 0.414 137.2 136.4 182.6 24.07 75.81 36.52 86.4 122.6 
Mean 123 139.9 128 22.35 91.97 25.603 140.1 106.5 
SD 27.43 28.89 32.21 2.087 27.67 6.442 51.37 14.53 
SEM 11.2 11.8 13.15 0.852 11.29 2.63 20.97 5.93 
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Table – 13.13 
Effect of ‘MECP’ (200 mg/kg) on Progesterone modulated biochemical parameters in female mice. 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(200 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.217 0.108 4.34 0.434 134.2 179.21 103.4 24.63 133.90 20.68 81.06 137.6 
2 0.211 0.105 4.22 0.422 93.3 140.3 68.4 22.83 103.79 13.68 117.9 83.4 
3 0.104 0.102 4.04 0.404 117.4 99.03 37.4 25.64 65.91 7.48 63.2 69.3 
4 0.246 0.123 4.92 0.492 86.4 107.3 112.3 25.77 59.07 22.46 151.0 99.1 
5 0.25 0.125 5.0 0.5 109.2 88.2 81.7 25.74 46.12 16.34 160.4 114.4 
6 0.236 0.118 4.72 0.472 131.0 119.7 119.2 29.67 66.19 23.84 104.6 126.5 
Mean 111.9 122.2 87.07 25.71 79.163 17.41 113 105.05 
SD 19.47 33.16 30.92 2.24 32.99 6.183 38.17 26.04 
SEM 7.95 13.54 12.62 0.915 13.46 2.524 15.58 10.63 
 
Table – 13.14 
Effect of ‘MECP’ (400 mg/kg) on Progesterone modulated biochemical parameters in female mice 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.224 0.112 8.96 0.448 152.2 92.31 55.3 26.74 54.51 11.06 88.2 29.4 
2 0.242 0.121 9.68 0.484 112.0 106.2 106.2 31.73 53.23 21.24 93.4 113.9 
3 0.234 0.117 9.36 0.468 135.6 72.62 59.7 30.61 30.07 11.94 114.6 121.2 
4 0.241 0.120 9.64 0.482 86.4 68.44 73.2 28.53 25.27 14.64 159.3 82.0 
5 0.219 0.109 8.76 0.438 91.2 112.89 37.2 26.74 78.71 7.44 119.0 56.2 
6 0.229 0.114 8.92 0.446 79.4 101.91 47.0 29.64 62.87 9.4 112.4 43.2 
Mean 109.47 92.4 63.1 28.99 50.77 12.62 114.4 74.32 
SD 29.28 18.25 24.34 2.044 20.12 4.867 25.17 37.78 
SEM 11.95 7.45 9.94 0.834 8.217 1.987 10.28 15.43 
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Table - 13.15 
Effect of ‘Sibutramine’ (10 mg/kg) on Progesterone modulated biochemical parameters in female mice 
Animal 
No 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
TC 
(mg/dl) 
TG 
(mg/dl) 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.233 0.116 0.233 0.233 134 106.3 56.1 34.62 34.62 11.22 120.2 64.1 
2 0.217 0.108 0.217 0.217 140 98.53 78.4 30.67 30.67 15.68 170.2 103.2 
3 0.224 0.112 0.224 0.224 149 94.63 46.9 29.63 29.63 9.38 99.1 56.6 
4 0.204 0.104 0.204 0.204 104 93.74 71.0 30.64 30.64 14.2 112.4 79.2 
5 0.246 0.123 0.246 0.246 139 90.63 51.3 31.63 31.63 10.26 84.2 83.5 
6 0.222 0.111 0.222 0.222 146 97.63 40.5 28.63 28.63 8.1 102.6 99.2 
Mean 135.33 96.91 57.37 30.97 30.97 11.47 114.7 80.97 
SD 16.24 5.403 14.57 2.06 2.06 2.91 29.79 18.52 
SEM 6.63 2.206 5.95 0.841 0.841 1.18 12.16 7.56 
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Table – 14 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone modulated wet weight of organ / body weight ratio (mg / gm) 
in female mice. 
Sr. No. 
(Groups) 
Treatment Heart Liver Right kidney Left kidney 
Group I Control (Vegetable oil) 5.43 ± 0.36 48.6 ± 2.28 5.83 ± 0.39 5.44  ± 0.34 
Group II Progesterone 5.06 ± 0.14 43.06 ±1.43 5.05 ± 0.22 5.04 ± 0.16 
Group III AESM (100 mg/kg) + Prog. 5.21± 0.4 51.25 ± 2.93* 4.89 ± 0.27 4.73 ± 0.22 
Group IV AESM (200 mg/kg) + Prog. 5.25± 7.51 41.84 ± 1.01 4.54 ± 0.08# 4.75 ± 0.22# 
Group V AESM (400 mg/kg) + Prog. 5.58 ± 0.58 48.47 ± 2.85* 5.6 ± 5.6* 5.4 ± 0.58* 
Group VI MESM (100 mg/kg) + Prog. 6.47 ± 0.44 52.98 ± 2.37*# 6.22 ± 0.6** 5.82 ± 0.58** 
Group VII MESM (200 mg/kg) + Prog. 4.07 ± 0.66 51.44 ± 2.4*# 5.18 ± 0.35 5.04 ± 0.34 
Group VIII MESM (400 mg/kg) + Prog. 4.87 ± 0.46 50.47 ± 3.65*## 5.19 ± 0.45 4.95 ± 0.43 
Group IX AECP (100 mg/kg) + Prog. 4.67 ± 0.15 46.14 ± 3.21* 5.6 ± 0.62 5.4 ± 0.58 
Group X AECP (200 mg/kg) + Prog. 5.32 ± 0.32 47.21 ± 2.15* 5.46 ± 0.37 5.24 ± 0.33 
Group XI AECP (400 mg/kg) + Prog. 5.14 ± 0.26 47.9 ± 2.13 5.47 ± 0.24 5.2 ± 0.26 
Group XII MECP (100 mg/kg) + Prog. 5.06 ± 0.29 49.65 ± 1.05* 5.2 ± 0.22 4.84 ± 0.22 
Group XIII MECP (200 mg/kg) + Prog. 5.27 ± 0.48 44.6 ± 1.57# 5.09 ± 0.1 4.87 ± 0.13 
Group XIV MECP (400 mg/kg) + Prog. 4.84 ± 0.12 40.63 ± 7.53## 5.15 ± 0.07 4.97 ± 0.09## 
Group XIV Sibutramine 10 mg/kg + Prog 4.68 ± 0.56 41.43 ± 0.59## 5.07 ± 0.67 4.93 ± 0.53## 
Effect of vegetable oil, Sibutramine (10 mg/kg, p.o.), Stellaria media and Clerodendrum phlomidis extracts on Progesterone modulated body 
weight and organ to body wt were studied in female mice, on 31st day after anesthesia with ether. Organs were isolated and weighed, the wet 
weight of organ to body weight were calculated and expresses as mean + SE. Results collected are analysed by one way analysis of variance 
(ANOVA) followed by Dunnett test in between normal control and treatment; disease control and treatment   P value less than 0.05 is 
considered as significant. *P<0.05, **P<0.01, ***P<0.001 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on Progesterone modulated wet weight of organ / body weight ratio (mg / gm) 
in female mice. 
There was significant increase in the organ / body weight ratio of liver, left kidney and right kidney in Progesterone treated animals which was 
significantly decreased by the  co-administration of  MECP 400 and Standard Sibutramine. 
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Table – 14.1 
Effect of vegetable oil on organ weight/ body weight ratio (mg/gm) in female 
mice. 
 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment (ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.085 0.085 5.93 47.18 7.12 5.89 
2 0.08 0.08 4.97 48.08 5.27 5.06 
3 0.09 0.09 4.65 49.34 5.21 4.82 
4 0.09 0.09 5.04 58.83 5.16 4.95 
5 0.1 0.1 7.01 46.12 7.01 6.93 
6 0.09 0.09 5 42.06 5.23 4.96 
Mean 5.43 48.6 5.83 5.44 
SD 0.88 5.59 0.96 0.83 
SEM 0.36 2.28 0.39 0.34 
 
 
 
 
 
 
 
 
 
Table – 14.2 
Effect of Progesterone on organ weight / body weight ratio (mg/gm) in female 
mice. 
 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.203 0.101 5.1 43.26 4.35 5.18 
2 0.214 0.101 4.87 48.02 5.16 4.8 
3 0.211 0.105 5.7 38.88 5.96 5.77 
4 0.234 0.117 4.88 45.38 4.78 4.74 
5 0.246 0.123 5.08 43.44 5.16 5.05 
6 0.232 0.116 4.75 39.36 4.9 4.71 
Mean 5.06 43.06 5.05 5.04 
SD 0.34 3.5 0.54 0.4 
SEM 0.14 1.43 0.22 0.16 
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Table – 14.3 
Effect of ‘AESM’ (100 mg/kg) on Progesterone modulated organ weight/ body 
weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 
mg/kg) 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.244 0.122 2.44 0.488 4.56 59.2 4.96 4.56 
2 0.232 0.116 2.32 0.446 5.06 44.33 4.37 5.06 
3 0.244 0.122 2.44 0.488 6.99 43.63 4.1 4.02 
4 0.25 0.125 2.5 0.5 4.84 51.75 4.8 4.61 
5 0.226 0.133 2.26 0.45 5.52 60.2 5.12 4.51 
6 0.248 0.124 2.48 0.49 4.26 48.41 5.99 5.62 
Mean 5.21 51.25 4.89 4.73 
SD 0.97 7.18 0.66 0.55 
SEM 0.4 2.93 0.27 0.22 
 
 
 
Table – 14.4 
Effect of ‘AESM’ (200 mg/kg) on Progesterone modulated organ weight/ body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.211 0.105 4.2 0.422 5.1 41.96 4.85 4.05 
2 0.209 0.104 0.18 0.418 6.08 46.31 4.67 5.49 
3 0.234 0.117 4.68 0.468 6.41 41.43 4.34 5.01 
4 0.149 0.124 4.98 0.498 4.46 41.4 4.53 4.35 
5 0.25 0.125 5.0 0.50 4.41 38.68 4.52 4.48 
6 0.225 0.112 4.5 0.45 5.03 41.26 4.32 5.11 
Mean 5.25 41.84 4.54 4.75 
SD 0.829 2.48 0.2 0.54 
SEM 0.338 1.01 0.08 0.22 
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Table – 14.5 
Effect of ‘AESM’ (400 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.206 0.103 8.24 0.412 7.76 58.77 7.98 7.63 
2 0.244 0.122 9.76 0.488 4.84 39.54 4.28 4.54 
3 0.236 0.188 9.44 0.472 4.25 43.71 4.53 4.33 
4 0.226 0.113 8.92 0.446 5.3 47.81 5.7 5.22 
5 0.234 0.117 9.36 0.468 6.86 46.89 6.78 6.62 
6 0.25 0.125 10.0 0.5 4.44 54.12 4.33 4.08 
Mean 5.58 48.47 5.6 5.4 
SD 1.42 6.98 1.52 1.42 
SEM 0.58 2.85 0.62 0.58 
 
 
 
 
 
Table – 14.6 
Effect of ‘MESM’ (100 mg/kg) on Progesterone modulated organ weight/ body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.261  0.108 2.16 0.432 7.48 54.62 7.44 6.87 
2 0.224 0.112 2.24 0.448 4.74 52.99 5.38 4.52 
3 0.201 0.1 2.01 0.402 7.41 57.45 8.07 7.85 
4 0.246 0.123 2.46 0.492 6.33 45.41 4.42 4.34 
5 0.237 0.118 2.37 0.474 5.73 60.32 5.04 4.95 
6 0.242 0.121 2.42 0.484 7.12 47.08 6.96 6.38 
Mean 6.47 52.98 6.22 5.82 
SD 1.09 5.81 1.47 1.43 
SEM 0.44 2.37 0.6 0.58 
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Table – 14.7 
Effect of ‘MESM’ (200 mg/kg) on Progesterone modulated organ weight/ body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.221 0.110 4.42 0.442 4.76 60.4 4.88 4.76 
2 0.244 0.122 4.88 0.488 4.55 47.53 6.28 6.1 
3 0.231 0.115 4.62 0.462 5.07 55.3 4.88 4.96 
4 0.209 0.104 4.18 0.418 4.19 48.67 6.06 5.91 
5 0.216 0.108 4.32 0.432 .84 44.13 4.01 3.89 
6 0.227 0.113 4.54 0.454 5.01 52.58 4.94 4.62 
Mean 4.07 51.44 5.18 5.04 
SD 1.62 5.88 0.85 0.83 
SEM 0.66 2.4 0.35 0.34 
 
 
 
 
Table – 14.8 
Effect of ‘MESM’ (400 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.213 0.108 8.64 0.432 4.93 66.06 5.52 5.11 
2 0.227 0.113 9.08 0.454 4.35 47.02 5.0 4.43 
3 0.236 0.118 9.44 0.472 4.16 48.49 4.89 4.67 
4 0.218 0.109 8.72 0.436 7.09 55.45 7.22 6.95 
5 0.246 0.123 9.84 0.492 4.44 42.06 4.20 4.48 
6 0.25 0.125 10.00 0.5 4.24 43.73 4.31 4.04 
Mean 4.87 50.47 5.19 4.95 
SD 1.12 8.94 1.11 1.04 
SEM 0.46 3.65 0.45 0.43 
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Table- 14.9 
Effect of ‘AECP’ (100 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.25 0.125 2.5 0.5 5.0 48.67 7.98 7.63 
2 0.201 0.1 2.01 0.402 4.02 47.11 4.28 4.54 
3 0.216 0.108 2.16 0.432 5.08 59.66 4.53 4.33 
4 0.225 0.112 1.25 0.45 4.7 43.95 5.7 5.22 
5 0.242 0.121 2.42 0.484 4.56 40.28 6.78 6.62 
6 0.240 0.12 2.4 0.48 4.67 37.17 4.33 4.08 
Mean 4.67 46.14 5.6 5.4 
SD 0.38 7.87 1.52 1.42 
SEM 0.15 3.21 0.62 0.58 
 
 
 
 
Table – 14.10 
Effect of ‘AECP’ (200 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.242 0.121 4.84 0.484 4.83 44.98 5.09 4.64 
2 0.237 0.135 4.74 0.474 4.9 50.8 5.36 4.86 
3 0.242 0.121 4.84 0.484 4.67 44.23 4.27 4.56 
4 0.217 0.108 4.34 0.434 6.77 40.07 7.07 6.75 
5 0.206 0.103 4.12 0.412 5.14 54.93 5.31 5.22 
6 0.23 0.115 4.6 0.46 5.62 48.25 5.66 5.42 
Mean 5.32 47.21 5.46 5.24 
SD 0.78 5.26 0.92 0.81 
SEM 0.32 2.15 0.37 0.33 
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Table – 14.11 
Effect of ‘AECP’ (400 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.216 0.108 8.64 0.432 5.65 49.55 5.93 5.73 
2 0.246 0.123 9.84 0.492 5.77 40.96 6.29 6.0 
3 0.214 0.107 8.56 0.428 5.54 42.06 5.7 5.5 
4 0.226 0.113 9.04 0.452 4.6 49.24 4.88 4.6 
5 0.231 0.115 9.24 0.462 5.03 51.82 5.19 4.92 
6 0.24 0.12 9.6 0.48 4.22 53.75 4.85 4.44 
Mean 5.14 47.9 5.47 5.2 
SD 0.63 5.22 0.59 0.64 
SEM 0.26 2.13 0.24 0.26 
 
 
 
 
Table- 14.12 
Effect of ‘MECP’ (100 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.244 0.122 2.44 0.488 4.36 46.43 5.13 4.75 
2 0.248 0.124 2.48 0.196 5.31 38.95 4.83 4.26 
3 0.218 0.109 2.18 0.436 4.97 40.58 4.72 4.61 
4 0.224 0.112 2.24 0.448 4.70 47.62 5.12 4.78 
5 0.237 0.118 2.37 0.474 6.33 45.94 6.21 5.86 
6 0.207 0.103 2.07 0.414 4.67 48.06 5.19 4.80 
Mean 5.06 44.6 5.2 4.84 
SD 0.7 3.86 0.53 0.54 
SEM 0.29 1.57 0.22 0.22 
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Table – 14.13 
Effect of ‘MECP’ (200 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.217 0.108 4.34 0.434 4.91 5.04 5.04 4.74 
2 0.211 0.105 4.22 0.422 7.59 57.64 5.28 5.37 
3 0.104 0.102 4.04 0.404 5.02 46.41 5.44 5.1 
4 0.246 0.123 4.92 0.492 4.88 39.14 5.0 4.81 
5 0.25 0.125 5.0 0.5 4.22 46.15 4.79 4.52 
6 0.236 0.118 4.72 0.472 4.98 49.42 4.98 4.67 
Mean 5.27 40.63 5.09 4.87 
SD 1.18 18.44 0.23 0.31 
SEM 0.48 7.53 0.1 0.13 
 
 
 
Table – 14.14 
Effect of ‘MECP’ (400 mg/kg) on Progesterone modulated organ weight / body 
weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.224 0.112 8.96 0.448 4.93 46.8 5.27 4.76 
2 0.242 0.121 9.68 0.484 4.97 49.95 5.39 5.3 
3 0.234 0.117 9.36 0.468 5.27 46.38 5.14 4.93 
4 0.241 0.120 9.64 0.482 4.49 53.01 4.93 4.77 
5 0.219 0.109 8.76 0.438 4.89 51.07 5.06 5.19 
6 0.229 0.114 8.92 0.446 4.51 50.67 5.10 4.89 
Mean 4.84 49.65 5.15 4.97 
SD 0.3 2.58 0.16 0.22 
SEM 0.12 1.05 0.07 0.09 
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Table – 14.15 
Effect of ‘Sibutramine’ (10 mg/kg) on Progesterone modulated organ weight / 
body weight ratio (mg/gm) in female mice. 
Animal 
no. 
Dose of 
Progesterone 
(10mg/kg) 
Volume of 
Treatment 
(ml) 
Dose of 
Treatment 
10 mg/kg 
Volume of 
Treatment 
(ml) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.233 0.116 0.233 0.233 7.5 54.64 7.54 7.41 
2 0.217 0.108 0.217 0.217 5.6 51.2 5.6 5.5 
3 0.224 0.112 0.224 0.224 8.06 53.01 8.58 8.06 
4 0.204 0.104 0.204 0.204 7.17 51.01 5.15 6.86 
5 0.246 0.123 0.246 0.246 4.72 51.5 5.23 4.93 
6 0.222 0.111 0.222 0.222 7.96 53.24 8.61 7.87 
Mean 6.84 52.43 6.79 6.77 
SD 1.37 1.43 1.65 1.29 
SEM 0.56 0.59 0.67 0.53 
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ANIMAL MODEL NO. 2: FOOD INDUCED OBESITY 
7.1: Bases of experimental Design: 
Cafeteria diet induced obesity:  
Rats that are fed cafeteria diet (CD) are a widely used model of obesity. The so-called 
‘cafeteria diet’ involves feeding experimental animals a mixture of palatable 
commercially available supermarket foods to stimulate energy intake (Rothwell, 
1988). Characteristic for such diets is the combination of the high fat content with 
high carbohydrate content. Further, the components of the cafeteria diet are a variety 
of foods high in fat and sugar but usually low in protein, vitamins and minerals. Such 
diets have pronounced implications in the development of obesity, leading to 
significant body weight gain, fat deposition and also insulin resistance which are 
resembles to human beings (Prats, 1989).  It has been suggested that rats become 
more obese with cafeteria diets than with pure high fat diets, indicating a greater 
hyperphagia arising from the food variety, texture and palatability (Kretschmer, 
2005). Because of the above mentioned facts the ‘cafeteria diet’ model is considered 
for the study. 
A disadvantage of the cafeteria diet, however, is a lack of standardization. The 
nutrient composition cannot be controlled and accurate measurements of energy 
intake are difficult to achieve. 
 
7.2: Justification of the deign 
7.2-a: Rat strain: In this present model we have chosen Wistar rats because this 
metabolic syndrome can be induced more easily than other strains.  
7.2-b: Rat gender: Cafeteria diet causes hypertension in male rats which is not 
seen in female rats. Rise in hypertension may be because of expression of 
kidneys α2-AR in male rats. In female rats, the lack of alterations in renal 
α2-AR during cafeteria diet could play a pivotal role in the prevention of BP 
elevation. Moreover in this present study three models have been used in 
other two models we have used female mice, to minimize any errors in the 
results due to of hormonal variations (Coatmellec-Taglioni, Dausse, 
Giudicelli  & Ribière 2002).  
7.2-c: Age: Rats of this age have a considerably higher ability for deposition than 
older rats, at the end of the experimental duration the rats weighed less than 
250 g are easy to handle.  Moreover rats of this body mass and sex have 
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previously been used successfully to study anti obesity effect fed on 
cafeteria diet (Kaur & Kulkarni, 2000).  
 
7.3: Materials and Methods 
Materials 
Remi research centrifuge (R-24), Soxhlet extractor, Olampus Research 
microscope with computer connectivity and image capturing capacity, 
HPTLC, Shimadzu UV-visible spectrophotometer (UV1800), micrtone, Open 
field model was fabricated based on earlier standard literature., Stat Fax 
autoanalyser (2000), Afcoset digital balance (ER-180A). Sibutramine was 
gifted by the Ranbaxy Laboratory Ltd, Devas, MP. 250 µ pone nylon mesh, 
Micro pipette etc. 
Chemicals: Bovine Serum Albumin, Collagenase Type-1, Methylene blue, 
Oil red O, Trypsin, biochemical kits of Span diagnostics. All the chemicals 
used in the study were of analytical grade. 
7.4: Animal selection:  
90 female Wistar Albino rats of 80 to 120 g in this second model of obesity. 
They were housed six per cage under standard laboratory conditions at a room 
temperature at 22 ± 2oC with 12h light/dark cycle. The animals were 
maintained under standard nutritional and environmental conditions 
throughout the experiment. The experiment were carried out between 9: 00 – 
16:00 hours at ambient temperature. All the pharmacological experimental 
protocols were approved by the Institutional Animals Ethics Committee and 
CPCSEA (Ref: IAEC/HNSIPER/RJK/05/2009) Shree H. N. Shukla Institute 
of Pharmaceutical Education and Research. Rajkot- Gujarat. India. 
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7.5: Animal grouping: 
The animals were randomly divided into following 15 groups; each group 
consists of six animals. Animal grouping and their treatment was as 
follows:  
Cafeteria diet induced obesity 
Group- I:  Normal diet 
Group -II:  effect of CD 
Remaining all groups have received different types of extracts at different 
doses as follows. 
Group -III:  AESM (100 mg/kg) + CD 
Group- IV:  AESM (200 mg/kg) + CD 
Group -V:  AESM (400 mg/kg) + CD 
Group -VI:  MESM (100 mg/kg) + CD 
Group- VII:  MESM (200 mg/kg) + CD 
Group- VIII:  MESM (400 mg/kg) + CD 
Group- IX:  AECP (100 mg/kg) + CD 
Group- X:  AECP (200 mg/kg) + CD 
Group- XI:  AECP (400 mg/kg) + CD 
Group- XII:  MECP (100 mg/kg) + CD 
Group- XIII:  MECP (200 mg/kg) + CD 
Group- XIV:  MECP (400 mg/kg) + CD 
Group- XV:  Sibutramine (10 mg/kg) + CD 
 
Drug preparations:  
Test drug Preparation: 
All plant extracts (methanolic and alcoholic) were soluble in water so distilled 
water (DW) was used as media to dissolve extracts and preparation of test 
drugs. Standard Sibutramine is also soluble in water. While preparation of test 
drug concentration precaution has been taken that all animal groups should 
receive approximate same volume to avoid variation in their oral volume. All 
the test drugs and standard were given by oral gavages by p.o. route.  
  
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 157 
 
7.6: Induction of Cafeteria diet induced obesity in rats  
The cafeteria diet consisted of 3 diets (condensed milk, 48 g + bread,48 g), 
(chocolate, 18 g + biscuits, 36 g + dried coconut, 36 g), (cheese, 48 g + boiled 
potatoes, 60 g). The three diets were presented to group of 6 rats on day 1, 2 
and 3 respectively and then repeated in same succession till 48 days. The diet 
was provided in addition to normal pellet chow. The test drugs were 
administered half hour earlier to cafeteria diet presentation. The control 
animals received only the vehicle in the same volume (Kaur, & Kulkarni, 
2000). 
7.7: Evaluation:  
7.7-a: Body weight 
The body weights of rat (g) were recorded every alternate day throughout the 
experiment for 48 days in each group just before dosing. 
7.7-b: Exploratory behavior  
It was recorded on day 48 using open field behaviour test apparatus and 30 
min after test drug administration to treatment groups. The apparatus consists 
of floor of white tiles dividing field into 25 squares (15 x 15 cm) and wall with 
a height of 25 cm. Open field test was performed by placing the rat in the 
center and recording the ambulatory activity (squares crossed by horizontal 
movement), the frequency of rearing (standing up vertically) and grooming 
(face washing and repetitive licks directed to body). The rat was placed in the 
center of the field and observed was recorded by Sony handy cam for 5 min.  
Animals were kept under laboratory condition 1hour prior to test. Behavior 
was recorded by Sony handy cam for noting exact reading and storage of data. 
Between the trials the field was cleaned after every reading with wet sponge 
and tissue papers. 
7.7-c: Body temperature  
The body temperature of rats were recorded on 49 day using rectal 
telethermometer, before and after drug administration at 1 and 2 hrs.  After 
measuring the body weight, each animal was placed in specially designed 
restricter to measure rectal temperature. A Yellow Spring Instrument 
telethermometer with a series 500 probe was used. The probe was lubricated 
using petroleum jelly prior to use and was inserted between 2.0 and 2.5 cm 
into the rectum and held in position for 10 seconds before temperature was 
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determined. Measurements were made once for each animal and were 
conducted during a 2-hour period before 4 hours light offset. 
 
7.7-d: Biochemical parameters  
Preparation of serum: Blood for serum preparation was collected by retro 
orbital puncture on 49th day of study after the last administration of test drugs. 
Same protocol have been followed as mentioned in the first model of this 
study (pp- 94).   
7.7-e: Organ weights  
Rats were euthanised by ether over dose on day 50 then different organs 
kidneys, liver, heart and body fat (periovarian, perirenal, omental and 
mesenteric fat pad) was isolated, the wet weight of organ to body weight 
(mg/gm) ratio was recorded. After weighing of fat content it was preserved for 
the further study. Adiposity index, a quantitative measure of total fat mass, 
was also calculated using the previously determined equation (Gregoire, et. 
al., 2002).  
Adiposity Index (%) = [∑ (fat pad)/ Body weight X 100]  
7.7-f: Isolation of fat pads and experimental procedure: 
Four regions of adipose tissue were carefully dissected:  
1) The periovarian fat, ovaries were taken out by gentle squeezing from the peripheral 
fat and then by horizontal cut from all sides fat was isolated; care has been taken 
that too much traction was avoided on ovaries and fat.   
2) The retroperitoneal, by first separating the perirenal fat and then dissecting the 
retroperitoneal pad in toto.  
3) The mesenteric, all fat found along the mesentery starting at the lesser curvature of 
the stomach and ending at the sigmoid colon was considered mesenteric fat; 
obtained by cutting the intestine below the duodenal-jejunum junction and 
stripping the fat by gently pulling the intestinal loops apart.  
4)  The Omental, by separating its large fold which hangs down from the stomach, 
and extends from the stomach to the posterior abdominal , without producing any 
harm to the peripheral portion of the tissue.  
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7.7-g: Selection of periovarian fat: Periovarian fat was selected because it  
1) It is located within the abdominal cavity. 
2) It is large enough that it provides enough tissue for subsequent biochemical 
experiments, whereas other fat depots such as the omental, mesenteric, or 
perirenal are too small in the size of rat being used to provide sufficient 
tissue for biochemistry.  
3) It is easy to dissect out, making it possible to sacrifice all animals within a 
shorter period of time and decreasing the possibility of a time effect on any 
measured variable. 
 4) Periovarian making possible any potential comparison of results with the 
published literature. 
7.7-h: Procedure for Adipocyte Isolation and Cell Size Determination: 
Procedure: 
1) Krebs Ringers Buffer has been prepared and pH was adjusted to 7.4.  20 ml of 
above buffer containing 4% Bovine Serum Albumin for washing also prepared 
separately. For digestion of tissue, prepare 10 ml of BSA-Krebs buffer 
containing Collagenase Type I @ 1 mg/ml buffer. 
2)  Animal were sacrificed by cervical dislocation and immediately excise the fat 
tissue (epididymal fat pad, peri-renal fat, mesenteric fat etc) and rinsed in cold 
normal saline solution. 
3) Weight of fat tissue was record for each animal. About 1 g of tissue taken 
from each animal (for mice pooling of fat tissue from lean animals of same 
group can be done) and minced with sharp scissor. Minced tissue was placed 
in 15 ml polyethylene test tubes and 3 ml of collagenase-BSA buffer was add 
to it. (3 mg collagenase / g tissue)   
4) Contents of test were mixed thoroughly and the test tubes were incubated at 
370C for 1.5 hour in shaking water-bath at 60 - 80 strokes/ min. 
5) The contents of tube was mixed at every 15 minutes for proper digestion of 
tissue. 
6) After completion of digestion, the contents were filtered through 250 μ pore 
nylon mesh. 
7) The tubes with filtered cells suspension were then centrifuged at 400 X g for 3 
minute (Remi research centrifuge, R-24)). The upper layer consists of floating 
adipocyte cells and infranatant consists of mesenchymal and other cells.  
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About 2 ml infranatant was aspirated and discarded by taking care not to 
disturb the floating adipocyte cell layer. 
8) Adipocytes were washed by adding 2 ml of BSA-Krebs buffer (without 
collagenase) and centrifuged as above. Finally cells were re-suspend in 3 ml of 
Krebs buffer. 
9) 2% methylene blue solution was prepared in Krebs Buffer and 1 ml of it was 
added in per tube/sample. 
10) Staining was allowed for 30 minutes at room temperature. 
11) 100 μl of supernatant cell suspension was carefully aspirated with the help of 
pipette and placed a drop on clean glass slide then covered with cover slip and 
observed under microscope (200X magnification).   
12) The cells were seen as light colored spherical shaped bodies floating in the 
suspension with dark blue stained nucleus at the cell periphery. 
13) The free fat cells were distinguished from other cells and fat droplets by 
presence of cytoplasm and a nucleus and by their spherical shape.  
14) Record the image of different areas of slide under 100 X and calculate the area 
of each cell for. 
7.7-i: Counting & sizing of fat cells:  Add 0.2- to 0.4-ml aliquots of the stirred 
suspension of stained cells were placed on a siliconized glass slide and examined with 
a Zeiss microscope equipped with a Polaroid camera attachment. The insertion of a 
micrometer disc in a focusing eyepiece placed in the phototube of the camera 
attachment produced a projected caliper scale. At a magnification of 200 X, the 
caliper scale was calibrated so that the unit marks had a constant interval of 7 µ. The 
free fat cells, floating on the surface of the medium, were recognized by the spherical 
shape, the stained nucleus with one or two nucleoli, and the stained cytoplasm; the 
latter features readily distinguished the fat cells from occasional droplets of floating 
lipid. One hundred cells one by one from the same population were brought in the 
caliper field with systematic motion of the stage control knobs. The cells were aligned 
on the caliper scale, the equatorial plane of the cell was brought into focus, and the fat 
cell diameter was determined with accuracy. The sizing and grouping of 100 fat cells 
was performed by one observer in approximately 15-20 min. From this, the mean 
diameter and the standard deviation about the mean could be rapidly calculated by the 
usual formulas. 
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Calculation of mean surface area and volume of a fat cell population:  
From the data on diameters (D) of 100 fat cells in suspension, the frequency 
distributions could also be plotted for the fat cell  
(Surface area) SA = π.D2  
(Cell volume) V = π.D3/6 
Counting of fat cells: 
Number of Fat cells in adipose tissue:  
Number of Fat cells in adipose tissue was calculated by using following formula, 
 
        Total lipid content of fat tissue  
No. of fat cells = -------------------------------------------- 
                              Average lipid content of fat cells  
 
Lipid content of average fat cell= Mean cell volume X  lipid density 
Determination of lipid density: The lipid density was determined on the lipid 
extracted by chloroform-methanol as follows: after evaporation of the solvent in 
vacuum at 30 oC, the oily residue was again redissolved in the same solvent, 
centrifuged, filtered on Whatman paper no. 12, and the solvent again  evaporated to 
yield the adipose lipid as an oil. Three 0. l-ml volumetric pipettes were recalibrated by 
filling to the mark with mercury at 20 C, expelling the mercury into a tared vessel, 
and weighing it. The weight of the oil at 20-25 C over the volume of the calibrated 0.1 
ml pipette, in triplicate, provided a measure of the lipid density (figure 26). 
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  Figure: 31 Isolation procedure of adiposite  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic microscopic determination of fat cell 
diameter. Stained fat cells, floating on 
surface of medium, are aligned on caliper 
scale, brought into focus, and transverse 
diameter was recorded in units. 
Magnification 200X. 
Free fat cells seen in this photograph are 
derived from prioverian fat pads of a 150-g 
rat 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Microscopic structure of isolated fat cells , 
            Magnification 200 X 
 
Figure: 32 Isolated adiposite and measurement of diameter 
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7.7-j: Histopathological Examination: 
7.7-j: i) Histology of fat pad 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33 -a Treatment with Vehicle  &  
Normal Standard diet 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33 -b Treatment with Vehicle  &  CD 
 
Fig:33-c Treatment with AESM (100 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-d Treatment with AESM (200 
mg/kg)  &  CD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-e Treatment with AESM (400 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-f Treatment with MESM (100 
mg/kg)  &  CD 
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Fig: 33-g Treatment with MESM (200 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-h Treatment with MESM (400 
mg/kg)  &  CD 
 
 
 
 
 
 
Fig: 33-i Treatment with AECP (100 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-j Treatment with AECP (200 mg/kg)  
&  CD 
 
 
 
 
 
 
 
Fig: 33-k Treatment with AECP (400 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-l Treatment with MECP (100 
mg/kg)  &  CD 
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Fig: 33-m Treatment with  MECP (200 
mg/kg)  &  CD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33-n Treatment with MECP (400 mg/kg)  
&  CD 
 
 
 
 
 
 
Fig: 33-o Treatment with Sibutramine (10 
mg/kg)  &  CD 
 
Figure 33: Histology of Fat Pad:  
Light micrography of epididymal adipocytes in rats fed a normal or a high-fat diet (X 
200). Representative pictures of haematoxylin and eosin-stained sections of 
periovarian adipocytes from rats fed a normal control diet or a high-fat diet 
supplemented with extracts of S. media and C. phlomidis at various doses. CD feed 
rats show larger size of adipocytes compared to normal control diet. Treatment with 
AECP (400 mg/kg), MECP (200 mg/kg), MECP (400 mg/kg) and MESM (400 
mg/kg) along with CD have shown smaller size of adipocytes than rats feed plain CD.  
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7.7-j: ii) Histolopathology of fat Liver: 
 
 
 
 
 
 
 
Fig: 34-a Treatment with Vehicle  &  Normal 
Standard diet 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-b Treatment with Vehicle  &  CD 
 
 
 
 
 
 
 
 
 
Fig: 34-c Treatment with AESM (100 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-d Treatment with AESM (200 
mg/kg)  &  CD 
 
 
 
 
 
 
 
Fig: 34-e Treatment with AESM (400 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-f Treatment with MESM (100 
mg/kg)  &  CD 
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Fig: 34-g Treatment with MESM (200 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-h Treatment with MESM (400 
mg/kg)  &  CD 
 
 
 
 
 
 
 
 
 
Fig: 34-i Treatment with AECP (100 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-j Treatment with AECP (200 
mg/kg)  &  CD 
 
 
 
 
 
  
 
 
Fig: 34-k Treatment with AECP (400 mg/kg)  
&  CD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-l Treatment with MECP (100 
mg/kg)  &  CD 
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Fig: 34-m Treatment with  MECP (200 
mg/kg)  &  CD 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 34-n Treatment with MECP (400 
mg/kg)  &  CD 
 
 
 
 
 
 
 
 
Fig: 34-o Treatment with Sibutramine (10 
mg/kg)  &  CD 
 
Figure 34: Histopathology of fat Liver 
Light micrography of picture of liver in rats fed normal or high-fat diet (X 200). 
Representative pictures of haematoxylin and eosin-stained sections of hepatocytes from 
rats fed a normal control diet or a high-fat diet supplemented with extracts of S. media 
and C. phlomidis at various doses. No changes have been observed in hepatocytes 
architecture in any group. 
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7.8 Statistical analysis The results are expressed as mean ± SEM. Comparisons 
between the treatment groups and positive control; positive control and control were 
performed by one way analysis of variance (ANOVA) followed by Dunnett test. In all 
tests the criterion for statistical significance was p < 0.05 (95% level). The analysis 
was performed by using GraphPad Prism 4.  
P value P<0.05 is considered as significant *P<0.05, **P<0.01.  
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7.9 Results     
 
Table: 15 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on % change in body 
weight on Cafeteria rats fed rats for 48 days. 
Sr. No. 
(Groups) 
Treatment % Change in body weight 
Group I 
Normal diet 11.82   ± 1.016 
Group II 
Cafeteria diet 20.86 ± 3.73 
Group III 
AESM (100 mg/kg) + CD 25.41 ± 6.974 
Group IV 
AESM (200 mg/kg) + CD 22.77 ±  4.601 
Group V 
AESM (400 mg/kg) + CD 17.67  ± 3.191 
Group VI 
MESM (100 mg/kg) + CD 19.63  ± 2.539# 
Group VII 
MESM (200 mg/kg) + CD 10.48 ± 1.637## 
Group VIII 
MESM (400 mg/kg) + CD 15.45 ± 5.512 
Group IX 
AECP (100 mg/kg)  + CD 31.76 ± 6.781 
Group X 
AECP (200 mg/kg) + CD 25.82 ±  6.196 
Group XI 
AECP (400 mg/kg) + CD 19.58 ± 4.512 
Group XII 
MECP (100 mg/kg)  + CD 19.25 ± 2.213## 
Group XIII 
MECP (200 mg/kg) + CD 17.73 ±  2.191# 
Group XIV 
MECP (400 mg/kg) + CD 12.29 ±  1.116## 
Group XV 
Sibutramine (10 mg/kg)+ CD 8.78  ± 0.461## 
 
The results are expressed as mean ± SEM. Results collected are analysed by one way 
analysis of variance (ANOVA) followed by Dunnett test in between normal control 
and treatment; disease control and treatment   P value less than 0.05 is considered as 
significant. *P<0.05, **P<0.01, ***P<0.001 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on % change in body 
weight on Cafeteria rats fed rats for 48 days. 
There was no significant change in the body weight of Cafeteria diet group animals as 
compared to normal diet animals but there was significant decrease in body weights 
of the animals co-administered with MESM 100 and 200 mg/kg, MECP 100, 200 and 
400 mg/kg and Standard sibutramine was most significant in this case. 
 
Figure: 35 
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Effect of C. phlomidis on Cafeteria diet induced obesity in female rats % change 
in body weight 
 
 
Figure 36: Animals fed with CD showed significant increase in the body weight as 
compared to normal control animals which was significantly decreased in MECP 100, 
200 and 400 mg/kg in dose dependent manner and most significantly by Sibutramine 
compared to normal control and disease control animals.  
*Comparison of test and disease control with normal control 
# Comparison test with disease control 
 
 
-5
0
5
10
15
20
25
30
0 1 4 8 12 16 20 24 28 32 36 40 44 48
%
  C
h
an
ge
Days
Effect of C. phlomidis on Cafeteria diet induced obesity in female 
rats % change in body weight
Normal diet
Cafeteria diet
AECP (100 mg/kg)  + CD
AECP (200 mg/kg) + CD
AECP (400 mg/kg) + CD
MECP (100 mg/kg)  + CD
MECP (200 mg/kg) + CD
MECP (400 mg/kg) + CD
Sibutramine (10 mg/kg)+ CD
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 173 
 
Table - 15.1 
Effect of saline administration on body weight on normal diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
(2 ml/kg) 
Vol. of 
Treatme
nt ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 32nd 36th 40th 44th 48th 
1 0.17 0.17 86 88 87 89 91 90 92 93 93 94 96 95 95 
2 0.18 0.18 92 94 95 96 99 97 98 98 99 103 102 102 101 
3 0.22 0.22 112 116 114 119 121 123 121 124 126 128 128 129 129 
4 0.20 0.20 104 104 103 106 108 113 111 109 107 108 109 110 111 
5 0.22 0.22 112 113 115 117 119 122 122 124 129 128 130 129 131 
6 0.24 0.24 123 125 124 126 126 125 119 123 127 131 134 136 136 
Mean 104.8 106.7 106.3 108.8 110.7 111.7 110.5 111.8 113.5 115.3 116.5 116.8 117.2 
% Change in Body weight 00 1.81 1.43 3.81 5.62 6.58 5.43 6.67 8.3 10.01 11.16 11.45 11.82 
SD 13.8 14 13.9 14.4 13.7 14.8 12.8 14 15.8 15.7 16.2 16.8 17.2 
SEM 5.6 5.7 5.7 5.9 5.6 6.1 5.2 5.7 6.5 6.4 6.6 6.8 7.016 
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Table - 15.2 
Effect of saline administration on body weight on Cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
(2 ml/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 0.24 0.24 120 122 126 125 130 133 133 138 137 140 141 142 142 
2 0.23 0.23 118 119 119 124 129 128 130 132 133 135 136 138 136 
3 0.212 0.212 106 110 110 114 115 119 124 124 126 128 128 131 130 
4 0.202 0.202 101 100 102 101 106 108 112 112 116 117 119 121 119 
5 0.19 0.19 96 98 102 105 112 114 114 118 121 123 121 123 123 
6 0.224 0.224 112 110 114 117 121 126 126 124 130 133 135 135 139 
Mean 108.8 109.8 112.2 114.3 118.8 121.3 123.2 124.7 127.2 129.3 130 131.7 131.5 
% Change in Body weight 00 0.91 3.12 5.05 9.19 11.48 13.23 14.61 16.91 18.84 19.48 21.04 20.86 
SD 9.5 9.7 9.5 9.8 9.6 9.4 8.5 9.4 7.8 8.4 8.8 8.3 9.1 
SEM 3.9 4.0 3.9 4.0 3.9 3.8 3.5 3.8 3.2 3.4 3.6 3.4 3.73 
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Table: - 15.3 
Effect of AESM (100 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 10.2 0.52 104 104 102 109 112 130 128 132 130 128 129 130 130 
2 10.9 0.54 109 110 114 117 120 121 121 124 131 135 140 142 141 
3 11.1 0.55 111 112 116 115 118 121 119 121 123 126 128 129 129 
4 9.6 0.48 96 99 101 104 105 103 108 100 112 115 116 118 118 
5 12.0 0.6 120 124 126 125 130 132 138 139 142 146 156 158 161 
6 10.7 0.53 107 110 111 114 119 120 124 121 126 126 129 130 132 
Mean 107.8 109.8 111.7 114 117.3 121.2 123 122.8 127.3 129.3 133 134.5 135.2 
% Change in Body weight 00 1.85 3.61 5.75 8.81 12.43 14.1 13.91 18.08 19.94 23.37 24.76 25.41 
SD 107.8 109.8 111.7 114.0 117.3 121.2 123 122.8 127.3 129.3 133 134.5 135.2 
SEM 3.2 3.4 3.8 2.9 3.4 4.2 4.1 5.4 4.0 4.2 5.6 5.6 6.974 
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Table - 15.4 
Effect of AESM (200 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 22.4 0.56 112 111 114 116 121 122 128 130 131 134 132 133 133 
2 22.0 0.55 110 109 115 117 121 123 126 130 132 131 133 134 137 
3 20.4 0.51 102 100 101 109 108 112 114 116 116 120 123 122 121 
4 18.2 0.45 91 91 92 96 101 104 109 111 114 119 118 119 116 
5 19.6 0.49 98 99 99 104 107 108 109 113 114 116 118 119 119 
6 22.8 0.57 114 116 120 122 125 127 130 134 139 142 141 143 144 
Mean 104.5 104.3 106.8 110.7 113.8 116 119.3 122.3 124.3 127 127.5 128.3 128.3 
% Change in Body weight 00 -0.19 2.20 5.64 8.89 11 14.16 17.03 18.94 21.54 22 22.77 22.77 
SD 9.0 9.2 11.0 9.6 9.7 9.3 9.8 10.1 11.0 10.2 9.3 9.83 11.3 
SEM 3.7 3.8 4.5 3.9 4.0 3.8 4.0 4.1 4.5 4.2 3.8 4.01 4.601 
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Table - 15.5 
Effect of AESM (400 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
(mg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 32nd 36th 40th 44th 48th 
1 44.0 0.55 110 111 114 120 119 123 130 128 128 127 130 129 131 
2 42.8 0.53 107 108 112 111 115 116 118 121 120 120 118 122 122 
3 38.4 0.48 96 95 97 98 101 103 106 110 112 114 119 120 117 
4 44.8 0.56 112 109 110 114 117 122 121 125 127 130 129 132 133 
5 40.8 0.51 102 101 104 106 110 112 112 116 118 121 120 119 120 
6 47.2 0.59 118 117 121 126 127 125 129 131 133 134 134 135 136 
Mean 107.5 106.8 109.7 112.5 114.8 116.8 119.3 121.8 123 124.3 125 126.2 126.5 
% Change in Body weight 00 -0.65 2.04 4.65 6.79 8.65 10.97 13.30 14.41 15.62 16.27 17.39 17.67 
SD 7.7 7.8 8.3 10.0 8.8 8.3 9.4 7.8 7.7 7.3 6.8 6.7 7.8 
SEM 3.2 3.2 3.4 4.1 3.6 3.4 3.8 3.2 3.1 3.0 2.8 2.8 3.191 
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Table - 15.6 
Effect of MESM (100 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 11.4 0.57 114 110 115 117 121 123 126 125 130 132 134 135 136 
2 9.0 0.45 90 91 93 96 95 99 100 103 100 101 102 102 101 
3 9.8 0.49 98 99 100 104 108 110 114 117 118 118 120 122 121 
4 11.8 0.59 118 121 124 130 134 136 141 140 136 136 138 139 140 
5 1.0 0.6 120 118 121 123 127 125 130 132 134 135 136 137 139 
6 11.1 0.55 111 112 113 117 121 123 124 126 128 132 140 139 142 
Mean 108.5 108.5 111 114.5 117.7 119.3 122.5 123.8 124.3 125.7 128.3 129 129.8 
% Change in Body weight 00 00 2.3 5.52 8.47 9.95 12.9 14.1 14.56 15.85 18.24 18.89 19.63 
SD 11.9 11.5 12.1 12.5 14.0 12.9 14.1 12.8 13.5 13.7 14.7 14.7 16 
SEM 4.9 4.7 4.9 5.1 5.7 5.3 5.7 5.2 5.5 5.6 6.0 6.0 6.539 
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Table - 15.7 
Effect of MESM (200 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 20.4 0.51 102 100 103 105 107 109 111 113 115 113 113 110 111 
2 18.2 0.45 91 90 91 92 93 95 95 94 96 97 99 98 101 
3 19.2 0.48 96 94 95 99 98 101 102 104 104 106 105 106 107 
4 23.2 0.58 116 117 120 122 124 126 129 131 132 131 124 125 125 
5 23.8 0.59 119 119 120 120 122 124 126 127 124 127 130 132 136 
6 18.8 0.47 94 95 96 97 96 94 97 99 101 100 102 101 103 
Mean 103 102.5 104.2 105.8 106.7 108.2 110 111.3 112 112.3 112.2 112 113.8 
% Change in Body weight 00 -0.48 1.16 2.71 3.59 5.04 6.79 8.05 8.73 9.02 8.93 8.73 10.48 
SD 11.8 12.4 12.9 12.5 13.5 14.1 14.7 15.1 14.1 14.1 12.5 13.6 13.8 
SEM 4.8 5.1 5.3 5.1 5.5 5.8 6 6.2 5.8 5.7 5.1 5.6 5.637 
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Table - 15.8 
Effect of MESM (400 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 46.8 0.58 117 119 119 122 124 126 125 126 129 130 131 132 133 
2 38.4 0.48 96 99 95 99 96 99 102 106 106 108 110 111 114 
3 43.6 0.54 109 111 114 116 119 120 122 120 121 124 123 124 125 
4 47.2 0.59 118 120 123 124 126 129 130 131 132 133 134 133 135 
5 36.8 0.46 92 91 92 94 92 96 97 95 97 99 100 102 103 
6 35.6 0.44 89 91 93 90 95 96 98 100 102 104 103 104 107 
Mean 103.5 105.2 106 107.5 108.7 111 112.3 113 114.5 116.3 116.8 117.7 119.5 
% Change in Body weight 00 1.64 2.41 3.86 5.02 7.24 8.5 9.17 10.62 12.36 12.85 13.71 15.45 
SD 12.8 13.3 14.2 14.9 15.9 15.6 14.9 14.7 14.8 14.5 14.5 13.8 13.5 
SEM 5.2 5.4 5.8 6.1 6.5 6.4 6.1 6.0 6.0 5.9 5.9 5.6 5.512 
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Table - 15.9 
Effect of AECP (100 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 8.6 0.43 86 87 92 91 96 102 106 106 109 110 109 110 112 
2 10.5 0.52 105 102 106 110 116 117 121 120 119 124 126 130 137 
3 9.2 0.46 92 90 94 92 96 100 101 108 110 116 121 120 123 
4 11.0 0.55 110 110 112 116 123 128 130 132 137 141 145 144 149 
5 11.2 0.56 112 112 117 122 126 131 138 142 143 140 147 148 151 
6 9.4 0.47 94 92 96 97 102 108 109 111 114 114 115 116 117 
Mean 99.8 98.8 102.8 104.7 109.8 114.3 117.5 119.8 122 124.2 127.2 128 131.5 
% Change in Body weight 00 00 3 4.9 10.02 14.52 17.73 20.04 22.24 24.44 27.54 28.25 31.76 
SD 10.6 10.7 10.36 13.1 13.5 13.2 14.6 14.5 14.5 13.5 15.7 15.4 16.6 
SEM 4.3 4.4 4.23 5.4 5.5 5.4 6.0 5.9 5.9 5.5 6.4 6.3 6.781 
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Table - 15.10 
Effect of AECP (200 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 22.4 0.56 112 110 114 120 122 127 129 131 133 135 136 137 139 
2 23.6 0.59 118 118 119 122 130 132 136 137 140 140 142 144 142 
3 24.2 0.6 121 122 124 127 132 135 141 143 147 150 152 152 156 
4 20.4 0.51 102 103 106 112 116 118 121 120 121 122 123 124 124 
5 18.4 0.46 92 93 95 97 101 103 105 109 110 113 115 116 117 
6 17.8 0.44 89 91 94 96 100 102 105 110 112 116 118 120 120 
Mean 105.7 106.2 108.7 112.3 116.8 119.5 122.8 125 127.2 129.3 131 132.2 133 
% Change in Body weight 00 0.47 2.83 6.24 10.50 13.05 16.17 18.25 20.34 22.32 23.93 25.07 25.82 
SD 13.5 12.8 12.5 13.2 13.9 14.4 15.4 14.2 15.2 14.6 14.7 14.4 15.2 
SEM 5.5 5.2 5.1 5.4 5.7 5.9 6.3 5.8 6.2 6.0 6.0 5.9 6.196 
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Table - 15.11 
Effect of AECP (400 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 47.6 0.59 119 120 122 124 130 134 135 139 140 141 144 143 143 
2 40.0 0.5 100 101 106 108 111 113 115 116 114 116 121 122 120 
3 42.8 0.53 107 106 106 112 116 118 121 120 121 123 124 123 124 
4 39.6 0.49 99 99 100 102 106 110 112 112 114 116 118 121 117 
5 46.4 0.58 116 112 116 120 125 126 131 135 139 141 143 140 141 
6 40.8 0.51 102 100 101 106 109 112 114 117 120 121 123 123 124 
Mean 107.2 106.3 108.5 112 116.2 118.8 121.3 123.17 124.7 126.3 128.8 128.7 128.2 
% Change in Body weight 
00 -0.83 0.93 4.47 8.39 10.82 13.15 14.89 16.32 17.81 20.14 20.05 19.58 
SD 8.5 8.3 8.7 8.5 9.5 9.4 9.6 11.09 11.9 11.7 11.5 10.0 11.1 
SEM 3.5 3.4 3.6 3.5 3.9 3.8 3.9 4.53 4.8 4.8 4.7 4.1 4.512 
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Table - 15.12 
Effect of MECP (100 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 8.6 0.43 86 84 84 86 90 93 96 98 99 101 102 104 103 
2 9.0 0.45 90 91 93 95 97 98 100 102 103 105 107 107 109 
3 9.0 0.45 90 92 91 92 95 96 97 99 100 102 106 106 111 
4 11.4 0.57 114 110 112 115 118 122 126 131 132 134 133 135 136 
5 10.6 0.53 106 104 105 103 107 111 112 115 121 123 124 122 122 
6 10.9 0.54 109 110 112 115 117 121 122 124 125 127 128 130 129 
Mean 99.2 98.5 99.5 101.0 104.0 106.8 108.8 111.5 113.3 115.3 116.7 117.3 118.3 
% Change in Body weight 00 -0.70 0.30 1.81 4.83 7.66 9.67 12.39 14.21 16.22 17.64 18.24 19.25 
SD 11.9 11.0 11.8 12.1 11.8 12.9 13.1 14.0 14.4 14.4 13.2 13.5 12.8 
SEM 4.8 4.5 4.8 5.0 4.8 5.3 5.4 5.7 5.9 5.9 5.4 5.5 5.213 
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Table - 15.13 
Effect of MECP (200 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th  8th  12th  16th  20th  24th  28th  32nd  36th  40th  44th  48th    
1 20.4 0.51 102 100 102 104 104 105 107 109 111 114 115 116 117 
2 18.6 0.46 93 92 94 95 97 99 101 100 101 100 103 104 103 
3 22.8 0.57 114 110 112 114 116 121 124 124 126 127 130 129 128 
4 23.4 0.58 117 117 119 122 123 126 130 131 133 135 132 133 131 
5 18.0 0.45 90 92 94 97 96 94 93 97 99 102 104 102 100 
6 22.2 0.56 111 109 112 117 122 119 121 120 123 122 124 122 120 
Mean 99.2 98.5 99.5 101.0 104.0 106.8 108.8 111.5 113.3 115.3 116.7 117.3 116.5 
% Change in Body weight 00 -0.7 0.3 1.81 4.83 7.66 9.67 12.39 14.21 16.22 17.64 18.24 17.43 
SD 11.9 11.0 11.8 12.1 11.8 12.9 13.1 14.0 14.4 14.4 13.2 13.5 12.72 
SEM 4.8 4.5 4.8 5.0 4.8 5.3 5.4 5.7 5.9 5.9 5.4 5.5 5.19 
 
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 186 
 
Table - 15.14 
Effect of MECP (400 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 32nd 36th 40th 44th 48th 
1 46.4 0.58 116 120 118 121 122 124 126 129 130 133 131 130 131 
2 40.4 0.50 120 117 119 123 125 127 130 133 131 134 131 135 136 
3 37.2 0.46 93 91 94 92 90 93 95 97 95 98 101 103 103 
4 39.6 0.49 99 100 102 104 107 109 111 114 117 115 115 114 116 
5 47.2 0.59 118 115 117 122 120 123 124 120 126 124 125 126 129 
6 41.2 0.51 103 101 104 107 110 112 109 114 112 111 110 112 114 
Mean 
108.2 107.3 109 111.5 112.3 114.7 115.8 117.8 118.5 119.2 118.8 120 121.5 
% Change in Body weight 
00 -0.83 0.73 3.04 3.78 6 7.02 8.87 9.51 9.86 9.79 10.9 12.29 
SD 
11.3 11.6 10.4 12.6 13.0 12.8 13.2 12.8 13.7 13.9 12.2 12.25 12.5 
SEM 
4.6 4.7 4.3 5.1 5.3 5.2 5.4 5.2 5.6 5.7 5.0 5 5.116 
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Table - 15.15 
Effect of Standard Sibutramine (10 mg/kg) administration on body weight on cafeteria diet fed rats for 48 days. 
Animal 
No. 
Dose of 
Treatment 
 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 32nd 36th 40th 44th 48th 
1 1.12 0.56 112 109 111 114 117 115 116 120 122 124 120 121 123 
2 1.0 0.5 100 98 101 104 107 110 107 106 109 108 102 106 105 
3 0.94 0.47 94 92 92 91 93 95 95 97 99 101 103 105 107 
4 0.96 0.48 96 97 97 99 101 104 103 105 110 111 107 109 110 
5 1.0 0.5 100 101 101 102 105 102 99 99 98 101 103 100 103 
6 1.1 0.55 113 110 114 114 115 117 114 116 119 121 120 118 121 
Mean 102.5 101.2 102.7 104 106.3 107.2 105.7 107.2 109.5 111 109.2 109.8 111.5 
% Change in Body weight 00 -1.26 0.19 1.46 3.7 4.58 3.12 4.58 6.82 8.29 6.53 7.12 8.78 
SD 8.1 7.1 8.4 8.9 8.9 8.4 8.3 9.2 9.9 9.8 8.6 8.1 8.5 
SEM 3.3 2.9 3.4 3.6 3.6 3.4 3.4 3.7 4.0 4.0 3.5 3.3 3.461 
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Table – 16 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on body temperature (°C) in cafeteria diet fed rats before and after drug 
administration 
Sr. No. 
(Groups) 
Treatment Before 2 hr Before 1 hr After 1 hr After 2 hr 
Group I Normal diet 36.61 ± 0.1 36.44 ± 0.18 36.22 ± 0.15 35.94 ± 0.23 
Group II Cafeteria diet 36.27 ± 0.15 36.23 ± 0.14 36.57 ± 0.13 36.63 ± 0.10 
Group III AESM (100 mg/kg) + CD 36.29 ± 0.06* 36.30 ± 0.06 36.25 ± 0.05 36.52 ± 0.19** 
Group IV AESM (200 mg/kg) + CD 36.26 ± 0.07**## 36.32 ± 0.10 36.34 ± 0.06 36.33 ± 0.07 
Group V AESM (400 mg/kg) + CD 36.44 ± 0.07## 36.39 ± 0.07 36.47 ± 0.10 36.44 ± 0.08* 
Group VI MESM (100 mg/kg) + CD 36.25 ± 0.08## 36.32 ± 0.08 36.32 ± 0.10 36.39 ± 0.07 
Group VII MESM (200 mg/kg) + CD 36.33 ± 0.05 36.34 ± 0.08 36.46 ± 0.05 36.45 ± 0.05* 
Group VIII MESM (400 mg/kg) + CD 36.56 ± 0.10 36.36 ± 0.08 36.44 ± 0.08 36.49 ± 0.08** 
Group IX AECP (100 mg/kg)  + CD 36.32 ± 0.11**# 36.34 ± 0.11 36.13 ± 0.20 36.39 ± 0.09 
Group X AECP (200 mg/kg) + CD 36.19 ± 0.08## 36.21 ± 0.08# 36.28 ± 0.12 36.36 ± 0.08 
Group XI AECP (400 mg/kg) + CD 36.30 ± 0.05*# 36.33 ± 0.07 36.47 ± 0.07 36.59 ± 0.10* 
Group XII MECP (100 mg/kg)  + CD 36.24 ± 0.02## 36.22 ± 0.03# 36.43 ± 0.07 36.53 ± 0.07** 
Group XIII MECP (200 mg/kg) + CD 36.27 ± 0.05*# 36.28 ± 0.04 36.52 ± 0.06 36.64 ± 0.08** 
Group XIV MECP (400 mg/kg) + CD 36.23 ± 0.07**## 36.22 ± 0.05# 36.43 ± 0.08 36.60 ± 0.08**# 
Group XV Sibutramine (10 mg/kg) + CD 36.72 ± 0.08 36.66 ± 0.10 36.82 ± 0.09*# 37.02 ± 0.07**# 
Effect of Stellaria media and Clerodendrum phlomidis on body temperature (°C) in rats was carried out on 48th day of study. The body 
temperature was recorded by using digital telethermometer and was expressed in °C (with 10 sec contact period). The temperature was recorded 
at 2 hr and 1 hr before and after drug administration. Results collected are analyzed by one way analysis of variance (ANOVA) followed by 
Dunnett test in between normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. 
*P<0.05, **P<0.01. *Comparison of test and disease control with normal control.# Comparison test with Disease Control, CD: Cafeteria diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on body temperature (°C) in cafeteria diet fed rats before and after drug 
administration 
There was significant increase in the body temperature of Cafeteria diet group animals before 2 hr of administration which was significantly 
brought down by the administration of AECP 100,200 and 400 mg/kg and AECP 100, 200 and 400 mg/kg. Sibutramine was effective 2 hr after 
administration.   
  
Figure: 37
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Table - 16.1 
Effect of saline on body temperature (°C) in normal diet fed rats before and after 
drug administration. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 0.17 0.17 36.71 36.23 35.91 36.42 
2 0.18 0.18 36.52 36.72 36.32 35.81 
3 0.22 0.22 36.56 36.83 36.52 35.92 
4 0.20 0.20 36.82 35.74 36.41 36.74 
5 0.22 0.22 36.85 36.81 35.63 35.42 
6 0.24 0.24 36.21 36.31 36.53 35.31 
Mean 36.61 36.44 36.22 35.94 
SD 0.24 0.43 0.37 0.56 
SEM 0.1 0.18 0.15 0.23 
 
 
 
Table - 16.2 
Effect of saline on body temperature (°C) in cafeteria diet fed rats before and 
after drug administration. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 0.24 0.24 36.26 36.12 36.32 36.56 
2 0.23 0.23 36.24 36.37 36.84 36.44 
3 0.212 0.212 36.77 36.64 36.72 36.72 
4 0.202 0.202 36.62 36.56 36.10 36.91 
5 0.19 0.19 35.94 35.92 36.96 36.88 
6 0.224 0.224 35.81 35.76 36.46 36.26 
Mean 36.27 36.23 36.57 36.63 
SD 0.37 0.35 0.33 0.26 
SEM 0.15 0.14 0.13 0.1 
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Table - 16.3 
Effect of AESM (100 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration. 
Animal 
no. 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 10.4 0.52 36.24 36.20 36.34 36.37 
2 10.9 0.54 36.08 36.13 36.10 36.16 
3 11.1 0.55 36.40 36.36 36.14 36.21 
4 9.6 0.48 36.32 36.40 36.28 36.39 
5 12.0 0.6 36.46 36.52 36.4 36.55 
6 10.7 0.53 36.22 36.16 36.21 37.42 
Mean 36.29 36.30 36.25 36.52 
SD 0.14 0.16 0.12 0.46 
SEM 0.06 0.06 0.05 0.19 
 
 
 
 
Table - 16.4 
Effect of AESM (200 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration. 
Animal 
no. 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 22.4 0.56 36.09 36.12 36.14 36.07 
2 22.0 0.55 36.56 36.72 36.62 36.59 
3 20.4 0.51 36.14 36.10 36.36 36.42 
4 18.2 0.45 36.24 36.50 36.31 36.32 
5 19.6 0.49 36.34 36.22 36.30 36.36 
6 22.8 0.57 36.18 36.24 36.30 36.19 
Mean 36.26 36.32 36.34 36.33 
SD 0.17 0.24 0.16 0.18 
SEM 0.07 0.10 0.06 0.07 
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Table - 16.5 
Effect of AESM (400 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration. 
Animal 
No. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment  
ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 44.0 0.55 36.42 36.40 36.51 36.66 
2 42.8 0.53 36.62 36.54 36.72 36.24 
3 38.4 0.48 36.12 36.19 36.24 36.20 
4 44.8 0.56 36.49 36.36 36.46 36.57 
5 40.8 0.51 36.55 36.64 36.72 36.60 
6 47.2 0.59 36.41 36.22 36.16 36.39 
Mean 36.44 36.39 36.47 36.44 
SD 0.17 0.18 0.23 0.20 
SEM 0.07 0.07 0.10 0.08 
 
 
 
 
Table - 16.6 
Effect of MESM (100 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 11.4 0.57 36.45 36.51 36.33 36.49 
2 9.0 0.45 36.56 36.42 36.66 36.77 
3 9.8 0.49 36.18 36.29 36.19 36.44 
4 11.8 0.59 35.94 35.9 36.07 36.12 
5 1.0 0.6 36.62 36.70 36.34 36.24 
6 11.1 0.55 36.15 36.21 35.19 36.28 
Mean 36.32 36.34 36.13 36.39 
SD 0.27 0.27 0.50 0.23 
SEM 0.11 0.11 0.20 0.09 
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Table - 16.7 
Effect of MESM (200 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 20.4 0.51 35.86 35.90 35.80 36.02 
2 18.2 0.45 36.19 36.32 36.29 36.40 
3 19.2 0.48 36.31 36.35 36.42 36.53 
4 23.2 0.58 36.12 36.09 36.66 36.52 
5 23.8 0.59 36.39 36.46 36.21 36.25 
6 18.8 0.47 36.24 36.13 36.29 36.44 
Mean 36.19 36.21 36.28 36.36 
SD 0.18 0.21 0.28 0.20 
SEM 0.08 0.08 0.12 0.08 
 
 
 
 
 
Table - 16.8 
Effect of MESM (400 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 46.8 0.58 36.52 36.66 36.76 36.88 
2 38.4 0.48 36.21 36.15 36.42 36.24 
3 43.6 0.54 36.32 36.24 36.29 36.41 
4 47.2 0.59 36.16 36.24 36.39 36.56 
5 36.8 0.46 36.32 36.40 36.52 36.77 
6 35.6 0.44 36.29 36.30 36.46 36.69 
Mean 36.30 36.33 36.47 36.59 
SD 0.12 0.18 0.16 0.24 
SEM 0.05 0.07 0.07 0.10 
 
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 194 
 
Table - 16.9 
Effect of AECP (100 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 8.6 0.43 35.92 36.12 35.94 36.22 
2 10.5 0.52 36.42 36.56 36.60 36.46 
3 9.2 0.46 36.31 36.28 36.36 36.29 
4 11.0 0.55 36.24 36.18 36.29 36.36 
5 11.2 0.56 36.41 36.56 36.54 36.70 
6 9.4 0.47 36.19 36.24 36.21 36.30 
Mean 36.25 36.32 36.32 36.39 
SD 0.18 0.19 0.24 0.17 
SEM 0.08 0.08 0.10 0.07 
 
 
 
Table - 16.10 
Effect of AECP (200 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 22.4 0.56 36.25 36.34 36.41 36.26 
2 23.6 0.59 36.44 36.54 36.42 36.50 
3 24.2 0.6 36.29 36.26 36.32 36.56 
4 20.4 0.51 36.13 36.02 36.44 36.32 
5 18.4 0.46 36.42 36.31 36.54 36.60 
6 17.8 0.44 36.44 36.56 36.64 36.46 
Mean 36.33 36.34 36.46 36.45 
SD 0.13 0.20 0.11 0.13 
SEM 0.05 0.08 0.05 0.05 
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Table - 16.11 
Effect of AECP (400 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 47.6 0.59 36.72 36.59 36.65 36.65 
2 40.0 0.5 36.29 36.34 36.31 36.41 
3 42.8 0.53 36.77 36.62 36.66 36.72 
4 39.6 0.49 36.66 36.24 36.44 36.56 
5 46.4 0.58 36.70 36.12 36.43 36.14 
6 40.8 0.51 36.19 36.24 36.16 36.44 
Mean 36.56 36.36 36.44 36.49 
SD 0.25 0.20 0.19 0.21 
SEM 0.10 0.08 0.08 0.08 
 
 
 
 
Table - 16.12 
Effect of MECP (100 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 8.6 0.43 36.24 36.30 36.40 36.49 
2 9.0 0.45 36.29 36.19 36.24 36.37 
3 9.0 0.45 36.22 36.30 36.70 36.81 
4 11.4 0.57 36.16 36.14 36.52 36.62 
5 10.6 0.53 36.21 36.12 36.31 36.46 
6 10.9 0.54 36.29 36.24 36.39 36.42 
Mean 36.24 36.22 36.43 36.53 
SD 0.05 0.08 0.16 0.16 
SEM 0.02 0.03 0.07 0.07 
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Table - 16.13 
Effect of MECP (200 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
200 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 20.4 0.51 36.19 36.21 36.37 36.44 
2 18.6 0.46 36.29 36.34 36.49 36.62 
3 22.8 0.57 36.22 36.29 36.49 36.54 
4 23.4 0.58 36.16 36.26 36.39 36.49 
5 18.0 0.45 36.23 36.16 36.72 36.94 
6 22.2 0.56 36.52 36.40 36.67 36.79 
Mean 36.27 36.28 36.52 36.64 
SD 0.13 0.09 0.14 0.19 
SEM 0.05 0.04 0.06 0.08 
 
 
 
 
Table - 16.14 
Effect of MECP (400 mg/kg) on body temperature (°C) in cafeteria diet fed rats 
before and after drug administration 
Animal 
No 
Dose of 
Treatment 
400 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 46.4 0.58 35.95 36.04 36.19 36.24 
2 40.4 0.50 36.11 36.16 36.29 36.62 
3 37.2 0.46 36.24 36.19 36.32 36.51 
4 39.6 0.49 36.32 36.24 36.66 36.78 
5 47.2 0.59 36.41 36.27 36.54 36.71 
6 41.2 0.51 36.32 36.44 36.59 36.72 
Mean 36.23 36.22 36.43 36.60 
SD 0.17 0.13 0.19 0.20 
SEM 0.07 0.05 0.08 0.08 
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Table - 16.15 
Effect of Sibutramine 10 mg/kg on body temperature (°C) in cafeteria diet fed 
rats before and after drug administration 
Animal 
No 
Dose of 
Treatment 
10 mg/kg 
Volume of 
Treatment 
ml 
Before 2 hr Before 1 hr After 1 hr After 2 hr 
1 1.12 0.56 36.65 36.31 36.46 36.77 
2 1.0 0.5 36.71 36.65 36.82 36.96 
3 0.94 0.47 36.81 36.77 36.86 37.01 
4 0.96 0.48 36.94 36.91 36.96 37.12 
5 1.0 0.5 36.84 36.91 37.11 37.28 
6 1.1 0.55 36.36 36.42 36.72 36.96 
Mean 36.72 36.66 36.82 37.02 
SD 0.20 0.25 0.22 0.17 
SEM 0.08 0.10 0.09 0.07 
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Table: 17 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on exploratory behavior 
in cafeteria diet fed rats. 
Sr. No. 
(Groups) 
Treatment Ambulation Rearing Grooming 
Group I Normal diet 67.5 ± 4.1 13.2 ± 0.9 6.0 ± 1.2 
Group II CD 82.8 ± 6.0 34.8 ± 2.2** 5.3 ± 0.7 
Group III AESM (100 mg/kg) + CD 84.0 ± 8.1 29.5 ± 4.5* 4.3 ± 0.8 
Group IV AESM (200 mg/kg) + CD 76.3 ± 7.1 30.5 ± 3.8* 4.2 ± 0.9 
Group V AESM (400 mg/kg) + CD 86.5 ± 6.3 27.7± 4.8 5.0±1.0 
Group VI MESM (100 mg/kg) + CD 66.7±12.6 34.8 ± 6.1** 8.0 ±1.6 
Group VII MESM (200 mg/kg) + CD 85.8 ± 9.3 37.5 ± 5.3** 6.8 ±1.8 
Group VIII MESM (400 mg/kg) + CD 72.7 ±7.1 29.2 ± 4.5* 7.0 ±1.9 
Group IX AECP (100 mg/kg)  + CD 76.3 ±9.8 32.0 ± 4.0** 5.7 ± 0.8 
Group X AECP (200 mg/kg) + CD 79.7 ±9.8 35.2 ± 4.8** 5.0 ±1.4 
Group XI AECP (400 mg/kg) + CD 67.2 ±6.0 36.8 ± 2.6** 6.3 ±1.4 
Group XII MECP (100 mg/kg)  + CD 74.5 ±7.6 15.7 ± 2.7## 6.3 ±1.7 
Group XIII MECP (200 mg/kg) + CD 75.3 ±7.0 17.8 ± 2.5# 8.5 ±1.6 
Group XIV MECP (400 mg/kg) + CD 79.5 ±4.2 20.0 ± 1.9 8.7 ±1.2 
Group XV Sibutramine (10 mg/kg)+ CD 82.0 ±4.2 20.3 ± 0.9 8.2 ±1.1 
 
Exploration behaviour of CD induced obesity in female rats was studied by open field 
test on 49th day of study. Open field test carried out for 5 minutes, total number of 
ambulation, rearing and grooming were counted for each animal, and expressed as 
mean ± SE. Results collected are analysed by one way analysis of variance (ANOVA) 
followed by Dunnett test in between normal control and treatment; disease control and 
treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
 CD: Cafeteria diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on exploration behavior in cafeteria diet fed rats. 
There was no significant change in the exploratory behavior of CD group animals as compared to the control group animals but there was 
significant increase in number of rearings but co-administration of  none of the doses was able to decrease the number of rearings. 
 
Figure: 38 
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Table - 17.1 
Effect of saline on exploration behavior in normal diet fed rats. 
Animal 
No. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 0.17 0.17 72 10 4 
2 0.18 0.18 84 16 7 
3 0.22 0.22 65 13 5 
4 0.20 0.20 59 15 2 
5 0.22 0.22 69 11 8 
6 0.24 0.24 56 14 10 
Mean 67.5 13.2 6.0 
SD 10.1 2.3 2.9 
SEM 4.1 0.9 1.2 
 
 
 
Table - 17.2 
Effect of saline on exploration behavior in Cafeteria diet fed rats. 
Animal 
No. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 0.24 0.24 83 42 6 
2 0.23 0.23 97 33 6 
3 0.212 0.212 79 37 5 
4 0.202 0.202 101 30 3 
5 0.19 0.19 76 39 4 
6 0.224 0.224 61 28 8 
Mean 82.8 34.8 5.3 
SD 14.6 5.4 1.8 
SEM 6.0 2.2 0.7 
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Table - 17.3 
Effect of AESM (100 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 10.2 0.52 81 32 3 
2 10.9 0.54 88 49 7 
3 11.1 0.55 109 16 4 
4 9.6 0.48 101 24 2 
5 12.0 0.6 69 30 6 
6 10.7 0.53 56 26 4 
Mean 84.0 29.5 4.3 
SD 19.7 11.1 1.9 
SEM 8.1 4.5 0.8 
 
 
 
 
Table - 17.4 
Effect of AESM (200 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 22.4 0.56 70 34 2 
2 22.0 0.55 79 45 4 
3 20.4 0.51 103 26 4 
4 18.2 0.45 88 17 8 
5 19.6 0.49 62 28 2 
6 22.8 0.57 56 33 5 
Mean 76.3 30.5 4.2 
SD 17.4 9.4 2.2 
SEM 7.1 3.8 0.9 
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Table - 17.5 
Effect of AESM (400 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Ambulation Rearing Grooming 
1 44.0 0.55 69 49 6 
2 42.8 0.53 76 24 3 
3 38.4 0.48 114 32 2 
4 44.8 0.56 90 16 4 
5 40.8 0.51 82 19 9 
6 47.2 0.59 88 26 6 
Mean 86.5 27.7 5.0 
SD 15.5 11.8 2.5 
SEM 6.3 4.8 1.0 
 
 
 
 
Table - 17.6 
Effect of MESM (100 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 11.4 0.57 99 19 14 
2 9.0 0.45 107 46 9 
3 9.8 0.49 29 55 10 
4 11.8 0.59 67 33 3 
5 1.0 0.6 52 17 7 
6 11.1 0.55 46 39 5 
Mean 66.7 34.8 8.0 
SD 30.8 15.0 3.9 
SEM 12.6 6.1 1.6 
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Table - 17.7 
Effect of MESM (200 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 20.4 0.51 112 28 11 
2 18.2 0.45 93 48 9 
3 19.2 0.48 102 36 12 
4 23.2 0.58 67 17 3 
5 23.8 0.59 90 50 5 
6 18.8 0.47 51 46 1 
Mean 85.8 37.5 6.8 
SD 22.7 13.1 4.5 
SEM 9.3 5.3 1.8 
 
 
 
 
Table - 17.8 
Effect of MESM (400 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 46.8 0.58 55 25 10 
2 38.4 0.48 92 32 13 
3 43.6 0.54 71 46 4 
4 47.2 0.59 62 20 00 
5 36.8 0.46 96 36 6 
6 35.6 0.44 60 16 9 
Mean 72.7 29.2 7.0 
SD 17.4 11.1 4.6 
SEM 7.1 4.5 1.9 
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Table - 17.9 
Effect of AECP (100 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
(100 mg/kg) 
Volume of 
Treatment (ml) 
Ambulation Rearing Grooming 
1 8.6 0.43 111 17 7 
2 10.5 0.52 102 44 8 
3 9.2 0.46 61 39 5 
4 11.0 0.55 59 26 4 
5 11.2 0.56 56 30 7 
6 9.4 0.47 69 36 3 
Mean 76.3 32.0 5.7 
SD 23.9 9.7 2.0 
SEM 9.8 4.0 0.8 
 
 
 
 
Table - 17.10 
Effect of AECP (200 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
(200 mg/kg) 
Volume of 
Treatment (ml) 
Ambulation Rearing Grooming 
1 22.4 0.56 90 49 4 
2 23.6 0.59 55 43 9 
3 24.2 0.6 49 34 00 
4 20.4 0.51 112 29 8 
5 18.4 0.46 92 16 3 
6 17.8 0.44 80 40 6 
Mean 79.7 35.2 5.0 
SD 23.9 11.7 3.3 
SEM 9.8 4.8 1.4 
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Table - 17.11 
Effect of AECP (400 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 47.6 0.59 76 29 11 
2 40.0 0.5 88 42 7 
3 42.8 0.53 49 30 9 
4 39.6 0.49 66 36 2 
5 46.4 0.58 72 39 4 
6 40.8 0.51 52 45 5 
Mean 67.2 36.8 6.3 
SD 14.8 6.4 3.3 
SEM 6.0 2.6 1.4 
 
 
 
 
 
Table - 17.12 
Effect of MECP (100 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 8.6 0.43 52 21 12 
2 9.0 0.45 102 16 8 
3 9.0 0.45 73 9 10 
4 11.4 0.57 84 12 2 
5 10.6 0.53 56 10 4 
6 10.9 0.54 80 26 2 
Mean 74.5 15.7 6.3 
SD 18.6 6.7 4.3 
SEM 7.6 2.7 1.7 
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Table - 17.13 
Effect of MECP (200 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 20.4 0.51 106 9 10 
2 18.6 0.46 73 19 7 
3 22.8 0.57 59 26 4 
4 23.4 0.58 82 13 15 
5 18.0 0.45 70 18 9 
6 22.2 0.56 62 22 6 
Mean 75.3 17.8 8.5 
SD 17.1 6.1 3.8 
SEM 7.0 2.5 1.6 
 
 
 
Table - 17.14 
Effect of MECP (400 mg/kg) on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 46.4 0.58 72 17 12 
2 40.4 0.50 66 24 9 
3 37.2 0.46 89 20 11 
4 39.6 0.49 93 14 4 
5 47.2 0.59 80 27 7 
6 41.2 0.51 77 18 9 
Mean 79.5 20.0 8.7 
SD 10.2 4.8 2.9 
SEM 4.2 1.9 1.2 
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Table - 17.15 
Effect of Sibutramine 10 mg/kg on exploration behavior in cafeteria diet fed rats. 
Animal 
No. 
Dose of Treatment 
10 mg/kg 
Volume of 
Treatment ml 
Ambulation Rearing Grooming 
1 1.12 0.56 97 19 12 
2 1.0 0.5 88 23 9 
3 0.94 0.47 79 20 10 
4 0.96 0.48 82 22 7 
5 1.0 0.5 66 17 5 
6 1.1 0.55 80 21 6 
Mean 82.0 20.3 8.2 
SD 10.3 2.2 2.6 
SEM 4.2 0.9 1.1 
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Table: 18 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on biochemical parameters in cafeteria diet fed rats. 
Sr. No. 
(Groups) 
Treatment 
Glucose 
(mg/dl) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
Group I Normal diet 42.8 ± 2.7 99.24 ± 6.3 91.6  ± 8.9 33.85 ±1.066 39.6 ± 8.199 18.16±1.27 65.18 ±1.52 29.44 ± 0.719 
Group II Cafeteria diet 76.7 ± 3.1** 106 ± 3.8 105.6  ±  4.2 26.13 ± 1.67* 58.22 ± 2.914 21.29±0.76 101.01 ± 0.754** 51.435  ± 1.239** 
Group III AESM (100 mg/kg) + CD 80.8 ±  6.3** 143.6 ±  34.7 102.6 ±  6.3 25.32 ± 1.6** 48.58 ± 6.933 28.72±6.94 98.423 ± 1.384** 52.338 ± 0.954** 
Group IV AESM (200 mg/kg) + CD 81.3 ±  6.2** 135.9 ±  35.9 110.3 ±  5.6 24.13 ± 1.18** 58.99 ± 4.753 27.18±7.18 97.406 ± 1.677** 51.188 ± 1.211** 
Group V AESM (400 mg/kg) + CD 74.1 ±  8.7** 92.6 ±  6.2 106.8 ±  6 26 ± 1.32* 62.31 ± 5.155 18.52±1.24 98.125 ± 1.579** 51.426 ± 3.163** 
Group VI MESM (100 mg/kg) + CD 89.9 ±  9.3** 109.9 ±  11.8 105.7 ±  3.7 30.88 ± 1.523 52.8 ± 6.675 21.97±2.36 100.02 ± 0.969**## 51.901 ± 1.03** 
Group VII MESM (200 mg/kg) + CD 70.6 ±  6.5* 93.9 ±  4.3 100.3 ±  4.3 31.86 ± 1.444# 49.65 ± 3.360 18.79±0.86 80.261 ± 2.863**## 48.456 ± 1.515** 
Group VIII MESM (400 mg/kg) + CD 73.7 ±  6.2** 87.9 ± 3.9 97.6 ± 4.6 34.45 ± 1.864 45.6 ± 5.345 17.58±0.78 69.893 ± 1.99 30.81 ± 2.496 ## 
Group IX AECP (100 mg/kg)  + CD 82.6 ±  6.3** 98.5 ±  5.5 118.7 ±  7.5 23.52 ± 1.234** 75.5 ±7.563** 19.7±1.09 101.3 ± 2.621** 54.473 ± 1.792**## 
Group X AECP (200 mg/kg) + CD 87.1 ±  6.5** 95.4 ±  7.7 122.4 ±  10.4 25.95 ± 1.823* 77.34 ± 7.116** 19.08±1.54 97.608 ± 1.692** 61.043 ± 1.489** 
Group XI AECP (400 mg/kg) + CD 85.7 ±  4.1** 107.6 ±   8.8 111.6 ±  5.4 24.47 ±1.93**## 65.58 ± 5.339* 21.52±1.76 94.92± 1.902** 54.496 ± 1.668** 
Group XII MECP (100 mg/kg)  + CD 80.1 ±  6.5 99.9 ±  3.2 102.7 ±  6.3 38.19 ± 2.893## 44.52 ± 5.812 19.98±0.64 98.28 ± 0.907** 44.595 ± 1.478**# 
Group XIII MECP (200 mg/kg) + CD 63.5 ±  3.5 95.4 ±  3.5 97.8 ±  6 35.67 ± 1.595## 43.02 ± 5.938 19.08±0.7 77.166 ±  4**## 41.771 ± 1.752**## 
Group XIV MECP (400 mg/kg) + CD 53.1 ± 2.6 83.5 ±  5.2 81.2 ±  5.8# 34.82 ± 1.387## 29.69 ± 6.844# 16.69±1.04 68.32 6 ± 2.316## 32.475 ± 0.887## 
Group XV Sibutramine (10 mg/kg)+ CD 49.7 ±  3.2# 79.5 ±  5.5 73.7 ±  4.5## 35.27 ± 2.23## 24.62 ± 6.012## 15.9±1 62.678 ± 1.906## 28.731 ± 0.918## 
 
Effect of Stellaria media’ and ‘Clerodendrum phlomidis’ on CD modulated biochemical parameters in female rats was evaluated on 50th day of study. 
Blood was collected from retro orbital, centrifuged and separated serum obtained was used in biochemical analysis. Serum glucose, cholesterol, and 
Triglycerides were analysed by using Span diagnostic kits, Surat, India. Results collected are analysed by one way analysis of variance (ANOVA) 
followed by Dunnett test in between normal control and treatment; disease control and treatment.   P value less than 0.05 is considered as significant. 
*P<0.05, **P<0.01. *Comparison of test and disease control with normal control 
# Comparison test with Disease Control, CD: Cafeteria diet.
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on biochemical parameters in cafeteria diet fed rats. 
Feeding with CD caused significant increase in the glucose, insulin, SGOT, SGPT, TG, TC and LDL-C levels in CD group animals as compared 
to normal control animals which was significantly decreased by the administration of MECP 200 and 400 mg/kg andAECP 400 . Sibutramine 
was most significant. 
 
Figure: 39 
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Figure: 42   
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Figure: 43   
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Figure: 44   
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Figure: 45 
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Figure: 46 
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Table - 18.1 
Effect of Saline on Biochemical parameters in normal diet fed rats. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.17 0.17 42.56 89.34 77.36 34.37 25.12 17.86 66.63 30.63 
2 0.18 0.18 37.47 91.37 110.34 37.85 54.22 18.274 61.74 28.47 
3 0.22 0.22 52.34 113.70 72.57 33.28 16.55 22.74 69.64 26.67 
4 0.20 0.20 49.21 67.0 67.86 29.84 24.62 13.4 59.73 29.11 
5 0.22 0.22 39.78 84.21 102.39 34.74 50.81 16.842 67.53 30.15 
6 0.24 0.24 35.37 99.24 119.16 33.03 66.28 19.848 65.83 31.65 
Mean 42.8 90.8 91.6 33.85 39.6 18.16 65.18 29.44 
SD 6.7 15.5 21.7 2.61 20.08 3.108 3.72 1.762 
SEM 2.7 6.3 8.9 1.066 8.199 1.27 1.52 0.719 
 
Table - 18.2 
Effect of saline on biochemical parameters in Cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 0.24 0.24 76.41 104.32 103.37 24.53 57.98 20.864 99.53 51.64 
2 0.23 0.23 84.56 118.71 119.58 30.5 65.34 23.742 102.7 56.35 
3 0.212 0.212 78.21 99.36 108.16 26.18 62.11 19.872 100.83 49.75 
4 0.202 0.202 79.24 93.24 112.56 31.43 62.48 18.648 98.64 47.64 
5 0.19 0.19 62.41 112.93 99.79 21.13 56.07 22.586 103.53 50.1 
6 0.224 0.224 79.49 110.00 90.36 23.03 45.33 22 100.83 53.13 
Mean 76.7 106.4 105.6 26.13 58.218 21.29 101.01 51.435 
SD 7.5 9.3 10.2 4.12 7.139 1.863 1.84 3.036 
SEM 3.1 3.8 4.2 1.67 2.914 0.76 0.754 1.239 
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Table - 18.3 
Effect of AESM (100 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
ml 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 10.2 0.52 84.21 146.19 96.46 19.34 47.88 29.238 92.64 50.16 
2 10.9 0.54 73.72 303.55 118.31 25.37 32.23 60.71 97.73 52.46 
3 11.1 0.55 69.49 155.32 100.2 27.6 41.54 31.064 100.27 51.31 
4 9.6 0.48 103.41 99.74 79.42 26.05 33.42 19.948 102.63 53.64 
5 12.0 0.6 92.21 82.31 99.59 22.83 60.30 16.462 99.73 56.25 
6 10.7 0.53 61.56 74.56 121.74 30.73 76.10 14.912 97.54 50.21 
Mean 80.8 143.6 102.6 25.32 48.578 28.72 98.423 52.338 
SD 15.5 85.1 15.5 3.92 16.98 17.01 3.391 2.338 
SEM 6.3 34.7 6.3 1.6 6.933 6.94 1.384 0.954 
 
Table - 18.4 
Effect of AESM (200 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(200mg/kg) 
Volume of 
Treatment 
ml 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 22.4 0.56 93.1 155.1 124.35 27.53 65.80 31.02 97.35 55.26 
2 22.0 0.55 97.0 306.41 127.52 24.15 42.09 61.282 100.3 49.11 
3 20.4 0.51 66.42 84.06 112.57 21.74 74.02 16.812 94.64 47.15 
4 18.2 0.45 82.1 91.34 105.32 27.04 60.01 18.268 90.74 53.66 
5 19.6 0.49 89.34 79.34 99.14 20.16 63.11 15.868 99.65 50.42 
6 22.8 0.57 59.7 99.14 92.91 24.18 48.90 19.828 101.76 51.53 
Mean 81.3 135.9 110.3 24.13 58.988 27.18 97.406 51.188 
SD 15.1 87.9 13.8 2.88 11.642 17.58 4.109 2.967 
SEM 6.2 35.9 5.6 1.18 4.753 7.18 1.677 1.211 
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Table - 18.5 
Effect of AESM (400 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400 mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 44 0.55 106.21 111.26 115.31 30.00 63.06 22.252 100.63 47.25 
2 42.8 0.53 74.42 105.4 118.6 23.15 74.37 21.08 95.77 42.46 
3 38.4 0.48 46.17 94.32 124.67 26.37 79.44 18.864 91.63 63.26 
4 44.8 0.56 55.31 68.37 100.2 29.39 57.14 13.674 98.78 58.26 
5 40.8 0.51 83.47 90.34 93.5 22.06 53.37 18.068 99.51 49.1 
6 47.2 0.59 79.1 86.05 88.7 25.03 46.46 17.21 102.43 48.23 
Mean 74.1 92.6 106.8 26 62.307 18.52 98.125 51.426 
SD 21.3 15.2 14.7 3.23 12.628 3.033 3.87 7.748 
SEM 8.7 6.2 6.0 1.32 5.155 1.24 1.579 3.163 
 
Table -18.6 
Effect of MESM (100 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 11.4 0.57 106.41 152.36 96.88 34.53 31.88 30.472 96.53 53.64 
2 9.0 0.45 99.36 119.56 107.34 31.74 51.69 23.912 98.64 51.32 
3 9.8 0.49 76.21 89.12 121.56 28.51 75.23 17.824 100.83 50.76 
4 11.8 0.59 59.26 92.46 99.14 28.84 51.81 18.492 99.63 49.32 
5 1.0 0.6 77.39 129.56 100.6 35.62 39.07 25.912 101 50.25 
6 11.1 0.55 120.57 76.12 108.4 26.05 67.13 15.224 103.53 56.12 
Mean 89.9 109.9 105.7 30.88 52.802 21.97 100.02 51.901 
SD 22.7 28.8 9.0 3.731 16.351 5.768 2.373 2.523 
SEM 9.3 11.8 3.7 1.523 6.675 2.36 0.969 1.03 
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Table - 18.7 
Effect of MESM (200 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(200mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 20.4 0.51 88.24 107.4 113.46 37.6 54.38 21.48 88.62 54.2 
2 18.2 0.45 56.37 92.36 89.94 27.15 44.32 18.472 75.64 48.25 
3 19.2 0.48 72.31 99.34 97.34 32.86 44.61 19.868 85.51 51.03 
4 23.2 0.58 66.24 84.57 104.57 29.84 57.82 16.914 78.52 47.35 
5 23.8 0.59 89.24 79.34 87.42 32.97 38.58 15.868 69.64 43.63 
6 18.8 0.47 51.36 100.6 109.1 30.77 58.21 20.12 83.64 46.28 
Mean 70.6 93.9 100.3 31.86 49.653 18.79 80.261 48.456 
SD 15.8 10.6 10.5 3.54 8.231 2.113 7.014 3.712 
SEM 6.5 4.3 4.3 1.444 3.360 0.86 2.863 1.515 
 
Table - 18.8 
Effect of MESM (400 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 46.8 0.58 94.32 92.42 114.34 30.13 65.73 18.484 66.63 28.54 
2 38.4 0.48 88.64 101.6 94.16 38.74 35.10 20.32 72.54 31.96 
3 43.6 0.54 53.31 84.52 99.27 33.48 48.89 16.904 70.64 42.7 
4 47.2 0.59 69.42 93.52 101.55 40.42 42.43 18.704 63.53 27.03 
5 36.8 0.46 70.1 78.84 97.14 28.94 52.43 15.768 68.5 26.87 
6 35.6 0.44 66.42 76.61 79.39 35.03 29.04 15.322 77.52 27.76 
Mean 73.7 87.9 97.6 34.45 45.603 17.58 69.893 30.81 
SD 15.2 9.6 11.3 4.568 13.094 1.919 4.874 6.114 
SEM 6.2 3.9 4.6 1.864 5.345 0.78 1.99 2.496 
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Table - 18.9 
Effect of AECP (100 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(100 mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 8.6 0.43 95.21 110.26 137.37 24.27 91.05 22.052 112.74 53.87 
2 10.5 0.52 56.21 99.34 126.16 19.78 86.51 19.868 103.64 55.86 
3 9.2 0.46 85.42 116.56 130.57 22.88 84.38 23.312 96.64 53.67 
4 11.0 0.55 81.31 80.34 99.32 26.17 57.08 16.068 100.64 51.78 
5 11.2 0.56 77.36 95.56 126.58 20.6 86.87 19.112 94.63 56.88 
6 9.4 0.47 100.02 89.0 92.34 27.42 47.12 17.8 99.53 54.78 
Mean 82.6 98.5 118.7 23.52 75.503 19.7 101.3 54.473 
SD 15.5 13.4 18.3 3.023 18.525 2.674 6.420 0.7319 
SEM 6.3 5.5 7.5 1.234 7.563 1.09 2.621 1.792 
 
Table - 18.10 
Effect of AECP (200 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(200mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 22.4 0.56 112.42 116.51 156.46 31.73 101.43 23.302 99.63 66.87 
2 23.6 0.59 77.81 109.34 133.31 27.49 83.95 21.868 101.3 61.86 
3 24.2 0.6 93.34 111.34 142.48 29.74 90.47 22.268 89.54 58.23 
4 20.4 0.51 84.2 74.56 94.31 21.68 57.72 14.912 97.53 62.53 
5 18.4 0.46 65.21 79.34 110.4 24.55 69.98 15.868 98.53 60.34 
6 17.8 0.44 89.56 81.39 97.30 20.53 60.49 16.278 99.12 56.43 
Mean 87.1 95.4 122.4 25.95 77.34 19.08 97.608 61.043 
SD 15.9 18.9 25.5 4.465 17.432 3.776 4.146 3.647 
SEM 6.5 7.7 10.4 1.823 7.116 1.54 1.692 1.489 
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Table - 18.11 
Effect of AECP (400 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 47.6 0.59 96.34 96.34 111.4 18.52 73.61 19.268 97.63 56.78 
2 40.0 0.5 69.21 148.21 123.38 28.95 64.79 29.642 99.46 61.57 
3 42.8 0.53 78.72 104.56 97.46 21.06 55.49 20.912 92.46 51.2 
4 39.6 0.49 93.32 112.6 106.72 30.96 53.24 22.52 89.77 53.15 
5 46.4 0.58 86.21 93.51 130.89 24.52 87.67 18.702 90.2 53.64 
6 40.8 0.51 90.6 90.34 99.57 22.84 58.66 18.068 100 50.64 
Mean 85.7 107.6 111.6 24.47 65.577 21.52 94.92 19.268 
SD 10.2 21.5 13.3 4.73 13.077 4.295 4.66 4.087 
SEM 4.1 8.8 5.4 1.93 5.339 1.76 1.902 1.668 
 
Table - 18.12 
Effect of MECP (100 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 8.6 0.43 52.42 88.46 95.84 38.15 40.00 17.692 101.3 48.76 
2 9.0 0.45 76.62 112.64 99.57 36.87 40.17 22.528 98.63 39.76 
3 9.0 0.45 89.41 96.34 108.25 45.63 43.35 19.268 94.52 41.67 
4 11.4 0.57 82.34 101.6 77.54 30.37 26.85 20.32 97.63 47.54 
5 10.6 0.53 100.31 99.74 113.68 47.16 46.57 19.948 99.24 43 
6 10.9 0.54 79.42 100.5 121.19 30.95 70.14 20.1 98.36 46.84 
Mean 80.1 99.9 102.7 38.19 44.523 19.98 98.28 44.595 
SD 16.0 7.9 15.4 7.086 14.238 1.572 2.224 3.62 
SEM 6.5 3.2 6.3 2.893 5.812 0.64 0.907 1.478 
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Table - 18.13 
Effect of MECP (200 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 20.4 0.51 62.41 106.34 115.36 36.36 57.73 21.268 87.63 38.75 
2 18.6 0.46 57.71 92.57 104.57 37.44 48.62 18.514 73.74 43.65 
3 22.8 0.57 56.46 88.16 108.12 30.28 60.21 17.632 89.63 37.75 
4 23.4 0.58 79.42 98.59 97.19 41.41 36.06 19.718 77.63 39.64 
5 18.0 0.45 66.16 84.12 77.21 32.42 27.97 16.824 68.6 41.41 
6 22.2 0.56 59.00 102.6 84.18 36.12 27.54 20.52 65.77 49.43 
Mean 63.5 95.4 97.8 35.67 43.022 19.08 77.166 41.771 
SD 8.5 8.6 14.6 3.908 14.545 1.718 9.798 4.293 
SEM 3.5 3.5 6 1.595 5.938 0.7 4 1.752 
 
Table - 18.14 
Effect of MECP (400 mg/kg) on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
(400mg/kg) 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 46.4 0.58 52.42 73.56 94.52 32.5 47.31 14.712 76.66 29.5 
2 40.4 0.50 44.46 96.32 66.72 39.72 7.74 19.264 61.67 31.86 
3 37.2 0.46 49.31 100.57 101.52 30.48 50.93 20.114 73.1 30.56 
4 39.6 0.49 52.36 69.42 74.14 33.73 26.53 13.884 68.14 34.64 
5 47.2 0.59 63.56 76.34 81.16 37.74 28.15 15.268 63.65 33.65 
6 41.2 0.51 56.34 84.56 69.14 34.77 17.46 16.912 66.74 34.64 
Mean 53.1 83.5 81.2 34.82 29.687 16.69 68.326 32.475 
SD 6.5 12.7 14.1 3.404 16.765 2.537 5.673 2.174 
SEM 2.6 5.2 5.8 1.387 6.844 1.04 2.316 0.887 
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Table - 18.15 
Effect of Sibutramine 10 mg/kg on biochemical parameters in cafeteria diet fed rats. 
Animal 
No 
Dose of 
Treatment 
10 mg/kg 
Volume of 
Treatment 
(ml) 
Glucose 
(mg/dl) 
TG 
 (mg/dl) 
TC 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg %) 
VLDL-C 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
1 1.12 0.56 49.12 79.19 56.16 40.16 12.45 15.838 66.74 28.68 
2 1.0 0.5 52.0 87.0 72.42 34.15 20.87 17.4 60.25 29.12 
3 0.94 0.47 59.31 68.37 82.16 28.66 39.83 13.674 58.63 30.47 
4 0.96 0.48 56.55 102.42 69.36 41.54 7.34 20.484 63.03 31.43 
5 1.0 0.5 39.31 67.79 74.17 37.74 22.87 13.558 69.54 27.66 
6 1.1 0.55 42.02 72.46 88.2 29.36 44.35 14.492 57.88 25.03 
Mean 49.7 79.5 73.7 35.27 24.618 15.9 62.678 28.731 
SD 7.9 13.4 11 5.462 14.727 2.671 4.669 2.249 
SEM 3.2 5.5 4.5 2.23 6.012 1 1.906 0.918 
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Table:  19 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on organ / body weight ratio (mg / gm) in cafeteria diet fed rats. 
Sr. No. 
(Groups) Treatment Heart Liver Right kidney Left kidney Body fat 
Group I Normal diet 3.81 ± 0.46 33.73 ± 1.27 3.83 ± 0.16 3.5 ± 0.2 38.9 ± 1.6 
Group II Cafeteria diet 3.22 ± 0.15 35.93 ±  1 3.41 ±0.03** 3.0 ± 0.2 78.7 ± 0.9** 
Group III AESM (100 mg/kg) + CD 3.18 ± 0.13 24.71 ± .16**# 3.28 ±0.10** 2.9 ± 0.3 74.1 ± 2.3** 
Group IV AESM (200 mg/kg) + CD 3.17 ± 0.09 32.58 ± 1.20 3.33 ± .03** 3.2 ± 0.1 70.4 ± 1.0** 
Group V AESM (400 mg/kg) + CD 3.01 ± 0.06* 33.92 ±1.15 3.33 ±0.02** 3.1 ± 0.2 75.8 ± 2.8 
Group VI MESM (100 mg/kg) + CD 3.15 ± 0.17 28.52 ± 0.39 3.29 ±0 .06** 2.9 ± 0.1 61.7 ±1.7**## 
Group VII MESM (200 mg/kg) + CD 3.18 ± 0.26 31.20 ± 0.91 3.12 ±0.13** 3  ± 0.17 59.77 ± .48**## 
Group VIII MESM (400 mg/kg) + CD 3.1 ± 0.07 31.47 ± 0.95 3.22 ± .10** 2.9 ± 0.1 51.4 ± 1.3**## 
Group IX AECP (100 mg/kg)  + CD 2.99 ± 0.14* 29.06 ± 0.48 3.16 ±0.10** 2.7 ± 0.1 76.6 ± 1.9** 
Group X AECP (200 mg/kg) + CD 3.04 ±0.07* 28.74 ± 0.50 3.30 ±0.05** 3.1 ± 0.1* 80.4 ± 2.9** 
Group XI AECP (400 mg/kg) + CD 3.23 ± 0.15 29.74 ± 0.86 3.36 ±0.12** 2.7 ± 0.3 59.9 ± 3.2**## 
Group XII MECP (100 mg/kg)  CD 3.15 ± 0.13 32.61 ± 0.75 3.08 ±0.10** 2.8 ± 0.2* 71.2 ± 1.7** 
Group XIII MECP (200 mg/kg) + CD 3.31 ± 0.17 30.41 ± 0.75 3.27 ± .06** 2.8 ± 0.1 50.9 ± 5.4**## 
Group XIV MECP (400 mg/kg) + CD 3.2 ± 0.2 31.76 ±0.62 3.13 ±0.07** 2.94 ±  0.2 40.4 ± 1.4## 
Group XV Sibutramine (10 mg/kg)+ CD 3.3 ± 0.16 32.47 ±1.42 3.21 ± 0.11** 3.14 ±0.06 31.7 ± 1.5## 
 
On 51st day of study, rats were euthanised by ether over dose and organs isolated, weighed and wet weight of organ to body weight rat io was 
calculated for each animal. Results collected are analysed by one way analysis of variance (ANOVA) followed by Dunnett test in between 
normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control,  
CD: Cafeteria diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidi’s on organ / body weight ratio (mg / gm) in cafeteria diet fed rats. There was 
significant increase in the organ / body weight ratio (mg /gm) of right kidney and left kidney and body fat in cafeteria diet fed rats.  Only MECP  
400 mg/kg and Sibutramine were found to be significant in  reducing the body fat. 
 
 
Figure: 48   
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Table - 19.1 
Effect of saline on organ weight / body weight ratio (mg/gm) in normal diet fed 
rats. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 0.17 0.17 95 4.31 28.42 4.1 3.57 40.00 
2 0.18 0.18 101 4.35 37.62 3.76 3.16 40.79 
3 0.22 0.22 129 4.34 35.65 4.34 4.03 41.86 
4 0.20 0.20 111 1.61 33.33 3.96 3.96 42.25 
5 0.22 0.22 131 4.67 32.82 3.35 3.2 32.51 
6 0.24 0.24 136 3.60 34.55 3.45 3.01 36.1 
Mean 117.17 3.81 33.73 3.83 3.5 38.9 
SD 17.19 1.14 3.12 0.38 0.4 3.8 
SEM 7.02 0.46 1.27 0.16 0.2 1.6 
 
 
 
 
 
Table - 19.2 
Effect of saline on organ weight / body weight ratio (mg/gm) in cafeteria diet fed 
rats. 
Animal 
no. 
Dose of 
Treatment 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 0.24 0.24 142 2.88 39.50 3.30 3.02 78.3 
2 0.23 0.23 136 2.86 37.61 3.45 3.75 78.97 
3 0.212 0.212 130 3.07 35.38 3.46 3.153 75.38 
4 0.202 0.202 119 3.8 35.77 3.36 2.184 77.39 
5 0.19 0.19 123 3.41 32.27 3.41 2.6 81.86 
6 0.224 0.224 139 3.30 35.03 3.45 3.38 80.28 
Mean 131.50 3.22 35.93 3.41 3.0 78.7 
SD 9.14 0.36 2.45 0.06 0.6 2.3 
SEM 3.73 0.15 1 0.03 0.2 0.9 
  
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 229 
 
Table - 19.3 
Effect of AESM (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Anima
l no. 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body 
weight gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 10.2 0.52 130 3.0 35.38 3.38 3.23 78.46 
2 10.9 0.54 141 2.9 34.32 3.33 3.47 70.7 
3 11.1 0.55 129 3.79 36.97 2.79 1.70 80.0 
4 9.6 0.48 118 3.13 33.22 3.38 2.64 75.3 
5 12.0 0.6 161 3.16 34.78 3.47 3.04 64.9 
6 10.7 0.53 132 3.1 32.61 3.33 3.18 75.0 
Mean 135.17 3.18 34.55 3.28 2.9 74.1 
SD 14.63 0.31 1.56 0.25 0.6 5.5 
SEM 5.97 0.13 0.637 0.10 0.3 2.3 
 
 
 
 
 
Table - 19.4 
Effect of AESM (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Body wt 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 22.4 0.56 133 3.23 36.39 3.38 3.08 67.36 
2 22.0 0.55 137 3.54 32.55 3.35 3.50 70.0 
3 20.4 0.51 121 3.18 32.33 3.38 3.05 69.83 
4 18.2 0.45 116 2.84 33.53 3.36 3.10 72.06 
5 19.6 0.49 119 3.05 27.39 3.19 2.77 74.28 
6 22.8 0.57 144 3.19 33.26 3.33 3.54 68.8 
Mean 128.33 3.17 32.58 3.33 3.2 70.4 
SD 11.27 0.23 2.93 0.07 0.3 2.5 
SEM 4.60 0.09 1.20 0.03 0.1 1.0 
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Table - 19.5 
Effect of AESM (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Body 
weight gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 44.0 0.55 131 3.09 31.64 3.35 2.97 72.21 
2 42.8 0.53 122 2.86 31.60 3.36 3.11 82.13 
3 38.4 0.48 117 2.93 38.88 3.33 2.9 80.0 
4 44.8 0.56 133 3.18 32.47 3.38 4.21 67.21 
5 40.8 0.51 120 2.85 33.5 3.33 2.83 83 
6 47.2 0.59 136 3.16 35.44 3.23 2.87 70.0 
Mean 126.5 3.01 33.92 3.33 3.1 75.8 
SD 7.82 0.15 2.82 0.05 0.5 6.8 
SEM 3.19 0.06 1.15 0.02 0.2 2.8 
 
 
 
 
Table - 19.6 
Effect of MESM (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 11.4 0.57 136 3.97 27.5 3.38 3.01 60.36 
2 9.0 0.45 101 2.87 28.11 3.36 3.36 59.20 
3 9.8 0.49 121 2.97 27.6 3.38 2.39 59.83 
4 11.8 0.59 140 3.07 29.28 3.35 2.85 58.57 
5 1.0 0.6 139 3.16 29.92 3.23 2.94 62.15 
6 11.1 0.55 142 2.88 28.73 3.02 2.95 69.92 
Mean 129.83 3.15 28.52 3.29 2.9 61.7 
SD 16.02 0.42 0.96 0.14 0.3 4.2 
SEM 6.54 0.17 0.39 0.06 0.1 1.7 
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Table - 19.7 
Effect of MESM (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 20.4 0.51 111 2.8 27.38 2.88 2.79 60 
2 18.2 0.45 101 2.47 34.05 3.06 2.87 58.61 
3 19.2 0.48 107 2.9 31.58 2.71 2.64 60.93 
4 23.2 0.58 125 3.04 32.00 3.36 3.7 60.8 
5 23.8 0.59 136 4.14 31.91 3.60 3.51 58.08 
6 18.8 0.47 103 3.73 30.29 3.1 2.91 60.19 
Mean 113.83 3.18 31.20 3.12 3.07 59.77 
SD 13.81 0.62 2.23 0.32 0.42 1.17 
SEM 5.64 0.26 0.91 0.13 0.175 0.48 
 
 
 
Table - 19.8 
Effect of MESM (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 46.8 0.58 133 3.33 28.72 3.38 3.08 50 
2 38.4 0.48 114 3.13 29.47 2.98 2.80 50 
3 43.6 0.54 125 2.97 32.80 3.12 2.72 50.08 
4 47.2 0.59 135 3.25 31.11 3.11 2.74 49.62 
5 36.8 0.46 103 3.01 35.14 3.10 2.81 57.66 
6 35.6 0.44 107 2.89 31.58 3.64 2.99 51.02 
Mean 119.50 3.1 31.47 3.22 2.9 51.4 
SD 13.50 0.17 2.32 0.24 0.1 3.1 
SEM 5.51 0.07 0.95 0.10 0.1 1.3 
 
Chapter 7                                                       FOOD INDUCED OBESITY 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 232 
 
Table - 19.9 
Effect of AECP (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body weight 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 8.6 0.43 112 3.14 27.50 2.76 2.94 75.0 
2 10.5 0.52 137 2.84 30.51 3.06 2.91 75.47 
3 9.2 0.46 123 2.92 28.61 3.33 2.68 74.95 
4 11.0 0.55 149 3.08 29.93 3.35 2.81 70.26 
5 11.2 0.56 151 3.04 28.07 3.37 2.58 79.86 
6 9.4 0.47 117 2.97 29.74 3.07 2.47 84.10 
Mean 131.50 2.99 29.06 3.16 2.7 76.6 
SD 16.61 0.11 1.18 0.24 0.2 4.8 
SEM 6.78 0.04 0.48 0.10 0.1 1.9 
 
 
 
 
 
 
Table - 19.10 
Effect of AECP (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of Treatment 
200mg/kg 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 22.4 0.56 139 3.23 29.20 3.38 3.02 80.00 
2 23.6 0.59 142 3.02 29.43 3.38 3.30 72.46 
3 24.2 0.6 156 3.20 27.82 3.39 3.20 93.22 
4 20.4 0.51 124 2.90 29.57 3.14 3.38 80.32 
5 18.4 0.46 117 2.82 29.74 3.16 2.73 76.15 
6 17.8 0.44 120 3.08 26.66 3.33 3.00 80.00 
Mean 133 3.04 28.74 3.30 3.1 80.4 
SD 15.18 0.16 1.23 0.12 0.2 7 
SEM 6.20 0.07 0.50 0.05 0.1 2.9 
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Table - 19.11 
Effect of AECP (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 47.6 0.59 143 3.86 27.41 3.35 2.93 54.26 
2 40.0 0.5 120 3.21 27.5 3.93 3.83 60.00 
3 42.8 0.53 124 3.32 29.51 3.3 2.58 55.96 
4 39.6 0.49 117 2.99 29.74 3.24 2.05 75.38 
5 46.4 0.58 141 2.78 32.34 3.19 2.41 56.02 
6 40.8 0.51 124 3.19 31.93 3.14 2.5 58.06 
Mean 128.17 3.23 29.74 3.36 2.7 59.9 
SD 11.05 0.37 2.10 0.29 0.6 7.8 
SEM 4.51 0.15 0.86 0.12 0.3 3.2 
 
 
 
Table - 19.12 
Effect of MECP (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 8.6 0.43 103 3.42 35.14 2.81 3.00 70.19 
2 9.0 0.45 109 3.26 34.49 3.02 3.39 73.48 
3 9.0 0.45 111 2.61 31.89 2.79 2.16 70.00 
4 11.4 0.57 136 3.01 32.27 3.23 2.54 65.73 
5 10.6 0.53 122 3.45 30.40 3.36 2.95 70.00 
6 10.9 0.54 129 3.16 31.47 3.25 2.71 77.98 
Mean 118.33 3.15 32.61 3.08 2.8 71.2 
SD 12.77 0.31 1.83 0.24 0.4 4.1 
SEM 5.21 0.13 0.75 0.10 0.2 1.7 
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Table - 19.13 
Effect of MECP (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 20.4 0.51 117 3.73 32.3 2.99 2.64 77.95 
2 18.6 0.46 105 3.17 30.0 3.4 2.76 46.09 
3 22.8 0.57 130 3 33.07 3.23 2.61 45.53 
4 23.4 0.58 135 3.11 29.62 3.4 2.96 44.88 
5 18.0 0.45 107 2.96 28.78 3.36 2.99 45.98 
6 22.2 0.56 124 3.92 28.70 3.22 2.9 45.00 
Mean 119.67 3.31 30.41 3.27 2.8 50.9 
SD 12.19 0.4 1.85 0.16 0.2 13.3 
SEM 4.98 0.165 0.75 0.06 0.1 5.4 
 
 
 
 
Table - 19.14 
Effect of MECP (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm 
Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 46.4 0.58 131 3.9 30.31 3.12 1.83 40.03 
2 40.4 0.50 136 3.01 31.91 3.16 2.57 39.63 
3 37.2 0.46 103 3.52 31.86 2.81 3.13 35.13 
4 39.6 0.49 116 3.14 30.51 3.36 3.1 42.41 
5 47.2 0.59 129 2.48 32.32 3.17 2.63 45.42 
6 41.2 0.51 114 3.45 33.68 3.15 2.71 40.00 
Mean 121.50 3.25 31.76 3.13 2.7 40.4 
SD 12.53 0.49 1.24 0.18 0.5 3.4 
SEM 5.12 0.2 0.62 0.5 0.2 1.4 
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Table - 19.15 
Effect of Sibutramine 10 mg/kg on organ weight / body weight ratio (mg/gm) in 
cafeteria diet fed rats. 
Animal 
no. 
Dose of 
Treatment 
1mg/kg 
Volume of 
Treatment ml 
Body weight 
gm Heart Liver 
Right 
kidney 
Left 
kidney 
Body 
fat 
1 1.12 0.56 123 3.14 31.95 3.17 3.28 28.37 
2 1.0 0.5 105 3.21 31.42 3.04 3.16 32.66 
3 0.94 0.47 107 2.97 31.74 3.27 2.89 37.94 
4 0.96 0.48 110 4.04 39.00 2.81 3.2 32.72 
5 1.0 0.5 103 3.41 28.43 3.49 3.03 28.73 
6 1.1 0.55 121 3 32.25 3.47 3.26 29.75 
Mean 111.5 3.3 32.47 3.21 3.14 31.7 
SD 8.48 0.4 3.49 0.26 0.15 3.6 
SEM 3.46 0.16 1.42 0.11 0.06 1.5 
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Table – 20 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on WAT in cafeteria diet fed female rats 
Sr. No. 
(Groups) 
Treatment WAT (gm) 
Adipocyte 
Diameter (µm) 
Adiposity Index 
(%) 
Adipocyte cell No. 
(      x 106)  
Group I Normal diet 4.530 ± 0.238 74.445 ± 3.286 3.892 ± 0.156 16.85 ± 0.551 
Group II Cafeteria diet 10.35 ± 0.321** 104.463 ± 4.497** 7.870 ± 0.092** 17.108 ± 0.35 
Group III AESM (100 mg/kg) + CD 9.958 ± 0.23** 109.667 ± 3.575** 7.409 ± 0.225** 16.19± 0.382 
Group IV AESM (200 mg/kg) + CD 9.018 ± 0.253**# 99.65 ± 2.93** 7.04 ± 0.1** 16.295± 0.657 
Group V AESM (400 mg/kg) + CD 9.543 ± 0.164** 105.065 ± 3.926** 7.576 ± 0.277** 16.186± 0.354 
Group VI MESM (100 mg/kg) + CD 10.055 ± 0.509** 99.41 ± 5.797** 7.853 ± 0.584** 16.551± 0.742 
Group VII MESM (200 mg/kg) + CD 10.240 ± 0.399** 101.477 ± 4.353** 9.142 ± 0.652**# 15.9±  0.329 
Group VIII MESM (400 mg/kg) + CD 7.637 ± 0.28**## 105.065 ± 3.926 6.439 ± 0.304**# 16.486± 0.637 
Group IX AECP (100 mg/kg)  + CD 8.033 ± 0.544**## 97.967 ± 4.074** 6.216 ± 0.597**## 16.858± 0.624 
Group X AECP (200 mg/kg) + CD 6.812 ± 0.319**## 97.092 ± 4.275**## 5.206 ± 0.429## 15.776± 0.525 
Group XI AECP (400 mg/kg) + CD 6.118 ± 0.207**## 82.618 ± 5.359 4.798 ± 0.22 15.776± 0.525 
Group XII MECP (100 mg/kg)  + CD 8.425 ± 0.408**## 105.527 ± 3.977** 7.123 ± 0.168** 16.748± 0.739 
Group XIII MECP (200 mg/kg) + CD 5.43 ± 0.208## 91.597 ± 5.505 4.541 ± 0.022## 16.608±  0.537 
Group XIV MECP (400 mg/kg) + CD 5.132 ± 0.193## 75.503 ± 5.38## 4.237 ± 0.12## 17.158± 0.513 
Group XV Sibutramine (10 mg/kg) + CD 3.523 ± 0.145## 60.517 ± 3.014## 3.17 ± 0.147## 16.293± 0.574 
On 52st day of study, WAT (periovarian fat, retroperitonealMesenteric, Omental) were weighed and wet weight of WAT to body weight rat io, 
Adiposity index and Fat cell diameter  was calculated for each animal sample. Results collected are analysed by one way analysis of variance 
(ANOVA) followed by Dunnett test in between normal control and treatment; disease control and treatment   P value less than 0.05 is 
considered as significant. *P<0.05, **P<0.01 
*Comparison of test and disease control with normal control, # Comparison test with Disease Control, CD: Cafeteria Diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on WAT in cafeteria diet fed female rats 
There was significant increase in the WAT, Adiposity index and Adipocyte diameter in the HFD group animals as compared to the normal 
control animals. These parameters were significantly decreased by administration of MECP 200 and 400mg/kg. Sibutramine was found to be 
most significant in this regard. 
 
  
Figure: 49 
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Table - 20.1 
Effect of Saline on WAT in normal diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
(1% Bd wt) 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte 
cell No. 
(      x 106) 
1 0.17 0.17 3.8 4 76.36 15.75 
2 0.18 0.18 4.12 4.079 68.36 16.43 
3 0.22 0.22 5.4 4.186 63.17 17.36 
4 0.20 0.20 4.69 4.225 80.37 16.26 
5 0.22 0.22 4.26 3.251 73.05 15.96 
6 0.24 0.24 4.91 3.61 85.36 19.37 
Mean 4.530 3.892 74.445 16.85 
SD 0.583 0.383 8.050 1.351 
SEM 0.238 0.156 3.286 0.551 
 
 
 
 
 
Table - 20.2 
Effect of Saline on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
(1% Bd wt) 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte 
cell No. 
(     x 106) 
1 0.24 0.24 11.12 7.831 105.57 16.84 
2 0.23 0.23 10.74 7.897 110.53 16.83 
3 0.212 0.212 9.8 7.538 118.47 15.95 
4 0.202 0.202 9.21 7.739 97.23 18.37 
5 0.19 0.19 10.07 8.187 86.93 17.83 
6 0.224 0.224 11.16 8.029 108.05 16.83 
Mean 10.350 7.870 104.463 17.108 
SD 0.785 0.226 11.017 0.858 
SEM 0.321 0.092 4.497 0.35 
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Table - 20.3 
Effect of AESM (100 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(    x 106) 
1 10.2 0.52 10.2 7.846 119 15.84 
2 10.9 0.54 9.97 7.071 105 15.23 
3 11.1 0.55 10.32 8 118 17.73 
4 9.6 0.48 8.89 7.534 107 16.73 
5 12.0 0.6 10.46 6.497 96 15.36 
6 10.7 0.53 9.91 7.508 113 16.25 
Mean 9.958 7.409 109.667 16.19 
SD 0.563 0.550 8.756 0.938 
SEM 0.230 0.225 3.575 0.382 
 
 
 
 
 
 
 
Table - 20.4 
Effect of AESM (200 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte cell 
No. 
(     x 106) 
1 22.4 0.56 8.96 6.737 88.73 15.36 
2 22.0 0.55 9.59 7 110.5 14.25 
3 20.4 0.51 8.45 6.983 99.36 17.73 
4 18.2 0.45 8.36 7.207 103.42 16.05 
5 19.6 0.49 8.84 7.429 97.43 15.74 
6 22.8 0.57 9.91 6.882 98.46 18.64 
Mean 9.018 7.04 99.650 16.295 
SD 0.619 0.245 7.178 1.611 
SEM 0.253 0.1 2.93 0.657 
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Table - 20.5 
Effect of AESM (400 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(     x 106) 
1 44.0 0.55 9.46 7.221 106.85 17.03 
2 42.8 0.53 10.02 8.213 113.63 16.74 
3 38.4 0.48 9.36 8 102.93 15.63 
4 44.8 0.56 8.94 6.722 97.87 15.94 
5 40.8 0.51 9.96 8.3 117.38 14.84 
6 47.2 0.59 9.52 7 91.73 16. 94 
Mean 9.543 7.576 105.065 16.186 
SD 0.402 0.678 9.616 0.868 
SEM 0.164 0.277 3.926 0.354 
 
 
 
 
 
Table - 20.6 
Effect of MESM (100 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte cell 
No. 
(    x 106) 
1 11.4 0.57 8.4 6.176 96.92 16.75 
2 9.0 0.45 10.34 10.238 123.63 15.94 
3 9.8 0.49 9.22 7.620 82.13 16.63 
4 11.8 0.59 10.47 7.479 99.87 16.59 
5 1.0 0.6 12.06 8.676 104.18 15.63 
6 11.1 0.55 9.84 6.930 89.73 17.77 
Mean 10.055 7.853 99.410 16.551 
SD 1.245 1.430 14.199 0.742 
SEM 0.509 0.584 5.797 0.742 
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Table - 20.7 
Effect of MESM (200 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte 
cell No. 
(    x 106) 
1 20.4 0.51 11.12 10.018 119.86 15.56 
2 18.2 0.45 10.29 10.188 106.03 14.97 
3 19.2 0.48 11.56 10.804 100.07 16.49 
4 23.2 0.58 9.96 7.968 96.63 15.74 
5 23.8 0.59 8.91 6.551 88.38 15.44 
6 18.8 0.47 9.6 9.320 97.89 17.2 
Mean 10.240 9.142 101.477 15.9 
SD 0.977 1.597 10.663 0.806 
SEM 0.399 0.652 4.353 0.329 
 
 
 
 
Table - 20.8 
Effect of MESM (400 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte 
cell No. 
(    x 106) 
1 46.8 0.58 7.76 5.835 106.85 17.84 
2 38.4 0.48 7.2 6.316 113.63 18.73 
3 43.6 0.54 6.94 5.552 102.93 15.53 
4 47.2 0.59 8.82 6.533 97.87 16.77 
5 36.8 0.46 7.9 7.670 117.38 15.17 
6 35.6 0.44 7.2 6.729 91.73 14.88 
Mean 7.637 6.439 105.065 16.486 
SD 0.686 0.745 9.616 1.56 
SEM 0.280 0.304 3.926 0.637 
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Table - 20.9 
Effect of AECP (100 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(    x 106) 
1 8.6 0.43 8.21 7.330 97.72 16.74 
2 10.5 0.52 5.98 4.365 81.03 17.04 
3 9.2 0.46 7.24 5.886 102.27 15.94 
4 11.0 0.55 8.2 5.503 92.87 16.41 
5 11.2 0.56 8.64 5.722 105.38 17.57 
6 9.4 0.47 9.93 8.487 108.53 17.45 
Mean 8.033 6.216 97.967 16.858 
SD 1.332 1.462 9.979 0.254 
SEM 0.544 0.597 4.074 0.624 
 
 
 
 
Table - 20.10 
Effect of AECP (200 mg/kg) on WAT in cafeteria diet fed female Wistar rats.  
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(    x 106) 
1 22.4 0.56 6.66 4.791 96.65 17.46 
2 23.6 0.59 5.92 4.169 93.84 16.35 
3 24.2 0.6 6.56 4.205 99.72 15.36 
4 20.4 0.51 7.6 6.129 102.93 14.37 
5 18.4 0.46 7.91 6.761 110.28 16.76 
6 17.8 0.44 6.22 5.183 79.13 14.36 
Mean 6.812 5.206 97.092 15.776 
SD 0.782 1.051 10.472 1.287 
SEM 0.319 0.429 4.275 0.525 
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Table - 20.11 
Effect of AECP (400 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte 
cell No. 
(    x 106) 
1 47.6 0.59 6.65 4.650 74.94 15.56 
2 40.0 0.5 5.7 4.750 97.18 14.78 
3 42.8 0.53 6.26 5.048 100.53 18.75 
4 39.6 0.49 6.7 5.726 79.14 16.75 
5 46.4 0.58 5.94 4.213 75.87 15.56 
6 40.8 0.51 5.46 4.403 68.05 18.45 
Mean 6.118 4.798 82.618 15.776 
SD 0.506 0.538 13.128 1.287 
SEM 0.207 0.220 5.359 0.525 
 
 
 
 
 
Table - 20.12 
Effect of MECP (100 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(    x 106) 
1 8.6 0.43 7.23 7.019 120.55 17.55 
2 9.0 0.45 8.01 7.349 102.83 16.43 
3 9.0 0.45 7.77 7.000 97.93 15.66 
4 11.4 0.57 8.94 6.574 96.17 16.74 
5 10.6 0.53 8.54 7.000 114.38 14.38 
6 10.9 0.54 10.06 7.798 101.3 19.73 
Mean 8.425 7.123 105.527 16.748 
SD 0.998 0.412 9.741 1.812 
SEM 0.408 0.168 3.977 0.739 
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Table - 20.13 
Effect of MECP (200 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index 
(%) 
Adipocyte 
Diameter 
(µm) 
Adipocyte 
cell No. 
(    x 106) 
1 20.4 0.51 5.26 4.496 85.15 15.34 
2 18.6 0.46 4.84 4.61 67.83 15.09 
3 22.8 0.57 5.92 4.554 100.97 17.63 
4 23.4 0.58 6.06 4.489 97.17 16.53 
5 18.0 0.45 4.92 4.598 105.03 18.53 
6 22.2 0.56 5.58 4.5 93.43 16.53 
Mean 5.430 4.541 91.597 16.608 
SD 0.509 0.054 13.484 1.316 
SEM 0.208 0.022 5.505 0.537 
 
 
 
 
 
 
Table - 20.14 
Effect of MECP (400 mg/kg) on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
Adipocyte cell 
No.(x 106) 
1 46.4 0.58 5.28 4.031 76.65 17.53 
2 40.4 0.50 5.39 3.963 69.43 15.43 
3 37.2 0.46 4.78 4.641 100.06 18.78 
4 39.6 0.49 4.92 4.241 75.17 17.54 
5 47.2 0.59 5.86 4.543 70.38 17.78 
6 41.2 0.51 4.56 4 61.33 15.89 
Mean 5.132 4.237 75.503 17.158 
SD 0.472 0.293 13.179 1.256 
SEM 0.193 0.12 5.38 0.513 
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Table - 20.15 
Effect of Sibutramine 10 mg/kg on WAT in cafeteria diet fed female Wistar rats. 
Animal 
no. 
Dose of  
Treatment 
10 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index 
(%) 
Adipocyte 
Diameter (µm) 
Adipocyte cell 
No.(     x 106) 
1 1.12 0.56 3.49 2.837 66.15 17.63 
2 1.0 0.5 3.43 3.267 53.93 16.53 
3 0.94 0.47 4.06 3.794 70.15 17.83 
4 0.96 0.48 3.6 3.273 50.94 16.53 
5 1.0 0.5 2.96 2.874 58.47 14.74 
6 1.1 0.55 3.60 2.975 63.46 14.5 
Mean 3.523 3.170 60.517 16.293 
SD 0.354 0.359 7.382 1.406 
SEM 0.145 0.147 3.014 0.574 
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ANIMAL MODEL NO. 3: High fat fed C57BL/6J mouse (DIO mouse):  
8.1: Bases of experimental Design: 
The gold standard for a diet induced obese (DIO: Diet induced obesity) model 
is the female C57BL/6J mouse. The C57BL/6J mouse develops an obese 
phenotype only when allowed ad libitum access to a high-fat diet whereas on a 
low-fat diet, C57BL/6J mice remain normal (Surwit, et. al., 1995).The obesity 
in the C57BL/6J mouse results from both adipocyte hypertrophy and 
hyperplasia. The fat gained in the C57BL/6J mouse is deposited selectively in 
the mesentery. C57BL/6J mice exhibit an increased weight gain per ingested 
energy unit (feed efficiency rate) and the ability of ingested energy to be 
metabolized (metabolic efficiency) is lower in high-fat diet fed C57BL/6J 
mice compared with control mice (Parekh, 1998). The weight gain observed in 
C57BL/6J mice may thus not fully be explained by increased energy intake 
but is also caused by a reduced metabolic rate (Winzell, 2004).  In addition to 
obesity typical features developed by the C57BL/6J mouse on a high fat diet 
are gradually worsening insulin resistance, glucose intolerance, mild to modest 
hyperglycemia, dyslipidemia, hypoadiponectinemia, leptin 
resistance/hyperleptinemia and hypertension. The DIO C57BL/6J mouse also 
suffers from islet dysfunction and shows decreased UCP2 expression as well 
as down regulated ß3- adrenergic receptor expression and function (Surwit 
et.al., 1998; Collins et. al., 1997). All above features are resembles to morbid 
human obesity this will give a better correlation of this metabolic syndrome in 
human beings. Regarding the central adiposity, the gradual course of 
development of diabetes as well as the interaction of nutritional components 
and genetic variables the C57BL/6J mouse closely parallels the progression of 
common forms of the human disease. Typically, C57BL/6J females are fed a 
high fat diet containing 40–60% of calories derived from fat (control diet 5–
10% fat), for 8–16 weeks. The diabetic phenotype in the C57BL/6J mouse is 
evident latest after one month of eating a high fat diet: Baseline plasma 
glucose and insulin are elevated and glucose tolerance tests show reduced 
glucose elimination and impaired insulin secretion (Winzell et. al., 2004). At 
16 weeks C57BL/6J mice develop a fat mass increased by 93% (Surwit, et. al., 
1995).  It has been shown in numerous studies that the C57BL/6J DIO mouse 
Chapter 8                                           HIGH FAT FED C57BL/6J MOUSE 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 247 
 
model is suitable for examining novel therapeutic interventions. Diverse 
antidiabetic drugs, such as TZDs, DPPIV inhibitors as well as anti-obese drugs 
such as CB1 receptor antagonists exert in-vivo efficacy in the DIO mouse 
(Hildebrandt & Audrey et. al., 2003).  
 
8.2: Justification of the design: 
7.2-a: Mice strain: In this present model we have used high fat fed C57BL/6J 
female mouse (DIO mouse). The C57BL/6J mouse develops an obese 
phenotype only when allowed ad libitum access to a high-fat diet whereas 
on a low-fat diet, C57BL/6J mice remain normal. In marked comparison to 
C57BL/6J, other strains such as the A/J mouse or the C57BL/KsJ are 
relatively resistant to these effects when fed a high fat diet (Surwit et. al., 
1995).  
7.2-b: Mice gender:  As an animal model, we used C57BL/6J female mice and fed 
AIN93 diet containing 10% corn oil (CO) as a dietary fat source which 
promotes obesity and induces impaired glucose tolerance and insulin 
resistance, and thus represents as a useful model for studying the early 
stages in the development of obesity and type 2 diabetes (Winzell & Ahren, 
2004; Surwit et. al., 1988). 
 
7.2-c: Age: High fat diet to 6-month-old C57BL/6J female mice were chosen 
primarily to prevent age related muscle loss, as per the earlier literature 
∼10% muscle loss will be there as age progress (Halade, Rahman, & 
Fernandes, 2010). Measurement of body temperature was considered one of 
the parameter in our study, there is significant positive correlation between 
body weight and body temperature exists only for mice aged 6-12 months 
(Talan, 1984).  
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8.3: Materials and Methods 
Materials 
Remi research centrifuge (R-24), Soxhlet extractor, Olampus Research 
microscope with computer connectivity and image capturing capacity, 
Shimadzu UV-visible Spectrophotometer (UV1800), micrtone, Open field 
model was fabricated based on earlier standard literature, Stat Fax 
autoanalyser (2000), Afcoset digital balance (ER-180A). Sibutramine was 
gifted by the Ranbaxy Laboratory Ltd, Devas, MP. 250 µ pone nylon mesh, 
Micro pipette etc. 
Chemicals: Bovine Serum Albumin, Collagenase Type-1, Methylene blue, 
Oil red O, Trypsin, biochemical kits of Span diagnostics. All the chemicals 
used in the study were of analytical grade. 
8.4: Animal selection:  
Five months old 75 (Seventy five) C57BL/6J male mice weighing around 20 
to 24 g, were purchased from National Institute of Nutrition, Hyderabad 
(India). Animals were housed in a standard controlled animal care facility in 
cages (five mice/cage). The animals were maintained in a temperature-
controlled room (22–25°C, 45% humidity) on a 12:12-h dark–light cycle. 
Nations CPCSEA guidelines were strictly followed, and all the studies were 
approved by the Institutional Animal Ethical Committee (IAEC). The animals 
were maintained under standard nutritional and environmental conditions 
throughout the experiment. All the experiments were carried out between 9: 00 
– 16:00 hours at ambient temperature. All the pharmacological experimental 
protocols were approved by the Institutional Animals Ethics Committee (Ref: 
IAEC/HNSIPER/RJK/05/2009) Shree H. N. Shukla Institute of 
Pharmaceutical Education and Research. Rajkot- Gujarat. India. 
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8.5: Animal grouping:  
High fat fed C57BL/6J mouse (DIO mouse): 
Animal Groups 
          Treatment 
5 mice in each Group 
01 Vehicle  +  Normal Standard diet 
02 Vehicle + HFD 
03 AESM (100 mg/kg) + HFD 
04 AESM (200 mg/kg) + HFD 
05 AESM (400 mg/kg) + HFD 
06 MESM (100 mg/kg) + HFD 
07 MESM (200 mg/kg) + HFD 
08 MESM (400 mg/kg) + HFD 
09 AECP (100 mg/kg) + HFD 
10 AECP (200 mg/kg) + HFD 
11 AECP (400 mg/kg) + HFD 
12 MECP (100 mg/kg) + HFD 
13 MECP (200 mg/kg) + HFD 
 14 MECP (400 mg/kg) + HFD 
15 Sibutramine 10 mg/kg +  HFD 
 
 HFD:  High Fat diet 
AESM: Alcoholic extract of Stellaria media  
MESM: Methanolic extract of Stellaria media 
AESM: Alcoholic extract of Clerodendrum phlomidis 
MESM: Methanolic extract of Stellaria media 
 
8.6: Induction of High fat diet induced obesity 
Animals were divided in to 15 groups each group having 5 animals, first group 
(lean mice) had free access to standard pelleted chow which provided 76.8% 
of energy as carbohydrates, 19.2% as protein, and 4.3% as fat. Remaining 70 
mice were fed with a high fat diet providing 60% of energy as fat, 20% as 
protein and 20% as carbohydrates to the animals. Experimental obesity and 
other metabolic changes were induced by dietary manipulation (by proving 
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HFD) for 13 weeks to reaming 14 groups.  After 13 weeks mice were found to 
be obese, change in body weight during this period was not recorded.  Five 
mice in each group were given plant extracts at different doses or vehicle 
alone (Distilled water group). All drugs including plant extracts and standard 
Sibutramine were soluble in water so water was used as media to dissolve 
drugs and animals were administrated with 100 mg/kg, 200 mg/kg and 400 
mg/kg/day of plant extracts (MESM, AESM, MECP and AECP) by oral 
gavages for 4 weeks. Mice in first group (lean mice, kept on standard regular 
diet) were given an equal volume of DW. Body weight and food intake of all 
groups were monitored weekly throughout the treatment period. At the end of 
4 weeks of treatment, behavioral study was performed in all groups and mice 
from each group were sacrificed to check the physiological changes, serum 
biochemistry and other parameters.      
 
Drug preparations:  
Test drug Preparation: 
All plant extracts (alcoholic and methanolic extracts) were soluble in water so 
distilled water (DW) was used as media to dissolve extracts and preparation of 
test drugs. Standard Sibutramine is also soluble in water. While preparation of 
test drug concentration precaution has been taken that all animal groups 
should receive approximate same volume to avoid variation in their oral 
volume. Drug concentration was prepared as for 100 mg/kg body weight 20 
mg/ml; 200 mg/kg body weight, 40 mg/kg; 400 mg/kg body weight, 80 
mg/ml; For Sibutramine drug concentration was 2 mg/ml. All the drug 
concentration were prepared freshly just before administration. All the test 
drugs and standard were given by oral gavages by p.o. route.  
High fat diet to C57BL/6J mouse:   
High fat diet was administered to all C57BL/6J mice except first group for 28 
consecutive days. The composition of high fat diet is as follows. 
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Composition of Low and High Fat diet:  
 
Variable  High-Fat Diet 
kcal/g  5.55 
Macronutrients (as % of total calories)  
Fat  58% 
Carbohydrate  26% 
Protein  16% 
Ingredients (g/kg)  
Casein  167.0 
DL-Methionine  1.5 
Maltodextrin 10  124.0 
Corn starch  0.0 
Sucrose  128.0 
Soybean oil  18.3 
Coconut oil, hydrogenated  244.0 
Salt mix  29.3 
Sodium bicarbonate, 27.4% Na  7.7 
Potassium citrate, 1H20, 36,2% K  2.9 
Vitamin mix  7.3 
Choline bitartrate  1.5 
Yellow dye FD&C no. 5  0.00 
Blue dye FD&C no. 1  0.00 
Red dye FD&C no. 40  0.07 
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8.7: Evaluation:  
8.7-a: Assessment of food consumption behavior in Mice:  Same protocol was 
followed which was followed in the mice progesterone induced obesity by slight 
modification, here we have provided 20 g of  sweetened chow instead of 10 g  to the 
group of 5  mice.  This modification was made by doing pilot study in that we found 
that these animals consume fatty food more rapidly than simple Swiss albino mice.    
8.7-b: Body weight 
The body weight of mice (g) was recorded every week for 28 days in each group just 
before dosing by using precision balance of 10 mg sensitivity.  
8.7-c: Body temperature  
The body temperature of mice were recorded on 29 day, same protocol as followed in 
the CD induced obesity (pp- 153).  
 8.7-d: Biochemical parameters  
Preparation of serum: 24 h (29th day of study) after the last administration of test 
drugs animals were anaesthetized under light ether anesthesia and blood for serum 
preparation was collected by retro orbital puncture, using capillary into sterile plain 
tubes without anticoagulant. Same protocol as followed in the progesterone induced 
obesity in mice (pp- 93).  
8.7-e: Organ weights  
The mice were sacrificed by cervical dislocation on day 30 and then different organs 
kidneys, liver, heart, and body fat i.e. WAT (periovarian, perirenal, and mesenteric fat 
pad) were isolated, the organ to body weight (mg/gm) ratio was recorded. After 
weighing of fat content was preserved for the further study. 
8.7-f: Adiposite isolation 
Same protocol as followed in the Cafeteria diet induced obesity in rats 
8.7-g: Sizing of fat cells and Adiposite Index 
Same protocol as followed in the Cafeteria diet induced obesity in rats 
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Figure: 50 Basic microscopic determination of fat cell diameter. Stained fat cells, 
floating on surface of medium, are aligned on caliper scale, brought into focus, and 
transverse diameter was recorded in units. Magnification 200X. Free fat cells seen in 
this photograph are derived from prioverian fat pad of a C57BL/6J female mice. 
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8.7-j: Histopathological Examination: 
8.7-j: i) Histology of fat pad  
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 51-a Treatment with Vehicle  &  
Normal Standard diet 
    
 
 
 
 
 
 
 
 
 
 
 
Fig: 51-b Treatment with Vehicle  &  
HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 51-c Treatment with AESM (100 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 51-d Treatment with AESM (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 51-e Treatment with AESM (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 51-f Treatment with MESM (100 
mg/kg)  &  HFD 
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Fig: 51-g Treatment with MESM (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 51-h Treatment with MESM (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
Fig: 51-i Treatment with AECP (100 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 51-j Treatment with AECP (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
Fig: 51-k Treatment with AECP (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 51-l Treatment with MECP (100 
mg/kg)  &  HFD 
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Fig: 51-m Treatment with  MECP (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 51-n Treatment with MECP (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
Fig: 51-o Treatment with Sibutramine 
(10 mg/kg)  &  HFD 
  
Figure: 51 Histology of Fat Pad 
Light micrography of perioverian adipocytes in mice fed a normal or a high-fat diet, 
DIO) (X 200). Representative pictures of haematoxylin and eosin-stained sections of 
perioverian adipocytes from mice fed a normal control diet or a high-fat diet 
supplemented with extracts of C. phlomidis at various doses. DIO mice show larger size 
of adipocytes compared to normal control diet. Treatment with AECP (400 mg/kg), 
MECP (200 mg/kg) and MECP (400 mg/kg) along with HFD (High fat Diet) have 
shown smaller size of adipocytes than mice feed with plain HFD. 
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8.7-j: ii) Histology of Liver 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-a Treatment with Vehicle  &  
Normal Standard diet 
    
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-b Treatment with Vehicle  &  
HFD 
 
 
 
 
 
 
 
 
 
Fig: 52-c Treatment with AESM (100 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-d Treatment with AESM (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 52-e Treatment with AESM (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-f Treatment with MESM (100 
mg/kg)  &  HFD 
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Fig: 52-g Treatment with MESM (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-h Treatment with MESM (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
Fig: 52-i Treatment with AECP (100 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-j Treatment with AECP (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
Fig: 52-k Treatment with AECP (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-l Treatment with MECP (100 
mg/kg)  &  HFD 
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Fig: 52-m Treatment with  MECP (200 
mg/kg)  &  HFD 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 52-n Treatment with MECP (400 
mg/kg)  &  HFD 
 
 
 
 
 
 
Fig: 52-o Treatment with Sibutramine 
(10 mg/kg)  &  HFD 
 
Figure: 52 Histology of Liver 
Light micrography of picture of liver of C57BL/6J mice fed normal or high-fat diet (X 
200). Representative pictures of haematoxylin and eosin-stained sections of liver tissue 
from C57BL/6J mice fed a normal control diet or high-fat diet supplemented with of S. 
media and C. phlomidis.  Treatment with medium and high dose of MESM and MECP 
extracts show few fat droplets in hepatocytes while standard sibutramine has shown 
complete protection against fat accumulation. Fat accumulation indicated by the 
arrowheads. 
 
 
  
Chapter 8                                           HIGH FAT FED C57BL/6J MOUSE 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 260 
 
8.8: Statistical analysis:  The results are expressed as mean ± SEM. Comparisons 
between the treatment groups and positive control; positive control and control were 
performed by one way analysis of variance (ANOVA) followed by Dunnett test. In all 
tests the criterion for statistical significance was p < 0.05 (95% level). The analysis 
was performed by using GraphPad Prism 4.  
P value P<0.05 is considered as significant *P<0.05, **P<0.01. 
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8.9: Results    
Table- 21 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on HFD induced 
C57BL/6J female mice food consumption (gm / group). 
Sr. No. 
(Groups) 
Treatment 
Time 
0.5 hr 1 hr 2 hr 
Group I 
Control (Vegetable oil) 3.18 ± 0.51 5.08 ± 0.23 7.14 ± 0.27 
Group II 
HFD 6.86 ± 0.51** 10.2  ± 0.68** 12.4 ± 0.56** 
Group III 
AESM (100 mg/kg) + HFD 5.44 ± 0.06**# 9.62 ± 0.17**## 12.2 ± 0.79** 
Group IV 
AESM (200 mg/kg) + HFD 5.12 ± 0.25**## 7.66 ± 0.35**## 11.8 ±1.05** 
Group V 
AESM (400 mg/kg) + HFD 5.46 ± 0.143**# 9.06 ± 0.254**## 10.9 ± 0.27** 
Group VI 
MESM (100 mg/kg) + HFD 4.1 ± 0.12## 7.79 ± 0.34**## 10.78 ± 0.43** 
Group VII 
MESM (200 mg/kg) + HFD 3.68 ± 0.2## 6.32 ± 0.4## 9.2 ± 0.15## 
Group VIII 
MESM (400 mg/kg) + HFD 3.48 ± 0.37## 5.72 ± 0.33## 6.16 ± 0.14## 
Group IX 
AECP (100 mg/kg)  + HFD 5.34 ±  0.33**# 9.34 ± 0.22** 11.62 ± 0.41 
Group X 
AECP (200 mg/kg) + HFD 6.24 ± 0.26** 10.2 ± 0.37**# 11.2 ± 0.27** 
Group XI 
AECP (400 mg/kg) + HFD 5.7 ± 0.23** 10.84 ± 0.34** 12.54 ± 0.23** 
Group XII 
MECP (100 mg/kg)  + HFD 5.14 ± 0.59**## 8.54 ± 0.7**## 11.72 ± 1** 
Group XIII 
MECP (200 mg/kg) + HFD 5.08 ± 0.29**## 7.9 ± 0.47**## 10.52 ± 0.59** 
Group XIV 
MECP (400 mg/kg) + HFD 4 ± 0.44## 6.34 ± 0.61## 9.08 ± 0.46## 
Group XIV 
Sibutramine 10 mg/kg + HFD 2.88 ± 0.44## 5.8 ± 0.1## 7.32 ± 0.39## 
 
Food consumption pattern was recorded on every week 30 min after drug administration in 
all groups. Results collected are analysed by one way analysis of variance (ANOVA) 
followed by Dunnett test in between normal control and treatment; disease control and 
treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01. 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
HFD: High fat Diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on HFD induced 
C57BL/6J female mice food consumption (gm / group). 
The HFD group animals showed significantly increased food consumption as 
compared to the normal control group animals at 30 min, 1hr and 2 hr which was 
significantly decreased by the co-administration of  MESM 100, 200 and 400 mg, 
AECP 400 mg/kg and MECP 100 mg/kg. Standard sibutramine was most significant 
in this case. 
 
Figure: 53 
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Table - 21.1 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on HFD induced C57BL/6J female mice food consumption (gm / Grp). 
Sr. No. 
(Grps) 
Treatment 
Day / Time in hrs 
1st 7th 14th 21st 28th 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
0.5 
hr 
1 
hr 
2 
hr 
Grp I Control (Vegetable oil) 3.2 5.5 6.3 5.1 4.6 6.8 2.1 4.5 7.4 2.9 5.7 7.3 2.6 5.1 7.9 
Grp II HFD 8.1 10.3 11.4 7.4 10.8 12.2 6.5 8.3 12.4 7.2 12.3 14.5 5.1 9.3 11.5 
Grp III AESM (100 mg/kg) + HFD 6.2 9.7 13.9 7.2 10.2 12.4 5.7 9.6 12.2 6 9.1 13.2 2.1 5.7 9.3 
Grp IV AESM (200 mg/kg) + HFD 5.2 9.5 8.3 5.1 9.8 13.4 5.3 10.2 13.5 5.1 9.2 9.3 4.9 9.4 10.9 
Grp V AESM (400 mg/kg) + HFD 5.2 8.7 10.2 5.6 9.7 10.5 5.1 8.9 11.3 5.5 8.4 10.8 5.9 9.6 11.7 
Grp VI MESM (100 mg/kg) + HFD 3.9 6.6 10.2 4.1 8.9 9.6 4.2 7.9 11.8 4.5 8.4 11.7 3.8 7.7 10.6 
Grp VII MESM (200 mg/kg) + HFD 3.6 7.9 9.5 3.3 5.8 8.9 3.2 6.0 9.3 4.1 6.1 8.8 4.2 5.8 9.5 
Grp VIII MESM (400 mg/kg) + HFD 3.4 4.9 5.8 2.9 5.1 5.9 3.8 6.3 6.2 2.6 5.7 6.6 4.7 5.6 6.3 
Grp IX AECP (100 mg/kg)  + HFD 5.9 8.6 12.6 5.1 9.5 11.4 5.4 9.1 10.4 4.2 9.6 11.2 6.1 9.9 12.5 
Grp X AECP (200 mg/kg) + HFD 6.8 10.4 11.2 6.1 11.5 11.8 5.5 9.6 11.6 5.9 10.1 11.2 6.9 9.4 10.2 
Grp XI AECP (400 mg/kg) + HFD 5.3 10.6 12.3 6.4 10.1 11.8 5.2 11.6 13.2 5.5 10.2 12.6 6.1 11.7 12.8 
Grp XII MECP (100 mg/kg)  + HFD 6.9 10.4 14.7 5.7 9.1 13.2 5.1 8.6 10.2 4.7 8.5 11.3 3.3 6.1 9.2 
Grp XIII MECP (200 mg/kg) + HFD 5.3 8.8 11.5 4.8 8.9 12.2 5.7 8.2 10.2 5.5 7.1 9.8 4.1 6.5 8.9 
Grp  XIV MECP (400 mg/kg) + HFD 3.6 6.2 9.1 5.7 8.2 10.6 3.2 5.0 9.2 3.6 5.1 7.7 3.9 7.2 8.8 
Gp XIV Std (Sibutramine 10 mg/kg + HFD) 3.5 5.6 8.4 3.3 5.1 7.3 2.5 5.4 6.8 3.5 5.2 7.9 1.2 5.1 6.2 
Grp: Group, HFD:  High Fat diet, AESM: Alcoholic extract of Stellaria media , MESM: Methanolic extract of Stellaria media,      
AESM: Alcoholic extract of Clerodendrum phlomidis, MESM: Methanolic extract of Stellaria media 
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Tables: 22 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on HFD induced 
C57BL/6J female mice % change in body weight. 
Sr. No. 
(Groups) 
Treatment   % Change in body weight 
Group I Saline + Normal diet 3.217 ± 0.524 
Group II Saline + HFD 13.916 ± 0.454** 
Group III AESM (100 mg/kg) + HFD 11.292 ± 0.338**# 
Group IV AESM (200 mg/kg) + HFD 11.065 ± 0.889**# 
Group V AESM (400 mg/kg) + HFD 12.33 ± 0.43** 
Group VI MESM (100 mg/kg) + HFD 9.78 ± 0.585**## 
Group VII MESM (200 mg/kg) + HFD 5.311 ± 0.633## 
Group VIII MESM (400 mg/kg) + HFD 2.871 ± 0.698## 
Group IX AECP (100 mg/kg)  + HFD 13. 397 ± 0.461** 
Group X AECP (200 mg/kg) + HFD 12.55 ± 0.65** 
Group XI AECP (400 mg/kg) + HFD 12.66 ± 0.46** 
Group XII MECP (100 mg/kg)  + HFD 13.85 ± 0.602** 
Group XIII MECP (200 mg/kg) + HFD 6.013 ± 0.465*## 
Group XIV MECP (400 mg/kg) + HFD 2.428 ±0.499## 
Group XV Sibutramine 10 mg/kg + HFD -2.904 ± 0.894**## 
 
The percent change in body weight was calculated based on initial weight of mice and 
weight of mice on 28th day. Results collected are analysed by one way analysis of 
variance (ANOVA) followed by Dunnett test in between normal control and 
treatment; disease control and treatment   P value less than 0.05 is considered as 
significant. *P<0.05, **P<0.01 
*Comparison of test and disease control with normal control 
# Comparison test with Disease Control 
 
HFD:  High Fat diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on HFD induced C57BL/6J female mice % change in body weight. 
Animals fed with HFD showed significant %  increase in the body weight as compared to normal control animals which was significantly  
decreased in  MESM 100, 200 and 400 mg/kg, MECP 200 and 400 mg/kg and most significantly by Sibutramine. 
 
Figure: 54 
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Table - 22.1 
Effect of saline administration on body weight changes on normal diet fed 
C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Body 
wt) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 0.24 0.24 24.3 24.4 24.4 24.6 24.7 24.9 25 25.1 
2 0.22 0.22 22 22.1 22.2 22.2 22.3 22.2 22.3 22.4 
3 0.23 0.23 23.5 23.6 23.5 23.6 23.5 24.8 24.7 24.5 
4 0.23 0.23 23.7 23.6 23.9 24.6 24.5 24.7 24.4 24.5 
5 0.24 0.24 24.6 24.7 24.8 24.6 24.8 25.2 25.3 25.4 
Mean 23.62 23.68 23.76 23.92 23.96 24.36 24.34 24.38 
% Change in Body weight 00 0.254 0.59 1.27 1.43 3.13 3.04 3.21 
SD 1.03 1.01 1 1.05 1.06 1.22 1.18 1.173 
SEM 0.45 0.45 0.44 0.47 0.47 0.54 0.53 0.524 
 
Table - 22.2 
Effect of saline administration on body weight changes on High fat diet fed 
C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Body 
wt) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st  4th 8th 12th 16th 20th 24th 28th 
1 0.33 0.33 33.6 34.1 34.6 35.4 36.5 37.3 38.8 39.3 
2 0.34 0.34 34.2 34.6 35.6 35.4 36.2 36.6 37.8 38.4 
3 0.35 0.35 35.0 35.8 36.6 37.4 37.8 38.1 38.8 39.7 
4 0.32 0.32 32.1 33.3 33.9 34.5 35.2 35.5 36.9 37.2 
5 0.35 0.35 35.4 35.8 36.6 36.8 37.2 37.8 38.8 39.4 
Mean 34.06 34.72 35.46 35.9 36.58 37.06 38.22 38.8 
% Change in Body weight 00 1.93 4.11 5.40 7.39 8.80 12.21 13.91 
SD 1.30 1.08 1.20 1.17 0.99 1.04 0.85 1.017 
SEM 0.58 0.48 0.53 0.52 0.44 0.46 0.38 0.454 
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Table: 22.3 
Effect of AESM (100 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(100 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 3.32 0.16 33.2 33.6 34.6 35.4 35.9 35.6 36.8 37.2 
2 3.44 0.17 34.4 34.8 35.3 35.8 36.3 36.8 37.2 38.3 
3 3.5 0.17 35.0 35.8 35.9 36.4 36.9 37.4 37.8 38.9 
4 3.44 0.17 34.4 34.8 35.6 35.8 36.2 36.8 37.8 37.8 
5 3.48 0.17 34.8 35.2 35.7 36.4 37.3 37.1 38.3 39.0 
Mean 34.36 34.84 35.42 35.96 36.52 36.74 37.58 38.24 
% Change in Body weight 00 1.39 3.08 4.65 6.28 6.92 9.37 11.29 
SD 0.69 0.8 0.5 0.43 0.56 0.68 0.58 0.757 
SEM 0.31 0.36 0.22 0.19 0.25 0.3 0.26 0.338 
 
Table - 22.4 
Effect of AESM (200 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(200 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 6.78 0.16 33.9 34.3 34.8 35.4 35.8 36.3 36.8 37.1 
2 6.68 0.16 33.4 33.9 34.6 34.8 35.6 35.9 36.2 36.2 
3 7.98 0.19 36.9 37.8 37.7 38.3 38.8 39.3 39.8 41.2 
4 7 0.17 35 35.8 35.9 36.4 36.9 37.4 38.9 39 
5 6.5 0.16 32.5 32.9 33.6 33.9 34.4 35.9 36.8 37.2 
Mean 34.34 34.94 35.32 35.76 36.3 36.96 37.7 38.14 
% Change in Body weight 00 1.74 4.13 4.13 5.7 7.62 9.78 11.06 
SD 1.69 1.9 1.56 1.68 1.65 1.44 1.55 1.989 
SEM 0.75 0.85 0.69 0.75 0.74 0.64 0.69 0.889 
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Table - 22.5 
Effect of AESM (400 mg/kg) administration on body changes weight High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(400 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 13.56 0.16 33.9 34.5 34.8 35.2 35.6 36.3 36.7 39.9 
2 13.76 0.17 34.4 34.8 35.3 35.4 36.2 36.8 37.2 40.2 
3 13.8 0.17 34.7 35.1 35.3 35.6 35. 2 35.4 35.8 38.1 
4 14.7 0.18 36.8 37.2 37.6 38.4 38.7 37.2 38.0 39.4 
5 13.8 0.17 34.5 34.8 35.6 35.4 36.9 37 37.3 38.2 
Mean 34.86 35.28 35.72 36 36.24 36.54 37 39.16 
% Change in Body weight 00 1.2 2.46 3.27 3.95 4.81 6.13 12.33 
SD 1.12 1.09 1.08 1.34 1.377 0.71 0.81 0.96 
SEM 0.50 0.48 0.48 0.6 0.615 0.32 0.36 0.43 
 
Table - 22.6 
Effect of MESM (100 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(100 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 3.23 0.16 32.3 32.8 33.6 33.7 34.2 34.7 35.18 35.6 
2 3.55 0.17 35.5 35.8 36.4 36.9 37.2 37.9 38.8 38.7 
3 3.25 0.16 32.5 32.8 33.4 33.4 34.4 34.9 35.8 36 
4 3.52 0.17 35.2 35.6 36.1 36.4 37.1 37.6 38 38 
5 3.32 0.16 33.2 33.6 34.1 34.4 35.1 35.6 36.7 36.9 
Mean 33.74 34.12 34.72 34.96 35.6 36.14 36.89 37.04 
% Change in Body weight 00 1.12 2.9 3.61 5.51 7.11 9.33 9.78 
SD 1.51 1.4 1.42 1.59 1.45 1.51 1.5 1.308 
SEM 0.67 0.66 0.63 0.71 0.65 0.67 0.67 0.585 
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Table - 22.7 
Effect of MESM (200 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(200 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 6.62 0.17 33.1 33.5 34.1 34.4 34.9 35.3 35.8 35.1 
2 6.88 0.17 34.4 34.8 35.2 35.7 36.1 36.2 36 36.4 
3 7.02 0.18 35.1 35.5 36.1 36.4 36.7 37 37.1 37.2 
4 6.98 0.17 34.9 35.3 35.6 35.9 36. 2 36.0 36.3 36.7 
5 7.52 0.19 37.6 38 38.3 38.3 38.5 38.7 38.9 39 
Mean 35.02 35.42 35.86 36.14 36.48 36.64 36.82 36.88 
% Change in Body weight 00 1.14 2.39 3.19 4.16 4.62 5.13 5.31 
SD 1.63 1.63 1.55 1.41 1.308 1.30 1.26 1.416 
SEM 0.73 0.73 0.69 0.63 0.585 0.58 0.56 0.633 
 
Table - 22.8 
Effect of MESM (400 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(400 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 13.48 0.17 33.7 34.1 34.4 35.7 35.5 35.5 36.1 35 
2 12.12 0.15 30.3 30.2 30.4 30.3 30.5 30.8 30.8 31.2 
3 12.88 0.16 32.2 32.6 33.5 33.8 33.9 34 34.2 34.1 
4 13.36 0.17 33.4 33.5 33.6 33.8 34.0 34.4 34.2 34.0 
5 13.64 0.17 34.1 33.8 34.2 34.5 34.7 34.4 34.8 35 
Mean 32.74 32.84 33.22 33.62 33.72 33.82 34.02 33.86 
% Change in Body weight 00 0.3 1.46 2.68 2.99 3.92 3.9 3.42 
SD 1.53 1.57 1.62 2.01 1.91 1.77 1.96 1.561 
SEM 0.68 0.7 0.72 0.89 0.85 0.79 0.87 0.698 
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Table - 22.9 
Effect of AECP (100 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(100 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 3.3 0.17 33 33.8 33.9 35.1 35.9 36.9 37.5 38 
2 3.47 0.17 34.7 35.1 35.6 36.4 37.1 37.8 38.5 39.1 
3 3.27 0.16 32.7 33.8 33.6 34.4 34.2 35.1 35.8 36.3 
4 3.42 0.17 34.2 34.6 35.1 35.6 36.1 36.6 37.4 38.4 
5 3.26 0.16 32.6 33.2 33.5 34.7 35.5 35.9 36.4 37.8 
Mean 33.44 34.1 34.34 35.24 35.76 36.46 37.12 37.92 
% Change in Body weight 00 1.97 2.69 5.38 6.93 9.03 11 13.39 
SD 0.95 0.74 0.95 0.78 1.05 1.02 1.04 1.032 
SEM 0.42 0.33 0.42 0.35 0.47 0.45 0.46 0.461 
 
Table - 22.10 
Effect of AECP (200 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(200 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 6.36 0.16 31.8 32.2 32.6 33.2 33.7 34.2 34.6 35.4 
2 7.04 0.18 35.2 35.8 36.6 36.4 37.2 37.6 38 39.3 
3 6.32 0.16 31.6 32 32.6 33.4 34.5 34.3 34.8 36.5 
4 6.62 0.17 33.1 33.4 34.0 34.5 35.1 35.5 35.9 37.8 
5 6.8 0.17 34 34.5 34.9 35.4 35.8 36.4 36.9 37.5 
Mean 33.14 33.59 34.14 34.58 35.26 35.6 36.04 37.3 
% Change in Body weight 00 1.35 3.01 4.34 6.39 7.42 8.75 12.55 
SD 1.51 1.58 1.68 1.34 1.33 1.44 1.43 1.46 
SEM 0.67 0.7 0.75 0.6 0.59 0.64 0.64 0.65 
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Table - 22.11 
Effect of AECP (400 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(400 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 12.92 0.16 32.3 32.8 33.6 34.1 34.9 35.7 36.4 36.9 
2 12.6 0.16 31.5 31.8 32.6 33.1 33.9 34.5 35.2 36.1 
3 13.84 0.17 34.6 34.8 35.2 35.8 36.7 37.1 37.9 38.6 
4 13.4 0.17 33.5 33.6 34.4 34.8 35.4 35.9 36.4 37.8 
5 13.88 0.17 34.7 35.4 35.1 35.7 36.3 37 37.8 38.3 
Mean 33.32 33.68 34.18 34.7 35.44 36.04 36.74 37.54 
% Change in Body weight 00 1.08 2.58 4.14 6.36 8.16 10.26 12.66 
SD 1.4 1.46 1.091 1.13 1.11 1.06 1.12 1.03 
SEM 0.62 0.65 0.488 0.5 0.5 0.477 0.5 0.46 
 
Table - 22.12 
Effect of MECP (100 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(100 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 2.93 0.15 29.3 29.7 30.6 31.74 32.2 32.7 33.7 34.3 
2 3.34 0.17 33.4 33.8 34.6 34.8 35.2 35.8 36.8 37.2 
3 3.29 0.16 32.9 33.3 33.8 34.2 34.8 35.3 35.9 36.8 
4 3.03 0.15 30.3 31.7 32.6 33.7 34.2 35.4 36.6 37.2 
5 3.5 0.18 35 35.8 36.6 36.4 36.9 37.4 37.8 37.7 
Mean 32.18 32.86 33.64 34.16 34.66 35.32 36.16 36.64 
% Change in Body weight 00 2.11 4.53 6.15 7.7 9.75 12.37 13.85 
SD 2.33 2.29 2.23 1.69 1.7 1.69 1.53 1.346 
SEM 1.04 1.02 1.00 0.75 0.76 0.75 0.686 0.602 
 
  
Chapter 8                                           HIGH FAT FED C57BL/6J MOUSE 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 272 
 
Table - 22.13 
Effect of MECP (200 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(200 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 6.44 0.16 32.2 32.8 33.1 33.6 34.2 34.6 35 35.6 
2 6.34 0.16 31.7 31.8 32 32.4 32.6 33.1 33.5 33.5 
3 6.88 0.17 34.4 34.8 35 35.4 35.8 35.8 36.2 36.1 
4 6.76 0.17 33.8 33.9 34.4 34.5 34.7 34.9 35.3 35.2 
5 6.84 0.17 34.2 34.0 34.2 34. 4 34.9 35.2 35.8 35.9 
Mean 33.26 33.46 33.74 34.06 34.44 34.72 35.16 35.26 
% Change in Body weight 00 0.6 1.44 2.4 3.54 4.38 5.71 6.01 
SD 1.22 1.16 1.19 1.126 1.18 1.00 1.03 1.04 
SEM 0.54 0.52 0.53 0.503 0.52 0.45 0.46 0.465 
 
Table - 22.14 
Effect of MECP (400 mg/kg) administration on body weight changes on High fat 
diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(400 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 13.2 0.17 33 32.4 32.8 34.1 34. 2 34.4 33.8 33.8 
2 13.68 0.17 34.2 34.3 34.0 33.8 33.8 34.1 34.8 35.1 
3 13.52 0.17 33.8 33.8 34.3 34.7 34.7 35 35.2 35.0 
4 14.12 0.18 35.3 35.2 35. 6 35.7 35.2 35.7 35.8 35.9 
5 13.0 0.16 32.5 32.4 32.7 32.9 33.2 33.1 33.4 33.1 
Mean 33.76 33.62 33.88 34.24 34.22 34.46 34.6 34.58 
% Change in Body weight 00 -0.41 0.35 1.42 1.36 2.07 2.48 2.42 
SD 1.08 1.22 1.194 1.04 0.775 0.97 0.98 1.116 
SEM 0.48 0.54 0.534 0.466 0.346 0.43 0.44 0.499 
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Table - 22.15 
Effect of Sibutramine 10 mg/kg administration on body weight changes on High 
fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(10 mg/kg) 
Vol. of 
Treatment 
ml 
Day and body weight (gm) 
1st 4th 8th 12th 16th 20th 24th 28th 
1 0.31 0.16 31.3 31.42 31.2 31.0 31.3 31.1 31.3 31.7 
2 0.30 0.15 30.5 30.6 30.7 30.6 30.4 30.1 29.2 29.2 
3 0.34 0.17 34 34.1 34.2 34.1 33.8 33.9 34.2 34.5 
4 0.32 0.16 32.3 32.4 32.5 32.4 32.3 32 31.8 31.5 
5 0.33 0.17 33.7 33.8 32.9 32.0 32.2 30.8 31.1 30.2 
Mean 32.36 32.46 32.3 32.02 32 31.58 31.52 31.42 
% Change in Body weight 00 0.3 -0.18 -1.05 -1.11 -2.14 -2.59 -2.9 
SD 1.5 1.5 1.39 1.37 1.26 1.46 1.79 1.999 
SEM 0.67 0.67 0.62 0.61 0.56 0.65 0.8 0.894 
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Table – 23 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on body temperature (°C) in High fat diet fed C57BL/6J mice for 28 
days before and after drug administration. 
Sr. No. 
(Groups) 
Treatment Before 2hr Before 1hr After 1hr After 2hr 
Group I Normal diet 37.09 ± 0.024 38.02  ± 0.009 38.04 ± 0.012 38.04 ± 0.014 
Group II HFD 38.02  ± 0.02 38.02 ±  0.02 38.04 ±  0.03 38.03 ± 0.02 
Group III AESM (100 mg/kg) + HFD 38.01 ±0.025 38.01 ±  0.015 38.03 ± 0.021 38.04 ± 0.015 
Group IV AESM (200 mg/kg) + HFD 38.03 ±0.027 38.04 ±  0.023 38.04 ± 0.025 38.02 ± 0.025 
Group V AESM (400 mg/kg) + HFD 38.01 ± 0.024 37.97 ±  0.018 38.03 ± 0.019 38.07 ± 0.007 
Group VI MESM (100 mg/kg) + HFD 38.01 ± 0.020 38.03 ± 0.006 38.01 ± 0.020 38 ± 0.014 
Group VII MESM (200 mg/kg) + HFD 37.09 ± 0.024 38.02 ± 0.023 38.01 ± 0.017 38.11 ± 0.096 
Group VIII MESM (400 mg/kg) + HFD 38.09 ± 0.185 38.20 ± 0.08 38.02 ± 0.188 38.04 ± 0.192 
Group IX AECP (100 mg/kg)  + HFD 38.01 ± 0.015 38.01 ± 0.021 37.09 ± 0.015 38.01 ± 0.03 
Group X AECP (200 mg/kg) + HFD 38.01 ±  0.02 37.08 ±  0.026 38.02 ±0.008 38.02 ± 0.017 
Group XI AECP (400 mg/kg) + HFD 38.02 ± 0.022 38.02 ±  0.004 38.05 ± 0.011 38.05 ± 0.228 
Group XII MECP (100 mg/kg)  + HFD 38.02  ± 0.021 38.01 ± 0.012 38.05  ± 0.013 38.04 ± 0.008 
Group XIII MECP (200 mg/kg) + HFD 38 ± 0.019 38.01  ± 0.021 38.04 ± 0.017 38.03 ± 0.008 
Group XIV MECP (400 mg/kg) + HFD 38 ± 0.018 38.09 ± 0.235 38.03 ± 0.015 38.06 ± 0.009 
Group XV Sibutramine 10 mg/kg + HFD 37.09 ± 0.012 38.00 ± 0.010 38.02 ± 0.004 38.06 ± 0.009 
 
Effect of Stellaria media and Clerodendrum phlomidis on body temperature (°C) in C57BL/6J female mice was carried out on 29th day of 
study. The body temperature was recorded by using digital telethermometer and was expressed in °C (with 10 sec contact period). The 
temperature was recorded at 2 hr and 1 hr before and after drug administration. Results collected are analysed by one way analysis of 
variance (ANOVA) followed by Dunnett test in between normal control and treatment; disease control and treatment   P value less than 
0.05 is considered as significant. *P<0.05, **P<0.01,  
*Comparison of test and disease control with normal control,  
# Comparison test with Disease Control 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on body temperature (°C) in High fat diet fed C57BL/6J mice for 28 
days before and after drug administration. 
There wasn’t any significant change found in the body temperature in any of the group of animals 
 
Figure: 55 
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Table - 23.1 
Effect of saline on body temperature (°C) in normal diet fed C57BL/6J mice for 
28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
(1% Bd. wt.) 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 0.24 0.24 38.01 38.02 38.06 38.01 
2 0.22 0.22 37.91 38.03 38.07 38.03 
3 0.23 0.23 38.03 38.05 38 38.08 
4 0.23 0.23 38.04 38.02 38.05 38.03 
5 0.24 0.24 37.96 37.99 38.05 38.08 
Mean 37.99 38.022 38.046 38.046 
SD 0.054 0.0216 0.0270 0.0320 
SEM 0.024 0.009 0.012 0.014 
 
 
 
 
 
 
 
Table - 23.2 
Effect of saline on body temperature (°C) in High fat diet fed C57BL/6J mice for 
28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
(1% Bd. wt.) 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 0.33 0.33 38.08 37.97 38.05 38.1 
2 0.34 0.34 37.99 38.07 38.03 38.05 
3 0.35 0.35 38.03 38.05 38.04 38 
4 0.32 0.32 38.03 38.01 38.03 38 
5 0.35 0.35 37.96 38.02 38.05 38.02 
Mean 38.02 38.02 38.04 38.03 
SD 0.05 0.04 0.01 0.04 
SEM 0.02 0.02 0.00 0.02 
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Table - 23.3 
Effect of AESM (100 mg/kg) bromide on body temperature (°C) High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 3.32 0.16 38.07 38.06 37.96 38.02 
2 3.44 0.17 37.98 38.04 38.04 38.08 
3 3.5 0.17 38.05 38.01 38.06 38.02 
4 3.44 0.17 37.93 37.97 38.02 38.09 
5 3.48 0.17 38.02 38.01 38.08 38.03 
Mean 38.01 38.018 38.032 38.048 
SD 0.056 0.034 0.046 0.034 
SEM 0.025 0.015 0.021 0.015 
 
 
 
 
 
 
 
Table - 23.4 
Effect of AESM (200 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 6.78 0.16 37.93 37.98 38.01 37.97 
2 6.68 0.16 38.05 38.01 38.08 37.97 
3 7.98 0.19 38.03 38.05 37.97 38.07 
4 7 0.17 38.09 38.1 38.08 38.03 
5 6.5 0.16 38.06 38.09 38.1 38.09 
Mean 38.032 38.046 38.048 38.026 
SD 0.061 0.051 0.055 0.056 
SEM 0.027 0.023 0.025 0.025 
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Table - 23.5 
Effect of AESM (400 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 13.56 0.16 37.93 37.97 38.03 38.07 
2 13.76 0.17 38.05 38.02 38.04 38.08 
3 13.8 0.17 38.04  37.95 37.97 38.05 
4 14.7 0.18 37.99 37.93 38.08 38.07 
5 13.8 0.17 38.06 38.02 38.06 38.09 
Mean 38.014 37.978 38.036 38.072 
SD 0.054 0.041 0.042 0.015 
SEM 0.024 0.018 0.019 0.007 
 
 
 
 
 
Table - 23.6 
Effect of MESM (100 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 3.23 0.16 38.03 37.94 38.03 38.08 
2 3.55 0.17 37.97 38.06 38.03 37.9 
3 3.25 0.16 38.01 38.00 37.96 38.04 
4 3.52 0.17 38.06 38.03 38 37.98 
5 3.32 0.16 38.02 38.04 37.97 38.05 
Mean 38.018 38.014 37.998 38.010 
SD 0.033 0.047 0.033 0.071 
SEM 0.015 0.021 0.015 0.032 
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Table - 23.7 
Effect of MESM (200 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 6.62 0.17 37.99 37.94 38.01 38.05 
2 6.88 0.17 38.07 37.92 38.05 38.04 
3 7.02 0.18 38.03 38.06 38.01 38.0 
4 6.98 0.17 37.93 38.02 38.04 37.97 
5 7.52 0.19 38.04 38.00 38.02 38.06 
Mean 38.01 37.98 38.02 38.02 
SD 0.054 0.058 0.018 0.038 
SEM 0.024 0.026 0.008 0.017 
 
 
 
 
 
 
 
 
 
Table - 23.8 
Effect of MESM (400 mg/kg) on body temperature (°C) High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 13.48 0.17 38.04 38.02 38.06 38.08 
2 12.12 0.15 37.98 38.03 38.02 38.09 
3 12.88 0.16 38.08 38.04 38.07 39.02 
4 13.36 0.17 38.05 38.02 38.04 38.07 
5 13.64 0.17 37.96 38.02 38.08 39.00 
Mean 38.022 38.026 38.054 38.452 
SD 0.050 0.009 0.024 0.510 
SEM 0.022 0.004 0.011 0.228 
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Table - 23.9 
Effect of AECP (100 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 3.3 0.17 37.96 38.04 38.05 37.98 
2 3.47 0.17 37.99 38.05 38.04 38.02 
3 3.27 0.16 38.06 38.02 38.01 37.98 
4 3.42 0.17 38.01 38.05 37.94 38.05 
5 3.26 0.16 38.06 38.03 38.03 37.98 
Mean 38.016 38.038 38.014 38.002 
SD 0.044 0.013 0.044 0.032 
SEM 0.020 0.006 0.020 0.014 
 
 
 
 
 
 
 
 
Table - 23.10 
Effect of AECP (200 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 6.36 0.16 38.04 38.07 38.02 38.04 
2 7.04 0.18 37.93 38.03 38.05 38.02 
3 6.32 0.16 38.05 38.02 37.95 38.01 
4 6.62 0.17 38.02 38.06 38.03 38.5 
5 6.8 0.17 37.95 37.94 38.02 38.02 
Mean 37.998 38.024 38.014 38.118 
SD 0.055 0.051 0.038 0.214 
SEM 0.024 0.023 0.017 0.096 
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Table - 23.11 
Effect of AECP (400 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 12.92 0.16 38.05 38.03 37.95 38.04 
2 12.6 0.16 37.98 37.98 38.04 38.07 
3 13.84 0.17 38.93 38.02 38.08 38.07 
4 13.4 0.17 38.03 38.06 38.07 39.01 
5 13.88 0.17 37.97 38.94 38.97 38.03 
Mean 38.192 38.206 38.222 38.244 
SD 0.414 0.411 0.421 0.429 
SEM 0.185 0.184 0.188 0.192 
 
 
 
 
 
 
 
 
 
 
 
 
Table - 23.12 
Effect of MECP (100 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 2.93 0.15 38.06 38.03 38.07 38.04 
2 3.34 0.17 37.94 37.97 38.03 38.02 
3 3.29 0.16 38.05 38.04 38.01 38.07 
4 3.03 0.15 38.03 38.02 38.07 38.05 
5 3.5 0.18 38.03 38.01 38.07 38.04 
Mean 38.022 38.014 38.050 38.044 
SD 0.048 0.027 0.028 0.018 
SEM 0.021 0.012 0.013 0.008 
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Table - 23.13 
Effect of MECP (200 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 6.44 0.16 37.98 37.98 38.04 38.02 
2 6.34 0.16 38.02 38.03 38.06 38.05 
3 6.88 0.17 38.03 38.02 37.99 38.01 
4 6.76 0.17 37.94 37.95 38.03 38.05 
5 6.84 0.17 38.04 38.07 38.09 38.02 
Mean 38.002 38.010 38.042 38.030 
SD 0.041 0.046 0.037 0.019 
SEM 0.019 0.021 0.017 0.008 
 
 
 
 
 
 
 
 
Table - 23.14 
Effect of MECP (400 mg/kg) on body temperature (°C) in High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 13.2 0.17 38.05 38.03 38.07 38.08 
2 13.68 0.17 37.97 37.97 38.03 38.07 
3 13.52 0.17 37.96 38.98 38.02 38.08 
4 14.12 0.18 37.99 38.96 38.05 38.07 
5 13.0 0.16 38.04 38.04 37.98 38.03 
Mean 38.002 38.396 38.030 38.066 
SD 0.041 0.525 0.034 0.021 
SEM 0.018 0.235 0.015 0.009 
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Table - 23.15 
Effect of Sibutramine 10 mg/kg on body temperature (°C) High fat diet fed 
C57BL/6J mice for 28 days before and after drug administration. 
 
Animal 
No. 
Dose of Treatment 
10 mg/kg 
Volume of 
Treatment ml 
Before 2 hr Before 1 hr After1 hr After 2 hr 
1 0.31 0.16 38.03 38.01 38.04 38.09 
2 0.30 0.15 37.97 37.98 38.02 38.07 
3 0.34 0.17 38.01 38.04 38.02 38.08 
4 0.32 0.16 37.99 38.0 38.02 38.06 
5 0.33 0.17 37.97 37.99 38.03 38.04 
Mean 37.994 38.004 38.026 38.068 
SD 0.026 0.023 0.009 0.019 
SEM 0.012 0.010 0.004 0.009 
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Table – 24 
Effect of Stellaria media and Clerodendrum phlomidis on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Sr. No. 
(Groups) Treatment 
Glu 
(mg/dl) 
Insulin 
(ng/ml) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) HDL-C LDL-C 
Group I Normal diet 171.12 ± 4.97 
0.76 ±   
0.01 43.072± 1.174 14.122± 0.955 74.7 ±  3.39 125.38 ± 4.504 48.47± 1.748 61.958 ± 5.096 
Group II HFD 267.06 ± 5.591** 2.83 ±  0.08** 79.776±2.189** 27.366± 0.802** 179.94 ± 5.41**## 146.34 ± 2.65## 46.136±0.949 64.216 ± 3.046 
Group III AESM (100 mg/kg) + HFD 276.26 ±   2.37** 2.78 ±  0.08** 75.734±1.483** 26.456±1.142** 189.68 ±   5.65** 161.8 ± 6.89** 43.696±1.112 80.168 ±7.088 
Group IV AESM (200 mg/kg) + HFD 280.68 ± 4.23** 2.87 ± 0.11** 78.208±2.087** 28.286±0.844** 148.7 ±  6.58** 173.5 ±  3.19**## 45.03±1.514 98.73 ± 4.29## 
Group V AESM (400 mg/kg) + HFD 257.24  ± 8.44** 2.49 ±  0.17** 78.046±2.231** 26.648±1.034** 174.02 ± 2.75** 169.74 ± 4.07** 44.296±1.045 90.64 ±4.338**## 
Group VI MESM (100 mg/kg) + HFD 276.84 ±  5.94** 2.53 ±  0.1** 78.684±2.289** 25.136±2.001** 156.98 ± 6.91**# 134.2 ± 6.91## 40.674±1.777** 62.13 ± 4.216** 
Group VII MESM (200 mg/kg) + HFD 201.96 ± 8.394**## 1.76 ±  0.1**## 69.19±2.301**## 20.886±0.496**## 138.72 ±   5.72## 118.02 ± 6.67## 48.786±0.962 41.49 ±5.776# 
Group VIII MESM (400 mg/kg) + HFD 187.68 ± 9.356## 0.9 ±   0.1## 54.116±2.315**## 19.482±0.746**## 91.4 ±  5.06**## 120.76 ± 4.24## 47.43±1.2 55.05 ± 3.999* 
Group IX AECP (100 mg/kg)  + HFD 251.38 ±  4.3** 2.87 ±  0.19** 81.13±1.192** 30.102±0.542** 174.58 ± 5.96 167.6 ± 3.7**# 43.09±0.974* 89.594 ±3.695## 
Group X AECP (200 mg/kg) + HFD 223.9 ± 4. 18**## 2.42 ±  0.14** 76.78±1.72** 29.322±0.842** 149.76 ± 5.27**## 172.22 ± 5.66**## 46.828±0.981 99.44  ±6.372**## 
Group XI AECP (400 mg/kg) + HFD 191.92 ± 5.417## 1.94 ±  0.07**## 79.486±2.401** 28.584±0.798** 107.46 ± 5.24**## 153.74 ± 2.6** 44.134±1.798 88.114 ± 4.472**## 
Group XII MECP (100 mg/kg)  + HFD 264 ±  6.12** 1.68 ±  0.09**## 72.444±1.111** 25.428±0.641** 128.64 ± 3.00**## 156.02 ± 6.3** 43.976±0.901 86.316 ± 6.913**# 
Group XIII MECP (200 mg/kg) + HFD 211.86  ±4.18**## 0.94 ±   0.05## 59.356±2.304**## 19.62±1.1**## 99.64 ± 2.99**## 133.66 ± 3.03 47.932±1.511 65.8 ±2.836** 
Group XIV MECP (400 mg/kg) + HFD 176.18 ±  4.08## 0.82 ±  0.06## 49.426±2.204## 17.446±0.857## 71.40 ± 3.68**## 124.4 ± 4.31# 48.666±1.106 61.454 ± 4.61 
Group XV Sibutramine (10 mg/kg) + HFD 171.7 ±  5.63## 0.65 ±  0.05## 45.762±2.135## 21.026±1.021**## 68.36 ± 3.96## 115.73 ± 3.25## 48.782±1.164 53.282 ± 3.679 
 
Effect of Stellaria media and Clerodendrum phlomidis on HFD modulated biochemical parameters in C57BL/6J female mice was evaluated on 29th day of study. 
Blood was collected from retro orbital, centrifuged and separated serum obtained was used in biochemical analysis. Serum glucose, TC, TG, and HDL-C were 
analysed by using Span diagnostic kits, Surat, India. Insulin was analysed by radio immuneo assay. one way analysis of variance (ANOVA) followed by Dunnett 
test in between normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01, *Comparison of 
test and disease control with normal control.# Comparison test with Disease Control, CD: Cafeteria diet. Glu: Glucose, SGOT: Serum glutamate –oxaloacetate 
transaminase, SGPT: Serum glutamate –Pyruvate transaminase, TG: Total Triglyceride, TC: Total Cholesterol, HDL-C: High Density Lipoprtein Cholesterol,   
LDL-C: Low Density Lipoprotein cholesterol. 
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Effect of Stellaria media and Clerodendrum phlomidis on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
 
Feeding with HFD caused significant increase in the glucose, insulin, SGOT, SGPT, TG, TC and LDL-C levels in HFD group animals as 
compared to normal control animals which was significantly decreased by the administration of MESM 400 mg/kg, AECP 400 mg/kg 
and MECP mg/kg. 
 
 
Figure: 56 
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Figure: 57 
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Figure: 58 
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Table - 24.1 
Effect of Saline on Biochemical parameters in normal diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 0.24 0.24 170 0.81 43.63 14.24 73.7 136.2 51.54 69.92 
2 0.22 0.22 184.5 0.78 40.26 12.74 81.5 134.4 46.43 71.67 
3 0.23 0.23 179.3 0.75 42.76 11.74 83.4 117 .1 50.24 50.18 
4 0.23 0.23 156.5 0.72 47.18 17.36 69.4 125.6 42.57 69.15 
5 0.24 0.24 165.3 0.77 41.53 14.53 65.8 113.6 51.57 48.87 
Mean 171.12 0.76 43.072 14.122 74.7 125.38 48.47 61.958 
SD 11.12 0.03 2.625 2.135 7.58 10.072 3.909 11.39 
SEM 4.97 0.01 1.174 0.955 3.39 4.504 1.748 5.096 
 
 
Table - 24.2 
Effect of saline on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 0.33 0.33 277 2.91 77.35 28.64 181.3 147.1 42.86 67.98 
2 0.34 0.34 258.3 2.75 86.14 25.47 165.5 155.8 48.67 74.03 
3 0.35 0.35 283.6 2.77 73.15 29.53 188.1 146 46.78 61.60 
4 0.32 0.32 261.3 2.6 82.12 27.54 194.6 142.3 46.67 56.71 
5 0.35 0.35 255.1 3.12 80.12 25.65 170.2 140.5 45.7 60.76 
Mean 267.06 2.83 79.776 27.366 179.94 146.34 46.136 64.216 
SD 12.503 0.19 4.896 1.794 12.11 5.92 2.12 6.811 
SEM 5.591 0.08 2.189 0.802 5.41 2.65 0.949 3.046 
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Table - 24.3 
Effect of AESM (100 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 3.32 0.16 280.3 2.78 80.26 27.46 199.2 184.4 45.65 98.91 
2 3.44 0.17 272.5 3.11 73.17 30.26 204.3 144.8 42.54 61.40 
3 3.5 0.17 269.1 2.65 76.03 25.46 181.5 162 40.3 85.40 
4 3.44 0.17 281.6 2.7 77.28 23.46 173.3 167.1 43.46 88.98 
5 3.48 0.17 277.8 2.69 71.93 25.64 190.1 150.7 46.53 66.15 
Mean 276.26 2.78 75.734 26.456 189.68 161.8 43.696 80.168 
SD 5.30 0.18 3.316 2.555 12.64 15.41 2.488 15.851 
SEM 2.37 0.08 1.483 1.142 5.65 6.89 1.112 7.088 
 
 
Table - 24.4 
Effect of AESM (200 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 6.78 0.16 280.2 2.81 70.26 27.74 133.4 167.2 42.67 97.85 
2 6.68 0.16 291.5 3.31 80.31 28.63 144 182.5 43.67 110.03 
3 7.98 0.19 288.1 2.67 82.17 25.35 170.1 170.3 47.8 88.48 
4 7 0.17 275.6 2.83 80.17 29.46 156.7 179.8 41.61 106.85 
5 6.5 0.16 268 2.75 78.13 30.25 139.3 167.7 49.4 90.44 
Mean 280.68 2.87 78.208 28.286 148.7 173.5 45.03 98.73 
SD 9.47 0.25 4.667 1.888 14.71 7.14 3.386 9.594 
SEM 4.23 0.11 2.087 0.844 6.58 3.19 1.514 4.29 
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Table - 24.5 
Effect of AESM (400 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 13.56 0.16 269.2  2.46 73.12 29.36 174.4 166.4 41.53 89.99 
2 13.76 0.17 281.0 3.12 83.36 25.46 183.2 174.9 45.7 92.56 
3 13.8 0.17 247.7 2.55 81.34 26.46 168.3 156.1 47.26 75.18 
4 14.7 0.18 232.2 2.21 80.04 23.56 175.8 171.3 42.45 93.69 
5 13.8 0.17 256.1 2.11 72.37 28.4 168.4 180 44.54 101.78 
Mean 257.24 2.49 78.046 26.648 174.02 169.74 44.296 90.64 
SD 18.88 0.39 4.988 2.313 6.16 9.1 2.338 9.702 
SEM 8.44 0.17 2.231 1.034 2.75 4.07 1.045 4.338 
 
 
 
Table - 24.6 
Effect of MESM (100 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 3.23 0.16 266.2 2.39 70.26 21.73 166.4 145 33.76 77.96 
2 3.55 0.17 289.6 2.94 79.15 20.46 148 126 41.3 55.10 
3 3.25 0.16 265.2 2.58 81.35 23.78 140.2 131 42.32 60.64 
4 3.52 0.17 292.8 2.41 78.83 29.46 151.5 129 43.87 54.83 
5 3.32 0.16 270.4 2.35 83.83 30.25 178.8 140 42.12 62.12 
Mean 276.84 2.53 78.684 25.136 156.98 134.2 40.674 62.13 
SD 13.30 0.24 5.118 4.476 15.46 7.98 3.975 9.427 
SEM 5.94 0.1 2.289 2.001 6.91 6.91 1.777 4.216 
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Table - 24.7 
Effect of MESM (200 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 6.62 0.17 172.1 1.74 68.15 21.36 144.2 131.4 47.26 55.30 
2 6.88 0.17 199.1 1.8 71.63 19.41 156.4 134.3 49.17 53.85 
3 7.02 0.18 216.5 2.03 76.35 20.3 139.4 118.1 51.36 38.86 
4 6.98 0.17 202.9 1.41 67.26 21 130.6 101.5 50.12 25.26 
5 7.52 0.19 219.2 1.83 62.56 22.36 123 104.8 46.02 34.18 
Mean 201.96 1.76 69.19 20.886 138.72 118.02 48.786 41.49 
SD 10.5 0.22 5.147 1.110 12.8 14.93 2.152 12.915 
SEM 8.394 0.1 2.301 0.496 5.72 6.67 0.962 5.776 
 
Table - 24.8 
Effect of MESM (400 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 13.48 0.17 172.7 0.91 59.25 19.35 93.4 111.3 50.32 42.30 
2 12.12 0.15 163.2 1.22 53.25 20.41 101.8 135.6 47.72 67.52 
3 12.88 0.16 205.1 1.04 59.63 21.74 99.3 122.4 48.27 54.27 
4 13.36 0.17 212.5 0.7 50.2 18.46 73.1 113.8 43.01 56.17 
5 13.64 0.17 184.9 0.67 48.25 17.45 89.4 120.7 47.83 54.99 
Mean 187.68 0.9 54.116 19.482 91.4 120.76 47.43 55.05 
SD 12.8 0.23 5.178 1.669 11.32 9.49 2.685 8.943 
SEM 9.356 0.1 2.315 0.746 5.06 4.24 1.200 3.999 
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Table - 24.9 
Effect of AECP (100 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 3.3 0.17 245.3 2.88 83.26 30.16 190.1 156.5 41.85 76.63 
2 3.47 0.17 239.4 3.21 79.6 28.52 156.8 168.9 42.73 94.81 
3 3.27 0.16 262.3 2.13 80.13 31.74 174.8 162.1 40.31 86.83 
4 3.42 0.17 250.2 2.97 84.53 29.46 184.3 174.3 45.32 92.12 
5 3.26 0.16 259.7 3.2 78.13 30.63 166.9 176.2 45.24 97.58 
Mean 251.38 2.878 81.13 30.102 174.58 167.6 43.09 89.594 
SD 9.622 0.442 2.666 1.212 13.32 8.276 2.178 8.262 
SEM 4.303 0.197 1.192 0.542 5.960 3.701 0.974 3.695 
 
Table - 24.10 
Effect of AECP (200 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 6.36 0.16 227.3 2.23 74.63 30.24 144.7 191.3 39.83 122.53 
2 7.04 0.18 233.6 2.47 78.18 31.63 169.3 169.7 44.02 91.82 
3 6.32 0.16 230.2 2.33 82.88 28.46 150.4 174.2 42.73 101.39 
4 6.62 0.17 217.1 2.97 73.36 26.64 138.1 169.9 45.83 96.45 
5 6.8 0.17 211.3 2.12 74.85 29.64 146.3 156 41.73 85.01 
Mean 223.9 2.42 76.78 29.322 149.76 172.22 46.828 99.44 
SD 9.35 0.33 3.847 1.884 11.78 12.67 2.194 14.24 
SEM 4.18 0.14 1.720 0.842 5.27 5.66 0.981 6.372 
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Table - 24.11 
Effect of AECP (400 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 12.92 0.16 192.2 2.03 87.36 27.46 100.2 162.3 43.83 98.43 
2 12.6 0.16 210.5 1.92 78.1 28 91.4 155.5 40.23 96.99 
3 13.84 0.17 184.2 1.99 79.35 31.64 113.6 147.1 47.35 77.03 
4 13.4 0.17 194.1 2.11 72.36 28.58 121.3 154 40.24 89.50 
5 13.88 0.17 178.6 1.65 80.26 27.24 110.8 149.8 49.02 78.62 
Mean 191.92 1.94 79.486 28.584 107.46 153.74 44.134 88.114 
SD 11.20 0.17 5.369 1.785 11.73 5.83 4.022 10.00 
SEM 5.417 0.07 2.401 0.798 5.24 2.60 1.798 4.472 
 
 
Table - 24.12 
Effect of MECP (100 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 2.93 0.15 278.3 1.43 75.89 26.47 130.1 147.1 42.34 78.74 
2 3.34 0.17 256.1 1.66 72.56 27.24 139.6 141.7 43.12 70.66 
3 3.29 0.16 244.2 1.55 69.87 25.1 124.5 151.7 47.16 79.64 
4 3.03 0.15 269.6 2.01 70.26 23.63 126.4 162.3 44.74 92.28 
5 3.5 0.18 271.8 1.75 73.64 24.7 122.6 177.3 42.52 110.26 
Mean 264 1.68 72.444 25.428 128.64 156.02 43.976 86.316 
SD 13.7 0.22 2.485 1.435 6.72 14.1 2.015 15.459 
SEM 6.12 0.09 1.111 0.641 3.00 6.3 0.901 6.913 
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Table - 24.13 
Effect of MECP (200 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 6.44 0.16 216.4 1.12 67.35 19.35 100.2 135.2 47.24 67.92 
2 6.34 0.16 196.2 0.79 58.14 18.45 108.1 143.4 49.72 72.06 
3 6.88 0.17 212.6 0.88 60.53 21.54 89.4 130.7 42.64 70.18 
4 6.76 0.17 220.9 1.04 57.36 22.46 101.3 134.2 51.64 62.30 
5 6.84 0.17 213.2 0.89 53.4 16.3 99.2 124.8 48.42 56.54 
Mean 211.86 0.94 59.356 19.62 99.64 133.66 47.932 65.8 
SD 9.35 0.13 5.153 2.46 6.70 6.79 3.378 6.341 
SEM 4.18 0.05 2.304 1.1 2.99 3.03 1.511 2.836 
 
Table - 8.14 
Effect of MECP (400 mg/kg) on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 13.2 0.17 181.6 0.69 46.87 18.4 66.12 122 47.31 61.47 
2 13.68 0.17 160.9 0.76 49.35 16.37 81.3 112.5 48.15 48.09 
3 13.52 0.17 175.3 1.06 57.03 20.36 70.2 120.3 49.12 57.14 
4 14.12 0.18 179.1 0.91 50.14 16.4 61.4 129.2 52.63 64.29 
5 13.0 0.16 184.0 0.72 43.74 15.7 78 138 46.12 76.28 
Mean 176.18 0.82 49.426 17.446 71.40 124.4 48.666 61.454 
SD 9.12 0.15 4.929 1.917 8.22 9.64 2.475 10.308 
SEM 4.08 0.06 2.204 0.857 3.68 4.31 1.106 4.610 
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Table - 24.15 
Effect of Sibutramine 10 mg/kg on biochemical parameters in High fat diet fed C57BL/6J mice for 28 days. 
Animal 
No. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment 
(ml) 
Glu 
(mg/dl) 
Insulin 
(ng/ml)  
SGOT 
(IU/L) 
SGPT 
(IU/L) 
TG 
(mg/dl) 
TC 
(mg/dl) 
HDL-C LDL-C 
1 0.31 0.16 189.4 0.77 42.16 17.38 57.4 124.2 47.53 65.19 
2 0.30 0.15 172 0.56 40.36 23.03 69.2 108.5 46.74 47.92 
3 0.34 0.17 160.2 0.81 51.64 20.35 61.8 113.1 53.12 47.62 
4 0.32 0.16 177.6 0.63 49.52 22.63 74.3 122.78 49.26 58.66 
5 0.33 0.17 159.3 0.51 45.13 21.74 79.1 110.1 47.26 47.02 
Mean 171.7 0.65 45.762 21.026 68.36 115.73 48.782 53.282 
SD 12.59 0.13 4.775 2.283 8.86 7.28 2.602 8.227 
SEM 5.63 0.05 2.135 1.021 3.96 3.25 1.164 3.679 
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Table – 25 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on organ / body weight ratio (mg / gm) in High fat diet fed C57BL/6J 
mice. 
Sr. No. 
(Groups) 
Treatment Heart Liver Right kidney Left kidney 
Group I Normal diet 4.89 ± 0.15 48.69 ± 0.51 6.11 ± 0.32 5.68 ± 0.35 
Group II HFD 5.05 ± 0.25 51.39 ± 0.71 5.5 ±  0.11 5.3 ± 0.22 
Group III AESM (100 mg/kg) + HFD 4.92 ± 0.07 49.93 ± 0.59##  5.38 ± 0.14 5.02  ± 0.26 
Group IV AESM (200 mg/kg) + HFD 5.06 ± 0.06 49.47 ± 0.40 5.78 ± 0.14 5.30 ± 0.08 
Group V AESM (400 mg/kg) + HFD 5.07 ± 0.08 41.81 ± 0.14** 4.91 ± 0.22* 4.68 ± 0.15* 
Group VI MESM (100 mg/kg) + HFD 5.33 ±0.14 49.57 ± 0.13 5.23 ± 0.09 4.58 ± 0.11* 
Group VII MESM (200 mg/kg) + HFD 4.94 ± 0.06 45.52 ± 0.75## 5.19 ± 0.18 4.87 ±0.16 
Group VIII MESM (400 mg/kg) + HFD 5 ± 0.123 38.68 ± 2.31**## 5.69 ± 0.73 5.27 ± 0.60 
Group IX AECP (100 mg/kg)  + HFD 5.24 ± 0.07 50.15 ± 0.51 5.16  ± 0.04 5.11 ± 0.18 
Group X AECP (200 mg/kg) + HFD 5.22 ± 0.1 46.57 ± 0.97## 5.34 ± 0.23 4.95  ± 0.26 
Group XI AECP (400 mg/kg) + HFD 5.06 ± 0.14 40.26 ± 0.52**## 5.20 ± 0.14 5.23 ± 0.11 
Group XII MECP (100 mg/kg)  + HFD 5.13 ± 0.1 48.38 ± 0.566 5.47 ± 0.11 5.23 ± 0.11 
Group XIII MECP (200 mg/kg) + HFD 4.86 ± 0.12 49.05 ± 0.49 5.35 ± 0.19 5.25 ± 0.13 
Group XIV MECP (400 mg/kg) + HFD 4.94 ± 0.09 43.79 ± 0.64**## 5.46 ± 0.13 5.03 ± 0.18 
Group XV Sibutramine (10 mg/kg) + HFD 4.83 ± 0.12 43.12 ± 0.72**## 5.18 ± 0.13 4.90 ± 0.13 
On 30st day of study, mice were euthanised by spinal dislocation and organs were isolated, weighed and wet weight of organ to body 
weight ratio was calculated for each animal. Results collected are analysed by one way analysis of variance (ANOVA) followed by 
Dunnett test in between normal control and treatment; disease control and treatment   P value less than 0.05 is considered as significant. 
*P<0.05, **P<0.01, *Comparison of test and disease control with normal control 
# Comparison test with Disease Control, HFD: High fat diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on organ / body weight ratio (mg / gm) in High fat diet fed C57BL/6J 
mice. 
There was no significant change in the organ / body weight ratio (mg / gm) in HFD group animals but administration of The organ / body 
weight ratio (mg / gm) was significantly decreased by the AESM 400 mg/kg, MESM 400 mg/kg, AECP 400 mg/kg and MECP 400 
mg/kg as compared to normal control group animals as well as disease control animals. 
 
Figure: 65 
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Table - 25.1 
Effect of Saline on organ weight / body weight ratio (mg/gm) in normal diet fed 
C57BL/6J mice 
Animal 
no. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment ml 
Total body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.24 0.24 24.3 5.34 49.8 6.41 5.65 
2 0.22 0.22 22 4.94 50 5.44 4.91 
3 0.23 0.23 23.5 4.53 48.97 6.97 6.61 
4 0.23 0.23 23.7 4.56 48.16 6.24 5.71 
5 0.24 0.24 24.6 5.07 47.63 5.82 5.51 
Mean 23.62 4.89 48.69 6.11 5.68 
SD 1.01 0.34 1.03 0.65 0.70 
SEM 0.45 0.15 0.51 0.32 0.35 
 
 
 
 
 
 
 
Table - 25.2 
Effect of saline on organ weight / body weight ratio (mg/gm) in High fat diet fed 
C57BL/6J mice. 
Animal 
no. 
Dose of 
Treatment 
(1% Bd. wt.) 
Volume of 
Treatment ml 
Total body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.33 0.33 33.6 4.78 53.94 5.39 5.47 
2 0.34 0.34 34.2 4.91 50 5.88 5.62 
3 0.35 0.35 35.0 5.71 50.12 5.28 4.53 
4 0.32 0.32 32.1 4.48 51.61 5.62 5.1 
5 0.35 0.35 35.4 5.11 51.26 5.32 5.76 
Mean 34.06 5.05 51.39 5.5 5.3 
SD 1.3 0.51 1.59 0.25 0.49 
SEM 0.58 0.25 0.71 0.11 0.22 
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Table - 25.3 
Effect of AESM (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 3.32 0.16 33.2 4.93 50 5.64 4.83 
2 3.44 0.17 34.4 4.69 51.43 5.48 5.24 
3 3.5 0.17 35.0 4.85 47.81 4.88 4.11 
4 3.44 0.17 34.4 5.01 50.39 5.27 5.54 
5 3.48 0.17 34.8 5.12 50 5.64 5.38 
Mean 34.36 4.92 49.93 5.38 5.02 
SD 0.70 0.16 1.32 0.32 0.57 
SEM 0.31 0.07 0.59 0.14 0.26 
 
 
 
 
 
 
 
Table - 25.4 
Effect of AESM (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Body wt 
(gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 6.78 0.16 33.9 5.1 49.05 5.66 5.12 
2 6.68 0.16 33.4 5.19 49.44 6.35 5.52 
3 7.98 0.19 36.9 5.12 50.97 5.6 5.36 
4 7 0.17 35 4.87 49.23 5.64 5.38 
5 6.5 0.16 32.5 5.02 48.65 5.64 5.1 
Mean 34.34 5.06 49.47 5.78 5.30 
SD 1.69 0.122 0.89 0.32 0.18 
SEM 0.75 0.054 0.40 0.14 0.08 
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Table - 25.5 
Effect of AESM (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 13.56 0.16 33.9 3.79 42 5.42 4.33 
2 13.76 0.17 34.4 4.06 42.2 4.88 4.56 
3 13.8 0.17 34.7 4.43 41.82 5.26 4.98 
4 14.7 0.18 36.8 3.64 41.66 4.16 4.42 
5 13.8 0.17 34.5 4.56 41.39 4.83 5.1 
Mean 34.86 4.10 41.81 4.91 4.68 
SD 1.12 0.40 0.31 0.49 0.34 
SEM 0.50 0.18 0.14 0.22 0.15 
 
 
 
 
 
 
Table - 25.6 
Effect of MESM (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 3.23 0.16 32.3 5.21 50 5.33 4.77 
2 3.55 0.17 35.5 5.07 49.35 5.16 4.9 
3 3.25 0.16 32.5 5.65 49.7 5 4.44 
4 3.52 0.17 35.2 5.66 49.47 5.52 4.47 
5 3.32 0.16 33.2 5.06 49.32 5.14 4.33 
Mean 33.74 5.33 49.57 5.23 4.58 
SD 1.51 0.3 0.28 0.20 0.24 
SEM 0.67 0.14 0.13 0.09 0.11 
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Table - 25.7 
Effect of MESM (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 6.62 0.17 33.1 5.07 46.72 5.12 4.84 
2 6.88 0.17 34.4 4.89 46.7 5.21 4.94 
3 7.02 0.18 35.1 4.76 46.77 4.56 4.3 
4 6.98 0.17 34.9 4.88 43.32 5.44 5.17 
5 7.52 0.19 37.6 5.1 44.1 5.64 5.12 
Mean 35.02 4.94 45.52 5.19 4.87 
SD 1.64 0.14 1.68 0.41 0.35 
SEM 0.73 0.06 0.75 0.18 0.16 
 
 
 
 
 
 
Table - 25.8 
Effect of MESM (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 13.48 0.17 33.7 5.22 40.28 5.42 4.85 
2 12.12 0.15 30.3 4.99 35.89 6.41 6.08 
3 12.88 0.16 32.2 4.63 40.76 5.86 5.27 
4 13.36 0.17 33.4 5.32 36.47 6.17 5.58 
5 13.64 0.17 34.1 4.86 40 4.57 4.57 
Mean  32.74 5 38.68 5.69 5.27 
SD 1.54 0.28 2.31 0.73 0.60 
SEM 0.68 0.123 1.03 0.32 0.27 
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Table - 25.9 
Effect of AECP (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 3.3 0.17 33 5.33 50.52 5.26 5.26 
2 3.47 0.17 34.7 5.37 50.1 5.11 5.37 
3 3.27 0.16 32.7 5.23 49.31 5.23 5.5 
4 3.42 0.17 34.2 4.98 48.95 5.2 4.94 
5 3.26 0.16 32.6 5.3 51.85 5.02 4.49 
Mean 33.44 5.24 50.15 5.16 5.11 
SD 0.95 0.155 1.14 0.10 0.40 
SEM 0.42 0.07 0.51 0.04 0.18 
 
 
 
 
 
 
 
Table - 25.10 
Effect of AECP (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 6.36 0.16 31.8 5.25 48.99 5.44 4.87 
2 7.04 0.18 35.2 5.51 47.51 4.69 4.17 
3 6.32 0.16 31.6 4.96 47.64 5.88 5.58 
4 6.62 0.17 33.1 5.11 45.17 4.95 4.68 
5 6.8 0.17 34 5.31 43.56 5.75 5.47 
Mean 33.14 5.22 46.57 5.34 4.95 
SD 1.51 0.21 2.17 0.51 0.58 
SEM 0.67 0.1 0.97 0.23 0.26 
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Table - 25.11 
Effect of AECP (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 12.92 0.16 32.3 4.99 41.61 5.38 5.08 
2 12.6 0.16 31.5 5.36 41.12 4.67 5.04 
3 13.84 0.17 34.6 5.21 39.32 5.33 5.3 
4 13.4 0.17 33.5 4.57 38.85 5.17 5.62 
5 13.88 0.17 34.7 5.17 40.4 5.44 5.12 
Mean 33.32 5.06 40.26 5.20 5.23 
SD 1.4 0.31 1.17 0.31 0.24 
SEM 0.62 0.14 0.52 0.14 0.11 
 
 
 
 
Table - 25.12 
Effect of MECP (100 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
100 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 2.93 0.15 29.3 4.86 49.27 5.56 5.53 
2 3.34 0.17 33.4 4.92 48.65 5.67 5.37 
3 3.29 0.16 32.9 5.27 48.91 5.43 4.89 
4 3.03 0.15 30.3 5.37 48.92 5.67 5.1 
5 3.5 0.18 35 5.27 46.15 5.03 5.3 
Mean 32.18 5.13 48.38 5.47 5.23 
SD 2.33 0.231 1.26 0.26 0.24 
SEM 1.04 0.1 0.566 0.11 0.11 
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Table - 25.13 
Effect of MECP (200 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
200 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 6.44 0.16 32.2 4.77 47.75 5.61 5.33 
2 6.34 0.16 31.7 4.87 48.35 5.73 5.58 
3 6.88 0.17 34.4 4.65 50.41 4.65 4.81 
4 6.76 0.17 33.8 4.74 48.86 5.48 5.22 
5 6.84 0.17 34.2 5.29 49.86 5.29 5.32 
Mean 33.26 4.86 49.05 5.35 5.25 
SD 1.23 0.25 1.09 0.43 0.28 
SEM 0.55 0.12 0.49 0.19 0.13 
 
 
 
 
 
Table - 25.14 
Effect of MECP (400 mg/kg) on organ weight / body weight ratio (mg/gm) in 
High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
400 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 13.2 0.17 33 5.19 42.60 5.68 4.73 
2 13.68 0.17 34.2 4.77 42.73 5.66 5.58 
3 13.52 0.17 33.8 4.68 43.14 5.51 4.62 
4 14.12 0.18 35.3 4.95 44.56 4.98 5.32 
5 13.0 0.16 32.5 5.12 45.92 5.49 4.89 
Mean 33.76 4.94 43.79 5.46 5.03 
SD 1.09 0.22 1.42 0.28 0.41 
SEM 0.49 0.09 0.64 0.13 0.18 
 
  
Chapter 8                                           HIGH FAT FED C57BL/6J MOUSE 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 311 
 
Table - 25.15 
Effect of Drug Sibutramine 10 mg/kg on organ weight / body weight ratio 
(mg/gm) in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  Treatment 
10 mg/kg 
Volume of 
Treatment ml 
Body 
wt (gm) 
Heart Liver 
Right 
kidney 
Left 
kidney 
1 0.31 0.16 31.3 5.14 44.47 4.79 4.57 
2 0.30 0.15 30.5 4.52 45.2 5.47 5.23 
3 0.34 0.17 34 4.74 42.31 5.27 4.95 
4 0.32 0.16 32.3 5.04 41.9 5.39 5.11 
5 0.33 0.17 33.7 4.73 41.72 4.96 4.63 
Mean 32.36 4.83 43.12 5.18 4.90 
SD 1.51 0.252 1.60 0.29 0.29 
SEM 0.67 0.12 0.72 0.13 0.13 
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Table – 26 
Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on WAT in High fat diet fed C57BL/6J mice. 
Sr. No. 
(Groups) 
Treatment WAT (gm) Adiposity Index (%) 
Adipocyte Diameter 
(µm) 
Group I Normal diet 1.620 ±  0.130 6.647 ±  0.513 31.188 ±  3.421 
Group II HFD 5.357 ±  0.317** 13.791 ±  0.730** 52.866 ±  1.49** 
Group III AESM (100 mg/kg) + HFD 5.219 ± 0.153**# 13.65 ± 0.409** 49.169 ±  2.873** 
Group IV AESM (200 mg/kg) + HFD 4.322 ± 0.266**## 13.316 ±  0.358** 46.366 ± 2.058** 
Group V AESM (400 mg/kg) + HFD 3.888 ± 0.198** 12.058 ±  0.520** 40.566 ± 1.468# 
Group VI MESM (100 mg/kg) + HFD 5.062 ±  0.275**## 13.634 ±  0.536** 44.42 ±  2.840** 
Group VII MESM (200 mg/kg) + HFD 4.029 ±  0.235**## 10.918 ±  0.579**## 38.546 ±  3.447## 
Group VIII MESM (400 mg/kg) + HFD 3.629 ±  0.144**## 10.703 ±  0.243**## 33.506 ±  2.975## 
Group IX AECP (100 mg/kg)  + HFD 5.118 ±  0.254** 13.487  ± 0.604** 51.876 ±  1.495** 
Group X AECP (200 mg/kg) + HFD 4.517 ±  0.173** 12.561 ±  0.487** 40.056 ±  1.866**## 
Group XI AECP (400 mg/kg) + HFD 3.122 ±  0.211**## 9.132 ±  0.605**## 31.624 ± 3.600*## 
Group XII MECP (100 mg/kg)  + HFD 4.932 ±  0.103** 13.463 ±  0.206** 54.548 ±  2.473 
Group XIII MECP (200 mg/kg) + HFD 3.962 ± 0.318**## 11.255 ±   0.933**# 43.226 ±  2.925 
Group XIV MECP (400 mg/kg) + HFD 2.703 ±  0.267*## 7.801 ±   0.726## 31.338 ±  2.498## 
Group XV Sibutramine (10 mg/kg) + HFD 1.788 ±  0.177## 5.743 ±  0.682## 22.332 ±  2.332## 
On 31st day of study, WAT (periovarian fat, retroperitonealMesenteric, Omental) was weighed and wet weight of WAT to 
body weight ratio, Adiposity index and Fat cell diameter  was calculated for each animal sample. Results collected are 
analysed by one way analysis of variance (ANOVA) followed by Dunnett test in between normal control and treatment; 
disease control and treatment   P value less than 0.05 is considered as significant. *P<0.05, **P<0.01.  
*Comparison of test and disease control with normal control, # Comparison test with Disease Control, HFD: High fat diet 
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Effect of ‘Stellaria media’ and ‘Clerodendrum phlomidis’ on WAT in High fat diet fed C57BL/6J mice. 
 
Figure: 66 
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Table - 26.1 
Effect of Saline on WAT in normal diet fed C57BL/6J mice 
Animal 
no. 
Dose of  
Treatment 
(1% Bd wt) 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 0.24 0.24 1.212 4.828 26.13 
2 0.22 0.22 1.517 6.772 41.54 
3 0.23 0.23 1.568 6.4 37.2 
4 0.23 0.23 1.868 7.624 26.31 
5 0.24 0.24 1.933 7.610 24.76 
Mean 1.620 6.647 31.188 
SD 0.291 1.148 7.649 
SEM 0.130 0.513 3.421 
 
 
 
 
 
Table - 26.2 
Effect of saline on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
(1% Bd wt) 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 0.33 0.33 6.295 16.017 49.31 
2 0.34 0.34 4.412 11.489 57.14 
3 0.35 0.35 5.683 14.314 52.38 
4 0.32 0.32 4.986 13.403 50.15 
5 0.35 0.35 5.410 13.73 55.35 
Mean 5.357 13.791 52.866 
SD 0.7106 1.634 3.343 
SEM 0.317 0.730 1.49 
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Table - 26.3 
Effect of AESM (100 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 3.32 0.16 4.862 13.069 48.4125 
2 3.44 0.17 5.596 14.610 52.2425 
3 3.5 0.17 5.32 13.676 42.4825 
4 3.44 0.17 5.461 14.447 44.2525 
5 3.48 0.17 4.855 12.448 58.4525 
Mean 5.219 13.650 49.169 
SD 0.343 0.914 6.424 
SEM 0.153 0.409 2.873 
 
 
 
 
 
Table - 26.4 
Effect of AESM (200 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 6.78 0.16 4.263 14.185 45.41 
2 6.68 0.16 4.371 13.732 53.24 
3 7.98 0.19 5.163 12.531 45.48 
4 7 0.17 4.336 12.4 47.25 
5 6.5 0.16 3.478 13.731 40.45 
Mean 4.322 13.316 46.366 
SD 0.597 0.799 4.6 
SEM 0.266 0.358 2.058 
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Table - 26.5 
Effect of AESM (400 mg/kg) WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 13.56 0.16 4.067 11.021 41.41 
2 13.76 0.17 4.463 11.997 39.24 
3 13.8 0.17 3.951 10.944 36.48 
4 14.7 0.18 3.273 13.731 40.25 
5 13.8 0.17 3.686 12.596 45.45 
Mean 3.888 12.058 40.566 
SD 0.443 1.163 3.282 
SEM 0.198 0.520 1.468 
 
 
 
 
Table - 26.6 
Effect of MESM (100 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 3.23 0.16 4.588 12.887 53.064 
2 3.55 0.17 5.814 15.023 37.894 
3 3.25 0.16 4.343 12.063 42.134 
4 3.52 0.17 5.518 14.521 48.904 
5 3.32 0.16 5.047 13.677 40.104 
Mean 5.062 13.634 44.420 
SD 0.616 1.198 6.350 
SEM 0.275 0.536 2.840 
  
Chapter 8                                           HIGH FAT FED C57BL/6J MOUSE 
 
Dept. of Pharmaceutical Sciences, Saurashtra University, Rajkot. Page 317 
 
Table - 26.7 
Effect of MESM (200 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 6.62 0.17 3.606 10.273 33.26 
2 6.88 0.17 4.684 12.868 49.31 
3 7.02 0.18 3.582 9.629 43.12 
4 6.98 0.17 3.769 10.269 36.87 
5 7.52 0.19 4.506 11.553 30.17 
Mean 4.029 10.918 38.546 
SD 0.525 1.295 7.709 
SEM 0.235 0.579 3.447 
 
 
 
 
Table - 26.8 
Effect of MESM (400 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 13.48 0.17 3.764 10.754 26.69 
2 12.12 0.15 3.183 10.201 41.58 
3 12.88 0.16 3.582 10.504 39.63 
4 13.36 0.17 3.553 10.45 30.37 
5 13.64 0.17 4.063 11.608 29.26 
Mean 3.629 10.703 33.506 
SD 0.322 0.543 6.652 
SEM 0.144 0.243 2.975 
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Table - 26.9 
Effect of AECP (100 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 3.3 0.17 5.812 15.294 48.32 
2 3.47 0.17 5.619 14.37 56.15 
3 3.27 0.16 4.775 13.154 51.39 
4 3.42 0.17 4.892 12.739 49.16 
5 3.26 0.16 4.491 11.88 54.36 
Mean 5.118 13.487 51.876 
SD 0.569 1.351 3.343 
SEM 0.254 0.604 1.495 
 
 
 
Table - 26.10 
Effect of AECP (200 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 6.36 0.16 4.122 11.81 37.22 
2 7.04 0.18 4.249 11.093 46.85 
3 6.32 0.16 4.369 12.85 40.39 
4 6.62 0.17 4.835 13.319 36.16 
5 6.8 0.17 5.012 13.731 39.66 
Mean 4.517 12.561 40.056 
SD 0.386 1.089 4.173 
SEM 0.173 0.487 1.866 
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Table - 26.11 
Effect of AECP (400 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 12.92 0.16 2.616 7.832 22.63 
2 12.6 0.16 3.208 9.993 31.83 
3 13.84 0.17 2.988 8.393 28.62 
4 13.4 0.17 3.876 11.074 30.46 
5 13.88 0.17 2.921 8.369 44.58 
Mean 3.122 9.132 31.624 
SD 0.472 1.354 8.049 
SEM 0.211 0.605 3.600 
 
 
 
 
Table - 26.12 
Effect of MECP (100 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
100 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 2.93 0.15 4.66 13.586 48.75 
2 3.34 0.17 5.128 13.784 57.53 
3 3.29 0.16 5.053 13.73 61.47 
4 3.03 0.15 4.708 12.655 55.92 
5 3.5 0.18 5.113 13.562 49.07 
Mean 4.932 13.463 54.548 
SD 0.229 0.462 5.530 
SEM 0.103 0.206 2.473 
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Table - 26.13 
Effect of MECP (200 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
200 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 6.44 0.16 3.888 10.921 38.46 
2 6.34 0.16 4.201 12.54 51.85 
3 6.88 0.17 2.957 8.191 48.53 
4 6.76 0.17 3.833 10.889 37.24 
5 6.84 0.17 4.930 13.732 40.05 
Mean 3.962 11.255 43.226 
SD 0.712 2.087 6.541 
SEM 0.318 0.933 2.925 
 
 
 
 
Table - 26.14 
Effect of MECP (400 mg/kg) on WAT in High fat diet fed C57BL/6J mice. 
Animal 
no. 
Dose of  
Treatment 
400 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 13.2 0.17 2.641 7.813 32.87 
2 13.68 0.17 3.025 8.618 39.14 
3 13.52 0.17 3.506 10.017 32.85 
4 14.12 0.18 2. 398 6.679 26.38 
5 13.0 0.16 1.945 5.876 25.45 
Mean 2.703 7.801 31.338 
SD 0.596 1.623 5.585 
SEM 0.267 0.726 2.498 
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Table - 26.15 
Effect of Sibutramine 10 mg/kg on WAT in High fat diet fed C57BL/6J mice. 
 
Animal 
no. 
Dose of  
Treatment 
10 mg/kg 
Volume of 
Treatment ml 
WAT 
(gm) 
Adiposity 
Index (%) 
Adipocyte 
Diameter (µm) 
1 0.31 0.16 2.058 6.4921 24.05 
2 0.30 0.15 2.331 7.982 18.36 
3 0.34 0.17 1.538 4.457 30.42 
4 0.32 0.16 1.365 4.333 21.36 
5 0.33 0.17 1.647 5.453 17.47 
Mean 1.788 5.743 22.332 
SD 0.397 1.525 5.214 
SEM 0.177 0.682 2.332 
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DISCUSSION 
Obesity is a chronic metabolic disorder that results from the imbalance between energy intake 
and energy expenditure. Among the multiple factors contributing to its etiology, the sedentary 
life styles, white collar jobs, lack of exercise, psychological factors and the consumption of 
energy rich diets are the major ones. It is characterized by enlarged fat mass and elevated 
lipid concentration in blood. 
Globally, more than 1.1 billion adults worldwide are overweight and 312 million of them are 
obese. In addition, at least 155 million children worldwide are overweight or obese, according 
to the International Obesity Task Force. This task force and the World Health Organization 
(WHO) have revised the definition of obesity to adjust for ethnic differences, and this broader 
definition may reflect an even higher prevalence — with 1.7 billion people classified as 
overweight worldwide (Haslam & James, 2005).  
The medical problems caused by obesity begin at the head and end at the toes and involve 
almost every organ in between. Several of these problems contribute to the earlier mortality 
associated with obesity include adult-onset (type 2) diabetes mellitus, coronary artery disease, 
severe hypertension that may be refractory to medical management, impaired cardiac 
function, obesity hypoventilation and sleep apnea syndromes, cirrhosis, venous stasis and 
hypercoagulability with an increased risk of pulmonary embolism and necrotizing 
panniculitis (Dibaise, et. al., 2008). About 90% of type 2 diabetes is attributable to excess 
weight. Furthermore, approximately 197 million people worldwide have impaired glucose 
tolerance, most commonly because of obesity and the associated metabolic  syndrome. This 
number is expected to increase to 420 million by 2025. 
One of the most common physical consequences of obesity is the development of insulin 
resistance. Insulin resistance is an irreversible and progressive condition; once the body's 
cells do not respond to insulin, the glucose levels must be controlled through human 
intervention and monitoring. In obese persons, insulin resistance is another stressor on the 
body that heightens the considerable risk of early mortality. Insulin resistance has other 
serious consequences, as it will often lead to the progressive illness known as the metabolic 
syndrome, which is the combination of a series of distinct physical conditions. 
It has been noted that central (android, more prevalent in men) obesity is associated with a 
higher mortality than peripheral (gynoid, more prevalent in women) obesity. This 
discrepancy has been attributed to the fact that visceral adipose tissue is metabolically more 
active than subcutaneous fat, causing a greater rate of glucose production, type II diabetes 
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mellitus and hyperinsulinism. It has been suggested that the abdominal or android fat pattern 
may represent an increase in the size or number of more metabolically active intra-abdominal 
fat cells. These fat cells release free fatty acids directly into the portal circulation, which 
might interfere with insulin clearance in the liver and thus affect various metabolic processes 
(Fujioka, et. al., 1987). Increased insulin secretion is thought to increase sodium reabsorption 
and result in hypertension. Central obesity is also associated with increased production of 
cholesterol, primarily in the form of low-density lipoprotein, leading to increased incidence 
of atherosclerotic cardiovascular disease and gallstones. The increased visceral fat has been 
related to an increased waist: hip ratio or, in more common terms, as the ―apple‖ versus 
―pear‖ distribution of fat.  
The proposed mechanism for the insulin resistance is that an increased FA uptake ultimately 
resulted in an increase in the intramitochondrial acetyl CoA/CoA and NADH/NAD+ ratios 
with subsequent inactivation of the pyruvate dehydrogenase. The high uptake of FA will lead 
to an increase in the intracellular concentration of citrate, leading to inhibition of 
phosphofruktokinase (a rate limiting enzyme of glycolysis) and as a consequence, glucose 6 
phosphate will accumulate and inhibit glucose uptake. More recently, it has been shown that 
an increase in the intracellular concentration of FA metabolites (diacylglycerol, fatty acyl 
CoA) leads to activation of protein kinase C (PKC), c-Jun N-terminal kinase (JNK) and 
inhibitory kappa B kinase (IKK), which ultimately block the insulin signaling pathway 
through functional inhibition of insulin receptor substrate -1 (IRS-1) (Blaschke, Takata, 
Caglayan, Law & Hsueh, 2006; Itani, Ruderman, Schmieder & Boden, 2006). Last, but not 
least, release of endocrine factors from adipose tissue, alone or in combination with other 
factors like tumor necrosis factor alpha (TNFα), can lead to insulin resistance (Pittas, Joseph 
& Greenberg, 2004). 
Many attempts have been made to correct the metabolic disparity of the obesity condition, 
producing a number of reagents including Fibrates (PPARa agonists),   Sibutramine an 
anorectic or appetite suppressant (Lean, 2001; Poston and Foreyt, 2004; Tziomalos et. al., 
2009), sibutramine inhibits reuptake of both NA and 5-HT at the hypothalamic site which 
regulate the food intake, it also appears to stimulate thermogenesis by indirectly activating β-
3 receptors in adipose tissue (Triphati, 2008). Sibutramine is having the side effects like chest 
pain, increase in the HR and BP, dry mouth, constipation, anxiety, insomnia, mood swing etc. 
A number of serious of side effects have been received by US-FDA and drug committees in 
Europe. An ongoing study is assessing its impact on long-term morbidity and mortality.   
Orlistat which reduces intestinal fat absorption through inhibition of pancreatic lipase 
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(Ballinger and Peikin, 2002; Drew et. al., 2007; Hutton and Fergusson, 2004; Thurairajah et. 
al., 2005).  
Orlistat is also not free of from side effects like fluid motions, increase in HR and BP, 
steatorrhoea, abdominal pain, nausea, flatulence and vitamin deficiency etc.(Triphati, 2008).  
A number of anti-obesity drugs are currently undergoing clinical development, including 
centrally-acting drugs (e.g. radafaxine and oleoyl-estrone), drugs targeting peripheral 
episodic satiety signals (e.g. rimonabant and APD356), drugs blocking fat absorption (e.g. 
cetilistat and AOD9604), and human growth hormone fragments (Halford, 2006; Melnikova 
and Wages, 2006). 
At present, because of dissatisfaction with high costs and potentially hazardous side-effects, 
the potential of natural products for treating obesity is under exploration, and this may be an 
excellent alternative strategy for developing future effective, safe anti-obesity drugs.  A 
variety of natural products, including crude extracts and isolated compounds from plants, can 
induce body weight reduction and prevent diet-induced obesity. Therefore, they have been 
widely used in treating obesity (Moro and Basile, 2000; Rayalam et. al., 2008). 
A growing body of evidence indicates that natural products having anti-obesity effects can be 
arranged into five categories based on their distinct mechanisms; they produce (1) decreased 
lipid absorption, (2) decreased energy intake, (3) increased energy expenditure, (4) decreased 
pre-adipocyte differentiation and proliferation, or (5) decreased lipogenesis and increased 
lipolysis. 
The present investigation was carried out to evaluate the anti-obesity and obesity associated 
complications like T2DM and fatty liver, against alcoholic and methanolic extracts of 
Stellaria media and Clerodendrum phlomidis by using 3 different models of obesity. 
Clerodendrum phlomidis Linn. (Family: Verbenaceae) is a large bush or small tree with more 
or less pubescent branches (Kirtikar and Basu, 1975). It is a well known plant called 
‗Thaludalai‘ (Tamil), Arni, Urni (Hindi). It is reported to possess potent spasmolytic and anti-
diahoerial effect.  
The plant is commonly used as an anti-fungal and anti-pyretic agent. The santals rub the plant 
over their bodies in dropsy and also give it to their cattle to cure them of diarrhea and worms, 
or when the stomach swells (Chopra et. al., 1968). The juice of leaves is used as an alterative 
and bitter tonic. The decoction of root is slightly aromatic and astringent is used as a 
demulcent in gonorrhea. It is also given to children during convalescence of measles 
(Nadkarni et. al., 1954). The plant has been found to possess hypoglycemic activity (Pande, 
1978). Rural people of Tamilnadu use fresh juice of the leaves of the plant to treat mental 
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tension and mental disturbance. Methanolic extract of leaves of Clerodendrum phlomidis was 
found to have an effect on alteration in general behavioral profiles, including alertness, 
awareness, spontaneous activity, touch, pain and sound responses in mice and showed its 
characteristics as minor tranquilizer. 
Stellaria media, commonly known as chickweed, is found throughout the Himalayas up to an 
altitude of 4300 m. It is reported to be very useful in the treatment of inflammations of the 
digestive, renal, respiratory and reproductive tracts. The plant is employed in plasters used for 
broken bones and swellings. It also possesses diuretic, expectorant and antiasthmatic 
properties. Some phenolic acids, flavones, fatty esters and gypsogenin were reported earlier 
from this species. 
By the phytochemical investigation it was found that C. phlomidis contains triterpenoids, 
glycoside, carbohydrates, proteins, flavonoids, anthocynidine and saponins. Stellaria media 
contains triterpenoids, carbohydrates, proteins, flavonoids, anthocynidine, alkaloids and 
saponin, means these plant extracts contains some common chemical constituents like 
saponins, flavonids and some triterpenoids which have shown some promising anti-obesity 
effects (Yun, 2010).   
Based on this phytochemical study and ethnobotanical uses of these plants (Katewa and 
Galav, 2006; Dilip, Manashi, and Nazim, 2005) for treatment of obesity these plants were 
selected for carrying out this study against three different models of obesity.  
The first model against which the anti-obesity activity of extracts evaluated was drug 
(Progesterone) induced obesity. 
The neuroactive steroid progesterone is a female reproductive hormone. Its level increases 
during the second part of the menstrual cycle and control the secretory phase of 
endometrium. As the name suggesting, (Pro= for, gest = gestation), the higher endogenous 
levels of progesterone and its metabolites in pregnant women are reported to enhance food 
ingestion throughout pregnancy and conserve energy for the growing fetus. Progesterone also 
exerts antiesterogenic effects, which also been shown to increase in food intake. Further, 
some reports suggest that use of progesterone containing preparation as contraceptive or for 
hormonal replacement therapy cause significant weight gain by increasing fat deposition. 
Furthermore, progesterone has been reported as the most fattening of steroids hormone that 
promotes synthesis and storage of fats. Therefore, progesterone–induced hyperphagia causes 
weight gain and fat deposition is useful as animal model of drug-induced obesity.  
In this study administration of Progesterone to the control animals caused significant increase 
in the food consumption at 30 min, 1hr and 2hr which was significantly reduced by the 
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administration of AESM (100 mg/kg), MESM (100 mg/kg), AECP (100 mg/kg) at 30 min, 
AESM (400 mg/kg), MESM (400 mg/kg) and MECP (100 mg/kg) at 1hr as compared to the 
disease control animals. Whereas MECP (400 mg/kg) and the standard Sibutramine 
significantly decreased the food consumption at 30 min, 1hr and 2hr as compared to both 
normal control as well as disease controls.  
The administration of Progesterone caused significant increase in food intake compared to the 
control group animals which was significantly decreased by co-administration of MESM 200 
and 400 mg/kg as well as MECP 100, 200 and 400 mg/kg. Standard Sibutramine was found 
to be more significant in this case.  
As far as effect on exploratory behavior of Progesterone animals is concerned, there was no 
significant change in the exploratory behavior of Progesterone control animals as compared 
to the control group animals but co-administration of MECP 200 and 400 mg/kg significantly 
increased the number of ambutations and rearings but not the number of groomings.  
It is believed that progesterone producing hyperphagia via progestin receptors which have 
been reported to be expressed on the serotonergic neurons (Bethea, Gundlah & Mirkes, 
2000), & sibutramine suppresses the progesterone induced hyperphagia by inhibiting 
reuptake of 5-HT (serotonin) at the hypothalamic site which regulate the food intake, which 
suggests the possible interaction exists between the neurosteroid and serotonin receptor 
system in regulating food intake and body weight. Further, these data implicate that 
disturbances in the ovarian hormone levels may predispose females to eating disorders by 
causing alterations in the serotonin level or serotonergic receptor function (Kaur and 
Kulkarni, 2002). The reduction in the food intake by the administration of MECP at medium 
and high dose is may be due to its saponin content which is present in the methanolic extracts 
of both the plants, saponin has the appetite suppressant activity that are thought to be after 
absorption from GIT it cross the BBB (blood brain barrier)  and enter in the brain & amplify 
signaling in the basal hypothalamus energy sensing function which is the master regulator of 
food intake and energy expenditure or it may also possible that saponins inhibits the re-
uptake of 5-HT in the hypothalamus. Differences in this anorexic activity by the extracts may 
be due to total saponin content, which is more in the MECP as compare to MESM.  Moreover 
flavonids in the plant extracts have reported appetite suppressant activity. Some flavonids 
also causes to activate β- adrenergic receptors (Yun, 2010) which are involved in the burning 
of fats.   
Progesterone is also reported to exert various metabolic effects such as rising basal insulin 
levels, stimulating lipoprotein lipase activity and enhancing fat storage in the body. In this 
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study progesterone modulated various bio-chemical parameters in female mice. It caused 
significant increase in the serum glucose, TG, and VLDL-C levels decrease in HDL-C levels 
as compared to the normal control animals which were significantly reversed by co-
administration of MECP 100, 200 and 400 mg/kg as well as Standard Sibutramine. 
Decrease in the glucose level by the MECP may be due to tannins which is already having 
documented hypoglycemic activity for its leaves (Dhanabal, Mohan Marugaraja & Suresh, 
2008). Correction in the lipid profile by the MECP is may be due to decrease in food intake.  
This may be also useful to study pharmacological agents helpful for treatment of obesity 
caused in the female by consumption of progesterone containing contraceptive pills (which is 
a major cause of obesity in females), disturbances in menstrual cycle resulting alterations in 
level of progesterone, estrogen and testosterone as their secretion is interdependent.   
There was significant increase in the organ / body weight ratio of liver, left kidney and right 
kidney in Progesterone treated animals which were significantly decreased by the co-
administration of MECP 400 and Standard Sibutramine. 
In second model, obesity was induced in Wistar rats by cafeteria diet. Animals that are fed 
cafeteria diet (CD) are a widely used model of obesity. It involved feeding experimental 
animals a mixture of palatable commercially available supermarket foods containing 
combination of the high fat content with high carbohydrate content but low in protein, 
vitamins and minerals to stimulate energy intake (Rothwell, Stock & Warwick, 1988). Such 
diets have pronounced implications in the development of obesity, leading to significant body 
weight gain, fat deposition and also insulin resistance which resembles to human beings 
(Prats et. al. 1989). 
In this study there was‘nt any significant change in the body weight of CD group animals as 
compared to normal diet animals but there was significant decrease in body weights of the 
animals by co-administered with MESM 100 and 200 mg/kg, MECP 100, 200 and 400 mg/kg 
and standard Sibutramine was most significant in this case.  
It is well known that an increase in food ingestion results in the activation of both heat 
production and deposition of reserves, mainly fat (Stock and Rothwell, 1982). Consumption 
of CD results in overweight animals but also increased heat production through diet-induced 
thermogenesis (Stock and Rothwell, 1982), so measurement of rectal temperature recording 
was considered one of the parameter in this study.  There was a significant increase in the 
body temperature of CD group animals before 2 hr of administration which was significantly 
increased again by co-administration of MECP (100 mg/kg), MECP (200 mg/kg) & MECP 
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(400 mg/kg) in dose dependent manner indicating the thermogenic property of the test drugs. 
Sibutramine was the most effective in this regard after 2 hr after administration.   
Similarly, there was no significant change in the exploratory behavior of CD group animals 
as compared to the control group animals but there was significant increase in number of 
rearings but co-administration of none of the doses was able to decrease the number of 
rearings. 
Feeding with CD caused significant increase in the serum glucose, insulin, SGOT, SGPT, 
TG, TC, LDL-C and fall in HDL-C levels as compared to normal control animals which was 
significantly decreased by the administration of MECP 200 and 400 mg/kg and AECP 400 
mg/kg. Sibutramine was most significant in this case. Increase in the glucose as well as serum 
insulin level indicates obesity induced insulin resistance DM (T2DM).  
Several studies show that an increase in HDL cholesterol is associated with a decrease in 
cardiovascular risk which is a major complication of obesity associated dyslipidemia 
(Harrison, Kathy, Hornig, Drexler, 2003) and most of the drugs that decrease total cholesterol 
also decrease HDL cholesterol (Wilson, 1990). But in the present study the extract decreased 
the total cholesterol and LDL cholesterol and enhanced the HDL cholesterol significantly. 
This is an important advantage in treatment of hypercholesterolemia especially among 
Indians where low HDL cholesterol is the prevalent lipoprotein abnormality (Gupta, et. al., 
1994; Gupta, Kaul & Prakash, 1995). Total cholesterol/HDL cholesterol and LDL: HDL 
cholesterol ratios are also predictors of cardiovascular risks (National Cholesterol Education 
Program Expert Panel, 1994). In this study these ratios are markedly reduced by methanolic 
extract of S. media. 
High levels of TC and more importantly LDL cholesterol are major coronary risk factors 
(National Cholesterol Education Program Expert Panel, 1994). LDL carries cholesterol from 
the liver to the peripheral cells and smooth muscle cells of the arteries, a rise in LDL may 
cause deposition of cholesterol in the arteries and aorta and hence is bad for health and a 
direct risk factor for coronary heart disease. (Ramakrishnan, 1994). One species of LDL, 
Lipoprotein (a), which is associated with arthrosclerosis (and is localized in atherosclerotic 
lesions), contain a unique apoprotein, apo(a) and is similar in structure to plasminogen. 
Hence lipoprotein (a) competes with and inhibits the binding of plasminogen to its receptors 
on the endothelial cell. Plasminogen is normally the substrate for plasminogen activator. 
Plasminogen activator is secreted by and bound to endothelial cells, generating the 
fibrinolytic enzyme plasmin. The effect of this binding of lipoprotein (a) is that less plasmin 
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is generated, fibrinolysis is inhibited and thrombosis promoted. LDL also activate platelets, 
constituting a further thrombogenic effect. (Rang , Dale, Ritter and Moore, 2003). 
Administration of S. media (SM) lowered both total and LDL cholesterol in experimental 
animals. The lowering of TC and LDL in serum by 35 and 48% and 41 and 85% after 
administration of AESM and MESM, respectively, would reduce the incidence of obesity 
associated cardiovascular complications (Lipid Research Clinics Program, 1984b.)  
The decrease of serum TG level is an important finding of this experiment. Recent studies 
also show that triglycerides are independently related to obesity induced cardiovascular 
complications (Bainton, et. al., 1992; El-Hazmi & Warsy, 2001) and most of the 
antihypercholesterolemic drugs do not decrease triglycerides levels, but the test drug S. media 
lowered it significantly (P < 0.05) and this effect might be related to presence of sitosteroles 
in the extract. The presence of β-sitosterol and sterol compounds in the S. media have already 
been reported (Pande, et. al., 2000). Stigmasterols and β-sitosterol are the plant sterol with a 
structure similar to that of cholesterol. Among that β-sitosterol compound having more 
comparable except for the substitution of an ethyl groups at   C-24 of its side chain and it is 
cholesterol lowering agent (Lees, et. al., 1977). β-sitosterol reduced absorption of cholesterol 
by 42% in a meal containing 500 mg of cholesterol (Mattson, Grundy and Crouse, 1982). 
Therefore, β-sitosterol may be a bioactive phytoconstituent in S. media which may decreased 
the serum cholesterol by increasing the LDL receptor activity. 
There was significant increase in the organ / body weight ratio (mg /gm) of right kidney and 
left kidney and body fat in cafeteria diet fed rats.  Only MESM 400 mg/kg and Sibutramine 
were found to be significant in reducing the body fat. 
In this model the CD significantly increased WAT, adiposity index and adipocyte diameter 
significantly & increase in number of fat cell non significantly as compared to the normal 
control animals. These parameters were significantly decreased by administration of MESM 
200 and 400 mg/kg which exhibited the inhibitory activity of the extracts against adipocyte 
differentiation and proliferation, it also reduces the adiposities diameter in dose dependent 
manner. Sibutramine was found to be most significant in this regard. 
Explanation in concern with the fat cell size is that, the amount of fat mass is increased when 
the number and/or size of adipocytes are multiplied by proliferation and differentiation. 
Adipocyte stores fatty acids (FAs) in the form of triglycerides (TGs) in their cytoplasm, with 
an involvement of various enzymes such as strearoyl-CoA desaturase-1 (SCD-1) and fatty 
acid synthase (FAS). This overall lipid synthetic process is called lipogenesis. Adiposity has 
been shown to have a strong linear correlation with elevated plasma levels of FA. If blood FA 
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levels are elevated for prolonged periods by excessive energy intake, TG can be accumulated 
in WAT (that causes increase in the size of adiposities) and in some non-adipose tissues 
including liver and muscle, which can lead to pathological consequences such as the 
development of fatty liver or ketosis. Reduction in adipocyte diameter by MESM may be due 
to the β-sitosterol which is present in the MESM do the physical competition with the dietary 
fat and reduce its absorption and body use stored TG from the fat cell as a source of energy 
that‘s why there may be reduction of adiposities diameter.  
Another possible explanation in this regard is methanolic extract of C. phlomides contains 
abundant quantity of flavonides which was determined by Chang, Yang, Wen & Chern 
method. These flavonids  may activate peroxisome proliferators-activated receptor (PPAR-α) 
which is known to be concerned in the expression of many lypolytic enzymes such as acyl-
CoA oxidase-1 (ACO-1), carnitine palmitoyltransferase- 1 (CPT-1), and uncoupling proteins 
(UCPs) which causes FA-oxidation mechanism that allows the FA to break down into CO2 
and ketone body, and be released into blood.  
In this study we have also tried to find out any long term effect on liver hepatocytes but 
except rise in SGOT and SGPT level there wasn‘t any change hepatocyte architecture.  
In third model obesity was induced by feeding with high fat diet to female C57BL/6J 
mouse. The C57BL/6J mouse develops an obese phenotype only when allowed ad libitum 
access to a high-fat diet whereas on a low-fat diet, C57BL/6J mice remain normal. (Surwit et. 
al., 1995). The obesity in the C57BL/6J mouse results from both adipocyte hypertrophy and 
hyperplasia. The fat gained in the C57BL/6J mouse is deposited selectively in the mesentery 
which indicates the central obesity.  
The HFD group animals showed significant increase in food consumption as compared to the 
normal control group animals at 30 min, 1hr and 2 hr which was significantly decreased by 
the co-administration of MECP 100, 200 and 400 mg and by AECP 400 mg/kg. Standard 
sibutramine was most significant in this case. 
C57BL/6J mice exhibits an increased weight gain per ingested energy unit (feed efficiency 
rate) and, the ability of ingested energy to be metabolized (metabolic efficiency) is lower in 
high-fat diet fed C57BL/6J mice compared with control mice (Parekh et. al., 1998).  
In this study animals fed with HFD showed significant % increase in the body weight as 
compared to normal control animals which was significantly decreased in MESM 100, 200 
and 400 mg/kg, MECP 200 and 400 mg/kg and most significantly by Sibutramine. There 
was‘nt any significant change in the body temperature in any of the group of animals.  
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In addition to obesity typical features developed by the C57BL/6J mouse on a high fat diet 
are gradually worsening insulin resistance, glucose intolerance, mild to modest 
hyperglycemia, dyslipidemia, hypoadiponectinemia, leptin resistance/hyperleptinemia and 
hypertension. The DIO C57BL/6J mouse also suffers from islet dysfunction and shows 
decreased UCP2 expression as well as down regulated β3- adrenergic receptor expression and 
function. (Surwit et. al., 1998). Regarding the central adiposity, the gradual course of 
development of diabetes as well as the interaction of nutritional components and genetic 
variables the C57BL/6J mouse closely parallels the progression of common forms of the 
human disease. 
The liver plays a central role as both victim and culprit in obesity-related disorders and 
diabetes. Fatty liver is one of the major complication of the obesity that same was observed in 
this DIO C57BL/6J mice but not seen in other two models of the study. On the one hand, 
insulin resistance (IR) of the white adipose tissue (WAT) results in increased fatty acid (FA) 
flux to the liver with subsequent ectopic fat deposition in hepatocytes (Browning, Horton, 
2004; Postic, Girard, 2008). Conversely, fatty liver disease per se has been linked to IR and 
progression of atherosclerosis and thus by itself may be a major aggravating factor in the 
pathogenesis and progression of the metabolic syndrome and its associated disorders 
(Targher, 2007). Non-alcoholic fatty liver disease (NAFLD) is defined as the accumulation of 
fat in the liver (conventionally set as more than 5% by weight) in the absence of secondary 
causes such as increased alcohol consumption and other forms of chronic liver disease (Xie, 
Barwick, et. al., 2000; Angulo, 2002).  
Fatty liver is one of the consequence of lipotixicity. Lipotoxicity of fatty liver changes seen 
when chronic exposure of non-adipose cells and tissues to elevated concentrations of FA, TG 
or cholesterol triggers toxic effects that contribute to the pathogenesis of IR, type II diabetes 
and the metabolic syndrome (Unger, 2002;  Schaffer, 2003). Thus, lipotoxicity in (fatty) liver 
can be viewed as the result of excess FA which may impair normal cell signalling, cause 
cellular dysfunction and in some circumstances can induce cell death (Malhi & Gores, 2008; 
Alkhouri, Dixon & Feldstein, 2009). Hepatic lipotoxicity may ensue when the hepatic 
capacity to utilize (oxidize), store and export FA as TG is overwhelmed by FA flux from the 
periphery (usually visceral WAT in the context of IR) or hepatic de novo lipogenesis 
(Alkhouri, Dixon & Feldstein, 2009). Another, novel – yet understudied factors – may be the 
breakdown of hepatocellular TG (stored in lipid droplets) by intracellular lipases and 
autophagy of lipid droplets (Zechner & Madeo 2009; Singh, Kaushik, Wang et. al., 2009), 
which may also contribute to (increased) intracellular FA load. In addition, alterations in the 
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expression of fatty acid transport (FATP) and binding proteins (FABP) may also critically 
determine the flux and concentration of FA in the liver and thereby promote lipotoxicity 
(Malhi & Gores, 2008). 
Liver toxicity in our study was confirmed by biochemical estimation and histopathological 
examination of liver. Two transaminase for the diagnostic use are SGOT and SGPT which 
gives idea about physiological status of the liver and increase sharply in many liver disorders. 
Rise in serum SGOT and SGPT level indicates improper liver function which is supported by 
histpathological examination of liver where fatty infiltration is clearly observed in plain HFD 
(High fat diet) treated groups as well as some other drug treated groups. This fatty infiltration 
was selectively reversed by high and medium dose of the MECP significantly which indicates 
protective effect against obesity and dyslipedemia associated liver toxicity. Sibutramine have 
shown more protective in this regard. 
There was no significant change in the organ / body weight ratio (mg / gm) in HFD group 
animals but the organ / body weight ratio (mg / gm) was significantly decreased by the 
AESM 400 mg/kg, MESM 400 mg/kg, AECP 400 mg/kg non-significantly but significantly 
by MECP 400 mg/kg as compared to normal control group animals as well as disease control 
animals. 
Feeding with HFD caused significant increase in the glucose, insulin, SGOT, SGPT, TG, TC 
and LDL-C levels in HFD group animals as compared to normal control animals which was 
significantly decreased by the administration of MESM 400 mg/kg, AECP 400 mg/kg and 
MECP 400 mg/kg. Body fat, especially abdominal fat, is harmful to human health. Visceral 
adipose tissue has a higher rate of lipolysis, resulting in elevated portal non-esterified fatty 
acids that increase hepatic very-low-density lipoprotein (VLDL), hepatic glucose production, 
and impair peripheral insulin sensitivity. The serum TC, TG, glucose levels and TC/HDL-C 
ratio were defined as the main risk factors for dyslipidemia. Our study found that the plant 
extract of C. phlomidis could decrease the plasma lipid parameters and parametrial adipose 
tissue weights. In the present study, C. phlomidis decreased the perirenal adipose tissue 
weight, parametrial plus peritoneal adipose tissue weight, serum lipids and liver lipids in 
mice.  
There was significant increase in the WAT, adiposity index and adipocyte diameter in the 
HFD group animals as compared to the normal control animals. These parameters were 
significantly decreased by administration of MESM 400, AECP 200 and 400 and MECP 200 
and 400 which exhibited the inhibitory activity of the extracts against adipocyte 
differentiation and proliferation. Sibutramine was found to be most significant in this regard.  
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The extracts produced significant anti-obesity effects on body weight and various lipid-
related parameters, including levels of triglyceride and total cholesterol, in a high fat diet-
induced obesity mouse model. The possible mechanism of action behind this may be the 
inhibition of pancreatic lipase which is the most important enzyme of the human lipases for 
digesting fats responsible for the hydrolysis of 50–70% of total dietary fats. Verger (1984) 
reported that dietary fat was hydrolyzed during digestion by pancreatic lipase. The two main 
products formed by the hydrolysis of pancreatic lipase are fatty acids and 2-
monoacylglycerols (Hernell et. al., 1990). These lipolytic products are mixed with bile salts, 
dispersed as micelles and carried in this form to the site of fat absorption. Lipid absorption 
takes place in the apical part of the plasma membrane of epithelial cells or enterocytes lining 
the gut. Previously, in in-vitro study of pancreatic lipase activity we found that MECP 
inhibited the hydrolysis of triolein emulsified with phosphatidylcholine in a pancreatic lipase 
activity assay. On the basis of these results, we designed in- vivo experiments and clarified 
that the increase in body and WAT weights induced by a high fat diet through inhibition of 
the intestinal absorption of dietary fat (Han et. al., 1999a). It has been reported in clinical 
studies that a pancreatic lipase inhibitor, orlistat (Ro 18–0647), prevented obesity and 
hyperlipidemia after treatment for 12 wk through inhibition of fat absorption (Drent et. al., 
1995a and 1995b, Drent and Van der veen 1995, Hauptman et. al., 1992). It has been reported 
that various saponins isolated from foodstuffs have anti-obesity (Kawano-Takahashi et al. 
1986) or hypolipidemic (Kimura et. al., 1983, Oakenfull et. al., 1979, Verrillo, et. al., 1985, 
Yamamoto et. al., 1975) actions. We found that the crude saponin fractions isolated from 
MECP strongly inhibited pancreatic lipase activity. Therefore, it seems likely that the obesity, 
T2DM, dyslipidemia and other obesity associated complications which were reversed by 
MECP may be attributed in part to its crude saponin fractions. Experiments are now in 
progress to clarify the anti-obesity action of pure saponin isolated from MESM and MECP in 
mice fed a high fat diet. 
It is worth mentioning that the plants S. media and C. phlomidis have effects on perirenal 
adipose tissue weight, parametrial plus peritoneal adipose tissue weight, serum lipids and 
liver lipids in mice in our present study.  
In our study both the plants could decrease effects on LDL-C. Our results suggest that both 
the plants played a more important role in anti-obesity might also be associated with its 
stronger inhibition activity of pancreatic lipase certified in vitro lipase experiments. 
In summary, plants S. media and C. phlomidis were significantly effective in preventing and 
ameliorating obesity, obesity induced DM, fatty liver and hypertriglyceridemia in mice in 
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various models of obesity. It suggested that the anti-obesity action in mice might be mostly 
the reason for inhibition of pancreatic lipase activity. Therefore, plants S. media and C. 
phlomidis may be useful for prevention and treatment of obesity and hypertriglyceridemia in 
humans. 
These findings suggest that that the plants S. media and C. phlomidis possess strong anti-
obesity effects against various models of obesity. The results indicate the great potential of 
extracts as metabolic regulators of lipogenic and lipolytic pathways, and ultimately as anti-
obesity reagents. Ideally this exploration and research will lead to a safer and more effective 
pharmacological treatment for obesity. 
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10.0: SUMMERY AND CONCLUSION  
The biological activities of alcoholic and methanolic extracts of Stellaria media and 
Clerodendrum phlomidis observed in this study strongly indicated their great potential as 
anti-obese and obesity associated complications like T2DM.  
Oral administration of extracts reduced the level of circulating lipids as well as the amount of 
adipose tissues, resulting in the decrease of body weights in various animal models of obesity 
bearing close resemblance to human obesity. Extracts appear to show such activities by 
modulating the lipid metabolism through the decreased activity in lipogenesis, inhibition of 
pancreatic lipase activity as well as increase in fatty acid oxidation. 
Among these two plants Clerodendrum phlomidis have shown more promising effects 
compared to Stellaria media this may be its multiple targets. Clerodendrum phlomidis 
contains more amount of β-sitosterol compared to Stellaria media as per the quantitative 
HPTLC study. Moreover as both the plants contains saponin and only Clerodendrum 
phlomidis have shown in-vitro inhibitory effect on pancreatic lipase activity indicating some 
specific saponin are present in this plant which are absent in the Stellaria media. Stellaria 
media have shown its antiobesity effect by its anorexic property. On the basis of this study 
we are concluding that Clerodendrum phlomidis have more potent activity compared to 
Stellaria media to reduce body weight and associated complications like T2DM. Further 
studies on phytochemical analysis, isolation and to explore more pharmacological properties 
of both the selected plants are going on in our laboratory hence, it has been warned. 
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